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Thesis Abstract 
 
 
The purpose of this study was, first, to evaluate the intraocular pressure characteristics in eyes 
with occludable anterior chamber angles and the influence of Peripheral Anterior Synechiae 
(PAS). Second, to further investigate the hypothesis that smaller values for Angle Opening 
Distance (AOD), Angle Recess Area (ARA), Trabecular-Iris Space Area (TISA) and Trabecular-Iris 
Angle (TIA), are associated with greater diurnal intraocular pressure fluctuation and extent of PAS. 
Third, to additionally investigate the effect of Laser Peripheral Iridotomy (LPI) and Argon Laser 
Peripheral Iridoplasty (ALPI), in treated eyes versus untreated, on the diurnal intraocular pressure 
fluctuation, the angle parameters aforementioned and the corneal endothelial cell density, 
polymegethism and pleomorphism. 
 
 
40 Caucasian patients with a gonioscopic diagnosis (less than 180 degrees posterior pigmented 
trabecular meshwork visible) of bilateral Primary Angle Closure (PAC), Primary Angle Closure 
Suspect (PACS) or a combination of both conditions and no ocular co-morbidity were recruited.  
 
After recruitment one eye was randomized to receive LPI and the fellow remained untreated as a 
control eye. Three months after LPI, those eyes in which the anterior chamber angle remained 
occludable were further randomized into either receiving ALPI or no further treatment. The follow 
up visits were set at 1 day, 1 week, 1.5 months, 3 months and 6 months after LPI. For ALPI, the 
treated eyes were assessed at 1 day, 1 week, 1.2 months and 2.5 months. 
 
Intraocular pressure (IOP) was measured hourly from 9.00 am to 4.00 pm with Goldmann 
applanation tonometry by the same examiner at the baseline and final visit. Diurnal intraocular 
pressure (DIOP) fluctuation was defined as the difference between the maximum and minimum 
IOP during that period.  
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Angle parameters were measured using the novel non-contact three-dimensional AS-OCT (CASIA) 
in dark (0.3-0.5 lux) and light (170-200 lux) conditions at every follow up visit. AOD, ARA, TISA and 
TIA were quantified in 8 different sections of the angle (Superior, Superior-Nasal, Nasal, Inferior-
Nasal, Inferior, Inferior-Temporal, Temporal and Superior-Temporal) and at 500 and 750m from 
the scleral spur. All the scans were acquired and evaluated by the same examiner. 
 
Measurements of DIOP in eyes with PAS were 1.5 mmHg (p=0.043) higher than in eyes without 
PAS.  
 
DIOP fluctuation varied from 1.50 mmHg to 14.50 mmHg (mean 5.99 mmHg, SD 2.70 mmHg). 
There was a statistically significant relationship between this fluctuation and the majority of angle 
parameters in Superior and Superior-Nasal sections, showing standardized coefficients from -254 
to -438, demonstrating an inverse relationship between angle parameters and DIOP in these 
sections. Additionally, the higher contribution to the multiple predictor models also 
demonstrated negative standardised coefficients showing a similar inverse relationship between 
magnitude of fluctuation and angle dimensions. These models were statistically significant 
(p<0.05) for AOD 750 (light), ARA 750 (light and dark), TISA 500 (light), TISA 750 (light), TIA 500 
(light) and TIA 750 (light and dark). The circumference of PAS (measured in degrees) and DIOP 
showed a statistically significant association (calculated using single factor or univariate 
regression) at every time measurement of the DIOP. 
 
There was a statistically significant widening effect of the parameters found in the Inferior-
Temporal section of the angle of those eyes treated with LPI, but no effect was found on the 
diurnal intraocular pressure fluctuation. After ALPI, the parameters found in Superior, Inferior-
Temporal and Superior-Temporal significantly increased 2.5 months after the treatment when 
compared to the untreated eye. Additionally, ALPI was associated with a reduction in the diurnal 
intraocular pressure fluctuation of 1.60 mmHg (SD 0.78 mmHg) that was of borderline statistical 
significance (p=0.056). 
 
There was not a clear effect on the endothelial cells density, polymegethism or pleomorphism 
after the LPI or ALPI treatments.    
 
Substantial changes in IOP occur throughout the day in patients with occludable anterior chamber 
angles. Narrower angle parameters and the presence of PAS are associated with greater diurnal 
fluctuation.  
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CHAPTER 1 General Introduction 
 
1.1 Burden of Angle Closure Glaucoma 
The World Health Organisation (WHO) rates glaucoma as the second leading cause of blindness 
worldwide, after cataract. Glaucoma is the principal cause of irreversible blindness (Resnikoff, et 
al., 2004). 
The number of people with glaucoma worldwide is increasing substantially. In 2005, Quigley and 
Broman (2006) estimated that, in 2010, 60.5 million people would have glaucoma worldwide 
which would increase by approximately 20 million by 2020. Their model suggested that over 8.4 
million people would be bilaterally blind from glaucoma in 2010 and 11.1 million in 2020. 
Although angle closure glaucoma is less common than open angle glaucoma, it causes greater 
morbidity and is estimated to be responsible for half of the blindness caused by glaucoma 
worldwide. It is predicted that approximately 10 million Chinese, 5 million Indians, 3 million South 
East Asians, 1.6 million Europeans, 0.5 million Latin Americans, 0.34 million Japanese, 0.32 million 
Africans and 0.25 million of the Middle Eastern population would suffer from angle closure 
glaucoma (ACG) by 2020 (Quigley and Broman, 2006).  
 
1.2 Definitions of Primary Angle Closure Suspects (PACS), Primary angle 
Closure (PAC) and Primary Angle Closure Glaucoma (PACG) 
As primary angle closure glaucoma (PACG) is regarded as the final stage in a series of pre-
glaucomatous stages of angle closure, namely Primary Angle Closure Suspects (PACS) and Primary 
Angle Closure (PAC), described by Foster, Buhrmann, Quigley and Johnson (2002). 
There is a variation in opinion about the circumferential extent of the posterior pigmented 
trabecular meshwork (TM) that needs to be obscured in order to meet a definition of an 
‘occludable’ angle. For example, we can find PACS/PAC diagnosed in those eyes with TM obscured 
in ≥ 270 degrees in some reports (Devereux, et al., 2000; Foster, 2002; Nolan, et al.,2003; Lei, 
Wang, Wang, and Wang, 2009) or in ≥180 degrees in others (Thomas, Arun, Muliyil and George, 
1999; Thomas, et al., 2003; Thomas, Parik, Muliyil and Kumar, 2003; Kumar, et al., 2008; Lavanya, 
et al., 2008; Jiang, et al.,2010; Lee, Kim and Choi, 2011). 
For the purpose of this research project, the definition of an occludable angle was chosen to 
match that of the Zhongshan Angle Closure Prevention Trial (Iridotomy for the Prevention of 
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Angle Closure in Southern China- currently on-going), (Jiang, et al., 2010), which will permit 
comparison between results.  PACS has been diagnosed in those eyes with posterior pigmented 
TM obscured in ≥180 degrees of the irido-trabecular angle. PAC, additionally includes adhesion of 
the peripheral iris over the TM (peripheral anterior synechiae, PAS*) and/or a raised intraocular 
pressure (IOP). 
 An IOP of 21mmHg or more is generally accepted as the IOP criterion, and for the purposes of 
this study thesis this was fulfilled if the IOP achieved this level at any point during office hours at 
the baseline visit for the study. 
*PAS defined as: abnormal adhesions of the iris to the angle extending to the anterior TM or more 
anteriorly (Kumar, et al., 2008) 
 
1.3 Mechanism of angle closure 
It is believed that the predominant mechanism for anterior chamber angle narrowing in the 
Caucasian population is pupil-block (He, Foster, Johnson and Khaw, 2006). Lowe (1964) indicated 
that pupillary block was due to contact between the posterior plane of the iris and the anterior 
surface of the lens. A differential of intraocular pressure could therefore build between anterior 
and posterior chambers. As a result, the iris root profile would bow forward and the peripheral 
iris would then narrow or occlude the irido-trabecular space. In a further theory developed in 
1966, the same author stated that the conflict of forces between dilator and sphincter pupil 
muscles could lead to the iris-lens contact explained by the earlier assertion (Lowe, 1966). Lowe 
observed that those angle closure eyes dilated with homatropine (muscarinic receptor antagonist- 
acts blocking the parasympathetic innervations in the sphincter muscle) presented a lower risk of 
an acute episode than those dilated with phenylephrine ( agonist- acts stimulating the 
sympathetic innervations in the dilator muscle). The author observed that when the homatropine 
was acting on the sphincter muscle, the iris was experiencing a more peripheral posterior force 
for dilating and, although it was narrowing the angle, the aqueous humour flow through the pupil 
was not impaired. However, when the pupils were dilated with phenylephrine, the dilator muscle 
forces where acting over a tonic sphincter muscle and the posteriorly directed forces would be 
placed closer to the pupil. This would increase the contact between the anterior surface of the 
lens and the posterior iris leading to pupillary block mechanisms (Lowe, 1966). If the pupil block 
takes place, pressure accumulates in the posterior chamber bowing the iris forward and 
narrowing the angle (Mapstone, 1976). Pupillary block mechanisms may occur without 
pharmacological inducement and relative pupillary block is present in most phakic eyes due to the 
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natural curvature of the lens. Additionally, the normal convex shape of the iris in a mid-dilated 
pupil narrows the trabeculo-iris space. This space can further decrease or close in eyes with a 
more anteriorly positioned lens leading to angle closure (Quigley, et al., 2003). 
Mechanisms other than pupil-block may be present such as an anteriorly positioned ciliary body 
where iris processes press the peripheral iris against the drainage area. This is known as iris 
plateau configuration (Salmon, 1999; Pavlin and Foster, 1999). Plateau iris syndrome refers to an 
episode of angle closure in an eye with plateau iris configuration (Ritch, Liebmann and Tello, 
1995). 
 
1.4 Prevalence of Primary Angle Closure Glaucoma (PACG)  
There is considerable variation in the prevalence of PACG worldwide. In the Greenland and 
Alaskan Inuit populations, the prevalence of PACG was estimated to be the highest with 5.1% for 
females and 1.6% for males older than 40 years (Alsbirk, 1976; Arkell, et al., 1987; Van Rens, 
Arkell and Doesburg, 1988). Prevalence rates for PACG in other populations are different, for 
example: Taiwan at 3% (Congdon, et al., 1996), South Africa (Cape-Malay) at 2.3% (Salmon, 1993), 
China (calculated through statistical models based in published literature) at 1.11% (Foster and 
Johnson, 2001), South West Mongolia at 1.05% in subjects older than 50 years (Nolan, et al., 
2003), Thailand with a 0.9% in population older than 50 years (Bourne, et al., 2003), Mongolia and 
Singapore with an equal prevalence of 0.8% (Foster, 2002), East Asians with 0.8% (Devereux, et 
al., 2000), Brazil with 0.8% (Sakata, et al., 2007), Central Sri Lanka with a 0.57% for inhabitants 
older than 40 (Casson, et al., 2009) , Japan with 0.2% for males and 0.4% for females older than 40 
years (Shiose, et al., 1991), Australia with 0.1%-0.3% (Mitchell, et al.,1996; Wensor, et al., 1998), 
USA with 0.1% (Klein, et al, 1992) and  0.0-0.1% in the case of Europe (Hollows and Graham, 1966; 
Bankes, et al., 1968;  Bengtsson, 1981; Coffey, et al., 1993; Dielemans, et al., 1994).  These values 
for prevalence have been summarised in Table 1.1. 
There is some contradiction between the European rates mentioned earlier and the rates Bonomi, 
et al. (2000) found in the Egna-Neumarkt Study of northern Italy. In this study, women were 
estimated to have a prevalence of PACG of 0.9%, with a prevalence of 0.2% in men. They noticed 
that not only were the PACG rates for women nearly 4 times higher than for men, but also that 
the percentage of narrow angles with predisposition to occlusion was 6% higher among women. 
The authors gave a possible explanation for these differences between their study and other 
European rates of prevalence. They mentioned that many of the previous prevalence studies 
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considered only acutely forms of PACG, which were less common. The authors also acknowledged 
a high incidence of endogamy within this population. 
Table 1.1. Examples of rate of PACG prevalence in different countries.  
 
To summarise these prevalence studies, PACG is considered a relatively uncommon type of 
glaucoma among Europeans but is relatively common among Asians (Quigley, Congdon and 
Friedman, 2001; Quigley, 2010; Wang, Wu and Fan, 2002; Rotchford, 2005; He, Foster, Johnson 
and Khaw, 2006; Lavanya, et al., 2008; Cedrone, et al., 2008; Mansouri, Sommerhalder and 
Shaarawy, 2010).  
 
1.5 Prevalence of Primary Angle Closure Suspects (PACS) and Primary 
angle Closure (PAC) 
An estimated 28.2 million people living in China are believed to have narrow anterior chamber 
angles; this figure approximately represents 10% of the Chinese population older than 50 years. 
Of these, 9.1 million are believed to have PAC (approximate 2.2 % of prevalence) and 19.9 million 
to have PACS (approximately 4.9 % of the total population) (Foster, 2002). In an East Asian based 
study, PACS prevalence rates were higher than those found for PAC, 3.3% and 2.7%, respectively 
(Devereux, et al., 2000). A screening study for narrow angles (PACS, PAC and PACG studied as a 
group) in Singapore, reported a prevalence of 20.4% in at least one eye (Lavanya, et al., 2008). In 
Author Country Age group % PACG 
Alsbirk, 1976 Greenland > 40 1.6 % males -5.1% females 
Arkell, et al., 1987 Alaska > 40 2.7 % 
Van Rens, Arkell and Doesburg, 1988 Alaska > 40 2.1 % males -5.5% females 
Congdon, et al., 1996 Taiwan > 40 3.0% 
Salmon, 1993 South Africa > 40 2.3% 
Foster and Johnson, 2001 China > 40 1.11% 
Bourne, et al., 2003 Thailand > 50 0.9% 
Foster, 2002 Mongolia and Singapore > 40 0.8% 
Devereux, et al., 2000 Mongolia > 40 0.8% 
Sakata, et al., 2007 Brazil > 40 0.8% 
Casson, et al., 2009 Sri Lanka > 40 0.6% 
Shiose, 1991 Japan > 40 0.34% 
Mitchell, et al., 1996 Australia > 49 0.3% 
Wensor, et al., 1998 Melbourne > 40 0.1% 
Klein, et al., 1992 United States > 43 0.1% 
Hollows and Graham, 1966 Wales > 40 0.1% 
Coffey, et al., 1993 Ireland > 50 0.01% 
Dielemans, et al., 1994 Netherlands > 55 0.0% 
Bankes, et al., 1968 England > 40 0.2% 
Bengtsson, 1981 Sweden From 55 to 69 0.0% 
Bonomi, et al., 2000 Italy > 40 0.6% 
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Mongolia, the prevalence of PACS and PAC was estimated to be 2.11% and 1.31% respectively 
(Nolan, et al., 2003); which was not dissimilar to prevalence estimates from Central Sri Lanka 
(Casson, et al., 2009). 
Generally, the prevalence of PACS and PAC, the pre-glaucomatous stages of PACG, has not been 
as thoroughly studied as the prevalence of PACG. One possible reason being that these early 
stages have been described as “narrow angles” (Martinez, Campbell, Reinken and Allan, 1982; 
Lee, Brubaker and Ilstrup, 1984) or “occludable angles” (Tomey, Traverso and Shammas, 1987; 
Bonomi, et al., 2000) in the literature or may have been grouped together (Nolan, et al., 2003; 
Thomas, Arun, Muliyil and George, 1999). However, since 2002, when there was some consensus 
on definitions (Foster, Buhrmann, Quigley and Johnson, 2002), there has been an increasing 
tendency among studies to distinguish between these stages (Su, et al., 2008; Lavanya, et al., 
2008; Mansouri, Burgener, Bagnoud and Shaarawy, 2009; Casson, et al., 2009; Ang and Wells, 
2011; Lee, Kim and Choi 2011).  
 
1.6 Prevalence of Primary Angle Closure in the United Kingdom 
In 1963, a population survey carried out in three villages of South Wales showed a prevalence of 
primary angle closure glaucoma (PACG) of 0.09% (Hollows and Graham, 1966). Bankes, et al. 
(1968) found a prevalence of 0.2% of PACG in Bedford. However, Perkins (1973a) found no cases 
of PACG in a review carried out in the same town. Glaucoma was found in 0.93% of the Bedford 
population and there was no case described as angle closure. After 5 years, a re-screening of 
‘normals’ (non-glaucomatous) again showed no evidence of angle closure among the additional 
0.52 % found to have glaucoma (Perkins, 1973b). 
 Since then, there has been a lack of published data on the prevalence of PACG within the UK. A 
relatively recent retrospective review of the glaucoma clinic database at Moorfields Eye Hospital 
showed that from 7186 patients attending the clinic, 4.6% were diagnosed with angle closure 
glaucoma, 42.1% were primary open angle glaucoma, 15.4% were ocular hypertensive and 32.4% 
were glaucoma suspects (Morley and Murdoch, 2006). Another similar retrospective study was 
based in a glaucoma clinic in Scotland (Aberdeen Royal Infirmary glaucoma clinic). All the 
Caucasian patients newly diagnosed with PACS, PAC, PACG or acute primary angle closure during 
2004 and 2005 were included in the report. It showed that of 104 patients, 23.1% had PACS, 
28.8% had PAC, 48.1% had PACG and 11.5% presented with acute primary angle closure (Ng, Ang 
and Azuara-Blanco, 2008). It was interesting that this Aberdeen clinic noted a higher proportion of 
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PACG than the pre-glaucomatous stages. In their report, the authors mention poor follow up in 
the community as a possible reason. 
This limited data from both population-based and clinic-based studies in the UK does not allow 
conclusions to be drawn about temporal trends in angle closure prevalence in the UK. However, a 
recent review of the PACG literature in Caucasian populations (UK, Europe and USA) has reported 
a predicted increase of cases in Caucasians (Day, et al., 2012). They estimated that the number of 
people, aged 40 or more, affected by PACG in UK was 130,000 in 2010 and that this number 
would increase to 195,000 cases by the year 2050 (Day, et al., 2012). 
Additionally, in recent years there does appear to be better case detection within the 
ophthalmology/optometry with referral refinement systems that include measures to detect eyes 
at risk of angle closure in the community (Ratnarajan, et al., 2013 a; b). Another study by Day and 
Foster (2011) showed data suggesting that prophylactic treatment in angle closure cases has 
decreased the number of acute angle closure within the UK from 1998 to 2010.  
An increase in immigration of individuals of Asian origin into the UK may also have an impact on 
angle closure prevalence.  
 
1.7 Prevalence of Primary Angle Closure due to Plateau Iris  
When angle closure is caused by a pupillary block mechanism, a peripheral iridotomy creates a 
new pathway for aqueous humour and relaxes the peripheral iris by restoring the pressure 
balance between the anterior and posterior chambers. However, as mentioned earlier, primary 
angle closure may be due to an anteriorly positioned ciliary body where an iridotomy may not 
resolve the peripheral apposition of the iris against the trabecular meshwork. This is known as 
plateau iris configuration. There is no published information on the circumferential extent of a 
plateau profile for a ‘plateau iris’ diagnosis to be made (Kumar, et al., 2008) nor is it known how 
much time is needed post-LPI for an angle to reach a configuration that remains stable. A lack of 
consensus on these issues probably explains the variation in reporting of “unsuccessful” LPIs (the 
angle remains occludable).  
Several studies based in Asian populations have reported prevalence rates for plateau iris. Kumar, 
et al. (2008) studied a sample of 205 PACS eyes (majority Chinese). Gonioscopy was performed 
before and one week after the laser peripheral iridotomy (LPI), finding that 89 eyes remained 
gonioscopically occludable (≤ 180° of trabecular meshwork visible). When the same sample was 
assessed with Ultrasound Biomicroscopy (UBM), plateau iris pre-LPI was found in 55 eyes out of 
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167 eyes and 42 remained plateau post-LPI. Using the UBM criteria, the prevalence of plateau iris 
in the sample was 25.14%, while the same prevalence based on gonioscopy was 43.41%. It can be 
argue that one week post-LPI may not have been time enough for pupillary-block to completely 
resolve and gonioscopy may have overestimated this prevalence. Similar rates as those described 
by Kumar and colleagues using the UBM were found in another study carried out in South India 
where a mixed sample of PAC and PACG was studied. The LPI was unsuccessful in opening the 
angles in 26.6% of eyes one month after the treatment (≤ 180° of trabecular meshwork visible in 
applanation gonioscopy), (Thomas, Arun, Muliyil and George, 1999). He, et al. (2007) found lower 
rates in a study based in Guangzhou, China, with a sample of 72 PACS eyes that received LPI with 
a review two weeks after the treatment. The criterion for diagnosing narrowing angle was based 
on 270° or more of trabecular meshwork obscured on applanation gonioscopy. Quite a different 
rate, a 2% was found by Nolan, et al. (2000) in a Mongolian sample of PAC, PACS and PACG. They 
reviewed 141 cases in a period of time that ranged between 10 to 37 months and only 3 treated 
eyes were diagnosed as still occludable (based ≤ 270° of trabecular meshwork visible in 
applanation gonioscopy).  
In a Caucasian population, Mansouri, Burgener, Bagnoud and Shaarawy (2009) studied a sample 
of 35 eyes presenting PAC or PACG. One week post-LPI, 22 eyes out of 30 were found 
unoccludable (>90° of trabecular meshwork visible). Similar rates were found in another study in a 
Caucasian population; Ang and Wells (2011) reporting that in a sample of 71 eyes with PAC, PACS 
or PACG nearly 24% of the eyes treated with LPI remained with narrow angles (≤ 180°of 
trabecular meshwork visible). The review was performed at a mean follow up of 5.9 weeks (SD 3.2 
weeks). 
Table 1.2 (below) summarises these findings. 
Author Ethnicity 
 
Ocular 
Condition 
Time since LPI % Of occludable eyes after LPI 
(Possible Iris Plateau) 
Kumar, et al. (2008) Chinese PACS 1 week 25.14% (UBM); 43.41% 
(Gonioscopy) 
Mansouri, Burgener, Bagnoud and 
Shaarawy (2009) 
Caucasian PAC/PACG 1 week 26.7% 
He, et al. (2007) 
 
Chinese PACS 2 weeks 19.44% 
Thomas, Arun, Muliyil and George 
(1999) 
Indian PAC/PACG 4 weeks 26.6%  
Ang and Wells (2011) Caucasian PAC/PACS/ 
PACG 
6 weeks 24% 
Nolan, et al. (2000) Mongolian PAC/PACS/ 
PACG 
10 to 37 
months 
2% 
Table 1.2. Summary of the rates of occludable angle despite of laser peripheral iridotomy in different ethnicities. 
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The literature search regarding prevalence of Primary Angle Closure Glaucoma, Primary Angle 
Closure, Primary Angle Closure Suspects and Iris Plateau was conducted by accessing the 
following databases: PubMed, Medline, AMED and EMBASE. The terms searched were 
“prevalence” and “angle closure” in the Title and Abstract.The aim of this literature search was to 
find studies that reported prevalence rates of these angle closure conditions in different 
geographical regions and ethnic groups worldwide. On occasion, some reports were obtained by 
searching references given in the reference list of some published studies. 
 
1.8 Risk factors 
Various genetic factors and ocular biometrical parameters may predispose individuals to angle 
closure. 
 
Age: 
It has been found that an increase in age is indirectly associated with occludable angles in 
different studies (Panek, et al., 1990; John, 1999; Bonomi, et al., 2000).  This association is 
believed to be mainly due to the natural growth of the lens that would lead to a smaller anterior 
chamber depth and, consequently, to a narrowing of the irido-trabecular space (Rabsilber, 
Khoramnia and Auffarth, 2006). 
 
Anterior chamber dimensions: 
Anterior chamber depth plays an important role as a risk factor in the risk of developing angle 
closure. Among Sri Lankans, a 1mm decrease in anterior chamber depth was associated with a 2.6 
times increase risk of angle closure (PACS, PAC and PACG were studied as a group), (Casson, et al., 
2009). 
 
Several reports indicate an association between the dimensions of the anterior chamber and its 
structures and narrow angles. Smaller dimensions of anterior chamber depth, volume and 
diameters have been associated with narrow angles (Lee, Brubaker and Ilstrup, 1984). In a study 
recently carried out in Singapore, it was reported that the average anterior chamber area and 
volume in patients with narrow angles were 5.5 mm² and 44.5mm3 respectively, which were 
smaller in dimension than in those patients who acted as controls (in whom average anterior 
chamber area and volume measurements were 21.1 mm² and 142.1 mm3, respectively (Wu, et al., 
2011). 
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Other studies have reported thicker or more anteriorly placed lenses, shorter axial ocular length 
and anterior chamber length as risk ocular factors for developing PACG (Marchini, 2002; Lavanya, 
et al., 2008). 
 
Iris configuration:  
There is some evidence showing a relationship between iris configuration and narrow angles. A 
Singapore-based study showed that a higher sectional iris curve, area and thickness were 
significantly associated with gonioscopically narrow angles (Wang, Wu and Fan, 2010). Aptel and 
Denis (2010) suggested that an increase in iris volume after dilation was directly associated with 
eyes predisposed to acute angle closure. All the patients in this latter study were European. 
Following this work, Quigley (2010) proposed that irises in patients with angle closure are less 
able to function as a sponge (absorb and release fluid as the pupil dilates then constricts) than 
those without. 
 
Gender:  
PACG seems to be more common in women. Quigley and Broman (2006) estimated that in 2010 
females would comprise 69.5% of the PACG cases worldwide. Other studies have also found 
higher number of cases among women (Shiose, et al., 1991; Bonomi, et al., 2000; Lavanya, et al., 
2008). This higher prevalence in females may be due to the narrower anterior chambers found in 
this gender when compared to males for three different ethnicities studied (Afro-Americans, 
Caucasians and Far East Asians), (Oh, Minelli, Spaeth and Steinman, 1994).  
 
In another community-based study conducted in Singapore it was found that women (Odds Ratio 
1.43; 95% CI: 1.06%-1.92%), had shorter axial lengths (Odds Ratio 0.69; 95% CI: 0.58%-0.81%) and 
shallower anterior chamber depths (Odds Ratio 42.5; 95% CI: 27.4%-66.2%). Additionally Chinese 
ethnicity (Odds Ratio 3.58; 95% CI: 2.29%-18.2%) was a statistically significant predictor for angle 
closure (Lavanya, et al., 2008). 
 
In a recent review of studies associating gender and glaucoma, the authors found that female 
gender is not only directly associated to a higher number of cases of angle closure but to a higher 
rate of blindness due to longer life expectancy among women (Vajaranant, Nayak, Wilensky and 
Joslin, 2010) 
 
 
Genetics:  
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A genetics study performed in 563 pairs of young Chinese twins (357 monozygotic and 206 
dizygotic whose ages were 7 to 15 years old) showed that there was a higher correlation for 
anterior chamber depth in the group of monozygotic twins (coefficient of 0.92) than in the 
dizygotic group (correlation coefficient 0.50). They found that 90% of the anterior chamber depth 
was due to heritability and the remaining 9.9% was due to unshared environment (He, et al., 
2008). A second study by He et al. in 462 Chinese twins, investigated the heritability of different 
parameters used to quantify the irido-trabecular angle (the angle opening distance, angle recess 
area and trabecular-iris space).  These parameters were measured in the Temporal and Nasal 
sections of the right eyes angles. They found that the correlation coefficient for the angle opening 
distance was higher in monozygotic than in dizygotic twins (0.73 and 0.36 respectively) while the 
coefficients for angle recess area and trabecular-iris space were similar in both groups. The 
heritability was determined as approximately 70% for the three parameters, the other 30 % being 
attributable to environmental factors (He, et al., 2008). These two studies suggested that 
parameters commonly defined as risk factors for angle closure seemed to be genetically shared in 
this Chinese sample. 
Other similar studies to determine heritability of the anterior chamber depth and lens thickness 
have been carried out in older Caucasians twins. In a sample of 53 monozygotic twins and 61 
dizygotic twins aged 20 to 45 years old, the heritability was defined as 0.88 and 0.94 for anterior 
chamber depth and lens thickness respectively (Lyhne, Sjølie, Kyvik and Green, 2001). Another 
study in Caucasian twins aged 18 to 88 years, found rates of heritability of axial length of 94% and 
92% for male and females respectively (Dirani, et al., 2006). These findings further support the 
concept of genetic predisposition to angle closure. 
 
Environmental factors: 
Alsbirk suggested that the small anterior chamber depths found in Inuit and populations living in 
low temperatures were an adaptation to the climate. The explanation being that the warmly 
perfused iris would be closer to the cornea thereby reducing the risk of corneal freezing  
(Alsbirk, 1976). 
Literature suggests no other association between PAC, PACS or PACG and environmental factors. 
However, environment appears to be associated with episodes of acute angle closure. A study 
carried out in Finland found an association between the number of acute episodes of angle 
closure and the number of hours without sunshine. Being in dark conditions would keep the 
pupils dilated for longer periods of time giving a rise in the intraocular pressure in eyes that were 
already predisposed (Teikari, O’Donnell, Nurminen and Raivio, 1991). Another study based in the 
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UK (Birmingham) found a direct association with hours of sunshine and acute episodes, but the 
authors could not fully explain the reasons for these results (Hillman and Turner, 1977).  
A review about environmental factors in PACG, reported published evidences about the 
association of unpleasant weather conditions and acute episodes of angle closure. Stress and 
adrenaline were additionally reported as further environmental factors directly associated with 
acute episodes. Adrenaline may precipitate an angle closure crisis (Subak-Sharpe, Low, Nolan and 
Foster, 2010). 
 
 
Ethnicity 
As noted by the aforementioned section on prevalence rates, Inuit and Chinese ethnicity is a 
major risk factor for angle closure (Alsbirk, 1975; Arkell, et al., 1987; Van Rens, Arkell and 
Doesburg, 1988; Foster and Johnson, 2001; Lavanya, et al., 2008).  
 
There have been very few comparative studies that have attempted to find biometric ocular 
factors that may predispose certain ethnic groups to angle closure. Shiose, et al. (1991) found that 
the mean intraocular pressure (IOP) in Caucasians was 3-4 mmHg lower than in Asians. Congdon, 
et al. (1997) observed that Chinese corneal radii were smaller than those studied in Caucasian 
subjects, and although it is certain that this would give a more crowded anterior chamber and a 
higher predisposition towards the angle closure, it does not fully explain the reasons for the 
marked variation in prevalence. A recent publication by Leung, et al. (2010), stating that Chinese 
eyes have a smaller anterior chamber width and a thicker iris than Caucasian eyes, may help 
explain some differences. Additionally, Wang, et al. (2012) studied a group of American 
Caucasian, American Chinese and Mainland Chinese without angle closure. They observed that 
the anterior chamber depth decreased with age in all groups. However, the speed of shallowing 
was greater in the Chinese group. Caucasians also had a wider and deeper anterior chamber than 
in the Chinese groups. These anatomical factors may explain the greater predisposition to angle 
closure in the Chinese population. 
In addition, the rate of the disease among Chinese has been reported to be 10-15 times higher 
than Caucasians (Wang, Wu and Fan, 2002). This may be due to the fact that when compared to 
Caucasians, PACG among Asian ethnicities has been reported to be more frequently chronic and 
to have fewer symptoms (Lowe, 1988; Congdon, et al., 1996; Foster, et al., 1996; Rotchford, 
2005).  It must be mentioned this is in contradiction with a recent short review of the angle 
closure condition where acute presentations of angle closure were reported as approximately 
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three times more common in the Chinese population as compared to Caucasians (Friedman, 
Foster, Aung and He 2012). Friedman and colleagues also acknowledged the study by Day and 
Foster (2011) where the number of laser peripheral iridotomy procedures, phacoemulsification 
operations and incidence of acute angle closure (symptomatic rise of IOP) between 1998 to 2010 
in the UK was reported. In this report there was evidence of an increase in number of peripheral 
iridotomy and lens extraction procedures and a decrease in the incidence of acute angle closure 
during that period in the UK. It is, therefore, possible that a higher access to angle closure 
prophylactic surgery in countries of majority Caucasian ethnicity may have influenced the 
incidence of the acute form of this disease.  
 
1.9 Rate of progression of the angle closure condition, from PACS to PAC 
and PACG 
The risk of conversion among the untreated different pathological stages of primary angle closure 
has been previously reported in a 5-year study based in an Asian population. They observed that 
22% of their PACS participants progressed to PAC over a 5-year time period while 28.5% of PAC 
cases converted to PACG over the same period (Thomas, et al., 2003; Thomas, Parikh, Muliyil and 
Kumar, 2003).  Another study in Asian patients showed that, despite prophylactic treatment with 
peripheral iridotomy, 28.9% of PACS eyes progressed to PAC in a period of two years (Kumar, 
Baskaran, Ronnie and Vijaya, 2009). The authors gave information about the mean opening rate 
of the angle quadrants at various follow-up visits, but did not mention how many of these eyes 
were considered to remain occludable after the LPI. It is possible that those eyes progressing to 
the PAC state were occludable regardless of a patent iridotomy. 
Among the Inuit, the risk of progression from untreated PACS to PACG was estimated to be 35% 
over 10 years. Eight percent of those with anterior chamber angles diagnosed as non-occludable 
developed PACG (Alsbirk, 1992). While for Caucasians the lowest rates so far have been 
described; Wilensky found a rate of conversion of 19% from the PACS stage to PAC over a period 
of nearly 3 years (Wilensky, et al., 1993) 
Factors influencing the rate of progression: 
As explained above the rate of progression is different depending on the ethnicity and it seems to 
be directly related to their already predisposed ocular biometrical characteristics. However, there 
are some common factors that may affect the progression of the condition independently of the 
ethnicity. The difference in definition between PAC and PACS stages is the IOP level and the 
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evidence of appositional contact between the peripheral iris and the trabecular meshwork. Some 
authors support the idea of an existing inverse relationship between anterior chamber 
dimensions and higher levels of IOP fluctuation (Lowen, Liu and Weinreb, 2010). 
It is not that clear which factors influence the transition from PAC to PACG. Salmon (1999) 
explained that one possible mechanism was the prolonged contact between iris and trabeculum. 
Peripheral anterior synechiae may spread to gradually seal the angle. The concept of ‘creeping’ 
angle closure has also been described in which narrowing of the angle starts from the inner 
structures. It is considered a type of plateau configuration. In both mechanisms, Salmon suggests 
a raised IOP as the additional causative factor for the glaucomatous stage (Salmon, 1999).  
Raised IOP is considered to be highly associated with glaucomatous damage.  
There is some evidence supporting a relationship between a higher IOP diurnal fluctuation 
(difference between diurnal IOP peak and trough) and glaucomatous change. Gonzalez, et al. 
(1996) studied 149 eyes of 149 patients diagnosed with ocular hypertension at baseline. They 
found that patients presenting a diurnal IOP fluctuation at baseline higher than 5 mmHg were 
more likely to develop visual field defects in the next 4 years than those with a diurnal IOP 
fluctuation lower or equal to 5 mmHg. There is also some evidence showing a relationship 
between a rise in IOP due to a period in the supine position and a deterioration of the visual field 
in normal-tension glaucoma (Kiuchi, Motoyama and Oshika, 2006).  
It is possible that wide variations in IOP affect the progression towards a glaucomatous stage. 
However, there is no consensus on the effect the fluctuation of the mean IOP (mean of IOP 
measurement per follow-up visit) and the long-term IOP fluctuation (visit-to-visit fluctuation) 
might have. Asrani, et al. (2000) observed the diurnal IOP fluctuations for 5 days in 105 eyes 
diagnosed with open angle glaucoma. They found highest hazard ratios for severe visual field loss 
at baseline with maximal IOP standard deviation (18.38; CI 95%: 6.82%-49.50%) for the 5 days of 
study. When adjusting for visual field losses and age, the IOP still held important hazard ratios as 
shown by the diurnal IOP fluctuation (in this case, the difference between peak IOP minus the 
trough IOP; 5.69, CI 95%: 1.86%-17.35%) and the DIOP range for the 5 days (maximal mean DIOP 
minus minimal mean IOP; 5.76%, CI 95%: 2.21%-14.98%). The mean IOP measured (2 
measurements with applanation tonometry at the beginning and at the end of the study) held no 
relationship with progression of the glaucomatous visual field. The Advance Glaucoma 
Intervention Study (AGIS) studied the long-term IOP fluctuation (defined as the standard 
deviation of the IOP measured until visual field worsening or end of follow up) and the mean IOP 
in a group of open angle glaucoma cases. They found that this fluctuation was associated with a 
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higher probability of visual field progression and the mean IOP was of borderline statistical 
significance (Caprioli and Colleman, 2008). On the other hand, The Early Manifest Glaucoma 
studied a group of cases diagnosed with open angle glaucoma, exfoliation glaucoma and normal-
tension glaucoma. They found that the long-term glaucoma fluctuation was not an independent 
factor for glaucoma progression, but that the mean IOP was a strong predictor (Bengtsson, et al., 
2007).  
The aforementioned studies show that, while there is a significant amount of research in the area 
of IOP levels and their relationship with the onset or progression of glaucomatous changes in 
other types of glaucoma, there is a lack of information about the same factors in the case of angle 
closure. Furthermore, the only study about IOP diurnal fluctuation in primary angle closure has 
been performed in Asian treated eyes. Additionally, there is a lack of information about the effect 
of the laser peripheral iridotomy and laser peripheral iridoplasty for angle closure on the levels of 
diurnal IOP fluctuation. Given the importance of IOP fluctuation in the onset of glaucomatous 
changes in open and hypertensive glaucoma, this is a risk factor that needs investigation in angle 
closure.  
 
1.10 Treatments for the stages PAC and PACS: Cataract surgery, Laser 
Peripheral Iridotomy and Argon Laser Peripheral Iridoplasty 
All of these treatments in angle closure aim to widen the angle and consequently decrease the 
risk of progression of the condition. It is, therefore, of interest to investigate their effect on 
preventing the factors that influence progression. 
1.10.1 Cataract surgery  
Indicated when a PACS or PAC patient presents with a cataractous lens that has a significant 
impact on quality of life. Cataract surgery has been demonstrated to widen the angle as the 
crystalline lens is substituted by the much thinner intraocular lens. Additionally, cataract surgery 
has been demonstrated to have an effect on diurnal IOP reducing the diurnal maximums (peaks) 
and minimums (troughs) (Kim, et al., 2009). 
Although the benefits of cataract surgery in a patient with a cataractous lens and narrow angle 
are obvious, it is still unclear whether performing cataract surgery in patients with angle closure 
and clear lenses is of benefit (Thomas, Walland and Parikh, 2011). Laser peripheral iridotomy 
remains the first step in the treatment of PAC and PACS. An ongoing study on the effectiveness of 
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lens extraction in patients with high-IOP PAC and PACG is expected to yield further evidence in 
this area (Azuara-Blanco, et al., 2011). 
1.10.2 Laser Peripheral Iridotomy (LPI) 
The principle, on which the peripheral iridotomy is founded, is to create a new pathway between 
anterior and posterior chambers, therefore normalising the difference in pressures between 
these chambers causing posterior relaxation of the peripheral iris and widening the trabeculo-iris 
space (Jin and Anderson, 1990).  
There is some evidence that laser peripheral iridotomy performed as a prophylactic treatment has 
a positive effect in reducing the rate of progression of the angle closure condition (Nolan, et al., 
2003). It is common practice to treat PAC and PACG with LPI in the absence of a cataractous lens 
(where cataract surgery may be indicated). However, when it comes to the PACS stage, the 
clinical guidelines are not that specific and some clinicians may opt for monitoring the condition 
until it progresses to PAC (American Academy of Ophthalmology Glaucoma Panel. Preferred 
Practice Pattern®, 2010). A recent UK national survey, in which all UK-registered consultant 
ophthalmologists were invited to take part (n=650), showed that 74.7% of the 408 participants 
performed prophylactic LPI in asymptomatic patients presenting with narrow angles (Sheth, Goel 
and Jain, 2005).  
LPI is therefore used by the majority of consultant ophthalmologists in the cases of PACS and PAC 
in the UK. However, and as shown in the section above on prevalence of iris plateau, there is no 
consensus of when to review patients who have undergone LPI in different countries and 
ethnicities. This absence of guidelines may be due to the lack of information about the duration of 
the LPI widening effect. Presumably the longer the time that elapses between LPI and the review, 
the higher the likeliness of that eye to be diagnosed as unoccludable. Is there a relationship 
between rate of opening and time elapsed? Does this effect have a perennial duration? Is this 
relationship constant for all the quadrants in the angle or does it vary? The present study 
investigates these research questions. 
Additionally, it has been mentioned earlier that cataract surgery appears to dampen the peaks 
and troughs of the diurnal IOP. It is possible that as both, cataract surgery and LPI, have a 
widening effect on the angle, LPI may have an effect on the diurnal IOP fluctuation. This also 
remains unknown and is addressed in the present study. 
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1.10.3 Argon Laser Peripheral Iridoplasty (ALPI) 
When angle closure mechanisms other than pupillary block are present, the LPI alone may be 
insufficient to widen the irido trabecular space. ALPI may be indicated in these cases.  
The laser is focused in order to create low energy burns in the most peripheral iris stroma. These 
burns are larger and of a longer duration than those created with the LPI. The aim is to contract 
the iris tissues and mechanically pull the iris root from the periphery (Ritch, Tham and Lamb, 
2007). 
In Asian populations, ALPI seems to be an effective treatment in widening angles that remained 
occludable after the LPI. Leung, et al. (2005) describes one case with PACG using anterior segment 
imaging technology. In cases of PACG in the same ethnicity, ALPI has been successful in changing 
the configuration of at least 180 of the angle in all the treated eyes (Chew and Yeo, 1995). In a 
Caucasian population, a long-term study in the treatment of plateau iris configuration, showed 
that ALPI is not only successful in opening the angle but that this effect is long standing in the 
majority of the eyes (Ritch, Tham and Lam, 2004). However, a recent review about the ALPI has 
pointed out that there is an absence of randomised trials showing the effect of this laser (Ng, Ang 
and Azuara-Blanco, 2012).  
There is also some information regarding the IOP lowering effect (Chew and Yeo, 1995), but an 
effect of ALPI on the diurnal IOP fluctuation remains unknown.  
The present study assesses the effect of ALPI on randomised eyes in comparison with eyes that, 
although remained occludable after LPI, did not receive ALPI. This effect is assessed in terms of 
widening of the angle together with the effect on IOP. Details about more specific gaps in the 
knowledge regarding ALPI and how to address them are given in the following section. 
 
1.11 Gaps in the knowledge and how to address them  
1.11.1 Diurnal and postural characteristics of intraocular pressure in Caucasian 
patients with angle closure  
Raised IOP is a major risk factor for glaucoma and is the principal modifiable factor in the 
treatment of patients with and at risk of glaucoma. Measurement of IOP in the clinical setting 
usually involves a single measurement with the patient in an upright seated position. However, it 
is recognised that there can be considerable variability of IOP during the day (diurnal IOP 
fluctuation, DIOP fluctuation) in non-glaucomatous and glaucomatous eyes (Barkana, 2006; 
  
17 
 
Baskaran,et al., 2009; Realini, Weinreb, Wisniewski, 2010) and that changes in posture can also 
result in marked increase in IOP in eyes with (Yamabayashi, 1991) and without glaucoma (Lam 
and Douthwaite, 1997). The effect of a change in posture from seated to supine positions was 
measured in one of the research studies of this thesis (supine IOP test, SIOP), as was the effect of 
darkness in addition to a change in posture (the darkroom provocation test, DRPT). Given the 
considerable burden of patients diagnosed with angle closure in Caucasian populations, there is a 
need to investigate these IOP characteristics in individuals with occludable anterior chamber 
angles and the possible relationship with narrow angle features such as PAS. The research 
hypothesis and results for this investigation can be found in Section 3.1. (Chapter 3). These results 
provide clinicians with an evidence base to guide the diagnostic classification of patients and the 
management strategy associated with this. 
Chapter 3- section 3.1. reports a study of the IOP characteristics and its relationship with the 
presence of PAS in Caucasian untreated PAC/PACS eyes. 
 
1.11.2  Investigation of static and dynamic anatomical characteristics of 
eyes with gonioscopically occludable anterior chamber angles using ocular 
coherence tomography: Is there an association with IOP?  
Many clinicians use anterior segment imaging in addition to gonioscopy as a screening or 
diagnosis tool for occludable anterior chamber angles.  Most published literature involving 
Anterior Segment Ocular Coherence Tomography (AS-OCT) reports on the horizontal and vertical 
meridians of the eye when monitoring changes or making a diagnosis (Lavanya, et al., 2008; 
Mansouri, Burgener, Bagnoud and Shaarawy, 2009; Ang and Wells, 2010). It is unknown how 
representative these dimensions are of the entire circumference of the anterior chamber angle. 
After all, the established technique of gonioscopy, on which clinical management decisions are 
based, involves a decision made on visibility of the structures in each of the four quadrants of the 
angle. Therefore an important objective of this thesis was to investigate how meridians imaged by 
the OCT differed in dimensions within individual eyes. Additionally, the AS-OCT may be used to 
quantify the dimensions of the anterior chamber angle. Measurements of these dimensions 
allowed an investigation of the relationship between anterior chamber angle anatomy and 
characteristics of IOP (DIOP fluctuation, SIOP and DRPT) in the untreated occludable angle. These 
investigations can be found in Section 3.2. (Chapter 3) of this thesis. 
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1.11.3  Relationship between the degree of anterior chamber angle 
opening following laser peripheral iridotomy and time elapsed. Is there an 
association between angle widening and the intraocular pressure levels? 
 In general, the practice in the UK is to offer LPI as a prophylactic treatment for PAC and PACS 
(Sheth, Goel and Jain, 2005), although there is variability between centres in the gonioscopic cut-
off used to denote an ‘occludable angle’ and some clinicians will postpone a decision on 
treatment of PACS in favour of awaiting the development of symptoms of PAC. There also exists 
variation in the time that is allowed to lapse between the LPI and the subsequent review of the 
patient in clinic to assess if the treatment has been effective in opening the anterior chamber 
angle. Published research studies in Caucasian populations have reviewed such patients at 1 week 
(Marraffa, et al., 1995; Mansouri, Burgener, Bagnoud and Shaarawy, 2009), 1 month (López-
Caballero, et al., 2010), and another at approximately 6 weeks (Ang and Wells, 2010; 2011) post 
LPI. In a clinical-based environment, guidelines stating when to review these patients post LPI 
would be helpful. However, there may be considerable inter-individual variation in the degree of 
opening at different time points after LPI, with some anterior chamber angles remaining closed at 
1 week post-LPI but subsequently opening at a later stage, perhaps after 1 month or even 6 
months. ALPI is a laser procedure that may be offered to patients in whom the anterior chamber 
angle remains closed after LPI. Given that the clinical decision to perform an ALPI is based on the 
LPI outcome, it would be advantageous to know or to be able to predict from baseline data (angle 
parameters) when the degree of opening of the angle of a given eye has reached a maximal state 
following the LPI. Additionally, there has been no attempt to correlate an IOP change associated 
with the LPI with the change in angle parameters over time.  This information would be of use in a 
clinical situation where a patient with PAC, in which the IOP is raised at the time point of the 
clinical examination, may be considered for the prescription of IOP lowering agents. Studies have 
shown lower (López-Caballero, et al., 2010) or baseline IOP levels (Moster, et al., 1986) after LPI is 
performed (finding observed at 1 month and 1 week respectively). Additionally, a drop in IOP 
levels has been related to a widening of the anterior chamber angle 1 month after the LPI (López-
Caballero, et al., 2010). However, the relationship was not specified. One may hypothesise that 
IOP change and angular rate of opening are related. This is given consideration and investigated in 
Section 4.1. (Chapter 4) of this thesis. 
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1.11.4  Effect of the laser peripheral iridotomy on the diurnal intraocular 
pressure (DIOP) fluctuation after 6 months 
Section 4.2. (Chapter 4) is devoted to the study of the effect of the LPI on the diurnal IOP 
fluctuation. LPI has been shown to affect the IOP; therefore, one may expect that it would also 
have an effect over the DIOP fluctuation. Previous studies have compared DIOP fluctuation 
following LPI at different stages of angle closure (Baskaran, et al., 2009). The effect however, of 
LPI on DIOP fluctuation by comparing treated and untreated eyes with occludable angles, has not 
been assessed. 
 
1.11.5  Assessment of variability of the effect of the laser peripheral 
iridotomy depending on the angle section when using Ocular Coherence 
Tomography Technology 
Mansouri, Burgener, Bagnoud and Shaarawy (2009) found a wider effect of the iridotomy on the 
Superior and Nasal sections of the angle (where the iridotomy was commonly placed) than in the 
Inferior and Temporal when measured in light conditions. These results were assessed with 
Ultrasound Biomicroscopy (UBM) and may suggest a different effect of the laser depending on the 
angular section. Section 4.3. (Chapter 4) is designed to test the hypothesis that sectors closer to 
the iridotomy site would show a greater widening. 
 
1.11.6  Relationship between degree of angle opening post ALPI treatment 
and intraocular pressure and the effect of ALPI on the intraocular pressure 
diurnal fluctuation after 3 months 
Section 5.1. (Chapter 5) reports the investigation of the effect of ALPI on the anterior chamber 
angle parameters and IOP characteristics in eyes that remained with a gonioscopically occludable 
angle post-LPI. Although there are minimal studies involving ALPI, it has been reported that ALPI is 
an effective treatment in opening those angles with a plateau iris configuration with a resultant 
lowering of IOP (Leung, et al., 2005). This procedure is also used in the treatment of acute angle 
closure (Lai, et al., 2002). It might also be expected that ALPI would have an additional effect of 
reducing IOP diurnal fluctuation and this is investigated in Section 5.2. (Chapter 5).  
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1.11.7  Assessment of variability of ALPI effect depending on the angle 
sector 
It was hypothesised earlier that the effect of the LPI would be higher in those sections closer to 
the iridotomy site. The equivalent hypothesis for the effect of ALPI would be that the effect might 
be similar in all the sections when comparing with pre-ALPI baseline data. This is studied in 
Section 5.3. (Chapter 5) 
 
1.11.8  Effect of argon laser iridoplasty in addition to laser peripheral 
iridotomy on the corneal endothelium 
The effect of the Nd:YAG laser on the integrity of the corneal endothelium following LPI has been 
reported in several studies (Robin and Pollack, 1984; Kerr-Muir and Sherrard, 1985; Panek, Lee 
and Christensen, 1991; Marraffa, et al., 1995; Kozobolis, Detorakis, Vlachonikolis and Pallikaris, 
1998). These studies have reported a decrease in cell density (Robin and Pollack, 1984; Panek, Lee 
and Christensen, 1991; Marraffa, et al., 1995; Kozobolis, Detorakis, Vlachonikolis and Pallikaris, 
1998) and a change in cell morphology (Kozobolis, Detorakis, Vlachonikolis and Pallikaris, 1998) 
following LPI. 
 
However, the integrity of the corneal endothelium that follows a LPI and then a subsequent ALPI 
laser has not been studied. This sequence of laser treatments is often followed clinically when the 
LPI does not successfully open the angle, when assessed by gonioscopy. The LPI involves an 
Nd:YAG laser delivering laser energy to the iridotomy site and the ALPI, performed 3 months later, 
involves argon laser energy (heat) delivered to 20 to 24 burn sites along the 360 degrees of the 
iris periphery. The recovery of the endothelium following this combination of procedures remains 
uninvestigated. This is of importance as a damaged corneal endothelium may lead to future visual 
sequelae for the patient such as reduced vision due to corneal decompensation, and the 
enhanced risk of this complication following intraocular surgery, such as cataract surgery. This is 
the subject of Section 6.1 (Chapter 6). 
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CHAPTER 2. General Methodology 
 
2.1. Ethical Approval and National Institute for Health Research (NIHR) 
portfolio adoption 
Ethical approval by Cambridgeshire Research Ethics Committee (REC) for this study was obtained 
on the 3rd August 2010. REC Reference 10/H0301/14. This approval was reviewed by the 
Hinchingbrooke Research and Development Steering Group and had agreement to proceed on 
the 25thAugust 2010. 
This study progressed through the NIHR Coordinated system and entered on the National 
Institute for Health Research Clinical Research Network (NIHR CRN) Portfolio on 9th September 
2010.NIHR CRN Study ID: 8955. 
 
 2.2 Study Design 
This is a longitudinal, prospective, double randomised research study.  
The following graph (Figure 2.1) gives a simple overview of the participant pathway. 
 
 
Figure 2.1. Participant’s pathway in the study. Primary Angle Closure (PAC); Primary Angle Closure Suspects (PACS); 
Laser Peripheral Iridotomy (LPI); No Further Treatment (NFT); Argon Laser Peripheral Iridoplasty (ALPI). 
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Eligible patients were identified consecutively from new referrals to Hinchingbrooke Hospital 
Glaucoma Service and Moorfields Bedford Glaucoma Service from the community. A “Patient 
Information Leaflet” was given to the potential participant by the consultant ophthalmologist at 
the patient’s first visit.  The potential participants were contacted by telephone not earlier than 
twenty-four hours after the information was given. If the patient wished to participate, a visit was 
booked in order to answer possible questions about the research.  
In the first visit of the study, Visit 1, and after clarifying any concerns, patients were asked to 
provide informed consent. Full details were given to the patients including their right to withdraw 
from the study.  
A copy of the “Patient Information Leaflet” can be found in Appendix 4 of this document. 
A letter was sent to each participant’s General Practitioner to inform him/her about their 
patient’s participation. A copy of this letter can be found in Appendix 4 of the present document. 
Once the patient was decided to be eligible (eligibility criterion is specified in Section 2.5.3. of this 
chapter), both of his/her eyes were included in the sample. At baseline, Visit 1, 20 right eyes and 
20 left eyes were included in the statistical analysis.  
After the first visit the participants were randomised to receive LPI in either their right or left eye 
(Details about the randomisation process can be found in Section 2.7. of this chapter). Once these 
participants received the laser treatment they were booked into three further monitoring visits. 
 Three months after the LPI was performed, the consultant ophthalmologist made the clinical 
decision of whether the anterior chamber angle of the treated eye remained occludable by 
gonioscopy. An angle was considered to remain occludable if 180 degrees or less of the posterior 
pigmented trabecular meshwork was visible with applanation gonioscopy. If this was the case, the 
participant was further randomised into:  
a. No further treatment. The participant came to the exit visit three months later 
b. Argon Laser Peripheral Iridoplasty (ALPI). The participant received ALPI in the treated eye 
and was invited to attend three more monitoring visits 
If the anterior chamber angle was not occludable three months after the LPI, the participant came 
to the exit visit three months later. 
Further details about the visits are described in section 2.4 of this chapter. 
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The following CONSORT diagram shows a detailed pathway of how the participants and their eyes 
were followed through the study: 
 
 
Continues on next page  
Assessed for eligibility (93 patients) 
Excluded (53 patients): 
   Not meeting inclusion criteria (1 patient) 
   Declined to participate (48 patients) 
   Other reasons (4 patients) 
Data recorded (n=39 eyes) 
Female – n=27 (RE=14, LE=13) 
Male – n=12 (RE=7, LE=5) 
 
 
Allocated to intervention group  
(n=40 eyes) 
Female - n= 27 (RE=14, LE=13) 
Male - n= 13 (RE=7, LE=6) 
 
 
Allocated to control group  
(n=40 fellow eyes) 
Female - n=27 (RE=13, LE=14) 
Male - n=13 (RE=6, LE=7) 
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VISIT 4 
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VISIT 5 
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Data recorded (n=39 eyes) 
Female – n=26 (RE=14, LE=12) 
Male – n=13 (RE=7, LE=6) 
 
Data recorded (n=39 eyes) 
Female – n=27 (RE=13, LE=14) 
Male – n=12 (RE=5, LE=7) 
 
 
Data recorded (n=39 eyes) 
Female – n=26 (RE=12, LE=14) 
Male – n=13 (RE=6, LE=7) 
 
Data recorded (n=40 eyes) 
Female - n= 27 (RE=14, LE=13) 
Male - n= 13 (RE=7, LE=6) 
 
 
Data recorded (n=40 eyes) 
Female - n=27 (RE=13, LE=14) 
Male - n=13 (RE=6, LE=7) 
 
 
Data recorded (n=40 eyes) 
Female - n= 27 (RE=14, LE=13) 
Male - n= 13 (RE=7, LE=6) 
 
 
Data recorded (n=40 eyes) 
Female - n=27 (RE=13, LE=14) 
Male - n=13 (RE=6, LE=7) 
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Continuation 
 
Figure 2.2. Consort Diagram showing the pathway of participants in the study. ALPI= Argon Laser Peripheral Iridoplasty, 
NFT= No Further Treatment, RE= Right Eye, LE= Left Eye. 
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2.3 Visits Description and Schedule, Time Windows and Visits Duration  
Table 2.1 illustrate the tests and the visits when they were performed.   Table 2.2 shows the 
approximate time frames* for the visit. (*Time windows: referred to the flexibility of timing of the 
visit either side of the intended date) 
 
 VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT 
7 
VISIT 
8 
VISIT 
9 
VISIT 
10 
VISIT 
11 
Visual Acuity Measurement X X X X X X X X X X X 
Autorrefraction and Keratometry X     X     X 
Subjective Refraction X     X     X 
Visual Field X*          X 
Non-dilated Biomicroscopy X    X X X X  X X X X  
Retinal Photography X          X 
Heidelberg Retina Tomography  X          X 
Posterior Ocular Coherence Tomography X          X 
Supine Intraocular Pressure and Dark 
Room Provocation Test 
X     X     X 
Gonioscopy X     X     X 
Anterior Segment Optical Coherence 
Tomography (light and dark conditions) 
X  X X X X X  X X X X 
Specular Microscope X  X X X X X X X X X X 
Biomicroscopy and Indirect 
Ophthalmoscopy (dilated pupils) 
X      X     X 
Monitoring Intraocular Pressure  X X X X X X X X X  
Diurnal Intraocular Pressure  X          X 
Pre and Post Laser Intraocular Pressure  X     X     
Laser Peripheral Iridotomy  X          
Argon Laser Peripheral Iridoplasty  
 
 
 
 
     X     
Table 2.1. Tests and visits when they were performed. (X*- only carried out when the previous visual field was 
performed within more than one month or was unreliable). 
 
 
 
 
Table 2.2. Time lines for the different visits with their corresponding time window. 
 
 
 VISIT 1 VISIT 
2 
VISIT 3 VISIT 4  VISIT 5  VISIT 6  VISIT 7  VISIT 8  VISIT 9  VISIT 
10 
VISIT 
11 
TIME TO 
VISIT 2 4 to 8.5 
weeks 
 
R
EF
ER
EN
C
E 
 
 
      1  
day 
 
      1  
week 
 
6 
weeks 
 
12 
weeks 
14 
weeks 
14 
weeks 
+ 1 day 
15 
weeks 
20  
weeks 
 
24  
weeks 
 
TIME 
WINDOW   ±0 
±2 
days 
+/-1 
week 
+/-1 
week 
+/-1 
week 
±0 
±2 
days 
+/-1 
weeks 
+6 
weeks/ 
-5 days 
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2.3.1 Visit 1 (Training Visit) 
The following tests were performed as part of this visit: 
- Diurnal Intraocular Pressure (Every hour from 9:00 to 16:00 hours) 
- Measurement of Visual Acuity (Unaided/Habitual and Pinhole)  
- Autorefraction and Keratometry  
- Subjective Refraction 
- Measurement of the Best Corrected Visual Acuity 
- Visual Field (only if the previous visual field performed in the Eye Clinic was unreliable or older 
than 1 month) 
- Biomicroscopy (undilated pupil) 
- Supine Intraocular Pressure 
- Dark Room Provocation Test 
- Gonioscopy 
- Anterior Segment Optical Coherence Tomography (light and dark conditions) 
- Instillation of Tropicamide 1% 
- Retinal Photograph 
- Heidelberg Retina Tomograph  
- Posterior Segment Ocular Coherence Tomography 
- Anterior Segment Optical Coherence Tomography (dilated pupil) 
- Dilated Pupil Biomicroscopy 
- Indirect Ophthalmoscopy (dilated pupil) 
- Specular Microscope 
- Post Dilation Intraocular Pressure 
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A further explanation of all these tests can be found in Section 2.4 of this chapter. 
This visit took place 4 to 8.5 weeks prior to Visit 2  
The duration of the visit was approximately eight hours.  
 
2.3.2 Visit 2 (Laser Peripheral Iridotomy Visit) 
This visit was set as a reference for timing the rest of the visits. Therefore, this visit was assigned 
time zero.  
The following processes and tests were performed as part of this visit: 
- Measurement of Visual Acuity (Unaided/Habitual and Pinhole) 
- Monitoring Intraocular Pressure 
- First Randomisation 
- Instillation of Pilocarpine 2% in both eyes 
- Anterior Segment Optical Coherence Tomography (constricted pupil)  
- Laser Peripheral Iridotomy 
- Post Laser Intraocular Pressure  
- Specular Microscope 
 
The duration of this visit varied from one and a half hours to three hours. 
A further explanation of all these tests and the randomisation process can be found in Sections 
2.4 and 2.7 of this chapter respectively. 
 
2.3.3 Visits 3, 4 and 5 (Follow-up Visits) 
The same sequence of tests was performed at each of these visits.  
The tests aimed to monitor any biometrical or structural ocular changes occurring after the laser 
treatment. They were performed at one day, one week and one month after Visit 2, respectively. 
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No time window was allowed for Visit 3. There was a time window of plus/minus 2 days and 
plus/minus 1 week for Visits 4 and 5, respectively. 
The following processes and tests were performed as part of this visit: 
- Measurement of Visual Acuity (Unaided/Habitual and Pinhole) 
- Monitoring Intraocular Pressure 
- Biomicroscopy (undilated pupil) 
- Anterior Segment Optical Coherence Tomography (light and dark conditions) 
- Specular Microscope 
 
The duration of the visit was one hour each. 
A further explanation of all these tests can be found in Section 2.4. 
 
2.3.4 Visit 6  
Three months after Visit 2, the same consultant ophthalmologist determined if the anterior 
chamber angle of the treated eye was still gonioscopically occludable.  
The angle of the eye was considered to remain occludable if 180° or less of the posterior 
trabecular meshwork was obscured on applanation gonioscopy.  
Participants with a gonioscopically occludable anterior chamber angle post-LPI undertook the 
second randomisation process. This randomisation took place at the end of this visit (Visit 6), with 
assignment of these patients to receive ALPI or No Further Treatment (NFT). The participant was 
informed. 
The following tests were performed as part of this visit: 
- Measurement of Visual Acuity (Unaided/Habitual and Pinhole) 
- Autorefraction and Keratometry 
- Subjective Refraction 
- Measurement of the Best Corrected Visual Acuity 
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- Monitoring Intraocular Pressure 
- Biomicroscopy (undilated pupil) 
- Supine Intraocular Pressure 
- Dark Room Provocation Test 
- Gonioscopy 
- Second Randomisation Process (when was indicated)  
- Anterior Segment Optical Coherence Tomography (light and dark conditions) 
- Instillation of Tropicamide 1% 
- Anterior Segment Optical Coherence Tomography (dilated pupil) 
- Dilated Pupil Biomicroscopy 
- Indirect Ophthalmoscopy (dilated pupil) 
- Specular Microscope 
- Post Dilation Intraocular Pressure 
The duration of this visit was three and a half hours approximately. 
A further explanation of all these tests and the randomisation process can be found in Sections 
2.4 and 2.7 of this chapter respectively. 
 
2.3.5 Visit 7 (Argon Laser Peripheral Iridoplasty- ALPI) 
Participants with a post-LPI gonioscopically occludable angle who were randomly placed into the 
group which was going to undertake ALPI attended Visit 7 to receive the procedure. This visit took 
place 14 weeks after Visit 2. The time window for this visit was plus/minus 1 week. 
The duration of this visit varied from two to four hours  
The following tests were performed as part of this visit: 
- Measurement of Visual Acuity (Unaided/Habitual and Pinhole) 
- Monitoring Intraocular Pressure 
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- Instillation of Pilocarpine 2% in the treated eye 
- Argon Laser Peripheral Iridoplasty 
- Post Laser Intraocular Pressure  
- Specular Microscope 
A further explanation of all these tests can be found in Section 2.4 of this chapter. 
 
2.3.6 Visits 8, 9 and 10 (Follow-up Visits) 
These visits were only attended by participants who received ALPI; taking place one day, one 
week and 6 weeks after ALPI respectively.  
If these times are related to Visit 2, these visits were then performed fourteen weeks and one 
day, fifteen weeks and twenty weeks after Visit 2 respectively. 
These visits were a mirror of Visits 3, 4 and 5 and, as such, they were aimed to monitor changes 
following the ALPI.  
The time windows and tests of these are equal to those specified for Visits 3, 4 and 5, in the same 
order. 
 
2.3.7 Visit 11 (Final Visit) 
Taking place six months after Visit 2, this visit was designed as a replica of Visit 1 and the same 
data was collected. Every participant attended this visit. 
The duration was similar to that set for Visit 1 and the time window was plus 4 weeks /minus 1 
week.  
 
2.4 Tests and Instrumentation 
The following tests and instrumentation were used in this research project: 
2.4.1 Visual Acuity (VA): Distance and Near 
2.4.1.1 Distance VA (DVA) 
Four types of DVA were measured at the different visits: 
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- Unaided VA (UVA), measured in those participants who were not wearing any 
refractive correction. Performed in these participants at every visit 
- Habitual VA (HVA), only assessed in those participants who were wearing a 
spectacle/contact lens correction. Performed in these participants at every visit 
- Optimal VA (OVA) or Best Corrected VA (BCVA). This VA was measured after 
subjective refraction and with the results placed in a trial frame. Performed in every 
patient in Visits 1, 6 and 11 
- Pinhole VA (PHVA), performed in every patient at every visit 
A logMAR chart was used as it is widely accepted for clinical research (Ferris and Bailey, 1996) and 
it has been proven to give more accurate visual acuity measurements than Snellen chart (Lovie-
Kitchin, 1988). The continuous nature of the scaling of visual acuity means that LogMAR results 
are more suited for statistical analysis than Snellen visual acuity.  
Examination room lighting was set for the luminance of the chart to be between 80 and 320cd/m² 
(Elliot, 2007). This chart was placed 3 meters from the participant. Distance and illumination were 
kept constant throughout the study.  
The DVA was always measured monocularly. Right eye measurements were taken first. The 
untested eye was covered with an opaque handheld occluder.  
Distance visual acuity was measured at every visit during the research.  
 
2.4.1.2. Near VA (NVA): 
The NVA was measured with the optimal near distance subjective refraction result worn by the 
participant while performing this test.  
An N-print chart was used as a near vision adequacy measurement was considered to be 
sufficient. The chart was held by the patient at his/her usual reading distance. No angle poise 
lamp was used and the illumination of the room was kept the same throughout the study.  
 NVA was measured monocularly and the right eye was always tested first. 
The NVA was measured in every patient after subjective refraction was performed. This took 
place in Visits 1, 6 and 11.  
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2.4.2 Autorefraction and Keratometry:  
The Topcon Auto Kerato-Refractometer N141276 was used on account of its automated function 
and the fact that it was non-contact.  
At least three measurements were taken per eye. Each measurement contained information of 
the two corneal ratios (power/millimetres) and the auto refraction. The device gives an average of 
the measurements.  
The keratometry readings were necessary to obtain accurate measurement from the Heidelberg 
Retinal Tomograph (HRT). The use of the HRT will be explained later in this section. 
The autorefraction data was used to guide the start of the subjective refraction. 
 
2.4.3 Subjective Refraction 
The trial frame method using the plus/minus technique was chosen for best vision sphere 
determination and the Jackson cross-cylinder technique to accurately determine astigmatism.  
The subjective refraction was performed monocularly with the exception of the near assessment 
where a binocular tentative reading addition technique was used. 
Subjective refraction was performed in every participant in Visits 1, 6 and 11.  
 
2.4.4 Visual Field 
Humphrey- Field Analyser was used. MODEL 745 S/N:7451-5247. Carl Zeiss. Meditec Inc. Dublin, 
CA.USA 
Two 24-2 SITA Fast Visual Field (VF) tests were performed as part of the study.  
The first VF was performed at the time of recruitment, during Visit 1, or within the previous 
month. The second VF was performed at the end of the study, during Visit 11.  
The aim of performing the first VF test was to decide whether the patient was eligible to 
participate in the study and for use as base line data. The aim of the second VF test was to 
determine repeatability of the first VF test. 
  
33 
 
If the VF was unreliable*, the test was explained again to the participant and it was repeated. If 
the VF was unreliable a second time, the participant was booked for an alternative date as soon 
as possible for repeat testing.  
*A VF plot was considered reliable when: 
- Fixation Losses (FL) <20% 
- False Positives (FP) <15% 
 
2.4.5 Biomicroscopy 
The device used was a BQ 900 mobile slit lamp, Haag-Streit International. The same device was 
used throughout the study for all participants. 
2.4.5.1 Undilated Pupil Biomicroscopy examination: 
- Assessment of eyelids: to evaluate if there was upper eyelid retraction (exclusion 
criterion) 
- Assessment of cornea: to grade anomalies such as Krukenberg´s spindle or posterior 
embryotoxon. 
- Assessment of iris: in terms of thickness, colour, transillumination or any other 
relevant information 
- Assessment of pupils: to assess for the presence of a Relative Afferent Pupillary 
Defect (RAPD) 
- Assessment of the angle using the Van Herick Technique. This measurement was 
performed and recorded using the modified Van Herick Technique proposed by 
Foster, et al., 2000) 
 
This test was performed in every visit with the exception of Visits 2 and 7. 
 
2.4.5.2 Dilated Pupil Biomicroscopy examination: 
- Assessment for the presence of pseudoexfoliative material 
- Cataract assessment using the LOCS III, (Chylac, et al., 1993): 
Degree of nuclear, cortical and posterior subcapsular cataract 
 This test was performed in conjunction with the fundus examination (Section 2.6.14 of 
this chapter) and when the participant had her/his pupils dilated on Visits 1, 6 and 11.    
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2.4.6 Intraocular Pressure (IOP) measurement:  
The IOP was measured with the Goldman Tonometer HS Haag-Street International AT900. 
The Goldman Tonometer is considered the benchmark tonometer for research studies.  
 
Only disposable probes were used to reduce the risk of cross-contamination.  
The same tonometer was used for every IOP measurement for every participant. Care was taken 
in checking the tonometer was calibrated at the beginning of every week. No calibration errors 
were found throughout the study. 
Every measurement was taken twice in the same eye. In order to maintain the reliability of the 
results, the measurements must have been only 1 mmHg difference between them.  
One drop of Proxymetacaine 0.5% and Fluorescein 0.25% was instilled prior to every IOP 
measurement. 
As is the case with other topical ocular anaesthetics, proxymetacaine can cause an inhibition of 
the blinking reflex and make the eye vulnerable to trauma. To decrease this risk one drop of saline 
was instilled in each eye after every IOP measurement. 
 
2.4.6.1 Monitoring IOP 
This test was performed once at the beginning of the Visits 3, 4, 5, 6, 8, 9 and 10. 
2.4.6.2 Diurnal IOP  
In Visit 1 and Visit 11, IOP was measured every hour from 9:00h to 16:00h. A time window of  15 
minutes around the o’clock times was considered acceptable. 
2.4.6.3 IOP 45 minutes post laser 
In Visit 2 and Visit 7, the IOP was measured before and 45 minutes after the laser procedure. This 
was considered a safe measurement as IOP has been reported to achieve a peak 1 hour after this 
type of laser intervention (Moster, et al., 1986). 
2.4.6.4 IOP 40 minutes post dilation 
An additional measurement was taken 40 minutes after instilling Tropicamide 1 % at the end of 
the same visits. This was considered a safe measurement as IOP has been reported to achieve a 
peak 40 minutes after instillation of this drug (Marchini, et al., 2003). 
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2.4.7 Dark Room Provocation Test 
The room luminance was adjusted to less than 0.1 lux. The level was measured with the ISO-Tech 
RS-1332A Digital Lux Meter (Range 0.01-20000 lux) 
The patient was precisely instructed on the dynamics of this test as measurements of the IOP 
needed to be taken immediately before and after the test.  A single IOP per eye was measured 
while the participant was seated, no more than 1 minute after this measurement, the participant 
laid prone for 15 minutes. The IOP was then immediately measured in each eye in the seated 
position.  
Participants were awake during the test. 
Several studies have used a longer version of this test as a diagnostic tool for acute attacks of 
angle closure; Wilensky, et al. (1993) 45 minutes; Ishikawa, et al. (1999) 1 to 2 hours. However, a 
shorter duration was chosen to be able to compare results with the ZAP study (The Zhongshan 
Angle Closure Prevention Trial, Iridotomy for the Prevention of Angle Closure in Southern China), 
(Jiang, et al., 2010). 
This test was performed in Visits 1, 6 and 11. 
 
2.4.8 Supine Intra Ocular Pressure (SIOP) measurement:  
Measured with the Perkins Tonometer MK2 by HS Clement Clarke International SN T12360. 
The participant was asked to lay supine. After 5 minutes, the IOP was measured while the 
participant was resting in the same position.   
Only one measurement per eye was taken. 
This test was performed in Visits 1, 6 and 11. 
 
2.4.9 Gonioscopy and Angle Evaluation 
Gonioscopy was performed with and without indentation; the Zeiss Four Mirror lens and the 
Magnaview lens were used respectively. 
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As a more detailed gonioscopy was required for this thesis study, the Spaeth Gonioscopic Grading 
System was used (Marsh and Cantor, 2005). 
The same consultant ophthalmologist, with extensive gonioscopy experience, performed this 
gonioscopy, as the interpretation of the gonioscopical view can be extremely subjective.  
This test was performed in Visits 1, 6 and 11. 
 
2.4.10 Anterior Segment Imaging:   
Cornea/Anterior Segment Optical Coherent Tomography: CASIA SS-1000, Tomey GmbH.  
This device is a three-dimensional corneal and anterior segment optical coherence tomography 
(ASOCT) based on Swept Source OCT techniques which provide a faster acquisition of scans 
(30000 A Scans/second). This increase in speed provides a higher resolution of the two-
dimensional images and the possibility of building three-dimensional ones. This system achieves 
high resolution imaging of 10 μm (Axial) and 30 μm (Transverse).  
This technology and its advantages over time domain (used in the Visante OCT Carl Zeiss Meditec, 
Inc.) were explained in a study by Yasuno, et al. (2005; 2009). In the case of our study, this new 
resolution was translated in a more accurate identification of the scleral spur by the examiner. 
The CASIA OCT is equipped with storage and analysis software (Version 6H). This software 
provides angle analysis (semi-automated analysis) with the possibility of assessing the angle 
opening distance (AOD), the trabecular-iris angle (TIA) (Pavlin, Harasiewicz and Foster, 1992), the 
angle recess area (ARA) (Ishikawa, et al., 1999) and the trabecular iris space area (TISA) 
(Radhakrishnan, Huang and Smith, 2005). These parameters were measured at 500 and 750 
microns from the Scleral Spur. A visual representation can be found in the following figure (Figure 
2.3). 
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Figure 2.3. Irido-trabecular angle parameters as measured with the CASIA AS-OCT analysis software. AOD (Angle 
Opening Distance), ARA (Angle Recess Area), TISA  (Trabecular-Iris Space Area) and TIA (Trabecular-Iris Angle) at 500 
and 750m are highlighted in bright green colour. SS (in yellow ink)=Scleral Spur; AR (in red ink)=Angle Recession. 
These dimensions can be analysed in up to 360° of the irido-trabecular angle. For an example of a 
scan taken with the CASIA, please see Figure 2.4. 
The software automatically detects the front and posterior cornea and front iris profile. However, 
if this trace is not accurate, it can be manually modified.  
The scan range was 16x16x6mm. 
 
Figure 2.4. Image scan taken with the CASIA OCT. It shows a horizontal cut of the anterior chamber (Nasal and Temporal 
sections of the angle of a Left Eye). SS=Scleral Spur; AR=Angle Recession. AOD (mm)=Angle Opening Distance. ARA 
(mm
2
)=Angle Recess Area; TISA (mm
2
)= Trabecular Iris Space Area; TIA ()= Trabecular-Iris Angle. 
500m 
TISA TIA 
 
AOD ARA 
 
750m 
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Testangle Radial Scan was set as default analysis as it was the scan providing the highest 
resolution, 10µm. This scan consisted in 512 A/B scans plus 256 B/C scans 
The duration of the acquisition was 4.6 seconds and the participant’s upper eyelid was held 
during the test. Care was taken to not to put any pressure on the eyeball as this would have 
modified the result. Proxymetacaine 0.5% and Fluorescein 0.25% was used only if the participant 
experienced difficulty maintaining his/her eye open for the required image acquisition time. 
A scan was considered valid only if the scleral spur was visible throughout 360 degrees of the 
angle circumference. This was assessed immediately after every scan. If the scan failed in the 
validity criteria, it was re-taken after allowing the participant to recover for several seconds. 
 
A scan sequence per eye was performed in the following light conditions: 
2.4.10.1 Non dilated pupil in dark conditions 
Dark conditions were set as a luminance of no higher than 0.5 lux. A lower luminance level was 
not possible due to the residual light coming from the device computer screen. 
To accurately measure the luminance, the lux meter (described in section 2.4.8) was placed in the 
same location where the participant´s eye was going to be situated. The luminance was measured 
prior to every measurement and it was maintained throughout the study. 
This scan was taken in every visit with the exception of Visits 2 and 7. 
 
2.4.10.2 Non dilated pupil in light conditions 
Light conditions were set as 150-200 lux (Recommended by CIBSE (2002) as Places of Public 
Assembly and General Areas Illumination). To achieve this level of luminance an extensible 
ceiling-attached angle poise lamp was used. The angle of the lamp was modified until the desired 
luminance was achieved. 
The procedure of how the light was measured is equal to that described in section 2.4.10.1 
This scan was taken at every visit with the exception of Visits 2 and 7. 
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2.4.11 Imaging of the Corneal Endothelium 
For this propose a non-contact device was chosen, the EM-3000 Specular Microscope by Tomey 
GmbH. This testing unit was formed by 2 systems: 
 
A. Tomey EM-3000 Specular Microscope (SM) 
            This is the microscope that acquires the images of the corneal 
endothelium 
 
B.   Tomey Analysis and Storage Software: VS-100 
   External software connected to the EM-3000 SM. 
 
This instrument is a non-contact auto focus device. 7 images per eye were taken. The participants 
were asked to look in the following directions (Figure 2.5): 
 
 
 
 
      
 
 
 
Figure 2.5. Sequence followed by the examiner when testing with the specular microscope. 
 
The endothelial sampling was always started with the participant looking at the central target 
followed by the sequence indicated by the arrow in the previous figure.  
For every position tested, the device gave 15 different images that were temporarily recorded for 
the examiner to make a choice. Only one shot per position could be stored, therefore the decision 
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on which image to retain was made immediately after taking the measurement. The image with 
the highest number of cells images and the highest contrast was chosen.  
Once the image is selected the information is saved in the storage device in three different 
formats: 
- Jpeg picture of the EM-3000 SM automated analysis (Figure 2.6). This analysis 
provided the following information: 
Number :          The number of analysed endothelial cells 
CD :                 The density of the analysed endothelial cells 
   (Number of cells per mm2) 
AVG :                The average dimension of the analysed 
endothelial cells 
 
SD :                  The standard deviation of the analysed 
   endothelial cell dimensions 
 
CV :                  The coefficient of variation of the analysed 
   endothelial cells, derived by dividing the 
   average dimension by the standard deviation 
 
Max :                The dimension of the largest analysed 
   endothelial cell 
 
Min :                 The dimension of the smallest analysed 
   endothelial cell 
 
Area (Polymegathism): expressed as a percentage  
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Apex (Pleomorphism): expressed as a percentage 
Corneal Thickness: only given when testing central corneal endothelium 
 
- CSV file containing the information shown in the Jpeg file 
- Exam data storage file. Only to be read with the Tomey Analysis and Storage Software 
VS-100 
 
 
 
 
 
 
Figure 2.6. Screen shot of the specular microscopy performed with the Tomey 3000 in central cornea of the left eye of 
the participant. The abbreviations in this image have already been discussed in the previous page. 
 
Specular Microscopy of the corneal endothelium was performed at every visit. This means that 
some participants had this test performed on 7 and some on 11 different occasions. These testing 
times were chosen following the findings of the study by Kozobolis, Detorakis, Vlachonikolis and 
Pallikaris (1998) that reported changes to the endothelium following laser.  
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2.4.12 Indirect Fundus Examination 
Performed in both eyes when the participant had dilated pupils (Tropicamide 1%). The same slit 
lamp described in section 2.4.6 was used in conjunction with a fundoscopy lens of 66 Diopters. 
The assessment included: 
2.4.12.1 Assessment of the Optic Nerve Disc: 
Cup/disc ratio 
ISNT rule 
Vertical Disc Diameter 
Presence of Nerve fibre layer haemorrhages 
Presence of Nerve Fibre Layer Defect  
Presence of Neuroretinal Rim (NRR) Thinning 
 
2.4.12.2             Assessment of the Macular area: 
Presence of any abnormality 
2.4.12.3             Assessment of the peripheral Retina: 
Presence of any abnormality 
     
2.4.13 Posterior Segment Imaging 
2.4.13.1 Fundus photography: 
Topcon TRC NVV65 Non-Mydriatic Retinal Camera   
2.4.13.2 Retinal Tomography: 
Heidelberg Retinal Tomograph (HRT) by Heidelberg Engineering HRTI 
2.4.13.3 Posterior Segment Optical Coherent Tomography: 
OCT Spectralis by Heidelberg Engineering HRTI 
 
Posterior segment imaging was performed on Visits 1, 6 and 11.  
The aim of these imaging tests was to be able to keep an objective record of the retinal and optic 
nerve function.  
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2.4.14 Laser Peripheral Iridotomy (LPI) 
Nd:YAG Laser VISULAS YAG II plus Zeiss ZIP by Zeiss Meditec 
The LPI was always performed by the same consultant ophthalmologist (RB) throughout the 
study. 
The dynamics of this procedure are explained as follows: 
2.4.14.1 Prior to the LPI: 
- Pilocarpine Hydrochloride 2% was instilled in both eyes at least 20 minutes before the laser 
  - Consent for the laser procedure was taken by the consultant 
- One drop of Iopidine was instilled in the eye that randomly selected to undergo the laser 
treatment 
 
2.4.14.2 During the LPI, the following information was recorded: 
  - Time the procedure took place at 
  - Power range (Minimum/Maximum) 
  - Total power used 
  - Number of shots 
  - Complications during the procedure 
  - Name of the professional who performed the test 
 
2.4.14.3 After the LPI: 
- 250mg Diamox tablet was given to the patient immediately after the laser was performed 
- Maxidex was prescribed to be applied every hour the first day and every four hours during the 
following week 
 
This procedure dynamic complies with that describe in the Nd:YAG Peripheral Iridotomy clinic 
guidelines developed by the Department of Ophthalmology at Hinchingbrooke Hospital NHS 
Trust, November 2008, Version 3. 
 
Information regarding the concentration of the drugs used can be found in section 2.6.18. A brief 
description of possible secondary effects of the drugs was given to the participant. 
This laser took place in Visit 2.  
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2.4.15 Argon Laser Peripheral Iridoplasty (ALPI) 
Lumenis Novus Specta by Lumenis Gmb. 
This laser device was formed by two units: 
- The laser power generator 
- The laser link, which was adapted into a Haag Streit Bern M90045409 Slit Lamp 
The laser ALPI was always performed by the same consultant ophthalmologist (RB) throughout 
the study. 
 
The dynamics of this procedure are explained as follows: 
2.4.15.1 Prior to the ALPI: 
- Pilocarpine Hydrochloride 2% was instilled only in the eye that was going to receive the 
procedure. This drop was administrated at least 20 minutes before the laser 
- Consent for the laser procedure was taken by the consultant 
 
2.4.15.2 During the ALPI, the following information was recorded: 
 - Time the procedure took place at 
 - Power range (Minimum/Maximum) 
 - Spot size 
 - Duration of each shot 
 - Number of shots 
 - Complications during the procedure 
 - Name of the professional who performed the test 
 
2.4.15.3 After the ALPI: 
- Pred Forte was prescribed to be instilled 4 times/day for a week 
- Pilocarpine Hydrochloride 2% was prescribed only if peripheral anterior synechiae were present. 
To be instilled 3 times/day for a week 
 
2.4.16 Eye Drops and Pre/Post-laser Medication 
- Minims ® Proxymetacaine 0.5% and Fluorescein 0.25%(B&L)  
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- Minims® Saline (B&L)  
- Minims ® Tropicamide 1% (B&L)  
- Pilocarpine Hydrochloride 2% (Non- Proprietary) 
- Maxidex ® Dexamethasone 0.1% and Hypromellose 0.5% (Alcon) 
- Diamox ® (Acetazolamide 250mg)- Oral administration 
- Iopidine ® (Apraclonidine 1%) 
- Pred Forte ® (Prednisolone acetate 1%) 
The use and doses of these drugs has been described in previous sections of this chapter. 
This laser procedure is identical to that used in the Clinical Safety of Hinchingbrooke Hospital 
Guidelines. 
 
2.5 Participants 
2.5.1 Sample size calculation 
At the time this study was designed (January 2010), the literature review related to this study 
aims showed very few studies in this subject area 
In order to justify a sample size of 40 participants, the most similar published studies to the 
present aims and their sample size are specified in the following table. The sample power was set 
at 80% as this was considered reasonable and the alpha was set at 0.05 to achieve statistical 
significant differences of 5%. 
The mean differences to be detected were chosen either from the published literature when it 
was available, or if unavailable, it was decided to consider the minimal detectable difference for 
the given parameter in a clinical setting (the minimal difference detectable in IOP with Goldmann 
tonometer is 1mmHg). None of the publications mentioned in the table below showed standard 
deviations or standard errors for the mean differences found in their outcomes, therefore the 
widest standard deviations (SD) specified in the publication descriptive statistics were chosen to 
calculate the effect on the sample size calculation. 
When several parameters for the same outcome could have been chosen from the same 
publication, only those giving the larger sample size are shown in Table 2.3. 
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Present Study Research  
Outcome 
Sample 
required 
Mean difference to be 
detected (SD) 
Author Sample 
characteristics 
Diurnal Intraocular Pressure 
Profile 
n=12 eyes 1mmHg (0.5) Liu, et al., 1999 21 healthy 
individuals of 
mixed ethnicity 
without ocular 
pathologies 
Supine Intraocular Pressure n=52 eyes 2mmHg (2.25) Lam and 
Douthwaite, 1997 
33  Chinese 
healthy individuals 
without ocular 
pathologies Dark Room Provocation Test n=12 eyes 6mmHg (3.27) 
Diurnal Intraocular Pressure 
Fluctuation 
n=12 eyes 4.53 mmHg (2.33) Baskaran, et al., 
2009 
119 participants 
enrolled after LPI. 
Most subjects 
were Chinese (32 
PACS, 34 PAC and 
32 PACG 
Change in angle parameters due 
to change in lighting conditions 
n=12 eyes AOD 500=146m (82) Leung, 2007 18 Chinese 
subjects with 
narrow angles  
n=24 eyes TISA 500=0.05mm
2
 
(0.04)
 
Change in angle parameters due 
to the effect of the LPI 
n=70 eyes Superior TIA= 4.29 
(6.3) 
Mansouri, 
Burgener, 
Bagnoud and 
Shaarawy, 2009 
35 eyes of 28 
European 
participants: 
19 PAC  
16 PACG 
Superior AOD 500= 
0.056m (0.08) 
Change in the Intraocular Pressure 
due to the effect of the LPI 
n=100* 1.9 mmHg (3.3) Lei, Wang, Wang 
and Wang, 2009 
15 eyes of 15 
Chinese PAC 
patients 
Change in the Intraocular Pressure 
Fluctuation due to the effect of 
the LPI 
n=? No publications No publications 
Change in angle parameters due 
to the effect of the ALPI 
n=? No publications No publications 
Change in the Intraocular Pressure 
due to the effect of the ALPI 
n=18 8.57 mmHg (5.94) Chew and Yeo, 
1995 
11 PACG eyes 
already treated 
with LPI. All the 
eyes were under 
ocular -blockers 
and pilocarpine. 
Change in the Intraocular Pressure 
Fluctuation due to the effect of 
the ALPI 
n=? No publications No publications 
Change in Central Corneal 
Thickness due to the effect of the 
LPI 
n=20 0.011mm (0.008) Kozobolis, 
Detorakis, 
Vlachonikolis and 
Pallikaris, 1998 
10 eyes of 10 
participants 
(AAC fellow eyes; No 
ethnicity specified) 
Change in Endothelial Cell Density 
due to the effect of the LPI 
n=46 170 cells/mm
2
 (199.67) 
Change in Endothelial 
Polymegathism due to the effect 
of the LPI 
n=220 46.2 m
2 
(120.295) 
Change in Endothelial 
Pleomorphism due to the effect of 
the LPI 
n=68 5% (7.177) 
Change in Central Corneal 
Thickness due to the effect of the 
ALPI 
n=? No publications No publications 
 
 
   Table continues in next page 
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Table 2.3. Sample size calculation for statistically differences of 5% and a power of 80% for the different research 
outcomes. 
 
*(n=100 as required sample); To have a sample of 70 eyes in this case reduces the power of the 
sample to a 65%. 
** In this publication a change of 0.041% was reported as a non-statistically significant change in 
hexagonality rate after the Argon Laser Trabeculoplasty when compared to baseline. To detect a 
statistically significant difference of this magnitude a sample of 1550396 eyes would be needed. A 
change of 5% was decided to be sufficient for detection of change in hexagonality rates. 
As can be observed in Table 1, the sample size required often exceeded the sample of the present 
study (80 eyes at baseline; 40 eyes for assessing LPI effect (after 1st Randomisation); 7-8 eyes for 
assessing ALPI effect (After 2nd Randomisation)). In spite of this, the published studies from which 
this data was withdrawn had a smaller sample than the present study, the main reason for this 
being the lack of information about standard deviations for the mean differences in published 
literature. It is additionally rare to find the mean differences published even when these are 
reported as statistically significant. In the case of the studies listed in the table above, only the 
descriptive statistics and the p values were given. The standard deviation used for calculating the 
sample size required in the present study for every outcome was the highest specified by the 
descriptive statistics of the same reported outcomes. Therefore, it is possible that this sample 
calculation was overestimating the sample required. 
It was of interest for the present study to have an approximation of what would be the power of 
detection given by a sample of 80 eyes at baseline. This was calculated only for those outcomes in 
which the “calculated sample” was larger than the present sample. The results can be found in 
Table 2.4 (bellow). For the outcomes related to the effect of the LPI the sample size of the present 
study was adequate. The sample of eight eyes for the study of the effect of the ALPI on the 
Change in Endothelial Cell Density 
due to the effect of the ALPI 
n=78 
 
106 cells/mm
2
 (161) 
 
Thoming, Van 
Buskirk and 
Samples, 1987 
 
 
Rates reported for 
Argon laser 
Trabeculoplasty. 
-20 eyes of 17 
participants with 
Open Angle 
Glaucoma 
-No statistically 
significant 
differences were 
found 
Change in Endothelial 
Pleomorphism due to the effect of 
the ALPI 
n=106** 5% (9.08) 
Change in Endothelial 
Polymegathism due to the effect 
of the ALPI 
n=58 18m
2 
(24) Hong, Kitazawa 
and Tanishima, 
1983 
10 eyes with Open 
Angle Glaucoma 
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endothelium may have been insufficient for the study of the endothelium. At the outset of the 
study, the number of eyes to be randomised into the ALPI allocation was unknown. 
 
Table 2.4. Power of detection by a sample size of 80 eyes at baseline. The minimal clinical difference is the same as 
described in Table 2.3 and the levels for statistical significance remain at 5%. 
 
2.5.2 Enumeration of participants 
Participants recruited for this research study were identified from consecutive eligible patients 
attending as new referrals to the Department of Ophthalmology at Hinchingbrooke Hospital NHS 
Trust, Huntingdon, Cambridgeshire, UK (the study centre). 
To facilitate recruitment, permission was granted for Moorfields Bedford to act as a Patient 
Identification Centre patients to the ophthalmology department at Hinchingbrooke Hospital, 
Huntingdon. The recruitment for this site started on 30th of March 2011.  
The total recruitment period took place from 25th of August 2010 to 25th of April 2011. The first 
participant was recruited on 6th of October 2010 and the last on 15th of April 2011. 
Ninety-three patients diagnosed with PACS and/or PAC in either eye were invited to participate in 
the study. Fifty-three of these patients declined participation. The recruitment period, initially set 
at three months, was extended to eight months in order to achieve a sample size of at least forty 
participants.  
From the 40 participants recruited, 27 were female and 13 were male. The average age in the 
group was 59,6 years at the time of recruitment (range 25-77 years). 
Outcome Present Sample Power of detection  
Change in angle parameters due to the effect of the LPI n=40 67% to 70% 
Change in the Intraocular Pressure due to the effect of the LPI n=40 55% 
Change in the Intraocular Pressure due to the effect of the ALPI n=8 56% 
Change in Endothelial Cell Density due to the effect of the LPI n=40 84% 
Change in Endothelial Polymegathism due to the effect of the LPI n=40 32% 
Change in Endothelial Pleomorphism due to the effect of the LPI n=40 69% 
Change in Endothelial Cell Density due to the effect of the ALPI 
n=8 
 
21% 
Change in Endothelial Pleomorphism due to the effect of the ALPI n=8 24% 
Change in Endothelial Polymegathism due to the effect of the ALPI n=8 17% 
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All were Caucasian. 
At the time of recruitment, 23 participants were diagnosed with bilateral PAC, 14 with bilateral 
PACS and 3 with a combination of both conditions.  
 
2.5.3 Inclusion and exclusion criteria: 
2.5.3.1. Eligibility and Inclusion Criteria  
Consecutive patients newly diagnosed with either PACS or PAC in both eyes (or PACS in one and 
PAC in the fellow eye) according to the gonioscopic definition of an occludable angle (posterior 
pigmented trabecular meshwork visible in 180 degrees or less of the circumference of the 
anterior chamber angle on applanation gonioscopy) were invited to participate in the study.  
2.5.3.2. Exclusion Criteria  
- Patients with any ophthalmic co-morbidity other than cataract with an important 
influence on visual field deterioration or optic nerve head damage 
- Patients included in other glaucoma therapeutic studies 
- Patients with PAC with an IOP of ≥30 mmHg in either eye 
- Patients with upper eyelid retraction 
- Patients who have undergone cataract surgery 
- Inability to give consent (where applicable) 
- Patients with no capacity to consent (Mental Capacity Act) 
 
2.6 Study endpoints 
2.6.1 Intraocular Pressure 
If the IOP was higher than 35mmHg in either eye measured on two successive occasions the 
participant was subsequently withdrawn from the study.  
 
This cut-off was chosen with respect to the Guidelines for the Management of Open Angle 
Glaucoma and Ocular Hypertension, 2004, Royal College of Ophthalmologists. “A constant IOP 
over 35 mmHg merits treatment as at these levels mechanical damage occurs to the optic nerve 
head”. 
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2.6.2 Glaucomatous Optic Neuropathy 
The second study endpoint was described as a glaucomatous visual field defect or glaucomatous 
optic nerve appearance as defined in the UK Glaucoma Treatment Study.  
 
2.7 Randomisation Process 
The randomisation process was designed prior recruitment and it was formed by two different 
randomisations. 
For doing this, the following information was taken in account: 
 
70 potential participants to be recruited 
(Data obtained through estimation of flow of patients diagnosed with bilateral PAC/PACS at  
The Department of Ophthalmology at Hinchingbrooke Hospital NHS Trust) 
 
Only one eye of these subjects to be treated 
 
Participants to be randomised into Right Eye treated or Left Eye treated with LPI 
FIRST RANDOMISATION 
 
 
 
Based on previous studies 20% to 43% of the irido-trabecular angles would not open (Thomas, et 
al., 1999; Kumar, et al., 2008) 
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Taking in account the most restrictive scenario (20% do not open), this would have given 14 
participants 
 
 
 
Participants to be randomised into “Further treatment (ALPI)” or “No further treatment” 
SECOND RANDOMISATION 
 
 
2.7.1 First Randomisation 
A random sampling of numbers was generated by computer software. 
This random sampling unsorted set of unique numbers ranged from number 1 to number 70. 
As an example, the following set was generated by the software: 
 
SET : 43, 52, 18, 32, 17, 21, 62, 31, 56, 20, 46, 22, 28, 13, 64, 66, 51, 45, 48, 54, 53, 44, 9, 29, 30, 
34, 4, 65, 49, 10, 37, 7, 50, 27, 19, 35, 67, 59, 61, 26, 24, 15, 60, 57, 39, 14, 23, 3, 36, 16, 11, 55, 2, 
40, 38, 12, 41, 42, 33, 6, 68, 69, 1, 25, 8, 63, 47, 58, 70, 5 
 
Right Eye was identified with the even numbers and the Left Eye with odd numbers. 
 
Random Set 
Number 
Participant’s 
study number 
Eye to be 
treated 
43 1001 Left Eye 
52 1002 Right Eye 
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18 1003 Right Eye 
 
The information relating to the “Participant’s number” associated to the “Eye to be treated” was 
placed in envelopes at the beginning of the study and before the recruitment. 
 
The envelope was only identifiable by the participant’s study number. 
The “Form 1”was kept inside the envelope. The only information written in this form at that point 
was the patient study number and the eye which was assigned the laser procedure. 
A copy of Form 1 can be found in the Appendix 4. 
A person external to the research team carried out the randomisation. This person had no 
knowledge of the study and wrote only the “Patient Study N°” and the “Eye which was 
undertaking LPI”. The investigator who opened the envelope at the pertinent time completed the 
remaining details. 
The corresponding envelope was attached to the participant’s file at the moment of the 
recruitment and was opened at VISIT 2 pre-laser. 
The participant was informed of the result at the same time. 
 
2.7.2 Second Randomisation 
As in the First Randomisation, a random sampling unsorted set of unique numbers was generated 
by computer software. 
It was not possible to predict how many participants would remain with occludable angles after 
LPI. However, we proposed a randomisation process in blocks of 14 participants was decided. This 
number was based on previous studies which state that approximately 20% of the post-LPI angles 
would remain occludable (Thomas, Arun, Muliyil and George, 1999).  
 
As an example, the following 5 sets were generated by the software: 
SET 1: 12, 11, 8, 14, 5, 13, 9, 7, 1, 10, 6, 3, 2, 4 
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SET 2: 23, 20, 18, 28, 21, 25, 17, 19, 27, 16, 15, 24, 22, 26 
SET 3: 36, 41, 42, 37, 40, 38, 30, 29, 33, 31, 34, 32, 35, 39 
SET 4: 53, 44, 51, 50, 56, 52, 46, 48, 45, 54, 43, 47, 49, 55 
SET 5: 60, 70, 65, 67, 59, 57, 58, 62, 68, 69, 64, 61, 63, 66 
 
Odd numbers corresponded to “ALPI” and even numbers to “no further treatment”. 
 
As an example: 
 
SET 1 
Randomisation 
Number 
Participants with occludable 
angles after LPI 
Outcome 
12 A1 No further treatment 
11 A2 ALPI 
8 A3 No further treatment 
 
In this case, participants with a post-LPI occludable angle were named as A1, A2, A3… A70. The 
number was assigned following the order of diagnosis. These new notation was used only for 
randomisation proposes and it did not modify the patient identification number. 
The envelope was only identifiable by the randomisation “A-numbers” written on them. 
A second type of form, “Form 2”, was kept inside the envelope. In this case the external person in 
charge of preparing the randomisation will write only the “Randomisation Patient A-Number” and 
the “outcome”. 
A copy of Form 2 can be found in the Appendix 4 of this thesis. 
The investigator who opened the envelope completed the remaining details. 
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The corresponding envelope for each participant was attached to his/her file at the moment of 
diagnosis of post-LPI occludable angle in Visit 6 and was opened at the end of the same visit. The 
participant was informed of the result at the same time. 
 
2.8 Data Collection and Confidentiality 
In order to maintain the confidentiality of the participants, patients were identified with a 4-digit 
code at the time of the recruitment. The first two digits identified the centre, and the last two 
identified the patient. The key list translating patients’ study numbers to their true identities 
remained at the investigator’s master trial file. This file was kept in a location only accessible by 
hospital identification and access key. 
The information collected from the different tests in the different visits was recorded into a Case 
Report Form (CRF). Which was transferred into a SPSS *file afterwards. 
*SPSS: Statistical Package for the Social Sciences (SPSS Inc) 
Participants’ visual field and imaging data were kept confidential by recording study identification 
number and date of birth only.  
 
2.9 Statistical analysis and assumption of normality 
Statistical Package for the Social Sciences (SPSS) was chosen as the analysis software to be used in 
with this thesis. The collected data was transferred from paper record onto a pre-prepared  SPSS 
database.  
The SPSS package was used for the majority of the statistical analyses.  
Prior to the statistical plan, the distribution of the data was checked for normality. Probability- 
probability plots were produced to visually inspect the assumption of normality for every type of 
measurement under study. It was observed that the majority of these plots showed a normal 
distribution to a very good approximation. It was therefore justified to use parametric methods. 
P values less than or equal to 0.05 were considered statistically significant. 
 
The statistical analysis used in every chapter is specified as follows: 
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Chapter 3- All the eyes (80 eyes) were included in the statistical analysis of this chapter. 
Section 3.1: 
- To test the slope present in the Diurnal Intraocular Pressure (DIOP), the analysis 
Repeated Measures of Variance was performed. This same analysis was used to test 
the relationship between presence of Peripheral Anterior Synechiae (PAS) and DIOP. 
- The relationship between PAS and higher levels of DIOP and furthermore its 
relationship with higher DIOP fluctuations was tested with Linear Regression. 
- The Supine Intraocular Pressure (SIOP) and Dark Room Provocation Test (DRPT) 
results were calculated using Paired Samples T-Test. Independent Samples T-Test was 
used to show the differences in the results of both tests for eyes with and without 
PAS. A further relationship between the results of these tests and presence of PAS 
was investigated with Univariate Regression. 
Section 3.2:  
- To find which of the 8 angle sections was the widest and which one was the 
narrowest, analysis of variance followed by Tuckey HSD multiple comparisons was 
performed. The same analysis was used to investigate the differences between the 
Superior, Nasal, Temporal amd Inferior sections and their adjacent sections (Superior-
Nasal, Inferior-Nasal, Superior-Temporal and Inferior-Temporal). 
- Paired Samples T-Test was performed to find the dimensionsl differences in the 
angular parameters between light and dark conditions. 
- The confidence limits for the Sensitivity and Specificity tests were performed with 
Wilson’s method. 
Chapter 4- At this point of the study 40 eyes had been treated with LPI and 40 fellow eyes were 
acting as controls. 
Section 4.1-The statistical analysis was divided in two sub-sections depending on the hypothesis 
to be tested: 
- 1st Hypothesis: “The treated eye angle parameters would experience a widening 
effect after the LPI while the untreated eyes parameters would remain unchanged. 
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Furthermore, in the case of the treated eye, this widening would be directly 
associated with time elapsed since the procedure” 
To statistically show the effect of the LPI on the angle parameters of treated and 
untreated eyes, two different statistical models were performed. The first statistical 
approach was to use paired samples t-test to compare Visit 4, Visit 5, Visit 6 and Visit 
11 against Visit 1 (baseline) for the treated eye angle parameters and a separate 
analysis for the untreated ones. These analyses would show differences through time 
for both groups, but not differences between groups. A second analysis was designed 
to show differences through time between treated and untreated eyes adjusted for 
differences at baseline. Analysis of covariance was used with this aim. Both groups 
were compared against each other at Visits 4, 5, 6 and 11 while these differences 
were adjusted for the differences between the same groups at Visit 1. 
The association with time was investigated with mixed effects models (Using “R”) 
between time elapsed since the LPI and the adjusted mean differences in the 
parameters found between the treated and untreated groups. 
- 2nd Hypothesis: “There may be an association between, first, the widening effect on 
the angle and time elapsed since LPI (direct association) and, second, between this 
effect and a decrease in IOP levels (inverse association)” 
These associations were investigated using mixed effects models (Using “R”). The 
adjusted mean differences between the parameters for the two groups (treated and 
untreated) were associated to adjusted differences in time elapsed (first regression 
model) and IOP (second regression model) for both groups. 
Section 4.2- Diurnal IOP fluctuation data of 29 participants who only received LPI (no subsequent 
ALPI treatment) during the study were analysed. The study design involved random selection of 
one eye of each participant for LPI treatment and the fellow eye was left untreated. Three months 
after the LPI was performed in these 29 randomly selected eyes, 19 eyes were considered to be 
open and 10 to be occludable using gonioscopy.  
- 1st Hypothesis Methodology 
To test this objective’s first hypothesis of a reduction in DIOP fluctuation in those eyes 
treated with LPI, DIOP fluctuation 6 months (Mean 5.85 months; SD 0.37 months) after 
the LPI treatment was compared with their fellow untreated eyes. Analysis of covariance 
was used as this gave the advantage to adjust the model to the differences found at Visit 
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1 between the treated and their fellow untreated eyes. Three statistical models were 
carried out:  
 
- 1st statistical model: Aimed to test if LPI reduced the DIOP fluctuation 6 months after the 
LPI independently of the outcome of the treatment (gonioscopically occludable or 
unoccludable eyes as diagnosed 3 months post-LPI, n=29). This was achieved by 
comparing the DIOP fluctuation of those treated eyes with their fellows at Visit 11 and 
adjusted for the data found at Visit 1. 
 
- 2nd statistical model: To test if there was a reduction of DIOP fluctuation in those eyes 
with post-LPI unoccludable angles (n=19) when compared with their fellow eyes (n=19). 
This was achieved by comparing those treated eyes with gonioscopically open post-laser 
angles with their fellow eyes at Visit 11 (6 months after LPI) and adjusted for baseline 
data (Visit 1). 
- 3rd statistical model: Comparing treated eyes that remained with occludable angles 
(n=10) with their fellow eyes (n=10) at Visit 11 and adjusted for baseline data (Visit 1).  
- 2nd Hypothesis Methodology 
To test the second hypothesis, which is that those eyes with occludable anterior chamber 
angles (established using gonioscopy, n=10), would show a higher diurnal IOP fluctuation 
than those with open anterior chamber angles after the LPI treatment (n=19), analysis of 
covariance was used. DIOP fluctuation, peaks and troughs were compared between those 
eyes with gonioscopically occludable angle (3 months post-laser) and those with an open 
angle (3 months post-laser). Only the data for the treated eyes was used and the 
statistical model was adjusted for Visit 1 differences (baseline, pre-LPI). 
 
Section 4.3- Data from 24 eyes of 24 participants who only received LPI in the randomised eye 
were used in this analysis. Ten angle sections of the scans (light and dark conditions) of each of 
these eyes were analysed. These 10 sections account for the ones already described (Superior, 
Superior-Temporal, Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and Superior-
Temporal) plus 2 new sections which are the sections on both sides of the angle in the meridian of 
the iridotomy, one on the side that incorporates the iridotomy and the other on the opposing side 
Only two time points Visit 1 and Visit 11 were compared.  
Chapter 5: 
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Section 5.1- The statistical analysis was split into two statistical sub-analyses.  
The first analysis was aiming to assess the difference through time in the angle dimensions when 
assessing solely the eye that was treated with ALPI. This analysis used the paired samples t test to 
compare the parameter dimensions assessed at baseline (Visit 6, 12.55 days, SD 5.24 days, prior 
to ALPI) with the same data collected at Visit 8 (1 day after ALPI, SD 0.00 days), Visit 9 (7 days 
after ALPI, SD 0.89 days), Visit 10 (1.43 months after ALPI, SD 0.18 moths) and Visit 11 (2.39 
months after ALPI, SD 0.30 months). Secondly, it was of interest to assess the differences in angle 
parameter dimensions between those participants whose angle remained gonioscopically 
occludable 3 months after LPI but did not receive further treatment (NFT group; n=10 eyes) 
compared to those whose angles were treated with ALPI (n=11 eyes). The comparison was carried 
out at two time points, Visit 6 (12.55 days, SD 5.24 days, before ALPI) and Visit 11 (2.09 months, 
SD 0.30, months after ALPI). Only those scans taken in dark conditions were quantified. The 
statistical analysis was performed using analysis of covariance to assess the differences in angle 
parameter dimensions depending on the group at Visit 11 while being adjusted for differences at 
Visit 6 (ALPI or NFT). For more schematic information please see Figure 5.1. 
 
The second analysis, performed with mixed effects refression models, aimed to assess how the 
angle dimensions (parameters) change through time and if a relationship between this change 
and the IOP exists. The data those eyes whose angles were treated with ALPI (n=11 eyes) were 
used. To assess the relationship between IOP and time was not possible as the IOP for these 
participants were measured at different times of the day.  
IOP and parameters dimensions data (scans in darkness) collected in Visit 6 (12.55 days, SD 5.241 
days, before laser), Visit 8 (1 day, SD 0.00, after ALPI), Visit 9 (7 days, SD 0.894, after ALPI), Visit 10 
(5.91 weeks, SD 0.944, after ALPI) and Visit 11 (3 months after ALPI) for those eyes treated with 
ALPI and NFT (when applicable) was statistically studied using analysis of covariance.  
 
Section 5.2- To test the hypothesis that ALPI would decrease the DIOP fluctuation 
The statistical analysis was designed to investigate the differences in DIOP fluctuation within the 
same eye before and after the ALPI (time lines: Visit 1 and Visit 11).  As this group of eyes was 
already treated with LPI, it was necessary to isolate the effect of the ALPI. The way this was done 
was using the NFT (group of eyes with similar features as the ALPI group with the exception that 
they did not receive the ALPI).  This was carried out using analysis of covariance at Visit 11 and 
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adjusted for the differences in DIOP fluctuation for the two groups. If a statistically difference was 
to be found, this would have been due to the effect of ALPI solely. 
The mean time between ALPI, carried out in Visit 7, and Visit 11 was 2.39 months, SD 0.29 
months.  
Section 5.3- Analysis of variance followed by Tukey HSD was used to statistically test the 
differences in angle parameters for the different 10 sections in light and dark conditions and 
before and after the ALPI (time points: Visit 6 (12.55 days, SD 5.24 days, before ALPI) and Visit 11 
(2.09 months, SD 0.302, after ALPI)) in the 11 eyes that received the treatment.  
 
Chapter 6:  The assessment of cell density and degree of polymegethism and pleomorphism in 7 
different regions of the corneal endothelium (1 central and 6 peripheral: Superior, Superior-Nasal, 
Inferior-Nasal, Inferior, Inferior-Temporal and Superior-Temporal) were obtained with the 
TOMEY- 3000 non-contact specular microscope analysis software.  
The statistical analysis was carried out in several statistical comparisons and divided in two parts. 
The first part of the analysis was aimed to investigate the effect of the LPI on the corneal 
endothelium in terms of density of endothelial cells, pleomorphism and polymegethism 
compared to baseline. The measurements were taken before LPI was performed at Visit 1 (2.31 
weeks; SD 2.34 weeks, pre-LPI) and after LPI at the following visits: Visit 2 (1:54 hours; SD 25 
minutes, post-LPI), Visit 3 (1 day; SD 0.00, post-LPI), Visit 4 (1.10 weeks; SD 0.13 weeks, post LPI), 
Visit 5 (1.44 months; SD 0.18 months, post-LPI), Visit 6 (3.05 months; SD 0.27 months, post-LPI) 
and Visit 11 (5.83 months; SD 0.37 months, post-LPI). 
The second part of the analysis aimed to investigate the effect of the ALPI on the corneal 
endothelium (same parameters studied as for the LPI and specified in the paragraph above). The 
data used in this part of the analysis was collected from eyes whose angles remained occludable 3 
months after the LPI. Only 11 of these 21 eyes were randomised to receive the ALPI and the 
analysis focused on this group. Data from baseline, in this case Visit 6 (1.79 weeks; SD 0.75 weeks, 
pre-ALPI), and consecutive posterior visits, Visit 7 (1:32 hours; SD 31 minutes, post-ALPI), Visit 8 (1 
day; SD 0.00, post-ALPI), visit 9 (1 week; SD 0.13 weeks, post-ALPI), Visit 10 (1.43 months, SD 0.18 
months, post-ALPI) and Visit 11 (2.39 months; SD 0.29 months, post-ALPI) were used for the 
statistical analysis. 
The objective was studied in two groups of eyes: 
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Group 1- Forty eyes treated with LPI and their untreated fellow eyes.  The data for those eyes that 
had received the ALPI were excluded in Visit 11. 
Group 2- Twenty-one eyes with occludable angles after LPI, for which eleven received ALPI. Their 
fellow eyes were not included, but those occludable eyes that were randomised to not to receive 
ALPI (n=10) acted as the control eyes for the evaluation of the ALPI effect. 
With the aim of studying the effect of the lasers through time, paired samples t-test was 
performed between the baseline visit and each of the consecutive visits. This analysis was 
performed in the treated and in the untreated fellow eye, using this latter as a control. 
A second aim was to find if there were differences in the effect of these lasers when treated and 
untreated eyes were compared. This was achieved through analysis of covariance and adjusting 
all the models for the data found at baseline. 
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CHAPTER 3.    Diurnal and postural characteristics of IOP 
in Caucasian patients with angle closure and the 
relationship with the anatomy of the anterior chamber 
angle  
 
3.1 Study of the diurnal and postural characteristics of IOP in Caucasian 
patients with angle closure  
 
3.1.1 Introduction 
Raised IOP is an important risk factor for glaucoma, and is the principal modifiable factor in the 
treatment of patients with and at risk of glaucoma. Measurement of IOP in the clinical setting 
usually involves a single measurement with the patient in an upright seated position. However, it 
is recognised that there can be considerable variability of IOP during the day (diurnal fluctuation) 
and that changes in posture can also result in marked increase in IOP. IOP and the presence or 
absence of peripheral anterior synechiae (PAS) is used by clinicians to categorise a patient into 
differing disease categories that reflect a differing risk for glaucoma and which can be categorised 
into PACS and PAC (Foster, Buhrmann, Quigley and Johnson, 2002). It is important therefore to 
understand how such a single IOP measurement in the seated position, is reflective of the diurnal 
seated IOP variation. The majority of studies that have investigated such IOP characteristics have 
been conducted in individuals with open anterior chamber angles. Given the considerable burden 
of patients diagnosed with angle closure in Caucasian populations, there is a need to investigate 
these IOP characteristics in individuals with occludable anterior chamber angles. Diurnal 
measurement of IOP is an important management tool when diagnosing or treating patients with 
open angle glaucoma, and there is therefore an interest in understanding these IOP 
characteristics in those with closed angles.  
Several studies have reported diurnal fluctuation of IOP for normal (non-glaucomatous) and 
glaucomatous eyes (Barkana, et al., 2006; Baskaran, et al., 2009; Realini, Weinreb and Wisniewski, 
2010). A literature search failed to identify a study of diurnal IOP fluctuation among untreated 
individuals with angle closure in the absence of glaucoma. In a study of patients whose eyes had 
previously been treated with LPI with a diagnosis of PAC or PACG, Baskaran, et al. (2009) reported 
higher levels of fluctuations in these patients (fluctuation defined as the difference between 
peaks and troughs of diurnal intraocular pressure). PAC and PACG patients presented a level 
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diurnal fluctuation of 5.42.4 and 4.52.3 mmHg respectively, (IOP measured every hour from 
8:30 to 16:30h) compared to those with PACS and normal subjects with open angles, 3.7 1.2 and 
3.8.1.1 mmHg, respectively. The same study reported an association between the degree of PAS 
and the diurnal fluctuation of IOP in same eye of patients of Chinese origin. Like IOP, the presence 
or absence of PAS is used as a criterion to classify patients into diagnostic categories that are 
considered to indicate different risks of glaucoma. PAS are areas of iridotrabecular contact and 
have been shown by a histological study to be accompanied by surrounding damage to the 
trabecular meshwork (Sihota, et al., 2001).  
Given the limited evidence described above, one might hypothesise that eyes with occludable 
angles in the absence of glaucoma would exhibit a greater range of IOP (greater IOP ‘fluctuation’) 
within the diurnal period than healthy eyes with open angles. One might also hypothesize that the 
presence of PAS, a sign of damage to the trabecular meshwork, would be associated with greater 
IOP fluctuation.  
IOP is known to change with a change in posture, with a higher IOP measured in the supine 
position than the upright seated position, the latter posture being the usual position of the 
patient in clinical practice. This postural difference in IOP has been reported in patients with 
glaucoma   (Yamabayashi, 1991) and without glaucoma (Lam and Douthwaite, 1997), the 
explanation being most probably a rise in episcleral venous pressure associated with a supine 
posture (Blondeau, Tetraul and Papamarkakis, 2001; Friberg, Sanborg and Weinreb, 1987). These 
aforementioned studies have been conducted in patients with eyes that have open anterior 
chamber angles. It may be hypothesised that eyes with angle closure would exhibit different 
postural changes in IOP, given the anatomical relationship of the iris in relation to the trabecular 
meshwork. The darkroom provocation test involves placing a patient in a prone position in a dark 
environment. This test is used to guide clinicians as to the likelihood of an acute rise in IOP, given 
that the gravitational effect of the prone position and pupil dilation would accentuate the 
narrowing of the angle. It was hypothesised that eyes, in which PAS are present, may have a more 
marked rise in IOP following the dark room provocation test.  
 
3.1.2 Methodology 
Intraocular pressure measurements performed on the participants’ first visit were used. Diurnal 
Intraocular Pressure (DIOP) data was available for all 40 participants. Two participants were 
unable to perform the Dark Room Provocation Test (DRPT) and one could not undergo the Supine 
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Intraocular Pressure (SIOP) investigation, on account of difficulties adopting a prone or supine 
position. 
The intraocular pressure (IOP) was performed every hour from 9:00h to 16:00h, a total of 8 
measurements formed the DIOP. The SIOP was performed as close to noon as possible (SD around 
12:00 was 1:16h) and it was defined as the difference between the earlier DIOP measurement 
(seated measurement) and the IOP in a supine position measured 5 minutes after adopting this 
posture. 
The DRPT was performed after the SIOP at approximately noon (variation around this time, SD 
1:14hours), and it was defined as the difference found between the IOP measured in the seated 
position before and 15 minutes after the participant had adopted a prone posture in a dark 
environment (lux  0.5).  
Gonioscopy was performed by the same consultant ophthalmologist for all participants. 
For further information about the methodology and instrumentation used in these tests, please 
refer to Chapter 2 of this thesis. 
 
3.1.3 Results 
Diurnal Intraocular Pressure (DIOP) 
 
Figure 3.1. Mean values and standard deviation for 80 eyes with gonioscopically occludable anterior chamber angles (40 
patients) 
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The mean peak of DIOP for the 80 eyes of the sample at every diurnal hour of measurement is 
represented in Figure 3.1. The peak for this sample of means was 18.5 mmHg (4.27SD; Range: 
12.0- 30.5) and was found to be at 9:00 hours.  
Inspecting the individual DIOP peak for every participant, this was found to be at 9:00h for 28 
participants, at 10:00h for 5 participants, at 11:00h for 4, at 13:00h for 1, at 14:00h for 3 and at 
15:00h for 1. In summary, the maximal IOP was measured in the morning (9:00 to 11:30h) for the 
majority of participants. The maximum IOP value between eyes of every participant was chosen 
to decide the final participant’s DIOP peak.  
 
Effect of the presence of Peripheral Anterior Synechiae  (PAS) in the Diurnal Intraocular Pressure 
(DIOP) 
Figure 3.2 shows DIOP measured for two groups of eyes, those with PAS (n=31) and those without 
(n=49). The mean IOP at each time point appears higher in eyes with PAS.  
A repeated measures analysis of variance showed a significant decline in IOP as the day 
progressed (p<0.001), which was independent of whether an eye had PAS or not. In other words, 
there was no significant interaction between Presence/Absence of PAS and time of measurement 
(p=0.458).  
However, there was an overall significant effect of presence of PAS on IOP across all time points 
of the DIOP. An average of difference between means was found to be 1.5 mmHg higher for those 
eyes with PAS, p=0.043. This effect was independent of the time of measurement. Therefore eyes 
with PAS would exhibit higher average DIOP than those eyes without PAS. 
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 Figure 3.2. Mean IOP differences between Presence of PAS and Absence during the DIOP times. 
The circumference of PAS (measured in degrees)* and DIOP showed a statistically significant 
association (calculated using univariate regression), at every time measurement of the DIOP. 
These models showed a similar relationship between the dependent (IOP at different times-DIOP) 
and the predictor (degree of PAS), which were all statistically significant except the measurement 
taken at 12:00h. Please see Table 3.1 for p values, standardized coefficients and R2. All the 
standardized coefficients showed a direct association between IOP levels and degree of PAS, 
meaning that an eye with a higher degree of PAS would exhibit higher levels of IOP. 
*The variable circumference of PAS included eyes without PAS (cero degree of PAS).  
 
 
 
 
 
 
Table 3.1. Univariate regression over IOP measurements adjusted for degree of PAS at every time-hour of the diurnal 
IOP. Statistically significant p values have been flagged with an asterisk. 
 Univariate Regression Analysis 
 Degree of PAS (independent) 
 
Standardized 
Coefficients 
Adj. R
2
 P value
 
IOP at 9:00h 0.341 0.105 0.002* 
IOP at 10:00h 0.341 0.105 0.002* 
IOP at 11:00h 0.332 0.099 0.003* 
IOP at 12:00h 0.197 0.026 0.080 
IOP at 13:00h 0.312 0.086 0.005* 
IOP at 14:00h 0.282 0.068 0.011* 
IOP at 15:00h 0.261 0.056 0.021* 
IOP at 16:00h 0.288 0.071 0.011* 
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Diurnal Intraocular Pressure Fluctuation (DIOP Fluctuation) and the presence of Peripheral 
Anterior Synechiae (PAS) 
The average fluctuation in DIOP was defined as the difference between the average for the 
maximum value of IOP attained during the DIOP (20.03 mmHg; SD 4.18) and the minimum for a 
given eye (14.04mmHg; 2.82). The mean fluctuation for this sample of eyes was found to be 5.99 
mmHg (2.70 SD); paired samples t test p<0.001. An interesting finding was the range of 
fluctuation, showing a variation from as little as 1.50 mmHg to as much as 14.50 mmHg.  
A regression model was fitted in order to investigate an association between DIOP fluctuation and 
age, gender, presence/absence of PAS and circumferential degrees of PAS.  
When this model was fitted with age and gender adjusted (univariate and multivariate model), no 
association among factors was found for presence/absence of PAS or circumferential degrees of 
PAS and range of fluctuation of DIOP. For p values, standardised coefficients and R2 please refer to 
Table 3.2.  
 
 Univariate Regression Analysis Multivariate Regression Analysis 
 Standardized 
Coefficients 
P value Adj. R
2 
Standardized 
Coefficients 
P value Adj. R
2
 
Gender -0.061 0.590 -0.009 -0.043 0.705 -0.014 
Age 0.114 0.316 0.000 0.150 0.242 
Presence/Absence 
of PAS 
-0.055 0.625 -0.010 -0.178 0.251 
Degree of PAS 0.045 0.691 -0.011 0.182 0.242 
Table 3.2 Univariate and multivariate regression models over DIOP fluctuation with age, gender, presence/absence of 
PAS and degree of PAS adjusted. 
 
 
Supine Intraocular Pressure (SIOP) 
The difference between mean values of IOP measured in the supine versus the upright position 
was 1.7mmHg (2.12 SD; paired samples t-test, p<0.001). Supine and upright posture IOP was 
highly associated (Standardised Coefficient 0.868, p<0.001). This is represented in Figure 3.1. The 
majority of eyes (50 eyes out of 78 eyes, 64.10%) were found to have higher pressures after the 
participant adopted a supine position for 5 minutes.  
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Figure 3.3.  Scatter plot of the IOP measured in 78 eyes of before and after the adoption of a supine posture from a 
seated position (SIOP)  
 
Association of Peripheral Anterior Synechiae (PAS) with the Supine Intraocular Pressure (SIOP) 
The mean value for the Supine Intraocular Pressure (SIOP) found in those eyes with presence of 
Peripheral Anterior Synechiae (PAS), (n=31), was 1.50 mmHg (SD 2.50 mmHg) while for those 
without PAS (n=47) it was slightly higher 1.83 mmHg (1.85 mmHg). An independent sample t-test 
showed no statistically significant difference between the mean values for postural difference in 
IOP between eyes with PAS and without PAS (Mean difference between groups 0.33 mmHg; 
p=0.116).  
 
When univariate regression was used to test the association between circumferential degrees of 
PAS and postural change in IOP, no statistically significant association was found (Univariate 
regression: Standardised Coefficient 0.109; Adjusted R2 0.012; p value=0.341). This is visually 
represented in the graph below (Figure 3.4) 
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Figure 3.4. Scatter plot of the resulted SIOP measured in 78 eyes against the degree of PAS found in the same eyes. 
 
The plot above shows the lack of relationship between the amount of PAS present in an eye and 
the difference of IOP found as a result of being in the supine position for 5 minutes. 
 
 
The Dark Room Provocation Test (DRPT)  
The mean difference in IOP before and after the dark room provocation test was 3.05mmHg (SD, 
2.85 mmHg, paired samples t-test, p<0.001). IOP measured before and after this test was highly 
associated (Figure 3.5, Standardised coefficient, 0.802; p=0.003). Higher IOP post-provocation was 
noted in 63 eyes (82.9%). 
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Figure 3.5. Scatter plot of the IOP measured in this sample showing the relationship in IOP levels found before and after 
the DRPT  
 
Association of Peripheral Anterior Synechiae (PAS) and the Dark Room Provocation Test (DRPT) 
Of the 76 eyes in this analysis, there was no statistically significant difference between eyes with 
PAS (n=31) and eyes with no PAS (n=45) before and after dark room provocation (independent 
samples t test, p=0.895). Furthermore, the circumferential degrees of PAS present in an eye was 
not statistically significantly correlated to higher levels of IOP after the DRPT (Univariate 
regression; Standardised Coefficient – 0.127; Adjusted R2 0.016; p value=0.274). A visual 
representation of this regression can be found in Figure 3.6 (next page). 
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Figure 3.6.  Scatter plot of the resulted SIOP measured in 78 eyes against the degree of PAS found in the same eyes 
 
3.1.4 Discussion 
Of 80 eyes of 40 patients examined at Visit 1, 49 were diagnosed as PAC and 31 as PACS. From 
those eyes diagnosed as PAC, 17 were due to presence of PAS only and 18 were due a raised IOP 
only (IOP higher or equal to 21mmHg at any time between 9:00 and 16:00 hours) and 14 were 
due to a combination of PAS and IOP criteria. Of the 18 eyes diagnosed with PAC due to IOP levels 
only, 15 would have been diagnosed as PACS had the IOP measurements been taken in the 
afternoon (12:30h to 16:00h). This highlights the observation that the timing of a single IOP 
measurement by a clinician is of importance when considering what diagnosis to ascribe a patient 
with angle closure. In this case, 6 participants might be ascribed the lower risk PACS diagnosis, 
had the single afternoon IOP measurement been the only measure used to reach a diagnosis. The 
management and follow-up of patients may be very different with patients with PAC than with 
those with a diagnosis of PACS. 
Wilensky (1991) observed that 65% of normal subjects (defined as subjects with normal IOPs, 
normal visual acuity, healthy optic nerve heads and no history of ocular disease) had diurnal IOP 
peaks between 8:00 and 14:00h while 30% exhibited a peak IOP between 04:00 and 08:00. 
Differing results were reported for those diagnosed as ocular hypertensive (IOP >22mmHg and no 
signs of glaucoma) where 51% presented their peaks between 4:00 and 8:00 and 42% between 
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8:00 and 14:00. In the case of the present  study, if an equivalent IOP based criterion (cut off of 
22mmHg) to that of Wilensky et al. is used and PAS presence is not taken in account, 28 of 40 
participants (70%) had IOP 22mmHg in both eyes during the DIOP. Of these 28 participants, 27 
(96%) exhibited an IOP peak between 9:00 and 14:00h. From the participants showing 
IOP>22mmHg in at least one eye (n=12), 100% showed their peak between 9:00h and 11:00h. To 
summarize, in both this study and that of Wilensky, diurnal peaks are more frequently found in 
the morning than in the late afternoon (after 14:00h) and this was independent of a particular IOP 
cut off. 
The DIOP curve profile found for this group of subjects is similar to that in a study described in the 
literature for 21 healthy individuals in a similar age group and ethnicity (15 out of 21 were 
Caucasian), (Liu, et al., 1999). There was a peak in the early morning of approximately 18mmHg, 
decreases through the morning to levels of 17mmHg, with a moderate increase in the middle of 
the day (12:00h) of about half a mmHg, decreasing to levels of 17 mmHg in the early evening 
(16:00h). It is curious that, despite the fact that the participants in the present study had narrow 
angles and higher DIOP fluctuation, the DIOP curves behaved similar to patients with open angles 
from other studies.  
To date there have not been any studies published that report the association of PAS with the 
DIOP curve. The present study has found a statistically significant effect of presence of PAS over 
the DIOP curve. An eye with PAS would exhibit an average of nearly 1.5 mmHg higher than an eye 
without PAS. Furthermore, the degree of PAS present in an eye was found to be directly 
associated with an increase in IOP at the majority of the diurnal times.  
The fluctuation of DIOP was not related to age, gender or PAS. This result differs from a report by 
Baskaran, et al. (2009), where association was found between fluctuation and degree of PAS. In 
the case of the present study the lack of an association is not unexpected given that the DIOP 
curves of those eyes with presence of PAS and those eyes without were very similar (Figure 3.2). 
Although there may have been differences between the peaks and troughs between curves, the 
fluctuation obtained would have been similar. It has to be mentioned that in Baskaran’s study, the 
data showed a high degree of variation and, although the association was reported as statistically 
significant (p= 0.013), the association was weak (R2, 0.139). However, this does not fully explain 
the differences between studies. 
Lam and Douthwaite (1997), using non-contact tonometry, found that after 8 minutes in the 
prone position the IOP increased from 13.5±2.01 mmHg (sitting position) to 20.0±3.27 mmHg 
(prone position) in individuals without any ocular pathology. An increase from 12.7±1.90 mmHg 
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(sitting position) to 14.1±1.92 mmHg (supine position) was found when the same individuals 
adopted a supine position for the same period of time (illumination 370lux). Even higher levels of 
IOP measured in the prone position were reported in individuals with normal eyes by Walick, 
Kragh, Ward and Crawford, (2007), where levels of IOP increased from 19.3±2.9 mmHg (sitting 
position) to 29.7±4.1 mmHg (prone position) after 10 minutes. Buchanan and Williams (1985) 
found a difference between the mean IOP measured for upright and post-supine postures of 
4.11±1.82 mmHg with contact tonometry, but the duration of the test was not specified. When 
individuals remained for a longer duration in the supine position (30 minutes), the result was 
found to be higher; increases of 4.4mmHg (2.0 SD), 4.1 mmHg (1.8 SD) and 4.0 mmHg (SD 2.0) 
were found for normals (no ocular pathologies influencing IOP), low tension glaucoma and ocular 
hypertensive individuals, respectively (Yamabayashi, et al., 1991). It is interesting that the 
glaucomatous and ocular hypertensive individuals exhibited lower differences in IOP due to 
change in position as these individuals were not taking ocular hypotensive medication prior to or 
during the study. In the present study, a direct association has been found between the IOP levels 
prior and post supine; meaning that the higher the first, the higher the second. As ocular 
hypertensive eyes are diagnosed based on high IOP measurements made in the seated position, it 
might be expected that this group would exhibit the highest IOP variation. 
When comparing published IOP results with those found in this study thesis, the rise in IOP level 
following adoption of a prone posture (DRPT) from the seated position is approximately half of 
that found by Lam and Douthwaite. However, the change in IOP from seated to supine postures 
was very similar. The differences between this study and those of Yamabayashi might be due to 
differences in instrumentation. They used the Alcon Pneumatonograph and, although care was 
taken in checking the calibration of this device on a regular basis, comparison with the Goldmann 
tonometer was not performed. It is further unlikely that these differences were caused by the 
duration of the tests as the change in IOP in the supine position was immediate and remained 
stable for the next 30 minutes.  
 
The DRPT results differences between the present study and that performed by Lam and 
Douthwaite and Walick, Kragh, Ward and Crawford, may be explained on account of the different 
methods of measurement. In this study measurements were taken in the seated position before 
and immediately after the test while in these other published studies the second measurement 
was performed with the patient remaining in the prone position.  
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The IOP measurements after adopting a supine posture (SIOP) and following darkroom 
provocation (DRPT) were strongly and positively associated to the IOP measured at baseline in the 
seated position. Meaning that the higher the IOPs were prior the tests, the higher they were 
going to be after the tests. This was unsurprising as the majority of the eyes presented higher 
IOPs after the test. 
However, and as explained previously, these postural changes in IOP were frequently lower than 
in previous literature.  
 
3.1.5 Conclusion 
Clinicians should be aware of changes in IOP that occur throughout the day in patients with 
occludable anterior chamber angles and that the circumferential extent of PAS is associated with 
higher IOP levels during the day compared to normals. In clinical centres where laser peripheral 
iridotomy is only applied to those individuals with a more advanced pre-glaucomatous stage 
(PAC), the present findings would support measuring IOP in the early morning to establish the 
maximal IOP.  
It has been shown that adoption of a supine or prone position will raise the IOP of the majority of 
individuals. The data show that the presence of PAS was not associated with larger postural 
excursions of IOP with either the DRPT or the supine test.  
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3.2 Investigation of static and dynamic anatomical characteristics of eyes 
with gonioscopically occludable anterior chamber angles using ocular 
coherence tomography: Is there an association with IOP?  
 
3.2.3 Introduction 
Different anterior segment imaging devices have been used in the past to describe dimensions 
and structures of the anterior segment of the eye. These include the ultrasound biomicroscope 
(UBM), the Orbscan, the Pentacam with rotating Scheimpflug imaging and the 2 dimensional 
Anterior Segment Optical Coherence Tomography (2D AS-OCT) instruments.  
There are certain advantages of one instrument over another depending on the structures that 
one wishes to image and the convenience of image acquisition. The AS-OCT offers images of the 
anterior chamber angle at a higher resolution than the UBM and the acquisition, of a non-contact 
character, is taken with the patient in a seated position. When comparing AS-OCT to the 
Pentacam and Orbscan, the three devices are non-contact, however, only the AS-OCT offers direct 
angle visualisation (Konstantopoulos, Hossain and Anderson, 2007), which is necessary for the 
quantification of the angle parameters.  
In terms of depth of imaging, the UBM can provide visualization of more posteriorly located 
structures such as the retroiridial structures (Ursea and Silverman, 2010) and the Orbscan and 
Pentacam may also be used to monitor cataract formation in the crystalline lens (OCULUS 
Optikgeräte GmbH, 2008).  
When evaluating the irido-corneal angle, one study suggested an excellent correlation with 
gonioscopical findings when using UBM and 2D AS-OCT. In the same study, sensitivity and 
specificity for detecting occludable angles when comparing to gonioscopy findings were found to 
be slightly better with 2D AS-OCT than with UBM (Radhakrishnan, Huang and Smith, 2005). 
Additionally, a more recent study showed poor agreement in the anterior chamber dimensions 
measurements taken with 2D AS-OCT and the UBM (Mansouri, Sommerhalder and Shaarawy, 
2010). Between the Pentacam and the 2D AS-OCT there were no significant differences when the 
angle was estimated in degrees (Yi ,et al., 2008) or when comparing sensitivity for diagnosis of 
narrow angles between devices (Hong, et al., 2009).  
Imaging techniques, such as those described above, have been frequently used in the past for 
monitoring changes in the angle. Specifically, the UBM (Marraffa, et al., 1995; Gazzard, et al., 
2003; Kaushik, et al., 2007; He, et al., 2007, Mansouri, Burgener, Bagnoud and Shaarawy, 2009), 
  
75 
 
Pentacam (López-Caballero, et al., 2010; Antoniazzi, et al., 2010; Li, et al., 2010) and the 2D AS-
OCT (Chalita, et al., 2005; Memarzadeh, et al., 2007; See, et al., 2007; Lei, et al., 2009; Ang and 
Wells, 2010) have previously been used to quantify anterior chamber dimensions following LPI. 
Additionally, the 2D AS-OCT has been used for screening and diagnosis of occludable angles 
(Nolan, et al., 2007) and in studies investigating the mechanism of angle closure (Leung, 2007; Liu, 
2008; See, et al., 2007).   
In summary, the AS-OCT does not involve contact with the eye which makes this a more 
acceptable technique than UBM for patients. When comparing the AS-OCT with the Orbscan and 
Pentacam in general terms, the main advantage of the AS-OCT is high-resolution visualization of 
the angle recess area and a more comprehensive quantification of the angle dimensions using the 
analysis software supplied with this instrument. 
New advances in AS-OCT technology has made 3-dimensional (3D) swept-source OCT now 
possible. This technology based on the Fourier Domain technique gives the highest scanning 
resolution (11.6m axial) for the angle space currently described (Yasuno, et al., 2009). As the 
analysis of the angle is based on the accurate detection of the scleral spur, it is expected that this 
higher resolution would give a more precise identification of its position. A study that compared 
2D and 3D AS-OCT devices found no significant difference in central corneal thickness or anterior 
chamber width between them, but the intraclass coefficients of repeatability and reproducibility 
were marginally higher with the 3D AS-OCT device (Fukuda, Kawana, Yasuno and Oshida, 2010). 
These findings and the advantages of AS-OCT mentioned above, led to the decision to use this 
instrument for measurement of anterior chamber angle dimensions in this study.  
Most published literature involving the 2D AS-OCT reports on the horizontal and vertical 
meridians of the eye when monitoring changes or making a diagnosis with the 2D AS-OCT (Nolan, 
et al., 2007; Lavanya, et al., 2008; Mansouri, Burgener, Bagnoud and Shaarawy, 2009; Ang and 
Wells, 2010). It is unknown how representative these dimensions are of the entire circumference 
of the anterior chamber angle. After all, the established technique of gonioscopy, on which 
clinical management decisions are based, involves a decision made on visibility of the structures 
in each of the four quadrants of the angle. Therefore an important objective of this thesis was to 
investigate how meridians differed in dimensions within individual eyes.  
Peripheral anterior synechiae are believed to occur as a result of prolonged apposition of the root 
of the iris against the trabecular meshwork. Intuitively, one would expect more coverage of PAS in 
a given sector of the angle of an eye to be associated with smaller dimensions for that angle 
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section. Su, et al., (2008) reported a weak correlation between the angle width and the extent of 
PAS. 
  
The relationship between degree of narrowing of an anterior chamber angle and fluctuation of 
diurnal IOP (during office hours) remains unexplored (Baskaran, et al., 2009). One may 
hypothesise that eyes with narrower anterior chamber angles would exhibit a greater diurnal 
variability in IOP. There may also be a relationship between degree of angle narrowing and the 
change in IOP associated with a change in posture between upright and supine positions, or in 
association with the changes in IOP associated with the darkroom provocation test. These 
relationships have not been tested previously.  
Wang, et al. (2010) found a statistically significant association between numbers of closed 
sections in the angle of a given eye in dark conditions and a positive result in the dark room 
provocative test (DRPT). A possible association between higher IOPs after prone position in 
darkness and narrower dimensions of the anterior chamber angle parameters therefore deserves 
study and is an aim in this Section 3.2. These questions have important clinical relevance in terms 
of advice for patients and predictions of those eyes that have more risk with changes in posture 
or light levels. 
 
3.2.2 Methodology 
The collection of IOP data for the purpose of investigating IOP fluctuation, and the results of the 
dark room provocation test (DRPT) and supine IOP (SIOP) tests have been described previously. 
Three-dimensional AS-OCT (Casia device, Tomey, Japan) images were obtained on the same day 
as these IOP measurements. The scans were taken in darkness (between 0.3 and 0.5 lux) and in 
light conditions (between 170 and 199 lux) and the images taken were subsequently analysed 
using the commercially available software with this instrument. Acquisition and analysis of images 
was undertaken by the same examiner (LSP) throughout.  
The analysis of AS-OCT images acquired in dark and light conditions involved calculation for each 
eye of the following parameters: the angle opening distance (AOD), the trabecular-iris angle 
(TIA)(Pavlin, Harasiewicz and Foster, 1992), the angle recess area (ARA) (Ishikawa, et al., 1999) 
and the trabecular iris space area (TISA)(Radhakrishnan, Huang and Smith, 2005). Figure 3.7 gives 
a visual representation of these angle parameters. 
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Figure 3.7. Irido-trabecular angle parameters as measured with the CASIA AS-OCT analysis software. AOD (Angle 
Opening Distance), ARA (angle Recess Are), TISA (Trabecular-Iris Space Area) and TIA (Trabecular-Iris Angle) at 500 and 
750m are highlighted in bright green colour. 
 
These parameters were quantified in 8 different sections of the angle (Superior, Superior-Nasal, 
Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and Superior-Temporal) and at 500 
and 750m from the scleral spur. Figure 3.8 gives a schematic view of these angle sections: 
 
 
 
 
 
 
 
 
 
Figure 3.8. Schematic explanation of the eight irido-trabecular angle sections under study (please note that these are 
corresponding to a Right Eye). The abbreviations found in this figure are those corresponding to the sections and 
position-degree in the ocular circumference. Abbreviations: S=Superior (90 degrees), S-N=Superior-Nasal (45 degrees), 
N=Nasal (0 degrees), I-N= Inferior-Nasal (315 degrees), I=Inferior (270 degrees), I-T=Interior-Temporal (235 degrees), 
T=Temporal (180 degrees), S-T=Superior-Temporal (135 degrees). 
S-N 45° 
S 90° 
I-N 315° 
N 0° 
I 270° 
I-T 235° 
 T 180° 
S-T 135° 
500m 
TISA TIA 
 
AOD ARA 
 
750m 
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To facilitate the interpretation of the results, these 8 sections were grouped into 3 independent 
sectors, Superior, Horizontal and Inferior. The Superior Sector incorporated Superior, Superior-
Nasal and Superior-Temporal Sections; the Horizontal Sector the Temporal and Nasal Sections; 
while the Inferior Sector comprised the Inferior, Inferior-Temporal and Inferior-Nasal sections. 
Right and left eyes of 35 participants were included in the analysis. Five out of a total of 40 
participants in the study were imaged with a different AS-OCT device at the beginning of the 
study therefore their results were excluded for this analysis. The justification for using both eyes 
of every participant is explained in detailed in the Appendix 2 of this thesis. 
Diagnostic criterion for angles when using AS-OCT 
A section of angle was diagnosed as closed if there was contact anterior to the scleral spur at any 
point between anterior iris surface and posterior corneal surface (trabecular meshwork or corneal 
endothelium). Therefore, as with the criterion followed for gonioscopy, an angle was diagnosed as 
closed if 2 or more sections were closed when using 4 sections for the diagnosis or if 4 or more 
sections were closed when using 8 sections for the diagnosis. 
 
3.2.3 Results 
Assessment of variability among the anterior chamber angle parameters for different angle 
sections 
When comparing the mean (n=70 eyes) value for each of the angle parameters (AOD, ARA, TIA, 
TISA) in each imaged section of the eye, the lowest values (i.e. the narrowest section) in light and 
dark conditions for every parameter were found in the Superior section. The sections where angle 
parameters were largest (i.e. widest angle) were noted in Nasal and Inferior-Nasal sections for 
both light and dark conditions. Among the parameters investigated, only mean values for TISA 
500 were found to be maximal in the Temporal section under light conditions. This can be visually 
observed in the following graphs (Figures 3.9 to 3.16).  
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Figures 3.9 and 3.10.  Mean value of AOD (Angle Opening Distance) and ARA (Angle Recess Area) at 500 and 750m for 
70 participants under light conditions for eight sections of the angle under light conditions 
Figure 3.9 
Figure 3.10 
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Figures 3.11 and 3.12.  Mean value of TISA (Trabecular-Iris Space Area) and TIA (Trabecular-Iris Angle) at 500 and 
750m for 70 participants under light conditions for eight sections of the angle under light conditions. 
Figure 3.11 
Figure 3.12 
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Figures 3.13 and 3.14.  Mean value of AOD (Angle Opening Distance) and ARA (Angle Recess Area) at 500 and 750m 
for 70 participants under dark conditions for eight sections of the angle under dark conditions. 
Figure 3.13 
Figure 3.14 
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Figures 3.15 and 3.16  Mean value of TISA (Trabecular-Iris Space Area) and TIA (Trabecular-Iris Angle) at 500 and 750m 
for 70 participants under dark conditions for eight sections of the angle under dark conditions. 
 
Figure 3.15 
Figure 3.16 
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The section in which minimum and maximum mean values for each angle parameter was found 
are given in Table 3.3, in both light and dark conditions. 
 
CONDITION LIGHT DARK 
RANGE MINIMUM MEAN 
VALUE (LOCATION) 
MAXIMUM MEAN 
VALUE (LOCATION) 
MINIMUM MEAN 
VALUE (LOCATION) 
MAXIMUM MEAN 
VALUE (LOCATION) 
AOD 500 0.0425 (Superior) 0.1419 (Nasal) 0.0378 (Superior) 0.1275 (Nasal) 
AOD 750 0.0828 (Superior) 0.2082 (Inferior-Nasal) 0.0746 (Superior) 0.1943 (Inferior-Nasal) 
ARA 500 0.0153 (Superior) 0.0652 (Nasal) 0.0126 (Superior) 0.0608 (Nasal) 
ARA 750 0.0329 (Superior) 0.1105 (Nasal) 0.0261 (Superior) 0.1034 (Nasal) 
TISA 500 0.0149 (Superior) 0.0577 (Temporal) 0.0117 (Superior) 0.0538 (Nasal) 
TISA 750 0.0322 (Superior) 0.1022 (Nasal) 0.0250 (Superior) 0.0964 (Nasal) 
TIA 500 3.2954 (Superior) 12.718 (Nasal) 2.9898 (Superior) 11,084 (Nasal) 
TIA 750 4.6323 (Superior) 13.398 (Inferior-Nasal) 4.2911 (Superior) 12.182 (Inferior-Nasal) 
Table 3.3.  Maximum and minimum values and their section location for the angle parameters in light and darkness. 
AOD (Angle Opening Distance), ARA (angle Recess Area), TISA (Trabecular-Iris Space Area) and TIA (Trabecular-Iris 
Angle) measured at 500 and 750m. 
 
Differences between the narrowest and widest angle sections and the remaining sections  
To assess the differences of every parameter in every section compared to maximum value and 
minimum value found for the same parameter (as described in Table 3.3), analysis of variance 
followed by Tukey HSD multiple comparisons was performed (the complete analysis performed 
using Tukey HSD can be found in the attached compact disc).   
 The minimum mean value was found to be in the Superior section for all the parameters; the 
difference between the Superior section’s mean value and those corresponding to the same 
parameter in the other 2 sections of the Superior sector was statistically non-significant for all the 
parameters in the Superior-Temporal section in light or dark. However, when this mean was 
compared against the Superior Nasal section there was a statistical significant difference in dark 
for ARA 500, ARA 750, TISA 500 and TISA 750 and in light conditions for ARA 750, TISA 750 AND 
TIA 750.  
When the parameters in the superior section were compared to the Horizontal and Inferior 
sectors parameters, the differences were all statistically significant (P<0.05) for light and dark 
conditions. The Inferior section was an exception, where ARA 500, ARA 750, TISA 750 and TIA 500 
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were not found to be significantly different from the minimum mean value in either light or dark 
conditions.  Inferior section TISA 500 in dark condition was another exception.  This is represented 
in Figure 3.17. The detailed analysis is presented in Tables 3.4 to 3.11 (Appendix 1, pages 1 to 2). 
 
 
Figure 3.17. Representation of those sections in the angle whose majority of parameters were found not to be 
statistically significantly different to the narrowest section in the angle, the Superior section (these are represented in 
blue colour). Those other sections whose parameters were found statistically significant different are coloured in grey. 
 
When comparing the maximum value for a given parameter (found in the Horizontal and Inferior 
sectors, more specifically in the Nasal, Temporal and Inferior-Nasal sections) with the rest of the 
means of the analysed parameter and for the other sections, the differences between the means 
found in the Superior sector (Superior, Superior-Temporal or Superior-Nasal) and the mentioned 
maximum mean value were all statistically significant (p<0.05). However, when the comparison 
was carried out between the maximum mean value and the rest of the sections found in the 
Horizontal and Inferior sector, these differences resulted non-statistically significant in the 
majority of the parameters. The Inferior section was an exception to this affirmation for all the 
parameters in light and dark conditions where the differences were statistically significant. AOD 
500 (light) and ARA 750 (light) in the Temporal section were two other exceptions. Figure 3.18 
shows a visual representation, but the detailed analysis is presented in Tables 3.4 to 3.11 
(Appendix 1). 
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Figure 3.18. Representation of those sections in the angle whose majority of parameters were found not to be 
statistically significantly different to the widest sections in the angle, the Nasal, Temporal and Inferior-Nasal sections 
(these are represented in pink colour). Those other sections whose parameters were found statistically significantly 
different are coloured in grey. 
 
Between the Inferior and temporal sections the majority of the parameters were statistically 
significantly different. Exceptions to this result were AOD 500 and 750 (light and dark) and TIA 500 
and 750 in darkness.  
 
Comparison between the parameters found in the Superior, Nasal, Inferior and Temporal sectors 
and their adjacent sections (Superior-Nasal, Inferior-Nasal, Inferior-Temporal and Superior-
Temporal) 
The same statistical analysis results were used when comparing the 4 most commonly described 
sections in the literature for quantification of the angle (Superior, Nasal, Inferior and Temporal) 
with their adjacent sections (Superior-Nasal and Superior Temporal against Superior, Superior-
Nasal and Inferior-Nasal against Nasal, Inferior-Nasal and Inferior-Temporal against Inferior and 
Inferior-Temporal and Superior-Temporal against Temporal).  
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Figure 3.19.  Representation of whether the differences between the four main four sections (Superior, Nasal, Inferior, 
Temporal) and their adjacent sections were statistically or not statistically significant. When no statistically significant 
differences were found between the sections, they were filled with the same colour (i.e. Superior and Superior-
Temporal parameters were found to not to be statistically significantly different, therefore, both of them were coloured 
in green). 
 
There were no statistically significant differences between the Superior and Superior-Temporal, 
for every angle parameter and for light and dark conditions. However, half of the parameters in 
the Superior-Nasal were statistically significant different to those in the Superior section.  
In the case of the Inferior section, all the parameter mean differences found with the Inferior-
Nasal section were statistically significantly different. When compared to Inferior-Temporal the 
majority of these differences (13 out of 16 parameters) were found as well to be statistically 
significant. This was the case for dark and light conditions. 
Differences in Nasal section parameters were all significantly different from the Superior-Nasal 
section parameters in light and darkness (with the exception of TIA 500 light) but no statistical 
differences were found with the other adjacent section, Inferior-Nasal, independent of lighting 
conditions (with the exception of ARA 500 light). Differences in Temporal section parameters 
were all statistically significantly different from the Superior-Temporal section parameters in light 
and darkness (with the exception of TISA 500 light and TIA 500 dark) and not statistically different 
from those found in the Inferior-Temporal, independent of lighting conditions. Please, refer to 
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Table 3.12 for more information (Appendix 1).  Figure 3.19 gives a visual representation of the 
results of this analysis. 
 
The influence of light and dark conditions on dimensions of the anterior chamber angle  
All the anterior chamber parameters were found to be smaller in darkness, as one would expect 
when the pupil is in a dilated position. A comparison between angle parameters in light and 
darkness was performed for each parameter using the Paired Samples t-test. The mean 
difference, standard deviation and p values are given in Table 3.13 (Appendix 1). 
The most marked difference in angle opening as an effect of change of lighting was noted in the 
Temporal section. All the parameters in this section were significantly narrower in dark 
conditions. Additionally, Inferior-Temporal and Superior-Temporal sections showed statistically 
significant changes similar but smaller to those found in the Temporal section. The Superior 
section was least influenced by light conditions although this difference was not statistically 
significant. Figures 3.20 to 3.27 present the effect of light and dark conditions on these 
parameters  
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Figures 3.20 and 3.21 Mean value of AOD (Angle Opening Distance) at 500 and 750m for 70 participants under light 
and dark conditions for eight sections of the angle. 
Figure 3.20 
Figure 3.21 
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Figures 3.22 and 3.23.  Mean value of ARA (Angle Recess Area) at 500 and 750m for 70 participants under light and 
dark conditions for eight sections of the angle. 
 
Figure 3.22 
Figure 3.23 
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Figures 3.24 and 3.25.  Mean value of TISA (Trabeculo-Iris Space Area) at 500 and 750m for 70 participants under light 
and dark conditions for eight sections of the angle. 
Figure 3.24 
Figure 3.25 
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Figures 3.26 and 3.27.  Mean value of TIA (Trabeculo-iris Angle) at 500 and 750m for 70 participants under light and 
dark conditions for eight sections of the angle. 
Figure 3.26 
Figure 3.27 
  
92 
 
Investigation of a gonioscopically occludable angle using anterior segment ocular coherence 
tomography  
When using the AS-OCT for diagnosis to verify the gonioscopic finding of an occludable angle (an 
angle in which the posterior pigmented trabecular meshwork could not be visualised in the 
primary position of gaze using applanation gonioscopy) taking into account the 4 main sections 
(Superior, Nasal, Inferior and Temporal), 62 eyes out of 70 were found to be occludable (2 or 
more sections appeared to be closed) and 8 non-occludable (3 or more sections appeared to be 
open) in light conditions. Using the OCT in dark conditions, 66 of the 70 eyes were found to be 
occludable and 4 non-occludable. If a decision on whether the angle was closed was made using 8 
sections, fewer eyes were diagnosed with occludable angles in both dark and light conditions; 46 
eyes were diagnosed as occludable (4 or more sections appeared to be closed) and 24 non-
occludable (5 or more sections appear to be open) in light conditions. In darkness, 62 were found 
occludable and 8 non-occludable.  A summary of this data can be found in Table 3.14. Sensitivity 
was determined using gonioscopy as the standard reference.  
Specificity could not be calculated as no patients with gonioscopically open angles were recruited. 
Confidence limits were calculated by Wilson’s method (as recommended by Agresti and Coull 
(1998)). 
 
  Diagnosis using 4 sections Diagnosis using 8 sections 
Occludable angle 
with gonioscopy 
 AS-OCT occludable AS-OCT non-
occludable 
AS- OCT occludable AS-OCT non-
occludable 
Gonioscopy found all 
the eyes were 
occludable n=70  
LIGHT 
n=62 
Sensitivity of 88.6% 
(79.0%-94.0%)CI 
95% 
n=8 n=46 
Sensitivity of 65.7% 
(54.0%-75.7%) CI 
95% 
n=24 
DARK 
n=66 
Sensitivity of 94.3% 
(86.2%-97.7%) CI 
95% 
n=4 n=62 
Sensitivity of 88.6% 
(79.0%-94.0%) CI 
95% 
n=8 
 
Table 3.14. Number of gonioscopical occludable angles detected with AS-OCT depending of number of sections taken in 
account and lighting conditions. Sensitivity values for the AS-OCT diagnosis are given only for those angles found to be 
occludable with both methods, gonioscopy and AS-OCT. CI= Confidence Interval 
 
A more detailed comparison between gonioscopical and AS-OCT diagnosis of the sections was 
carried out for the 4 main sections (Superior, Nasal, Temporal and Inferior). As shown in Tables 
3.15 and 3.16, it was found that in light and dark conditions, AS-OCT showed a higher number of 
occludable angles in the Superior section (45 eyes) while gonioscopy found higher numbers of 
occludable angles in the Inferior Section (28 eyes in light and 31 eyes in darkness). 
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The AS-OCT showed a high sensitivity for gonioscopically occludable angles in Superior and 
Inferior sections in light and dark, but this decreased for Temporal and Nasal for the same lighting 
conditions. Specificity was highest in the Nasal section in light (64.2%) and lowest for the Inferior 
section in dark. 
The diagnosis of occludable sections, independently of position or lighting conditions, was always 
higher in number using the AS-OCT than using gonioscopy.  
 
ANALYSIS OF 70 
EYES 
Superior Inferior Nasal Temporal 
 AS-OCT LIGHT AS-OCT LIGHT AS-OCT LIGHT AS-OCT LIGHT 
 Closed Open Closed Open Closed Open Closed Open 
Gonioscopy Closed n=45 
 
n=2 
 
n=34 
 
n=4 n=14 
 
n=42 n=15 
 
n=39 
 
Gonioscopy Open n=21 
 
n=2 
 
n=28 
 
n=4 n=5 
 
n=9 n=8 
 
n=8 
 
Total n=66 n=4 
 
n=62 
 
n=8 n=19 
 
n=51 n=23 
 
n=47 
 
Sensitivity AS-OCT 
in LIGHT 
95.7% 
(85.7%-98.8%) CI 95% 
89.7% 
(75.9%-95.8%) CI 95% 
25.0% 
(15.5%-37.7%) CI 95% 
27.7% 
(17.6%-40.9) CI 95% 
Specificity AS-OCT 
in LIGHT  
8.7 % 
(2.4%-26.8%) CI 95% 
12.5% 
(5.0%-28.1%) CI 95% 
64.28% 
(38.8%-83.6%) CI 95% 
50.0% 
(28.0%-72.0%) CI 95% 
 
Table 3.15. Number of gonioscopical occludable sections detected with AS-OCT and gonioscopy depending on position 
of the section in light condition. Sensitivity values for the AS-OCT diagnosis are given only for those sections found to be 
occludable with both methods, gonioscopy and AS-OCT. Specificity values are given only when both methods found the 
section non-occludable. CI= Confidence Interval 
 
ANALYSIS OF 70 
EYES 
Superior Inferior Nasal Temporal 
 AS-OCT DARK AS-OCT DARK AS-OCT DARK AS-OCT DARK 
 Closed Open Closed Open Closed Open Closed Open 
Gonioscopy Closed n=45 
 
n=2 
 
n=35 
 
n=3 n=23 
 
n=33 n=22 
 
n=32 
 
Gonioscopy Open n=20 
 
n=3 
 
n=31 
 
n=1 n=8 
 
n=6 n=8 
 
n=8 
 
Total n=65 n=5 
 
n=66 
 
n=4 n=31 
 
n=6 n=30 
 
n=40 
 
Sensitivity AS-OCT 
in DARK 
95.7% 
(85.7%-98.8%) CI 95% 
92.1%  
(79.2%-97.3%) CI 95% 
41.1%  
(29.2%-54.1%) CI 95% 
40.7%  
(28.7%-54.0%) CI 95% 
Specificity AS-OCT 
in DARK  
13.0% 
(4.5%-32.1%) CI 95% 
3.1%  
(0.5%-15.7%) CI 95% 
57.1%  
(21.4%-67.4%) CI 95% 
50.0%  
(28.0%-72.0%) CI 95% 
 
Table 3.16. Number of gonioscopical occludable sections detected with AS-OCT and gonioscopy depending on position 
of the section in darkness. Sensitivity values for the AS-OCT diagnosis are given only for those sections found to be 
occludable with both methods, gonioscopy and AS-OCT. Specificity values are given only when both methods found the 
section non-occludable. CI= Confidence Interval. 
 
Correlation between PAS and smaller dimensions of anterior chamber angle parameters 
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Correlation (Pearson’s 2-tailed test) between the percentage/extend of PAS* found on 
gonioscopy and the values of the parameters found in the same sections with the CASIA OCT for 
light and dark conditions was analysed. 70 eyes were included in this analysis. Only the 4 
gonioscopic quadrants/sections that would be described by gonioscopy were studied (Superior, 
Nasal, Inferior and Temporal). There was no statistically significant correlation (p>0.05) for any of 
the four studied angle sections with the exception of AOD and TIA 750 Temporal section in light 
conditions, which showed a weak association with presence of PAS in the same section with 
correlation coefficients of r=0.309 (p=0.007) and r=0.304 (p=0.010), respectively. 
*All eyes were included in this analysis including those with no PAS (0% of PAS). 
 
Relationship between IOP behaviour (DIOP fluctuation, DRPT and SIOP) and anterior chamber 
angle dimensions 
Using both univariate and multivariate regression models the levels of fluctuation for the DIOP 
found earlier in this report were related to each angle section in both light and dark conditions. 
The higher contribution to the model was achieved by negative standardised coefficients showing 
an inverse relationship between magnitude of fluctuation and angle dimensions. The multivariate 
models were statistically significant (p<0.05) for AOD 750 (light), ARA 750 (light and dark), TISA 
500 (light), TISA 750 (light), TIA 500 (light) and TIA 750 (light and dark). Detailed results are given 
in Tables 3.17 to 3.24 (Appendix 1).  
The dark room provocation test result showed a statistically significant inverse relationship with 
four parameters measured in light conditions (AOD 750, ARA 500 and ARA and TIA 750). However, 
in the case of the supine IOP test, the same statistical models did not show any relationship 
between these IOP test results and any of the angle parameters independent of lighting 
conditions. Detailed results are given in Tables 3.25 to 3.32 for DRPT results, and in Tables 3.33 to 
3.40 for the supine IOP test measurements. These tables can be found in Appendix 1. 
 
3.2.4 Discussion  
The dimensions of the anterior chamber angle of the Superior section were shown to be 
statistically different to the other sectors of the circumference of the angle, with the exception of 
the Superior-Temporal parameters and some parameters of the Inferior and Superior-Nasal 
sections. Additionally, there were significant differences in most angle parameters between the 
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Inferior section and the Nasal section. Similar results for the narrowest section were found by He, 
et al. (2007) in a study of Chinese subjects. Using ultrasound biomicroscopy (UBM), they 
described the Superior section parameters AOD 250 and 500 as narrowest when compared to the 
other 3 sections under study (Temporal, Nasal and Inferior) in a sample of PACS eyes. The widest 
was found to be the Temporal section, which differed from the present study results. Although, 
their data were not tested for statistical significance they were very similar to another study 
carried out by See and colleagues in eyes of Chinese and Eurasian ethnicity (See, et al., 2007). See, 
et al. (2007) found a statistically significant difference in the parameter dimensions among the 
three sections they studied with an AS-OCT in light conditions (Temporal, Nasal and Inferior 
sections) in an untreated sample of patients with diagnoses of PAC, PACS and PACG. They 
reported that the two parameters under study, AOD 500 and TISA 750, were significantly 
narrower in the Inferior section and wider in the Temporal section. These results were consistent 
with those found in the present study in the case of their narrowest section, but not in the widest. 
Although See and colleagues did not include the Superior section in their analysis, if in the present 
study only Temporal, Nasal and Inferior sections would have been the only sections to be 
considered, the Nasal section may have remained as the narrowest.  These differences may be 
due to differences in ethnicity. Leung, et al. (2010) studied a group of 30 Chinese and 30 
Caucasian subjects who presented with narrow angles. In their study AOD, TISA and TIA were 
measured in Nasal and Temporal using an AS-OCT in both Chinese and Caucasian eyes. They 
found that there were no differences between these parameters in the two ethnicities, but their 
data showed that the Nasal parameters were larger than the Temporal in the Caucasian group 
and similar for the Chinese. Another study in Caucasian participants diagnosed with PACS, PAC or 
PACG showed that TIA was widest in the Nasal section and narrowest in the Superior as measured 
with AS-OCT (Mansouri, Sommerhalder and Shaarawy, 2010). Although these differences were 
not statistically tested for the last two studies mentioned, it is possible that Chinese eyes present 
wider angles in the Temporal section while Caucasian present it in the Nasal. 
Given that the present study involved testing for differences between angle sectors in an image 
set acquired over less than 5 seconds, potential bias that may occur due to differences in lighting 
conditions and different time points, is minimised. Additionally these measurements were made 
under physiological conditions without any intervention from pharmacologic agents. In order to 
relate the average of the dimensions found in the studied sectors for every parameter to other 
factors such as peripheral anterior synechiae (PAS) or changes in the IOP, prior tests to check the 
statistical homogeneity of the parameters dimensions should be performed. Additionally, by 
averaging the parameters found in different sections, the contribution of single sections on their 
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own to the correlation may be missed. Hence, in this study the 8 sections parameters (Superior, 
Superior-Nasal, Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and Superior-
temporal) were included for statistical analysis. Several studies in the published literature, have 
taken an average of only 3 sections, for example, Su, et al., (2008) studied a sample of Chinese 
Singaporean eyes with PACS, PAC, PACG, primary open glaucoma and normal healthy eyes. 
They found a correlation between the mean value of AOD, ARA, TISA 500 and ARA and TISA 750 in 
3 sections (Inferior, Nasal and Temporal) with AS-OCT and the PAS found on gonioscopy for the 
same sections. Although the correlation was weak in every case, it showed a statistically 
significant inverse association between the clock hours of PAS and the averaged dimension of the 
parameters. In this thesis, separate correlations between percentages of PAS and smaller 
dimensions of the parameters of the main 4 sections in light and dark conditions were not found 
for the majority of the parameters. With the aim of being able to compare the present study’s 
result and those found by Su and colleagues, the average of the three sections together with the 
degree of presence of PAS was correlated (mirroring Su et al’s methods). The Spearman’s 
coefficients showed an extremely weak inverse association between averaged parameters and 
degree of PAS (-0.027, -0.096, -0.088, -0.048 and -0.041 for of AOD, ARA, TISA 500 and ARA and 
TISA 750 respectively). Additionally, none of these correlations were statistically significant. The 
differences between studies were therefore unlikely to be due to the different statistical 
methodology. It is still unclear whether these differences are due to different mechanisms of 
angle closure in Chinese and Caucasians. Aung, et al., (2005) found that while PAS increased as 
the anterior chamber depth (ACD) decreased in Singaporeans, in Mongolians there was a 
threshold where PAS were not commonly found (ACD of 2.4 mm or more).  It is possible that the 
rate of PAS in Caucasians is not related to narrowing of the angle until a certain threshold is 
reached, akin to that observed in the Mongolian study. It would be for further studies comparing 
Chinese and Caucasian populations to determine this. 
Relatively good concordance was found between AS-OCT and gonioscopy when diagnosing an 
occludable angle in dark conditions. It is not surprising that the highest sensitivity (of the OCT in 
predicting a gonioscopically occludable angle) was achieved when using OCT scans of the 4 
principal sections and also when making the comparison using OCT in dark conditions rather than 
in the light. The higher sensitivity in dark conditions can be explained on account of the similarity 
in light intensity used for gonioscopy to that of the OCT measurement in darkness. The improved 
agreement when considering 4 sections rather than more than 4 sub-sections can be explained by 
the fact that the gonioscopy technique used in this study involved specific description of 4 
quadrants, the technique most commonly employed in clinical practice. This gonioscopic 
technique involves the examiner observing the corneal wedge in low lighting, with the slit-lamp 
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beam aimed at the centre of the quadrant. It would have been interesting to perform gonioscopy 
in the diagonal sections and re-assessed sensitivity of the AS-OCT taking in account these 8 
sections again. If the sensitivity would have been similar to that found using 4 sections, 
gonioscopy may have been overestimating the number of occludable angles in the clinical 
environment. This can be determined in the future.  
Nolan, et al. (2007) reported that among 152 eyes gonioscopically diagnosed with angle closure, 
the AS-OCT was able to detect 143 in darkness (94.1% sensitivity) and that this number decreased 
when the diagnosis was performed using the scans taken in light conditions, where the AS-OCT 
detected only 127 occludable angles out of 149 diagnosed by gonioscopy (85.23% sensitivity). 
However, in their study the OCT occludable diagnosis criterion was based on the analysis of only 3 
sections (Nasal, Inferior and Temporal). The authors diagnosed an occludable angle if one or more 
sections were occludable. This criterion may have resulted in their reporting higher rates of 
sensitivity for the AS-OCT on account of the increased likelihood of detecting 1 section closed of 3 
possible sections than 2 sections closed of 4 sections, the latter being the criteria for the present 
study. The reason why this present study found similar results to that of Nolan et al. is probably 
because the present study found occludable angles more commonly in the Superior section. To 
explore this assertion, we used Nolan et al’s criterion to re-analyse the data and this led to 
increased values for sensitivity to 97.1% (95% CI: 90.1%-99.2%) for darkness and to 92.85% (95% 
CI: 84.3%-96.9%) for light conditions.  
Additionally, Nolan et al. reported values for sensitivity of the OCT in the Inferior section that 
were very similar to the ones found in the present study, but Nolan’s Nasal and Temporal sections 
sensitivities were higher (81.5% and 66.1%, respectively). In Nolan’s study there is no allusion to 
whether the sensitivity results related to these sections were calculated when comparing AS-OCT 
in light or AS-OCT in dark versus gonioscopy and it is therefore difficult to deduce a possible 
reason for these differences. 
The low rates of specificity found with the AS-OCT instrument may be explained if one considers 
the differences in how the diagnosis is made with the OCT image compared to that with 
gonioscopy. As described in the methodology, a section was diagnosed as occludable if there was 
irido-corneal contact anterior to the scleral spur observed with AS-OCT. While, in the case of 
gonioscopy, an occludable angle was diagnosed when the posterior pigmented trabecular 
meshwork was not visible. On occasion there can be contact between iris and cornea anterior to 
the scleral spur noted on OCT (‘occludable’ by OCT), while on gonioscopy the area of contact is 
judged to be sufficiently posterior with adequate visibility of the posterior trabecular meshwork 
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to justify a diagnosis of a gonioscopically open angle (i.e. the OCT is calling a ‘false positive’). The 
choice of this OCT criterion in this study is justified, given the absence of a more accurate method 
for judging the height or extent of the posterior pigmented trabecular meshwork on current OCT 
instruments.  
The results found for diurnal IOP fluctuation suggested that an eye with smaller angle dimensions 
would exhibit a greater range of IOP (difference between peak and trough) during the day. 
Furthermore, the multiple predictor statistical models were able to predict this fluctuation from 
OCT measurements of anterior chamber angle parameters. This is a novel finding. Were this to be 
confirmed with a larger sample size, OCT angle parameter measurements could be used to predict 
IOP diurnal fluctuations in at-risk patients, allowing clinicians to selectively offer laser treatment 
to those where a higher diurnal IOP range would be judged as high-risk.  This could be explored in 
a future study.  
Wang, et al., (2010) reported a statistically significant relationship between numbers of closed 
sections in the angle of a given eye in dark conditions and a positive result in the dark room 
provocative test (DRPT). In their study, a positive DRPT result was considered when the IOP rose  
 8mmHg after the subject had remained in the prone position for 1.5 hours in darkness. The level 
of IOP after the test and not the difference pre and post-test was used in their statistical 
correlation with sectors of angle closure. Additionally a sector was considered closed if the scleral 
spur was obscured by the root of the iris in the AS-OCT scan. This definition of closure may 
overestimate the number of closed sections (physiologically the trabecular meshwork is placed 
anterior to the scleral spur and, therefore, sections of the eyes where only the scleral spur and 
posterior areas are obscured should still drain aqueous humour). The association they reported 
involved an association between a simple variable for angle closure, namely ‘closed’ or ‘open’, 
and the IOP level post-DRPT. They found a direct association between those two variables 
(r=0.755, R2 of 0.074, p<0.001). Quantitative measurements of the anterior chamber angle such as 
angle opening distance were not used in their analyses. In the case of the present study, an 
inverse association between the change in IOP pre and post-DRPT and smaller dimensions for only 
three parameters in light was found. It was not possible to accurately replicate Wang’s study, as 
the DRPT duration in the present study was 15 minutes. However, in an attempt, a regression 
model was fitted with the number of closed sections found with gonioscopy and the IOP found 
after the DRPT. A statistically significant association was found with an r-value of 0.272 and an R2 
of 0.074. When the same number of sections was fitted in another regression model with the 
DRPT result (IOP post DRPT minus IOP pre DRPT), no association was found (r=0.068, R2 of 0.005, 
p=0.585). It was possible that the number of closed sections in the angle was associated with the 
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IOP independently to the time of measurement (before or after the DRPT). Another regression 
model was then fitted for finding a possible association between the number of closed sections 
and the IOP found pre-DRPT. This model gave a statistically significant association between the 
two variables (r=0.248, R2 of 0.061, p=0.045). It is, therefore, possible that the number of closed 
angle sections found in an eye may be associated with the IOP level found for the same eye, but it 
seems to be unlikely to show a similar association with the IOP differential due to the DRPT. 
No published studies have been found regarding a possible association between the angle 
dimensions and the SIOP. This study did not demonstrate any differences in IOP between seated 
and supine IOP in those eyes with smaller angle dimensions.  
As shown in the results the Temporal section of the angle was the most affected by light changes. 
All the parameters of this section measured at 500m from the scleral spur duplicated or nearly 
duplicated their dimension because of the light effect (rates from 1.7 to 2.2 times the dimension 
of the parameter in dark).  In the case of the parameters found at 750 m, light increased the 
dimension 1.2 to 1.4 times. These results differ slightly from those found by Ang and Wells (2010) 
in the Temporal section of Caucasian eyes diagnosed with PAC, PACS or PACG. Their parameters 
increased dimension by 1.49 to 1.6 times and this increase was similar in the group of parameters 
measured at 500 and 750m. The Temporal section angle configuration in the present sample 
changes less at 750m than at 500m. Differences between this and the study by Ang and Wells 
(2010) may be due to different proportions of eyes with a plateau iris configuration in the two 
subject groups. One can hypothesize that eyes with a plateau iris configuration will differ from 
steep or regular iris configurations in terms of the angle opening at these two distances from the 
scleral spur in response to light.  
The Van Herick and the flashlight technique have been described as less accurate in the detection 
of narrow angles when compared with gonioscopy (Thomas, George, Braganza and Muliyil, 1996). 
Thomas, George, Braganza and Muliyil, (1996) performed a comparative study using gonioscopy 
as the gold standard versus the flashlight test and Van Herick’s test in the diagnosis of occludable 
angles. The specificity rates for the flashlight and Van Herick were 82.7% and 89.3% respectively. 
Their rates of sensitivity were lower, 45.5% and 61.9%, respectively.  Both of these tests are 
performed by focusing light on the temporal section of the angle. The Van Herick’s technique uses 
a lower amount of lighting (similar to that used in gonioscopy) than is used in the flashlight test. It 
is, therefore, unsurprising that higher rates of concordance were found for Van Herick’s than for 
the flashlight test when compared to gonioscopy. In the present study it has been found that 
there is a statistically significant widening of the Temporal sector of the angle due to the effect of 
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light (Temporal, Superior-Temporal and Inferior-Temporal). Furthermore, the Temporal sector 
seemed to be the most affected by the ambient light compared to the other sections. Following 
on from these results, it would be interesting to assess the sensitivity of the Van Herick technique 
with the lights of the room on (achieving similar levels of lux as in lighting conditions in the 
present study) and while considering the Van Herick as the gold standard when comparing to 
gonioscopical results. It may happen that the majority of eyes detected as narrow with Van Herick 
in light conditions would be further detected with gonioscopy in darkness.  
 
3.2.5 Conclusions  
The superior section of the anterior chamber angle was found to be narrower than the inferior 
and horizontal sectors.  The statistical analysis highlighted the importance of comparing OCT 
dimensions of different sections of the angle when using fewer than eight sections for multiple 
regression/and or correlation statistical analysis, a finding that has been overlooked in some 
studies in the current literature in this area.  
Examiners who may attempt a diagnosis of occludable angle using the AS-OCT should be aware of 
the difference in the outcomes when using 4 or 8 sections for a diagnosis. To achieve better 
concordance between OCT and gonioscopy, a diagnosis of an occludable angle based on the 4 
main sections in dark conditions is recommended.  
No statistical association was found between smaller dimensions of the angle found with AS-OCT 
and the extent of PAS in dark or light conditions. 
Professionals managing patients with narrow angles should be aware of the possible higher levels 
of IOP fluctuation that this study has found to be associated with narrower anterior chamber 
angles. 
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CHAPTER 4. Investigation of the effect of the Laser 
Peripheral Iridotomy (LPI) on the anterior chamber angle 
dimensions and on the diurnal intraocular pressure. 
 
4.1 Relationship between the degree of anterior chamber angle opening 
following laser peripheral iridotomy and intraocular pressure 
 
4.1.1 Introduction 
An understanding of how the anatomical dimensions change with time following laser peripheral 
iridotomy is of clinical importance. Most studies that have examined anterior segment imaging of 
Caucasian subjects with narrow angles report on a post-LPI assessment at less than 3 months. 
These assessments did not explore the longer-term effect of the laser on the chamber angle. 
Additionally, this effect has always been measured on the treated eye.  A comparison with an 
untreated fellow eye with an occludable angle has not been reported previously in the literature 
that involves anterior chamber imaging post-iridotomy (López-Caballero, et al., 2010; Mansouri, 
Burgener, Bagnoud and Shaarawy, 2009; Ang and Wells, 2010; Antoniazzi, et al., 2010). It is 
unknown what the effect of time is on the untreated eye’s anterior chamber dimensions.  
Previous studies report that the anterior chamber angle widens post-LPI. It is possible to 
hypothesise that in subjects with bilateral occludable angles, those eyes that received treatment 
with LPI would show an increase of the angle parameters (widening) as observed with AS-OCT 
whereas the fellow untreated eyes would remain unchanged (1st Hypothesis). 
Additionally, the post-LPI IOP level in Caucasian treated eyes has been reported as either 
remaining unchanged from a baseline measurement 1 week and 3 months post-LPI (Moster, et 
al., 1986) or to decrease by 1 month post-LPI  (López-Caballero, et al., 2010). One may also 
hypothesise that there exists a relationship between rate of opening and time of measurement 
post-LPI and that a reduction in IOP may be associated with the degree of opening (2nd 
Hypothesis).  
 
4.1.2 Methodology and Statistical Analysis plan 
The CASIA OCT scans and IOP data collected in Visit 1 (Baseline; Mean time from Visit 2= 17.4 
days, SD 16.5), Visit 4 (1 week post LPI; Mean time from Visit 2= 8.2 days, SD 2.0), Visit 5 (1 month 
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post LPI; Mean time from Visit 2= 43.6 days, SD 5.1), Visit 6 (3 moths post LPI; Mean time from 
Visit 2= 92.5 days, SD 8.4) and Visit 11 (6 months post LPI; Mean time from Visit 2= 178.4 days, SD 
11.1) were used for the analysis in this section. Those scans taken in dark conditions were 
quantified (this would allow comparison with other reports using the UBM and Pentacam, 
commonly taken in darkness). The data of 39 participants, 78 eyes scans (treated and fellow 
untreated) and IOP were used in the statistical analysis until the second randomisation took place 
(Visit 6). From that time point onwards only the data obtained for those patients who only 
received LPI as a laser treatment was used (28 treated and their fellow 28 untreated eyes scans 
for Visit 11 data). The figure below (Figure 4.1) shows a visual of the participants flow before and 
after the second randomisation (Visit 6). 
 
Figure 4.1. Participant pathway through the study. The upper half of the figure, as divided by the dashed line, shows the 
pathway of those eyes randomised to receive Laser Peripheral Iridotomy (LPI) and the lower half of the figure shows the 
pathway of the untreated fellow eyes. Abbreviations in this figure: n= number of eyes in each group. LPI= Laser 
Peripheral Iridotomy. OCC= Post-LPI eyes with occludable angles. UNOCC= Post-LPI eyes with unoccludable eyes. ALPI= 
Eyes with post-LPI occludable angles that were further randomised into receiving ALPI. NFT= Eyes with post-LPI 
occludable angles that were further randomised into not receiving further treatment. The data for the eyes in the red 
boxes was not used in the analysis for this section results. 
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Eight sectors (Superior, Superior-Nasal, Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, 
Temporal and Superior-Temporal) for every eye with their corresponding 8 parameters (AOD, 
ARA, TISA and TIA at 500 and 750 microns) were assessed with the CASIA analysis software.  
The IOP used for Visit 1 and Visit 11 was the diurnal IOP taken closest in time to the CASIA capture 
of images.  However, it is important to be aware that the aim of this section was not to show 
changes of the IOP through time, but to show changes associated with differences in the 
parameter dimensions between groups (treated versus untreated eyes) and measured at 
different time points. 
The mean total power used to perform the iridotomy was 16.11mJ (SD 10.879mJ) and the mean 
number of shots 13 (SD 8.6).  
A patent iridotomy post-LPI was present in all the treated eyes post-LPI and throughout the study. 
Patency was tested with the retroillumination technique using the same slit lamp. 
 
The statistical analysis was divided in two sub-sections depending on the hypothesis to be tested: 
1st Hypothesis: “The treated eye angle parameters would experience a widening effect after the 
LPI while the untreated eyes parameters would remain unchanged. Furthermore, in the case of 
the treated eye, this widening would be directly associated with time elapsed since the 
procedure” 
To statistically show the effect of the LPI on the angle parameters of treated and untreated eyes, 
two different statistical models were performed. The first statistical approach was to use paired 
samples t-test to compare Visit 4, Visit 5, Visit 6 and Visit 11 against Visit 1 (baseline) for the 
treated eye angle parameters and a separate analysis for the untreated ones. These analyses 
would show differences through time for both groups, but not differences between groups. A 
second analysis was designed to show differences through time between treated and untreated 
eyes adjusted for differences at baseline. Analysis of covariance was used with this aim. Both 
groups were compared against each other at Visits 4, 5, 6 and 11 while these differences were 
adjusted for the differences between the same groups at Visit 1. 
The association with time was investigated with mixed effects regression between time elapsed 
since the LPI and the adjusted mean differences in the parameters found between the treated 
and untreated groups. 
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2nd Hypothesis: “There may be an association between, first, the widening effect on the angle and 
time elapsed since LPI (direct association) and, second, between this effect and a decrease in IOP 
levels (inverse association)” 
These associations were investigated using mixed effects regression models. The adjusted mean 
differences between the parameters for the two groups (treated and untreated) were associated 
to adjusted differences in time elapsed (first regression model) and IOP (second regression model) 
for both groups. 
 
4.1.3 Results 
Forty eyes of forty patients received LPI. The eye receiving the LPI was randomly selected as 
previously described in this thesis. Three months after the LPI (Visit 6, Mean time 92.5 days, SD 
8.4), 21 eyes remained occludable as observed with applanation gonioscopy. Eleven eyes of these 
21 were further randomised to receive ALPI and were not included in the statistical analysis.  
The mean values for every parameter in every visit together with their standard deviation can be 
found in Table 4.1 (Appendix 1). Both treated and untreated eyes dimensions were graphed for 
the 8 sections and for each of the eight parameters studied through time (Visit 1, 4, 5, 6 and 11). 
These graphs/figures can be found in Appendix 1.  
Results 1st Hypothesis: “The treated eye parameters would experience a widening effect after the 
LPI while the untreated eyes parameters would remain unchanged”. 
The paired samples t-test showed a widening effect through time for the treated and untreated 
eye in the majority of the parameters for the sections under study. There were very few statistical 
significant differences between the follow-up visits angle parameters and those found at baseline.  
The most marked widening effect of the angle was found for the Inferior-Temporal in the case of 
the treated eye. In this section the parameters tended to increase through time until Visit 11 were 
there was a slight regression in widening. The majority of the mean differences in this section 
were statistically significant. As an example of this trend of widening through visits and final slight 
regression, Inferior-Temporal ARA 750 presented a mean difference with Visit 1 of 0.0201mm2 
(0.035) p=0.002 at Visit 4, 0.0277mm2 (0.046) p=0.001 at Visit 5, 0.0296mm2 (0.041) p<0.001 at 
Visit 6 and 0.0242mm2 (0.045) p=0.015 at Visit 11. Similar pattern was followed by TISA 750 in the 
same section, where the differences found at Visit 4 when compared to Visit 1 were 0.0157mm2 
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(0.030) p=0.005; at Visit 5, 0.0206mm2 (0.042) p=0.006; at Visit 6, 0.0235mm2 (0.035) p<0.001 and 
at Visit 11, 0.0189mm2 (0.038) p=0.024. 
There was a statistically significant widening of the treated eye in ARA 500 found in the Superior-
Nasal section between Visit 1 and Visits 4, 5 and 6. It increased by 0.090mm2 (0.016) p=0.002 at 
Visit 4, by 0.062mm2 (0.018) p=0.049 at Visit 5 and by 0.0067mm2 (0.019) p=0.050 at Visit 6. There 
was an increase of 0.058mm2 (0.020) at Visit 11, but this difference resulted non statistically 
significant (p=0.165). 
Nasal and Temporal sections also showed some statistically significant widening effect of the 
parameters. In the case of these two sections, the significant widening effect was as commonly 
found in the treated eye as it was in the untreated. For example, a statistically significant increase 
in Temporal AOD 500 was found at Visit 4 and Visit 5 for the treated eye (0.0254mm (0.052) 
p=0.007 and 0.0212mm (0.054) p=0.030, respectively) and similar widening occurred in the 
untreated eye for the same parameter (0.0189 (0.036) p=0.005 at Visit 4 and 0.0214mm (0.044) 
p= 0.009 at Visit 5). Additionally some statistically significant widening was observed in the 
untreated Temporal ARA and TISA 750 at Visits 4, 5 and 6. The same effect was statistically      
non-significant in the case of the treated eye for the same parameters. Something similar 
happened at Visit 4 when assessing the mean differences for the untreated eye in the case of 
Nasal ARA and TISA 500 and ARA and TISA 750. These four parameters experienced a statistically 
significant widening in the untreated eye while the treated eye was non-statistically significant. 
Superior-Temporal parameters widened in its majority at Visit 4 for both, treated and untreated 
eyes, although the effect was higher in the case of the treated group. For example, ARA 500 
increased by 0.0105mm (0.027) p=0.033 in the treated eye and by 0.0081mm (0.022) p=0.044 in 
the untreated eye. Similar widening differences between treated and untreated eyes were found 
for TISA 500 and AOD, ARA and TISA 750 for this section at Visit 4. At Visit 5, the statistically 
significant widening of the parameters in this section was only found in the treated eyes. 
The mean differences and p-values for every parameter under study can be found in Table 4.2 
(next 4 pages). The statistically significant mean differences are highlighted in yellow colour. 
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Table 4.2. Pair Samples t test comparing the dimensions of the angle parameters for treated and untreated eyes through time using Visit 1 as baseline. The eight angles sections were compared (Superior, Inferior, Superior-
Nasal, Inferior-Temporal, Nasal, Temporal, Inferior-Nasal and Superior-Temporal). Statistically significant values have been highlighted in yellow colour. M Diff=Mean difference. SD=Standard Deviation 
  
Paired Samples  
t test  
Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
SU
P
ER
IO
R
 
AOD500 
-0.0021 
(0.044) 0.777 
0.0094 
(0.037) 0.152 
0.0003 
(0.048) 0.967 
0.0096 
(0.034) 0.113 
0.0051 
(0.047) 0.529 
0.0060 
(0.040) 0.388 
-0.000 
(0.042) 0.969 
0.0126 
(0.038) 0.123 
ARA500 
-0.0021 
(0.016) 0.464 
0.0018 
(0.012) 0.389 
-0.0009 
(0.020) 0.777 
-0.0017 
(0.013) 0.467 
0.0007 
(0.016) 0.803 
-0.0007 
(0.012) 0.764 
0.0033 
(0.012) 0.198 
0.0025 
(0.010) 0.221 
TISA500 
-0.0020 
(0.015) 0.447 
0.0016 
(0.011) 0.398 
-0.0005 
(0.018) 0.873 
-0.0014 
(0.013) 0.542 
0.0011 
(0.015) 0.691 
-0.0006 
(0.012) 0.759 
0.0040 
(0.012) 0.124 
0.0023 
(0.009) 0.268 
TIA500 
-0.0059 
(4.018) 0.993 
0.6333 
(3.019) 0.237 
0.0943 
(3.886) 0.887 
0.7147 
(2.805) 0.147 
0.2471 
(3.365) 0.671 
0.2765 
(2.628) 0.544 
-0.2375 
(3.201) 0.720 
1.0130 
(3.110) 0.133 
AOD750 
0.0170 
(0.077) 0.207 
0.0055 
(0.059) 0.610 
0.0169 
(0.071) 0.168 
0.0067 
(0.052) 0.469 
0.0299 
(0.062) 0.009 
0.0013 
(0.075) 0.920 
0.0240 
(0.064) 0.087 
0.0127 
(0.054) 0.281 
ARA750 
0.0013 
(0.026) 0.772 
0.0046 
(0.021) 0.247 
0.0009 
(0.032) 0.861 
0.0010 
(0.023) 0.812 
0.0046 
(0.027) 0.338 
0.0037 
(0.026) 0.421 
0.0054 
(0.020) 0.209 
0.0059 
(0.018) 0.137 
TISA750 
0.0016 
(0.025) 0.719 
0.0042 
(0.021) 0.283 
0.0014 
(0.030) 0.791 
0.0015 
(0.023) 0.711 
0.0051 
(0.026) 0.267 
0.0038 
(0.026) 0.408 
0.0054 
(0.019) 0.193 
0.0063 
(0.017) 0.099 
TIA750 
0.9853 
(4.765) 0.237 
0.2633 
(3.067) 0.642 
0.7457 
(4.077) 0.287 
0.4375 
(2.492) 0.328 
1.4206 
(3.471) 0.023 
0.1906 
(3.557) 0.764 
0.5739 
2.791) 0.335 
0.9591 
(3.456) 0.207 
IN
FE
R
IO
R
 
AOD500 
-0.0022 
(0.053) 0.809 
-0.0085 
(0.055) 0.376 
0.0008 
(0.062) 0.938 
0.0020 
(0.059) 0.845 
-0.0016 
(0.063) 0.880 
-0.0110 
(0.053) 0.224 
-0.0157 
(0.090) 0.401 
0.0075 
(0.066) 0.586 
ARA500 
0.0027 
(0.019) 0.415 
-0.0024 
(0.030) 0.650 
0.0027 
(0.021) 0.464 
0.0039 
(0.020) 0.257 
-0.0005 
(0.016) 0.869 
-0.0011 
(0.018) 0.718 
-0.0055 
(0.021) 0.213 
0.0034 
(0.025) 0.512 
TISA500 
0.0022 
(0.014) 0.360 
-0.0020 
(0.028) 0.673 
0.0027 
(0.020) 0.433 
0.0043 
(0.020) 0.225 
-0.0003 
(0.015) 0.912 
-0.0013 
(0.016) 0.645 
-0.0049 
(0.020) 0.260 
0.0015 
(0.022) 0.737 
TIA500 
0.4559 
(3.543) 0.458 
-1.0618 
(4.818) 0.208 
0.4057 
(4.040) 0.556 
-0.3343 
(4.565) 0.668 
0.4971 
(4.211) 0.490 
-(1.0314 
(3.691) 0.107 
-0.6208 
(4.082) 0.464 
0.2833 
(4.755) 0.773 
AOD750 
0.0116 
(0.061) 0.272 
-0.0085 
(0.064) 0.452 
0.0098 
(0.078) 0.464 
0.0001 
(0.050) 0.995 
0.0297 
(0.083) 0.042 
-0.0091 
(0.082) 0.520 
-0.0012 
(0.077) 0.941 
-0.0165 
(0.083) 0.343 
ARA750 
0.0053 
(0.023) 0.191 
-0.0019 
(0.039) 0.788 
0.0042 
(0.033) 0.459 
0.0044 
(0.027) 0.330 
0.0033 
(0.028) 0.490 
-0.0017 
(0.029) 0.727 
-0.0068 
(0.035) 0.350 
0.0029 
(0.040) 0.728 
TISA750 
0.0049 
(0.020) 0.167 
-0.0019 
(0.037) 0.767 
0.0046 
(0.033) 0.429 
0.0045 
(0.027) 0.327 
0.0031 
(0.028) 0.529 
-0.0020 
(0.027) 0.669 
-0.0061 
(0.034) 0.401 
0.0011 
(0.038) 0.889 
TIA750 
0.5088 
(3.484) 0.401 
-0.7606 
(3.315) 0.197 
0.1057 
(4.114) 0.880 
-0.2543 
(2.753) 0.588 
1.4571 
(4.826) 0.083 
-0.6143 
(4.213) 0.394 
-0.3417 
(3.584) 0.645 
-0.8833 
(4.172) 0.310 
 107 
 
  
Paired Samples  
t test  
Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. (CONTINUATION). Pair Samples t test comparing the dimensions of the angle parameters for treated and untreated eyes through time using Visit 1 as baseline. The eight angles sections were compared (Superior, 
Inferior, Superior-Nasal, Inferior-Temporal, Nasal, Temporal, Inferior-Nasal and Superior-Temporal). Statistically significant values have been highlighted in yellow colour. M Diff=Mean difference. SD=Standard Deviation. 
SU
P
ER
IO
R
-N
A
SA
L 
  AOD500 
 0.0132 
(0.040) 
0.061 
-0.0009 
(0.030) 
0.858 
0.0135 
(0.036) 
0.034 
0.0006 
(0.042) 
0.935 
0.0109 
(0.044) 
0.151 
0.0129 
(0.037) 
0.054 
0.0143 
(0.050) 
0.176 
0.0075 
(0.050) 
0.476 
ARA500 
0.0090 
(0.016) 
0.002* 
0.0006 
(0.017) 
0.837 
0.0062 
(0.018) 
0.049* 
-0.0020 
(0.026) 
0.661 
0.0067 
(0.019) 
0.050* 
0.0032 
(0.016) 
0.263 
0.0058 
(0.020) 
0.165 
-0.0010 
(0.023) 
0.846 
TISA500 
0.0075 
(0.013) 
0.002* 
0.0010 
(0.015) 
0.718 
0.0055 
(0.016) 
0.053 
-0.0019 
(0.021) 
0.600 
0.0055 
(0.017) 
0.063 
0.0037 
(0.014) 
0.148 
0.0048 
(0.018) 
0.215 
-0.0001 
(0.021) 
0.984 
TIA500 
0.6794 
(3.935) 
0.321 
-0.6500 
2.836) 
0.190 
0.3514 
(3.627) 
0.570 
-0.1559 
(4.184) 
0.829 
-0.3657 
(4.009) 
0.593 
0.4727 
(4.503) 
0.551 
-0.0500 
(4.424) 
0.956 
0.2000 
(5.055) 
0.851 
AOD750 
0.0229 
(0.049) 
0.011* 
0.0153 
(0.051) 
0.091 
0.0127 
(0.052) 
0.155 
0.0168 
(0.053) 
0.068 
0.0206 
(0.055) 
0.040* 
0.0185 
(0.046) 
0.021 
0.0210 
(0.073) 
0.170 
0.0067 
(0.047) 
0.492 
ARA750 
0.0148 
(0.024) 
0.001* 
0.0029 
(0.023) 
0.471 
0.0110 
(0.027) 
0.020* 
0.0009 
(0.032) 
0.875 
0.0093 
(0.026) 
0.052 
0.0058 
(0.022) 
0.132 
0.0070 
(0.030) 
0.267 
-0.0003 
(0.029) 
0.967 
TISA750 
0.0130 
(0.021) 
0.001* 
0.0039 
(0.020) 
0.288 
0.0098 
(0.025) 
0.027* 
0.0008 
(0.026) 
0.863 
0.0079 
(0.025) 
0.074 
0.0062 
(0.020) 
0.083 
0.0058 
(0.028) 
0.323 
0.0006 
(0.026) 
0.914 
TIA750 
1.0882 
(3.377 
0.069 
0.3794 
(3.044) 
0.472 
0.1371 
(3.444) 
0.815 
0.8571 
(2.870) 
0.086 
0.0515 
(3.968) 
0.941 
0.5771 
(3.265) 
0.303 
0.2750 
(4.555) 
0.770 
-0.0750 
(3.281) 
0.912 
IN
FE
R
IO
R
-T
EM
P
O
R
A
L 
AOD500 
  0.0297 
(0.056) 
0.004* 
0.0047 
(0.048) 
0.579 
0.0263 
(0.074) 
0.044 
0.0132 
(0.056) 
0.181 
0.0386 
(0.056) 
<0.001* 
0.0085 
(0.055) 
0.369 
0.0308 
(0.068) 
0.036* 
0.0163 
(0.043) 
0.074 
ARA500 
0.0071 
(0.023) 
0.078 
-0.0009 
(0.022) 
0.828 
0.0135 
(0.029) 
0.010* 
0.0035 
(0.024) 
0.413 
0.0139 
(0.027) 
0.004* 
0.0032 
(0.023) 
0.426 
0.0083 
(0.024) 
0.111 
-0.0010 
(0.019) 
0.808 
TISA500 
0.0049 
(0.020) 
0.165 
-0.0018 
(0.020) 
0.612 
0.0087 
(0.025) 
0.051 
0.0029 
(0.024) 
0.481 
0.0100 
(0.024) 
0.019* 
0.0015 
(0.021) 
0.683 
0.0064 
(0.021) 
0.150 
-0.0021 
(0.017) 
0.563 
TIA500 
1.2971 
(5.933) 
0.211 
-0.6939 
(4.204) 
0.350 
-0.5886 
(5.748) 
0.549 
0.8471 
(5.847) 
0.404 
1.0486 
(6.049) 
0.312 
-0.7857 
(4.174) 
0.273 
0.3500 
(6.355) 
0.790 
0.6125 
(3.669) 
0.422 
AOD750 
0.0663 
(0.081 
<0.001* 
0.0024 
(0.074) 
0.851 
0.0602 
(0.092) 
<0.001* 
0.0169 
(0.068) 
0.148 
0.0707 
(0.071) 
<0.001* 
0.0202 
(0.069) 
0.102 
0.0653 
(0.110) 
0.008* 
0.0058 
(0.050) 
0.579 
ARA750 
0.0201 
(0.035) 
0.002* 
0.0014 
(0.034) 
0.811 
0.0277 
(0.046) 
0.001* 
0.0080 
(0.037) 
0.210 
0.0296 
(0.041) 
<0.001* 
0.0059 
(0.035) 
0.346 
0.0242 
(0.045) 
0.015* 
-0.0002 
(0.024) 
0.973 
TISA750 
0.0157 
(0.030) 
0.005* 
0.0003 
(0.032) 
0.957 
0.0206 
(0.042) 
0.006* 
0.0069 
(0.037) 
0.278 
0.0235 
(0.035) 
<0.001* 
0.0042 
(0.034) 
0.474   
0.0189 
(0.038) 
0.024* 
-0.0014 
(0.023) 
0.761 
TIA750 
2.3176 
(4.194 
0.003* 
-0.8588 
(4.145) 
0.236 
0.6200 
(4.507) 
0.421 
0.7229 
(4.631) 
0.362 
1.7000 
(3.893) 
0.014* 
-0.0606 
(3.439) 
0.920 
1.4875 
(5.632) 
0.209* 
-0.3208 
(2.579) 
0.548 
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Paired Samples  
t test  
Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE 
M. Diff 
(SD) 
P value M. Diff (SD) P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
N
A
SA
L 
AOD500 
  0.0120 
(0.058) 
0.234 
0.0126 
(0.054) 
0.182 
0.0098 
(0.054) 
0.288 
0.0114 
(0.045) 
0.139 
0.0133 
(0.049) 
0.117 
0.0130 
(0.044) 
0.091 
0.0217 
(0.052) 
0.054 
0.0049 
(0.060) 
0.700 
ARA500 
0.0021 
(0.027) 
0.654 
0.0137 
(0.032) 
0.018* 
0.0015 
(0.025) 
0.728 
0.0076 
(0.027) 
0.112 
0.0039 
(0.030) 
0.444 
0.0104 
(0.031) 
0.061 
-0.0002 
(0.024) 
0.967 
0.0085 
(0.039) 
0.314 
TISA500 
0.0018 
(0.023) 
0.660 
0.0117 
(0.026) 
0.014* 
0.0000 
(0.025 
0.995 
0.0071 
(0.021) 
0.053 
0.0020 
(0.028) 
0.670 
0.0097 
(0.027) 
0.043* 
-0.0013 
(0.021) 
0.765 
0.0060 
(0.030) 
0.341 
TIA500 
0.5706 
(5.978) 
0.582 
0.6647 
5.474) 
0.484 
-0.7486 
(5.526) 
0.428 
0.3771 
(4.717) 
0.639 
0.0314 
(5.186) 
0.972 
0.2294 
(3.799) 
0.727 
0.3667 
(4.556) 
0.697 
-1.1565 
(4.237) 
0.204 
AOD750 
0.0352 
(0.058) 
0.001* 
0.0094 
(0.052) 
0.298 
0.0149 
(0.053) 
0.102 
0.0217 
(0.069) 
0.075 
0.0349 
(0.053) 
<0.001 
0.0182 
(0.061) 
0.089 
0.0309 
(0.071) 
0.044* 
0.0133 
(0.085) 
0.452 
ARA750 
0.0100 
(0.034) 
0.098 
0.0142 
(0.040) 
0.048* 
0.0047 
(0.031) 
0.379 
0.0087 
(0.036) 
0.170 
0.0103 
(0.037) 
0.111 
0.0116 
(0.038) 
0.080 
0.0056 
(0.029) 
0.359 
0.0090 
(0.052) 
0.404 
TISA750 
0.0094 
(0.031) 
0.089 
0.028 
(0.036) 
0.047* 
0.0029 
(0.032) 
0.591 
0.0083 
(0.030) 
0.113 
0.0079 
(0.034) 
0.184 
0.0110 
(0.033) 
0.057 
0.0037 
(0.026) 
0.506 
0.0070 
(0.042) 
0.423 
TIA750 
1.6176 
(4.528) 
0.045* 
0.1147 
2.965) 
0.823 
-0.3057 
(3.752) 
0.633 
0.6029 
(3.388) 
0.307 
1.1857 
(3.870) 
0.079 
0.3886 
(3.201) 
0.478 
0.7500 
(3.615) 
0.320 
-0.3875 
(4.039) 
0.643 
TE
M
P
O
R
A
L 
AOD500 
  0.0254 
(0.052) 
0.007* 
0.0189 
(0.036) 
0.005* 
0.0212 
(0.054) 
0.030* 
0.0214 
(0.044) 
0.009* 
0.0167 
(0.062) 
0.121 
0.0181 
(0.036) 
0.006* 
0.0074 
(0.050) 
0.478 
0.0215 
(0.055) 
0.069 
ARA500 
0.0033 
(0.021) 
0.367 
0.0059 
(0.019) 
0.075 
0.0053 
(0.022) 
0.159 
0.0045 
(0.019) 
0.171 
0.0044 
(0.022) 
0.243 
0.0078 
(0.019) 
0.024* 
0.0002 
(0.019) 
0.966 
0.0083 
(0.025) 
0.116 
TISA500 
0.0024 
(0.020) 
0.489 
0.0051 
(0.015) 
0.062 
0.0024 
(0.018) 
0.431 
0.0046 
(0.015) 
0.082 
0.0029 
(0.020) 
0.405 
0.0085 
(0.015) 
0.002* 
-0.0020 
(0.019) 
0.612 
0.0082 
(0.022) 
0.082 
TIA500 
1.4853 
(4.927) 
0.088 
1.1324 
(3.764) 
0.089 
0.6559 
(5.269) 
0.473 
1.1242 
(4.262) 
0.139 
0.4286 
(5.972) 
0.674 
(1.2412 
(3.615) 
0.054 
-0.3292 
(4.417) 
0.718 
1.3458 
(5.446) 
0.238 
AOD750 
0.0227 
(0.056) 
0.024* 
0.0149 
(0.049) 
0.087 
0.0224 
(0.062) 
0.041* 
0.0287 
(0.038) 
<0.001 
0.0362 
(0.057) 
0.001* 
0.0345 
(0.055) 
0.001* 
0.0273 
(0.067) 
0.057 
0.0202 
(0.063) 
0.132 
ARA750 
0.0084 
(0.030) 
0.108 
0.0121 
(0.027) 
0.014* 
0.0065 
(0.032) 
0.232 
0.0142 
(0.028) 
0.005* 
0.0101 
(0.030) 
0.059 
0.0166 
(0.029) 
0.002* 
0.0033 
(0.030) 
0.590 
0.0158 
(0.037) 
0.046* 
TISA750 
0.0074 
(0.028) 
0.138 
0.0114 
(0.025) 
0.013* 
0.0036 
(0.028) 
0.459 
0.0139 
(0.025) 
0.002* 
0.0081 
(0.029) 
0.103 
0.0174 
(0.026) 
0.000* 
0.0010 
(0.029) 
0.863 
0.0158 
(0.035) 
0.035* 
 TIA750 
0.7676 
(3.596) 
0.222 
0.4529 
(3.227 
0.419 
0.3743 
(3.877) 
0.572 
1.0429 
(2.584) 
0.023* 
1.2229 
(3.449) 
0.043* 
(1.8543 
(3.586) 
0.004* 
0.9708 
(4.160) 
0.265 
0.6583 
(4.176) 
0.448 
Table 4.2. (CONTINUATION). Pair Samples t test comparing the dimensions of the angle parameters for treated and untreated eyes through time using Visit 1 as baseline. The eight angles sections were compared (Superior, 
Inferior, Superior-Nasal, Inferior-Temporal, Nasal, Temporal, Inferior-Nasal and Superior-Temporal). Statistically significant values have been highlighted in yellow colour. M Diff=Mean difference. SD=Standard Deviation. 
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Paired Samples  
t test  
Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE TREATED EYE UNTREATED EYE 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
M. Diff 
(SD) 
P value 
IN
FE
R
IO
R
-N
A
SA
L 
AOD500 
  0.0172 
(0.061) 
0.107 
-0.0047 
(0.064) 
0.673 
0.0027 
(0.077) 
0.835 
0.0133 
(0.058) 
0.183 
0.0245 
(0.054) 
0.012* 
0.0029 
(0.056) 
0.765 
0.0039 
(0.064) 
0.769 
-0.0152 
(0.069) 
0.289 
ARA500 
0.0019 
(0.020) 
0.582 
0.0060 
(0.029) 
0.240 
-0.0001 
(0.037) 
0.986 
0.0088 
(0.031) 
0.102 
0.0088 
(0.035) 
0.148 
0.0039 
(0.028) 
0.414 
-0.0068 
(0.027) 
0.237 
-0.0043 
(0.035) 
0.557 
TISA500 
0.0002 
(0.017) 
0.937 
0.0042 
(0.023) 
0.310 
-0.0033 
(0.034) 
0.562 
0.0059 
(0.023) 
0.144 
0.0038 
(0.025) 
0.377 
0.0029 
(0.023) 
0.464 
-0.0067 
(0.024) 
0.194 
-0.0049 
(0.030) 
0.436 
TIA500 
0.8168 
(5.420) 
0.386 
-0.9353 
(4.464) 
0.230 
-1.2266 
(6.862) 
0.298 
0.1114 
(5.629) 
0.907 
-0.0294 
(4.731) 
0.971 
-0.4114 
(5.371) 
0.653 
-1.4042 
(5.378) 
0.214 
-1.9250 
(5.956) 
0.127 
AOD750 
0.0149 
(0.067) 
0.205 
0.0065 
(0.065) 
0.567 
0.0090 
(0.088) 
0.546 
0.0144 
(0.070) 
0.232 
0.0413 
(0.068) 
0.001* 
0.0105 
(0.087) 
0.483 
0.0196 
(0.075) 
0.215 
-0.0001 
(0.108) 
0.997 
ARA750 
0.0054 
(0.033) 
0.343 
0.0102 
(0.039) 
0.140 
0.0002 
(0.057) 
0.986 
0.0121 
(0.043) 
0.102 
0.0150 
(0.044) 
0.053 
0.0069 
(0.044) 
0.357 
-0.0061 
(0.040) 
0.460 
-0.0052 
(0.055) 
0.649 
TISA750 
0.0044 
(0.031) 
0.410 
0.0078 
(0.034) 
0.211 
-0.0023 
(0.053) 
0.799 
0.0089 
(0.036) 
0.151 
0.0107 
(0.036) 
0.090 
0.0057 
(0.040) 
0.404 
-0.0062 
(0.037) 
0.424 
-0.0060 
(0.050) 
0.568 
TIA750 
0.1471 
(3.704) 
0.818 
-0.1061 
(3.599) 
0.867 
-1.0343 
(5.438) 
0.268 
0.2914 
(4.436) 
0.700 
0.5353 
(4.211) 
0.464 
0.1829 
(5.749) 
0.852 
-0.3750 
(5.251) 
0.730 
-0.4750 
(5.990) 
0.701 
SU
P
ER
IO
R
-T
EM
P
O
R
A
L 
AOD500 
  0.0275 
(0.053) 
0.005* 
0.0146 
(0.048) 
0.086 
0.0203 
(0.052) 
0.033* 
0.0044 
(0.045) 
0.573 
0.0074 
(0.039) 
0.274 
0.0095 
(0.040) 
0.164 
0.0027 
(0.037) 
0.720 
0.0211 
(0.062) 
0.111 
ARA500 
0.0105 
(0.027) 
0.033* 
0.0081 
(0.022) 
0.044* 
0.0080 
(0.019) 
0.024* 
0.0035 
(0.021) 
0.339 
0.0014 
(0.019) 
0.669 
0.0011 
(0.019) 
0.722 
0.0009 
(0.017) 
0.803 
0.0088 
(0.027) 
0.126 
TISA500 
0.0087 
(0.023) 
0.036* 
0.0073 
(0.019) 
0.035* 
0.0068 
(0.018) 
0.039* 
0.0031 
(0.019) 
0.359 
0.0008 
(0.019) 
0.806 
0.0012 
(0.017) 
0.677 
0.0004 
(0.016) 
0.899 
0.0076 
(0.025) 
0.151 
TIA500 
1.3853 
(4.232) 
0.065 
0.6413 
(4.244) 
0.385 
0.3303 
(4.353) 
0.666 
0.3412 
(4.693) 
0.674 
-0.4257 
(3.758) 
0.507 
0.6914 
(4.140) 
0.330 
-1.0417 
(3.428) 
0.150 
0.9458 
(5.479) 
0.406 
AOD750 
0.0390 
(0.071) 
0.003* 
0.0232 
(0.062) 
0.037* 
0.0285 
(0.064) 
0.015* 
0.0061 
(0.056) 
0.525 
0.0230 
(0.069) 
0.056 
0.0094 
(0.075) 
0.467 
0.0241 
(0.061) 
0.067 
0.0014 
(0.076) 
0.931 
ARA750 
0.0191 
(0.039) 
0.008* 
0.0194 
(0.038) 
0.005* 
0.0134 
(0.030) 
0.015* 
0.0075 
(0.031) 
0.167 
0.0044 
(0.027) 
0.348 
0.0055 
(0.030) 
0.296 
0.0045 
(0.025) 
0.381 
0.0085 
(0.041) 
0.331 
TISA750 
0.0171 
(0.035) 
0.007* 
0.0160 
(0.032) 
0.007* 
0.0120 
(0.029) 
0.020* 
0.0070 
(0.030) 
0.175 
0.0038 
(0.027) 
0.404 
0.0056 
(0.028) 
0.261 
0.0043 
(0.024) 
0.390 
0.0081 
(0.040) 
0.339 
TIA750 
1.4618 
(4.133) 
0.047* 
0.7153 
(4.017) 
0.307 
0.4265 
(3.826) 
0.520 
0.3200 
(3.700) 
0.612 
0.2514 
(4.354) 
0.735 
0.3647 
(4.663) 
0.651 
0.3917 
(4.071) 
0.642 
-0.6435 
(5.060) 
0.548 
Table 4.2 (CONTINUATION). Pair Samples t test comparing the dimensions of the angle parameters for treated and untreated eyes through time using Visit 1 as baseline. The eight angles sections were compared (Superior, 
Inferior, Superior-Nasal, Inferior-Temporal, Nasal, Temporal, Inferior-Nasal and Superior-Temporal). Statistically significant values have been highlighted in yellow colour. M Diff=Mean difference. SD=Standard Deviation. 
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At this point, it was necessary to test if the widening effect found in the parameters of the treated 
eye was due to the LPI or due to other uncontrolled factors (some widening effect has been found 
in the untreated eye using the paired samples t-test). The advantage of the analysis of covariance 
is that it compares the widening effect between the treated and untreated eyes at every visit 
while adjusting for their differences at Visit 1. When these adjustments were made in the 
statistical model, the angle parameters dimensions in the treated eye through the different visits 
were of a positive mean value in the majority of the cases. As the differences between treated 
and untreated eyes in the model were set as Treated minus Untreated, positive values meant 
wider parameters for the treated eye.  
A visual representation of these parameter dimensions for treated and untreated eyes can be 
found in Figure 4.2 to 4.33 in Appendix 1. 
Some of these positive values were statistically significant and commonly found in the Inferior-
Temporal section. As an example of parameter differences in this section, the graph below (Figure 
4.7) shows the dimensional change in the AOD 500 and 750 in the Inferior-Temporal section. In 
this graph, the treated eye experienced the most marked increase in dimension 1 week after the 
LPI (Visit 4) and, although in Visit 5 there was a slight decrease, at Visit 6 and 11 there was a 
tendency to increase again. In the case of the untreated eye the dimensional changes through 
time were minimal and constant. The dimensional widening in the treated eye while adjusted for 
the untreated eye in the case of AOD 750 was statistically significant for every visit. In the case of 
AOD 500, Visit 4 and 6 were the ones presenting the statistically significant widening. 
 
 
 111 
 
Figure 4.7. Mean values for the parameters AOD 500 and 750 in the Inferior-Temporal section for treated (TR) and 
untreated (UNTR) eyes at Visits 1, 4, 5, 6 and 11. 
 
 
Another example of this pattern can be found in the Inferior-Temporal section as well. Figure 4.15 
(below), shows the dimensional changes of ARA 500 and 750 for this section. It is clear in this 
graph the tendency of the treated eye to increase in dimension through time while the untreated 
eye remains within a minimal change range. The changes in the treated eye where found 
statistically significant for all the time points in the case of ARA 750 when adjusted for the 
untreated eye. Visits 4 and 6 showed as well statistically significant changes of the same nature 
for the parameter ARA 500, while the ones found at Visits 5 and 11 were not. 
 
 
 
Figure 4.15 Mean values for the parameters ARA 500 and 750 in the Inferior-Temporal section for treated (TR) and 
untreated (UNTR) eyes at Visits 1, 4, 5, 6 and 11. 
 
The two other parameters measured in the Inferior-Temporal section (TISA and TIA at 500 and 
750) presented similar behaviours to ARA and AOD, although not all the changes were statistically 
significant (changes found at Visits 5 and 11 resulted non-statistically significant).  Regarding the 
rest of the parameters found in the rest of the sections, the most of them showed an increase 
when compared to the untreated eye. The exceptional cases, when this did not happen, the 
change was found non-statistically significant. 
For more information about the adjusted mean differences in the treated eye and their p-values 
for all the parameters, see Table 4.3 in the next page (it continues for the next 3 pages). The 
statistically significant differences have been highlighted in yellow colour. 
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 VISIT 4 VISIT 5 VISIT 6 VISIT 11 
 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
SUPERIOR AOD500 -0.010   (0.010) 0.335 -0.006 (0.010) 0.556 0.003 (0.010) 0.747 -0.011 (0.012) 0.348 
SUPERIOR ARA500 -0.003 (0.003) 0.322 0.002 (0.004) 0.596 0.002 (0.003) 0.549 0.001 (0.003) 0.765 
SUPERIOR TISA500 -0.003 (0.003) 0.323 0.002 (0.003) 0.583 0.002 (0.003) 0.485 0.002 (0.003) 0.572 
SUPERIOR TIA500 -0.511 (0.881) 0.564 -0.420 (0.818) 0.609 0.249 (0.717) 0.729 -1.016 (0.924) 0.277 
SUPERIOR AOD750 0.012 (0.017) 0.466 0.012 (0.014) 0.407 0.032 (0.015) 0.032* 0.010 (0.017) 0.551 
SUPERIOR ARA750 -0.003 (0.006) 0.670 0.003 (0.006) 0.611 0.003 (0.006) 0.617 -0.000 (0.006) 0.937 
SUPERIOR TISA750 -0.002 (0.006) 0.759 0.003 (0.006) 0.645 0.004 (0.006) 0.564 -0.001 (0.006) 0.870 
SUPERIOR TIA750 0.848 (0.997) 0.398 0.496 (0.793) 0.534 1.539 (0.783) 0.054 -0.366 (0.914) 0.691 
INFERIOR AOD500 0.012 (0.012) 0.326 0.004 (0.013) 0.767 0.014 (0.013) 0.274 -0.014 (0.020) 0.482 
INFERIOR ARA500 0.007 (0.006) 0.227 -0.001 (0.005) 0.914 0.001 (0.004) 0.717 -0.007 (0.006) 0.246 
INFERIOR TISA500 0.006 (0.005) 0.221 -0.001 (0.005) 0.835 0.002 (0.004) 0.652 -0.004 (0.005) 0.431 
INFERIOR TIA500 1.704 (0.861) 0.052 0.924 (0.890) 0.303 1.648 (0.889) 0.068 -0.729 (1.128) 0.521 
INFERIOR AOD750 0.022 (0.014) 0.110 0.011 (0.015) 0.470 0.041 (0.018) 0.030* 0.016 (0.022) 0.474 
INFERIOR ARA750 0.010 (0.007) 0.196 0.001 (0.007) 0.919 0.006 (0.007) 0.348 -0.007 (0.010) 0.471 
INFERIOR TISA750 0.009 (0.007) 0.177 0.001 (0.007) 0.853 0.006 (0.007) 0.341 -0.004 (0.010) 0.669 
INFERIOR TIA750 1.476 (0.708) 0.041* 0.524 (0.769) 0.498 2.276 (1.002) 0.026* 0.609 (1.046) 0.563 
SUPERIOR-NASAL AOD500 0.014 (0.009) 0.120 0.011 (0.009) 0.230 -0.003 (0.010) 0.737 0.005 (0.015) 0.749 
SUPERIOR-NASAL ARA500 0.008 (0.004) 0.057 0.007 (0.005) 0.200 0.003 (0.004) 0.508 0.005 (0.006) 0.418 
SUPERIOR-NASAL TISA500 0.006 (0.003) 0.088 0.006 (0.004) 0.150 0.001 (0.004) 0.709 0.004 (0.006) 0.492 
SUPERIOR-NASAL TIA500 1.173 (0.806) 0.150 0.286 (0.893) 0.750 -1.243 (0.924) 0.183 -0.442 (1.271) 0.729 
SUPERIOR-NASAL AOD750 0.007 (0.012) 0.528 -0.004 (0.012) 0.753 0.003 (0.012) 0.813 0.018 (0.017) 0.306 
SUPERIOR-NASAL ARA750 0.011 (0.006) 0.057 0.009 (0.007) 0.205 0.003 (0.006) 0.595 0.007 (0.009) 0.441 
Table 4.3. Analysis of covariance comparing LPI treated eyes angle parameters versus untreated eyes parameters at Visits 4, 5, 6 and 11 and adjusting for baseline 
visit (Visit 1). Mean Diff=Mean differences; St= Standard. Statistically significant differences have been highlighted in yellow colour. 
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 VISIT 4 VISIT 5 VISIT 6 VISIT 11 
 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
SUPERIOR-NASAL TISA750 0.008 (0.005) 0.105 0.008 (0.006) 0.190 0.002 (0.006) 0.778 0.005 (0.008) 0.543 
SUPERIOR-NASAL TIA750 0.760 (0.704) 0.284 -0.655 (0.713) 0.362 -0.267 (0.740) 0.719 0.831 (0.988) 0.405 
INFERIOR TEMPORAL AOD500 0.027 (0.012) 0.025* 0.015 (0.016) 0.356 0.033 (0.012) 0.010* 0.016 (0.017) 0.328 
INFERIOR TEMPORAL ARA500 0.008 (0.005) 0.125 0.010 (0.006) 0.110 0.011 (0.006) 0.062 0.009 (0.006) 0.190 
INFERIOR TEMPORAL TISA500 0.007 (0.005) 0.129 0.006 (0.006) 0.279 0.009 (0.005) 0.078 0.009 (0.006) 0.143 
INFERIOR TEMPORAL TIA500 2.591 (1.116) 0.023* -0.932 (1.298) 0.475 2.634 (1.003) 0.011* 0.756 (1.457) 0.606 
INFERIOR TEMPORAL AOD750 0.063 (0.018) 0.001* 0.043 (0.019) 0.028* 0.048 (0.016) 0.004* 0.061 (0.025) 0.018* 
INFERIOR TEMPORAL ARA750 0.019 (0.008) 0.023* 0.020 (0.010) 0.050* 0.024 (0.009) 0.011* 0.022 (0.010) 0.040* 
INFERIOR TEMPORAL TISA750 0.017 (0.007) 0.029* 0.015 (0.009) 0.126 0.020 (0.008) 0.017* 0.019 (0.009) 0.051 
INFERIOR TEMPORAL TIA750 3.476 (0.965) 0.001* 0.105 (1.083) 0.923 2.039 (0.807) 0.014* 1.941 (1.308) 0.145 
 NASAL AOD500 -0.000 (0.013) 0.993 -0.001 (0.011) 0.955 0.001 (0.011) 0.956 0.015 (0.016) 0.348 
 NASAL ARA500 -0.011 (0.007) 0.127 -0.005 (0.006) 0.394 -0.006 (0.007) 0.427 -0.009 (0.009) 0.344 
 NASAL TISA500 -0.009 (0.006) 0.134 -0.006 (0.005) 0.270 -0.007 (0.006) 0.295 -0.007 (0.007) 0.362 
 NASAL TIA500 0.135 (1.313) 0.919 -0.776 (1.137) 0.497 0.030 (1.017) 0.977 1.556 (1.208) 0.205 
 NASAL AOD750 0.029 (0.013) 0.028* -0.006 (0.014) 0.696 0.018 (0.014) 0.188 0.019 (0.022) 0.381 
 NASAL ARA750 -0.003 (0.009) 0.709 -0.003 (0.008) 0.670 -0.001 (0.009) 0.948 -0.003 (0.012) 0.785 
 NASAL TISA750 -0.003 (0.008) 0.749 -0.005 (0.007) 0.526 -0.002 (0.008) 0.781 -0.003 (0.010) 0.793 
 NASAL TIA750 1.792 (0.885) 0.047* -0.771 (0.846) 0.365 0.973 (0.832) 0.247 1.313 (1.071) 0.227 
 TEMPORAL AOD500 0.007 (0.011) 0.505 -0.001 (0.011) 0.938 -0.001 (0.012) 0.908 -0.011 (0.015) 0.445 
 TEMPORAL ARA500 -0.002 (0.005) 0.630 0.001 (0.005) 0.895 -0.003 (0.005) 0.482 -0.007 (0.006) 0.236 
 TEMPORAL TISA500 -0.002 (0.004) 0.583 -0.002 (0.004) 0.583 -0.005 (0.004) 0.211 -0.009 (0.006) 0.125 
 TEMPORAL TIA500 0.470 (0.985) 0.635 -0.524 (1.012) 0.606 -0.777 (1.088) 0.478 -1.262 (1.345) 0.353 
Table 4.3. (CONTINUATION). Analysis of covariance comparing LPI treated eyes angle parameters versus untreated eyes parameters at Visits 4, 5, 6 and 11 and 
adjusting for baseline visit (Visit 1). Mean Diff=Mean differences; St= Standard. Statistically significant differences have been highlighted in yellow colour. 
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 VISIT 4 VISIT 5 VISIT 6 VISIT 11 
 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
Mean 
Diff 
 St 
Error P Value 
 TEMPORAL AOD750 0.010 (0.012) 0.418 -0.005 (0.012) 0.643 0.002 (0.013) 0.873 0.009 (0.018) 0.638 
 TEMPORAL ARA750 -0.003 (0.007) 0.694 -0.006 (0.007) 0.343 -0.006 (0.007) 0.402 -0.010 (0.009) 0.276 
 TEMPORAL TISA750 -0.003 (0.006) 0.669 -0.009 (0.006) 0.147 -0.009 (0.007) 0.186 -0.012 (0.009) 0.189 
 TEMPORAL TIA750 0.503 (0.746) 0.503 -0.552 (0.709) 0.439 -0.554 (0.814) 0.498 0.518 (1.152) 0.655 
INFERIOR-NASAL AOD500 0.022 (0.015) 0.134 -0.010 (0.016) 0.523 0.022 (0.013) 0.092 0.025 (0.018) 0.155 
INFERIOR-NASAL ARA500 -0.004 (0.006) 0.555 -0.009 (0.008) 0.290 0.005 (0.008) 0.484 0.000 (0.009) 0.998 
INFERIOR-NASAL TISA500 -0.003 (0.005) 0.483 -0.009 (0.007) 0.220 0.002 (0.006) 0.796 0.001 (0.008) 0.892 
INFERIOR-NASAL TIA500 1.937 (1.141) 0.094 -1.089 (1.417) 0.445 0.614 (1.115) 0.583 1.420 (1.430) 0.326 
INFERIOR-NASAL AOD750 0.010 (0.016) 0.527 -0.002 (0.018) 0.896 0.034 (0.018) 0.063 0.032 (0.025) 0.205 
INFERIOR-NASAL ARA750 -0.004 (0.009) 0.664 -0.011 (0.012) 0.348 0.009 (0.011) 0.376 0.005 (0.013) 0.726 
INFERIOR-NASAL TISA750 -0.003 (0.008) 0.740 -0.010 (0.011) 0.355 0.007 (0.009) 0.471 0.006 (0.012) 0.644 
INFERIOR-NASAL TIA750 0.474 (0.859) 0.582 -0.839 (1.092) 0.445 0.920 (1.138) 0.421 1.297 (1.455) 0.377 
SUPERIOR-TEMPORAL AOD500 0.014 (0.012) 0.267 0.020 (0.012) 0.099 0.001 (0.009) 0.947 -0.014 (0.015) 0.357 
SUPERIOR-TEMPORAL ARA500 0.003 (0.006) 0.672 0.005 (0.005) 0.336 0.001 (0.004) 0.825 -0.006 (0.006) 0.322 
SUPERIOR-TEMPORAL TISA500 0.002 (0.005) 0.757 0.004 (0.005) 0.371 -0.000 (0.004) 0.908 -0.005 (0.006) 0.364 
SUPERIOR-TEMPORAL TIA500 1.094 (1.002) 0.279 0.695 (1.036) 0.505 -0.625 (0.894) 0.487 -0.919 (1.215) 0.453 
SUPERIOR-TEMPORAL AOD750 0.016 (0.016) 0.321 0.025 (0.014) 0.079 0.016 (0.016) 0.324 0.022 (0.020) 0.260 
SUPERIOR-TEMPORAL ARA750 -0.000 (0.009) 0.999 0.007 (0.007) 0.352 0.001 (0.007) 0.879 -0.003 (0.010) 0.754 
SUPERIOR-TEMPORAL TISA750 0.001 (0.008) 0.872 0.006 (0.007) 0.379 0.001 (0.006) 0.931 -0.003 (0.009) 0.768 
SUPERIOR-TEMPORAL TIA750 0.900 (0.974) 0.359 0.511 (0.829) 0.540 0.304 (0.956) 0.752 1.257 (1.197) 0.299 
Table 4.3. (CONTINUATION). Analysis of covariance comparing LPI treated eyes angle parameters versus untreated eyes parameters at Visits 4, 5, 6 and 11 and 
adjusting for baseline visit (Visit 1). Mean Diff=Mean differences; St= Standard. Statistically significant differences have been highlighted in yellow colour. 
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2nd Hypothesis: “There may be an association between, first, the widening effect on the angle and 
time elapsed since LPI (direct association) and, second, between this effect and a decrease in IOP 
(inverse association)” 
The analysis was undertaken using the computer program ‘R ‘(Douglas Bates, Martin Maechler 
and Ben Bolker, 2012; R Core Team, 2013). In this case, the slopes indicate the direction and 
magnitude of the relationship between the parameters under study (similar to the 
unstandardised coefficients produced by regression models in SPSS). 
Table 4.4 shows the two regression models performed with ‘R’. First, showing the relationship 
between the widening or change in the parameters dimensions and the time since the LPI and, 
second, the relationship between widening and IOP levels. The first model showed the 
relationship was not statistically significant in the majority of the parameters, but, when it was, 
the relationship was direct (i.e. Superior, Inferior-Nasal and Temporal AOD 750). Additionally 
nearly all the sectional parameters found in the Inferior-Temporal section showed a widening 
effect statistically significant directly associated with time since LPI. However, the values of the 
slopes (relationship indicator) were very small (maximum slope of 0.00027 in Inferior-Temporal 
AOD 750), indicating the minimal effect that time since LPI may have had on the widening factor 
during the first 6 months after LPI. 
When looking at the second model assessing the relationship between widening of the angle and 
levels of IOP, the most of the slopes (indicator of relationship) resulted non-statistically 
significant. When these were, they were indicating a direct association (against the hypothesis). 
The statistically significant relationships were small (Slopes <0.0014) and found for Superior-Nasal 
ARA 500, ARA 750 and TISA 750 and for Inferior-Nasal ARA 500. The rest of the relationships given 
by the slopes magnitude were also small and they were not consistent, some being of a direct 
nature (majority of the parameters found in Superior, Superior-Temporal, Temporal, Inferior-
Temporal and Superior-Nasal) and some of an inverse nature (Nasal and Inferior sections). 
 
PARAMETER (dimension) Time slope P value IOP slope P Value 
DARK SUPERIOR AOD500 0.00004839 0.2012 0.0004773 0.5796 
DARK SUPERIOR ARA500 0.00002061 0.3253 -0.0001287 0.6987 
DARK SUPERIOR TISA500 0.00002235 0.2482 -0.0000782 0.7858 
DARK SUPERIOR TIA500 0.00140970 0.2703 0.0648794 0.2913 
DARK SUPERIOR AOD750 0.00016189 0.0370* 0.0017097 0.1922 
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DARK SUPERIOR ARA750 0.00004910 0.1431 0.0003512 0.5115 
DARK SUPERIOR TISA750 0.00004941 0.0981 0.0003992 0.4304 
DARK SUPERIOR TIA750 0.00482129 0.2202 0.1293918 0.0531 
DARK INFERIOR AOD500 -0.00004757 0.5696 -0.0015232 0.1281 
DARK INFERIOR ARA500 -0.00003379 0.1281 -0.0005428 0.1992 
DARK INFERIOR TISA500 -0.00002671 0.2482 -0.0003953 0.2743 
DARK INFERIOR TIA500 -0.00224742 0.6206 -0.0653873 0.3403 
DARK INFERIOR AOD750 0.00008367 0.3844 -0.0011322 0.3874 
DARK INFERIOR ARA750 -0.00002845 0.4354 -0.0006523 0.2913 
DARK INFERIOR TISA750 -0.00002059 0.6466 -0.0004669 0.4304 
DARK INFERIOR TIA750 0.00355190 0.6106 -0.0619405 0.3604 
DARK SUP NASAL AOD500 0.00003653 0.5335 0.0013604 0.0931 
DARK SUP NASAL ARA500 0.00000337 0.9530 0.0008162 0.0380* 
DARK SUP NASAL TISA500 0.00000686 0.9109 0.0006316 0.0831 
DARK SUP NASAL TIA500 -0.00179296 0.8759 0.0277948 0.6987 
DARK SUP NASAL AOD750 0.00008971 0.2282 0.0019353 0.0641 
DARK SUP NASAL ARA750 0.00001233 0.8589 0.0013311 0.0230* 
DARK SUP NASAL TISA750 0.00001221 0.8729 0.0011044 0.0370* 
DARK SUP NASAL TIA750 0.00150454 0.7197 0.0324475 0.6216 
DARK INF TEMPORAL AOD500 0.00018528 0.0020* 0.0008329 0.4515 
DARK INF TEMPORAL ARA500 0.00006310 0.0420* 0.0002916 0.5646 
DARK INF TEMPORAL TISA500 0.00005115 0.0420* 0.0002402 0.5996 
DARK INF TEMPORAL TIA500 0.00839855 0.2302 -0.0484288 0.6196 
DARK INF TEMPORAL AOD750 0.00027701 < 0.0001* 0.0013640 0.3514 
DARK INF TEMPORAL ARA750 0.00012817 0.0040* 0.0005024 0.5265 
DARK INF TEMPORAL TISA750 0.00010889 0.0070* 0.0004004 0.5846 
DARK INF TEMPORAL TIA750 0.00851575 0.1451 -0.0214800 0.7998 
DARK NASAL AOD500 0.00006795 0.2462 0.0000896 0.8929 
DARK NASAL ARA500 -0.00000873 0.4014 -0.0000910 0.8498 
DARK NASAL TISA500 -0.00001768 0.3884 0.0000520 0.8889 
DARK NASAL TIA500 -0.00199655 0.8739 -0.0138678 0.8859 
DARK NASAL AOD750 0.00011046 0.1882 -0.0000706 0.8909 
DARK NASAL ARA750 0.00000737 0.6096 -0.0002121 0.7938 
DARK NASAL TISA750 -0.00000449 0.6997 -0.0000478 0.8949 
DARK NASAL TIA750 0.00088970 0.9520 -0.0369770 0.6657 
DARK TEMPORAL AOD500 0.00005738 0.1251 0.0006025 0.5516 
DARK TEMPORAL ARA500 0.00001144 0.2863 0.0002842 0.5666 
DARK TEMPORAL TISA500 0.00000828 0.1782 0.0001617 0.7267 
DARK TEMPORAL TIA500 0.00266782 0.1792 -0.0265432 0.7788 
DARK TEMPORAL AOD750 0.00009929 0.0320* 0.0006131 0.6176 
DARK TEMPORAL ARA750 0.00002495 0.0821 0.0005342 0.4354 
DARK TEMPORAL TISA750 0.00001821 0.0601 0.0003869 0.5576 
DARK TEMPORAL TIA750 0.00412774 0.0551 -0.0413306 0.6046 
DARK INF NASAL AOD500 0.00011147 0.1502 0.0020448 0.1041 
DARK INF NASAL ARA500 0.00001229 0.7758 0.0012402 0.0420* 
DARK INF NASAL TISA500 0.00000215 0.8849 0.0009188 0.0671 
DARK INF NASAL TIA500 0.00145104 0.7888 0.0541778 0.5876 
DARK INF NASAL AOD750 0.00020544 0.0400* 0.0020035 0.1902 
DARK INF NASAL ARA750 0.00004116 0.5526 0.0017909 0.0501 
DARK INF NASAL TISA750 0.00003278 0.5475 0.0014544 0.0781 
DARK INF NASAL TIA750 0.00520786 0.5125 0.0347990 0.7197 
DARK SUP TEMPORAL AOD500 -0.00002348 0.6166 0.0004176 0.6967 
DARK SUP TEMPORAL ARA500 -0.00001404 0.8188 0.0004983 0.2503 
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DARK SUP TEMPORAL TISA500 -0.00001270 0.8078 0.0004644 0.2492 
DARK SUP TEMPORAL TIA500 -0.00541715 0.4184 -0.0068469 0.8819 
DARK SUP TEMPORAL AOD750 0.00002948 0.8869 0.0010845 0.4164 
DARK SUP TEMPORAL ARA750 -0.00002175 0.8038 0.0004776 0.4284 
DARK SUP TEMPORAL TISA750 -0.00001411 0.8769 0.0005587 0.3914 
DARK SUP TEMPORAL TIA750 -0.00177548 0.8929 0.0282718 0.6967 
Table 4.4. Slopes (similar to the unstandardised coefficients, is presented as an indicator of relationship between 
widening of the parameters and time and between the same widening and IOP); P values indicating statistical 
significant relationship among parameters, time and IOP and between the treated and untreated eye groups. 
 
4.1.4 Discussion 
There is considerable evidence in the published literature that reports the widening effect of LPI 
on the irido-trabecular angle in PAC/PACS eyes where the angle has previously been found to be 
gonioscopically narrow. When such effect has been quantified with anterior segment imaging 
technologies, it has commonly been measured solely in the vertical and horizontal meridians 
(Nasal and Temporal section) and often at one time point after the LPI. Caronia, et al. (1996) 
found an increase in AOD at 250m, anterior chamber angle and Iris-lens contact distance in the 
Temporal section measured with UBM at a single time point after the LPI in aphakic patients (1 
week). Lei, Wang, Wang and Wang (2009) found a statistically significant increase in anterior 
chamber volume and depth measured with AS-OCT in addition to a decrease in IOP (from 17.8 
mean, 3.3 SD, to 15.9 mean, 3.1 SD) in 15 PAC patients, 20.2 mean (12.7 SD) days after this laser 
treatment. Memarzadeh, et al. (2007), found a statistically significant increase in AOD, ARA and 
TIA at 500m and 750m in Temporal and Nasal sections when comparing pre and 1 week post-
LPI; however the description of the sample involved did not specify if these patients had 
glaucoma. He, et al. (2007) studied 72 PACS subjects using UBM scans taken before and 2 weeks 
after LPI. They quantified AOD at 250 and 500 m for the four main sections and found a 
statistically significant increase for the same parameters and for all the sections after LPI. They 
also measured the parameter ARA for the same four sections and found it increased statistically 
significantly through the same amount of time.  
It could be argued that all the studies mentioned in the paragraph above were based on mixed or 
Asian ethnicities; however, more recently, new evidence showing the effect of the LPI in 
Caucasian populations with narrow angles has been reported. López-Caballero ,et al., (2010) 
showed widening effect on the treated angle based in the four main sections (Superior, Inferior, 
Nasal and Temporal); the effect of the LPI was quantified in angle degrees of opening and 
assessed with Pentacam. They reported a significant increase in the anterior chamber angle, 
depth and volume in comparison with the measurements taken pre-laser. Mansouri, Burgener, 
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Bagnoud and Shaarawy (2009) studied PAC and PACG patients using the UBM to show post-LPI 
widening of TIA in the four main sections and AOD 500 in Superior and Inferior sections in light 
and dark conditions. Another study carried out by Ang and Wells (2010) in eyes diagnosed with 
PAC/PACS showed AOD, TISA and TIA (500 and 750) were statistically significantly wider after the 
LPI when compared to baseline measurements. Antoniazzi, et al., (2010) found a statistically 
significant increase in anterior chamber volume and anterior chamber angle measured with 
Pentacam in a PAC/PACS sample of 14 subjects 4 weeks after LPI. They reported a statistically 
significant increase in the peripheral anterior chamber angle of the 4 main sections at the same 
time point. All the above studies have studied the effect of the LPI uniquely in the treated eye and 
the results of this study for the same group are consistent with this published literature. However, 
when the fellow untreated eye was used as a control (analysis of covariance), the widening effect 
was shown to be of a lower magnitude than when assessing the treated eye on its own (t-tests). 
AOD 750 in the Inferior-Temporal section is an example of this assertion. For this parameter, the 
t-test comparing the treated eye between baseline and Visit 4 result was 0.066mm (SD 0.081mm; 
p<0.001*), between baseline and Visit 5 was 0.060mm (SD 0.092mm; p<0.001*) and between 
baseline and Visit 6 and 11 was 0.071mm (SD 0.071mm; p<0.001*) and 0.065mm (SD 0.110mm; 
p=0.008*) respectively. However, when analysis of covariance was fitted and adjusted to the 
untreated eye differences, the differences with baseline decreased to 0.063mm (SD 
0.018mm;p=0.001*) for Visit 4, 0.043mm (SD 0.019mm;p=0.028*) for Visit 5, 0.048mm (SD 
0.016mm; p=0.004*) for Visit 6 and 0.061mm (SD 0.025mm; p=0.018*) for Visit 11. It can be 
argued that this is one of the statistically significant comparisons given by both models, but when 
comparing the results given by the t-test and the analysis of covariance in the majority of the 
parameters the t-test gave wider mean differences than the analysis of variance. It is possible that 
previous reports in the literature may have overestimated the widening effect of the LPI. 
The fact that some angle sections in the untreated eye increased slightly in dimension through 
time is not contradictory to the progression rate described by Wilensky, et al., (1993) in Caucasian 
untreated eyes with narrow angles as the first assessment for narrow angle was carried out after 
one year since recruitment and followed for a maximum of 6 years. They found that after the first 
year of follow up, only 7 eyes out of 111 showed appositional or synechial closure in at least 180 
degrees as assessed with gonioscopy; in the second year 8 additional eyes out of 90 showed the 
same features and in the third, fourth, fifth and sixth year of follow up, the number of eyes with 
gonioscopically occludable angles increased and they were reported as 7 of 67 eyes, 2 of 38 eyes, 
3 of 21 eyes and 0 of 3 eyes, respectively. Therefore, it is possible that further follow up of the 
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present sample using the CASIA AS-OCT would show similar results to that of the study by 
Wilensky. 
The present study results have demonstrated that in only one angle section of the model there 
was a statistically significant association between parameter adjusted dimension differences and 
time. This was found in the Inferior-Temporal section and the relationship, although direct, was 
extremely small. There is some similarity in these results with a longer period LPI follow-up study 
performed by Kumar, Baskaran, Ronnie and Vijaya (2009) in PACS patients where no statistically 
significant differences were found between base line data and that found at 1 week, 6 months, 1 
year, 1.5 years and 2 years after the procedure. They used UBM to study AOD 500 and ACA 
(Anterior Chamber Angle) in the four main angle sections in treated eyes only.  
Additionally, these very few and direct statistically significant associations between IOP and 
difference in parameters dimensions between treated and untreated eyes may be explained on 
account of the relatively low levels of IOP measured at recruitment (the mean diurnal IOP peak 
was found to be 18.5 mmHg, SD 4.27 mmHg; Range: 12.0- 30.5; in Section 3.1). These baseline 
IOPs are similar to the pre-Nd:YAG laser treated eyes in a study by Moster, et al., (1986) where 
the mean IOP was found to be 17.1 mmHg (SD 5.2 mmHg). Their study reported that all the 
treated eyes showed a return of IOP to baseline within one week after the laser was performed 
and that it remained the same at one month and three months afterwards. In the present 
research study, such assessment was not attempted as not all the follow up visits took place at 
the same time of the day and therefore a possible fluctuation in the diurnal IOP would have 
biased the results. It is not possible to compare results between the IOP changes in both studies, 
but the assessment of the effect of LPI on the IOP diurnal fluctuation may show some light on this 
subject. Additionally, López-Caballero, et al., (2010) reported a correlation between angle 
widening due to the LPI effect and reduction in IOP in a group of patients with angle closure, 
some with glaucoma. They found a statistically significant correlation between a decrease in IOP 
levels and an increase in the anterior chamber depth. It needs to be pointed out that the graph 
showed in their study actually showed a direct association (higher IOP with deeper anterior 
chamber depth), but this must have been an editing error. In the case of the present study this 
relationship was either non-existent or direct (the wider the angle the higher the IOP) which was 
unexpected. It was not possible to compare results between studies as in López-Caballero’s; the 
widening assessment was only performed for the treated eye. However, in order to investigate 
this possible relationship a linear regression model was fitted using the present study treated eye 
data. This model attempted to simulate López-Caballero’s and therefore only TIA 500 and 750 in 
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Superior, Nasal, Inferior and Temporal sections were related to a change in the angle. The results 
for the model resulted non-statistically significant and the relationship was again direct 
(Univariate regression; Standardised Coefficient 0.250; Adjusted R2 0.063; p value=0.167). 
More recently, a retrospective study of 469 Caucasian eyes with an initial diagnosis of PAC (due 
only to PAS) or PACS reported a post-LPI IOP raise to more than 21 mmHg in 38.7% participants 10 
years after treatment with LPI (Blondeau, Jaworski and Turcotte, 2011). The IOP was found to be 
more than 21 mmHg at a mean follow up time of 3.2 years (SD 3.6) despite the fact all eyes had 
pre-LPI IOP levels lower than 21 mmHg. They also found that gonioscopic results following LPI 
predicted those eyes that would have an IOP increase, although these gonioscopical findings were 
not specified in their publication. The authors suggested that this increase might have been 
caused by the natural growth of the lens, which would have narrowed the angle. Nevertheless, 
their study confirmed that even when LPI has been performed, more than a third of their sample 
later developed high IOPs (Blondeau, Jaworski and Turcotte, 2011). It would be interesting to 
know how the patients in the present study would perform on a longer follow up period to 
confirm Blondeau’s findings. Advantages of the CASIA AS-OCT technology for quantifying angle 
parameters have already been explained in this thesis and its application over a longer period of 
follow up may confirm an association between higher IOP and gradual narrowing of the 
parameters post-LPI. 
In summary, the statistical modelling fit allows a prediction of change in parameters dimensions 
(widening of the angle) in the case of the Inferior-Temporal section 6 months after LPI for the 
present research sample. It is known that the crystalline lens continues to thicken throughout life 
and that this increase in lens thickness may further narrow the anterior chamber angle. If this is 
the case, it is possible that the LPI has no longstanding widening effect on the angle in phakic 
patients.  
To date there are no published studies showing a predictive model for changes in the angle 
related to time and IOP in treated eyes versus untreated.  
In future studies it would be helpful to quantify the change in OCT-measured angle dimensions 
that equates to a gonioscopic finding of an open angle.  This would mean the development of 
possible cut-off standards to determine the opening or closure of a given section. 
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4.1.5 Conclusions 
The widening effect due uniquely to the effect of the LPI over the iridotrabecular angle remains 
unclear. The use of a control eye has demonstrated that this widening post-LPI, so commonly 
reported in the literature, may be due to additional uncontrolled factors. 
It has been statistically significantly shown that, for this sample of eyes, at least one section of the 
angle parameters (Inferior-Temporal) increased in the treated eye in comparison to the untreated 
eye and that these differences in dimensions were weakly directly associated with time for the 
first 6 months after LPI. There was no statistical significant association between these differences 
and IOP for the majority of the measured angle parameters. 
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4.2 Effect of the laser peripheral iridotomy on the diurnal intraocular 
pressure (DIOP) fluctuation 6 months after the procedure 
 
4.2.1 Introduction 
DIOP fluctuation was reported in Section 3.1 to reach a range of up to 14.50 mmHg for the 
untreated eye (Mean DIOP fluctuation was 5.99 mmHg; 2.70 SD); however, little is known about 
the effect of laser peripheral iridotomy (LPI) on this fluctuation. Baskaran, et al. (2009) studied 
DIOP fluctuation in treated PAC and PACS in comparison with PACG and normals (non-
glaucomatous eyes), finding that this fluctuation was lower for PACS and normals than for PAC 
and PACG. The effect of the LPI on IOP fluctuation in their sample could not be studied as all the 
patients with occludable angles had already been treated. Considering the importance of IOP in 
the clinical management of patients with occludable angles, it is important to understand the 
effect of LPI on diurnal IOP fluctuation.  
One can hypothesise that the fluctuation of IOP would be lower in those eyes treated with LPI 
than in the untreated fellow eyes and that this effect may be dependent on the treatment 
outcome: treated eyes, which are found to be gonioscopically open after the LPI, would exhibit 
lower levels of fluctuation than the pre-laser state of the same eye and the fellow untreated eye, 
while those found to be occludable post-laser are predicted to show similar levels of fluctuation 
to their pre-laser state and the fellow untreated eye.  
A second hypothesis was that those eyes which have occludable anterior chamber angles 
(established using gonioscopy) would show a higher diurnal IOP fluctuation than those with open 
anterior chamber angles after the LPI treatment. 
 
4.2.2 Methodology and Statistical Analysis plan 
Diurnal IOP fluctuation data of 29 participants who only received LPI (no subsequent ALPI 
treatment) during the study were analysed. The study design involved random selection of one 
eye of each participant for LPI treatment and the fellow eye was left untreated. Three months 
after the LPI was performed in these 29 randomly selected eyes, 19 eyes were considered to be 
open and 10 to be occludable using gonioscopy. Figure 4.34 gives more information about the 
participant’s pathway throughout the study. 
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Prior to plan and perform the statistical analysis it was needed to test variability in the DIOP 
fluctuation, peaks and troughs due uniquely to time. This was tested through comparing the 
levels found in the untreated eyes between Visit 1 (baseline) and Visit 11 (the mean time from 
Visit 1 was 6.44 months, SD 0.56 months). Three comparisons were carried out using the paired 
samples t-test: 
- 1st Comparison: comparing the fellow untreated eyes of those eyes treated with LPI (n=29 eyes). 
This comparison was not differentiating between occludable or unoccludable post-LPI fellows. 
- 2nd Comparison: comparing the fellow eyes of those eyes observed to be gonioscopically 
unoccludable 3 months post-LPI (n=19 eyes). 
- 3rd Comparison: comparing the fellow eyes of those eyes that having been treated with LPI were 
observed to be gonioscopically occludable 3 months after the procedure (n=10 eyes).  
These results showed a lack of variability in any of the three comparisons and (these results can 
be found in the results section for this objective), therefore, there was a justification for 
comparisons between pre and post-LPI DIOP fluctuation data or for comparisons between post-
LPI data adjusting for pre-LPI data.  
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Figure 4.34. Participant pathway throughout the study. The upper half of the figure shows the pathway of those eyes 
randomised to receive Laser Peripheral Iridotomy (LPI) and the lower half of the figure shows the pathway of the 
untreated fellow eyes. Abbreviations in this figure: n= number of eyes in each group. LPI= Laser Peripheral Iridotomy. 
OCC= Post-LPI eyes with occludable angles. UNOCC= Post-LPI eyes with unoccludable eyes. ALPI= Eyes with post-LPI 
occludable angles that were further randomised into receiving ALPI. NFT= Eyes with post-LPI occludable angles that 
were further randomised into not receiving further treatment. 
1st Hypothesis Methodology 
To test this objective’s first hypothesis of a reduction in DIOP fluctuation in those eyes treated 
with LPI, DIOP fluctuation 6 months (Mean 5.85 months; SD 0.37 months) after the LPI treatment 
was compared with their fellow untreated eyes. Analysis of covariance was used as this gave the 
advantage to adjust the model to the differences found at Visit 1 between the treated and their 
fellow untreated eyes. Three statistical models were carried out:  
- 1st statistical model: Aimed to test if LPI reduced the DIOP fluctuation 6 months after the LPI 
independently of the outcome of the treatment (gonioscopically occludable or unoccludable eyes 
as diagnosed 3 months post-LPI, n=29). This was achieved by comparing the DIOP fluctuation of 
those treated eyes with their fellows at Visit 11 and adjusted for the data found at Visit 1. 
- 2nd statistical model: To test if there was a reduction of DIOP fluctuation in those eyes with post-
LPI unoccludable angles (n=19) when compared with their fellow eyes (n=19). This was achieved 
by comparing those treated eyes with gonioscopically open post-laser angles with their fellow 
eyes at Visit 11 (6 months after LPI) and adjusted for baseline data (Visit 1). 
- 3rd statistical model: Comparing treated eyes that remained with occludable angles (n=10) with 
their fellow eyes (n=10) at Visit 11 and adjusted for baseline data (Visit 1).  
2nd Hypothesis Methodology 
To test the second hypothesis, which is that those eyes with occludable anterior chamber angles 
(established using gonioscopy, n=10), would show a higher diurnal IOP fluctuation than those with 
open anterior chamber angles after the LPI treatment (n=19), analysis of covariance was used. 
DIOP fluctuation, peaks and troughs were compared between those eyes with gonioscopically 
occludable angle (3 months post-laser) and those with an open angle (3 months post-laser). Only 
the data for the treated eyes was used and the statistical model was adjusted for Visit 1 
differences (baseline, pre-LPI). 
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4.2.3 Results 
Investigation of variability of the data found for DIOP fluctuation due to time: 
1st Comparison:  
Using the paired samples t-test the data for DIOP fluctuation found at Visit 1 and Visit 11 for all 
the fellow untreated eyes of those eyes treated with LPI was compared. There were no 
statistically significant differences for the DIOP fluctuation values between Visits 1 and 11. To 
further test that the DIOP fluctuation was within the same levels in both visits, a further two 
paired samples t-tests were carried out for the peaks and the troughs. None of these two later 
tests showed statistically significant differences. Additionally, the differences in IOP for these 
three parameters (fluctuation, peaks and troughs) were lower than 1 mmHg. The table below 
presents more information about the values of DIOP fluctuation, peaks and troughs in Visit 1 and 
V11, their means difference and the paired samples t-tests p values. 
DIOP Untreated eyes  
Visit 1 data 
Mean (SD) 
Untreated eyes  
Visit 11 data 
Mean (SD) 
Mean difference 
(SD) 
T test P value 
Fluctuation (mmHg) 6.02 (2.61) 6.02 (2.61) 0.14 (2.96) 0.800 
Peak (mmHg) 20.03 (4.47) 20.17 (3.91) 0.16 (1.80) 0.640 
Trough (mmHg) 14.02 (3.06) 14.17 (2.99) 0.02 (3.03) 0.975 
Table 4.5 Paired Samples t test comparing DIOP fluctuation, peaks and troughs between Visit 1 and Visit 11 of the 
untreated eyes. SD= Standard Deviation.  
2nd Comparison:  
Paired samples t-test was used to analyse the differences between the DIOP fluctuation of the 
fellow untreated eyes of those observed to be gonioscopically unoccludable 3 months post-LPI 
found at Visit 1 and Visit 11. The test showed no statistically significant differences between the 
DIOP fluctuation found for this group of eyes at Visit 1 and their correspondent found at Visit 11. 
Two further paired samples t-tests showed that there were no statistically significant differences 
between the peaks or between the troughs when comparing both visits. 
For more information about the mean values for DIOP fluctuation, peaks and troughs for this 
group of eyes at Visit 1 and 11 together with the results for the paired samples t-test please see 
table 4.6.  
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DIOP Fellow untreated eyes of post-LPI 
gonioscopically unoccludable eyes 
Visit 1 data 
Mean (SD) 
Fellow untreated eyes of post-LPI 
gonioscopically unoccludable  
Visit 11 data 
Mean (SD) 
Mean 
difference 
(SD) 
T test P 
value 
Fluctuation (mmHg) 5.87 (2.53) 5.84 (2.09) 0.03 (2.76) 0.967 
Peak (mmHg) 19.76 (4.42) 20.05 (4.31) 0.29 (1.53) 0.662 
Trough (mmHg) 13.89 (2.90) 14.21 (3.35) 0.31 (3.58) 0.380 
Table 4.6. Paired Samples t test comparing DIOP fluctuation, peaks and troughs between Visit 1 and Visit 11 of the 
fellow untreated eyes of post-LPI gonioscopically unoccludable eyes. SD= Standard Deviation.  
 
3rd Comparison:  
In order to test the differences in DIOP fluctuation between Visit 1 and Visit 11 of the fellow eyes 
of those that, having been treated with LPI, were observed to be gonioscopically occludable, a 
paired samples t-test was used. This statistical test showed no statistically significant differences 
in DIOP fluctuation, peaks or troughs for this group of eyes and between this two time points 
(Visit 1 and Visit 11). The differences for the three parameters tested (DIOP fluctuation, peaks and 
troughs) were lower than 1 mmHg. For more information about the mean values for DIOP 
fluctuation, peaks and troughs for this group of eyes at Visit 1 and 11 together with the results for 
the paired samples t-test please see table below.  
DIOP Fellow untreated eyes of post-LPI 
gonioscopically occludable eyes 
Visit 1 data 
Mean (SD) 
Fellow untreated eyes of post-LPI 
gonioscopically occludable  
Visit 11 data 
Mean (SD) 
Mean 
difference 
(SD) 
T test P 
value 
Fluctuation (mmHg) 6.33 (2.93) 6.33 (2.83) 0.00 (3.72) 1.000 
Peak (mmHg) 20.61 (4.81) 20.44 (3.12) 0.17 (3.34) 0.885 
Trough (mmHg) 14.28 (3.54) 14.11 (2.20) 0.40 (2.72) 0.837 
Table 4.7. Paired Samples t test comparing DIOP fluctuation, peaks and troughs between Visit 1 and Visit 11 of the 
fellow untreated eyes of post-LPI gonioscopically occludable eyes. SD= Standard Deviation.  
 
4.2.3.1 Results for 1st Hypothesis- “DIOP fluctuation would be lower in LPI treated eyes 
when compared with their fellow untreated eyes 6 months after the procedure” 
 
1st Comparison: Differences between DIOP fluctuation between LPI-treated eyes and their 
untreated fellows at Visit 11: 
Analysis of covariance showed no statistically significant result between the DIOP fluctuation of 
the post-LPI gonioscopically occludable eyes and their untreated fellows at Visit 11. The model 
was adjusted for differences in DIOP fluctuation found for these two groups at Visit 1. Two further 
analysis of covariance was performed to investigate differences in DIOP peaks and troughs 
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between these two groups of eyes at Visit 11 adjusted for the data found at Visit 1 for the same 
parameters (DIOP peaks and troughs). None of the models showed statistically significant 
differences for DIOP peaks or troughs. For information about the DIOP fluctuation, peaks and 
troughs mean values for the LPI treated eyes and their fellows at Visits 1 and 11, please see table 
below. Additionally, this table shows the mean differences in DIOP fluctuation, peaks and troughs 
between the LPI treated eyes and their fellows at Visit 11 and adjusted for Visit 1. 
 
DIOP Treated eyes 
Mean (SD) 
Fellow untreated eyes 
Mean (SD) 
Mean difference 
(SE) 
ANCOVA P 
value 
 Visit 1 Visit 11 Visit 1 Visit 11   
Fluctuation (mmHg) 6.46 (3.02) 6.43 (2.02) 5.95 (2.60) 6.00 (2.31) 0.32 (0.57) 0.576 
Peak (mmHg) 20.57 (4.67) 21.12 (4.06) 20.03 (4.39) 20.18 (3.90) 0.55 (0.71) 0.442 
Trough (mmHg) 14.10 (2.72) 14.70 (2.95) 14.09 (3.03) 14.18 (2.99) 0.45 (0.49) 0.365 
Table 4.8. Analysis of covariance (ANCOVA) comparing DIOP fluctuation, peaks and troughs between LPI treated eyes 
and their untreated fellows at Visit 11 adjusted for Visit 1 data. SD= Standard deviation. SE= Standard error. 
 
2nd Comparison: Differences in DIOP fluctuation between LPI-treated eyes that were 
gonioscopically unoccludable 3 months after the procedure and their untreated fellows at Visit 
11: 
It was not possible to find statistically significant differences in the DIOP fluctuation, peaks and 
troughs between LPI-treated eyes that were gonioscopically unoccludable 3 months after the 
procedure and their untreated fellows. Furthermore the differences found at Visit 11 (as adjusted 
for Visit 1) were in every case lower than 1 mmHg. 
The analysis of covariance was adjusted for the differences found for these three parameters and 
between these two groups of eyes at Visit 1.    
For more information about the mean values for DIOP fluctuation, peaks and troughs for these 
groups of eyes at Visit 1 and 11 together with their mean difference at Visit 11 (adjusted for the 
difference at Visit 1) please see table 4.9.  
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DIOP Post-LPI gonioscopically 
unoccludable eyes 
Mean (SD) 
Fellow eyes of Post-LPI 
gonioscopically unoccludable 
eyes 
Mean (SD) 
Mean difference 
(SE) 
ANCOVA P 
value 
 Visit 1 Visit 11 Visit 1 Visit 11   
Fluctuation (mmHg) 6.39 (3.12) 6.34 (2.21) 5.87 (2.53) 5.84 (2.09) 0.35 (0.66) 0.602 
Peak (mmHg) 19.95 (4.84) 20.92 (4.67) 19.76 (4.41) 20.05 (4.31) 0.73 (0.88) 0.414 
Trough (mmHg) 13.55 (2.94) 14.58 (3.38) 13.89 (2.90) 14.58 (3.38) 0.71 (0.56) 0.214 
Table 4.9. Analysis of covariance (ANCOVA) comparing DIOP fluctuation, peaks and troughs between post-LPI 
gonioscopically unoccludable eyes and their untreated fellows at Visit 11 adjusted for Visit 1 data. SD= Standard 
deviation. SE= Standard error. 
 
3rd Comparison: Differences between DIOP fluctuation between LPI-treated eyes that were 
gonioscopically occludable 3 months after the procedure and their untreated fellows at Visit 11 
and adjusted for baseline data (Visit 1): 
Analysis of covariance adjusted for the data found at Visit 1 found no statistically significant 
differences between the DIOP fluctuation of those eyes found gonioscopically occludable after LPI 
and their fellows at Visit 11. Furthermore, there was no statistically significant difference between 
the peaks and troughs of these two groups at Visit 11. For more information about the mean 
value for the DIOP fluctuation, peaks and troughs of these two groups at Visits 1 and 11, see table 
below (Table 4.10). The mean difference for these three values and the p-values of the analysis of 
covariance can be additionally found in this table. 
DIOP Post-LPI gonioscopically 
occludable eyes 
Mean (SD) 
Fellow eyes of Post-LPI 
gonioscopically occludable eyes 
Mean (SD) 
Mean difference 
(SE) 
ANCOVA P 
value 
 Visit 1 Visit 11 Visit 1 Visit 11   
Fluctuation (mmHg) 6.60 (2.99) 6.61 (1.63) 6.10 (2.85) 6.33 (2.83) 0.48 (1.46) 0.748 
Peak (mmHg) 21.75 (4.30) 21.55 (2.52) 20.55 (4.54) 20.44 (3.12) 0.37 (1.79) 0.838 
Trough (mmHg) 15.15 (1.96) 14.94 (1.88) 14.45 (3.39) 14.11 (2.20) 0.23 (1.09) 0.833 
Table 4.10. Analysis of covariance (ANCOVA) comparing DIOP fluctuation, peaks and troughs between post-LPI 
gonioscopically occludable eyes and their untreated fellows at Visit 11 adjusted for Visit 1 data. SD= Standard deviation. 
SE= Standard error. 
 
4.2.1.1 Results for 2nd Hypothesis-  “DIOP fluctuation measured 6 months post LPI would be 
lower in LPI-treated eyes that were found to be gonioscopically unoccludable when 
compared with those found to be gonioscopically occludable” 
 
Using analysis of covariance, the data for DIOP fluctuation found at Visit 11 for those LPI treated 
eyes that were gonioscopically occludable was compared to that found for those considered 
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unoccludable after LPI. There were no statistically significant differences for the DIOP fluctuation 
values at Visit 11 as adjusted for the differences found at Visit 1. To further test that the DIOP 
fluctuation was within the same levels at Visit 11, two more analyses of covariance were carried 
out for the peaks and the troughs. None of these two last models showed statistically significant 
differences. Additionally, the differences in DIOP fluctuation, peaks and troughs were lower than 
1 mmHg. Please, see table below for more information about the values of DIOP fluctuation, 
peaks and troughs in Visit 1 and V11, their means difference at Visit 11 (adjusted for Visit 1) and 
the analysis of covariance p-values. 
DIOP Post-LPI gonioscopically 
unoccludable eyes 
Mean (SD) 
Post-LPI gonioscopically 
occludable eyes 
Mean (SD) 
Mean 
difference 
(SE) 
ANCOVA P 
value 
 Visit 1 Visit 11 Visit 1 Visit 11   
Fluctuation (mmHg) 6.39 (3.12) 6.34 (2.21) 6.60 (2.99) 6.61 (1.64) 0.18 (0.81) 0.827 
Peak (mmHg) 19.95 (4.84) 20.92 (4.67) 21.75 (4.30) 21.55 (2.52) 0.78 (1.16) 0.506 
Trough (mmHg) 13.55 (2.94) 14.58 (3.38) 15.15 (1.96) 14.94 (1.88) 1.13 (0.81) 0.177 
Table 4.11. Analysis of covariance (ANCOVA) comparing DIOP fluctuation, peaks and troughs between post-LPI 
gonioscopically occludable eyes and their untreated fellows at Visit 11 adjusted for Visit 1 data. SD= Standard deviation. 
SE= Standard error. 
 
4.2.3 Discussion 
One previous study reported on repeatability of IOP measurements between eyes of bilateral 
glaucomatous and normal (no ocular pathology) subjects in consecutive visits (Realini, Barber, and 
Burton, 2002). A change of more than 3 mmHg was observed in 24 of the 38 glaucomatous 
(3.71.2 mmHg) and in 21 of the 42 normals (4.01.2 mmHg) as measured with Goldmann 
applanation tonometry. The number of visits for both groups was approximately 9 and the total 
number of observations (measurement of IOP between visits) was 284 for normals and 283 for 
glaucomatous. From the total number of observations, 39 showed a variation of more than 3 
mmHg in the normal group and 46 in the glaucomatous group. Only 31 observations in normals 
and 41 observations in glaucomatous had time of day recorded. Additionally, only 14 out of these 
31 observations for normals and 30 of these 41 for glaucomatous were performed within 90 
minutes of the same time of day. In the case of the glaucomatous group, although the same 
examiner measured the IOP, the authors acknowledged this result as expected as the mechanism 
of an elevated IOP in glaucoma is secondary to outflow obstruction and this may have been 
different in fellow glaucomatous eyes. In the case of the normal group, two different examiners 
measured the IOP throughout the study and no interobserver agreement was described. It was, 
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therefore, possible that the differences found between visits and between fellow normal eyes 
were due to a lack of good interobserver agreement.  
Based on the lack of consistent evidence that the IOP changes differently between eyes at 
different time points and that in the case of this study the fellow untreated eyes (control eyes) 
had similar DIOP fluctuation between Visits 1 and 11 (period of time= 6.44 months, SD 0.56 
months), comparisons between these two time points were justified for the treated eyes. 
Therefore, if a change in DIOP fluctuation was noticed in the treated group of eyes, this would 
have been due to the treatment with LPI and not to the time elapsed between Visits 1 and 11.  
The results for this section showed that LPI treatment did not reduce DIOP fluctuation on this 
sample of treated eyes when compared to the fellow untreated group of eyes.  The means for 
DIOP fluctuation for laser treated eyes that remained unoccludable and occludable post-laser 
compared with their respective fellows were very similar giving a non-statistically significant 
difference. However, the treated eyes that remained with an occludable angle showed a higher 
DIOP fluctuation than those that were open post laser treatment. From a clinical standpoint, such 
a small difference in fluctuation (of less than 1 mmHg) is unlikely to have any clinical significance. 
Furthermore, the DIOP for the different groups seemed to fluctuate within similar ranges.  
It is not possible to compare these results to previous published literature on the same topic due 
to the novel nature of these results. The only research performed in DIOP fluctuation on narrow 
angle eyes has been that carried out by Baskaran in Asian subjects (89.1% were Chinese) on laser-
treated eyes (Baskaran, et al., 2009). In Baskaran’s study the eyes were divided in 4 groups 
(Normals, treated PACS, treated PAC, and treated PACG) and their DIOP fluctuation was studied 
separately. For normals the fluctuation was found to be 3.75 mmHg (SD 1.09), for PACS 3.75 
mmHg (SD 1.24), for PAC 4.53 mmHg (SD 2.33) and for the PACG group 5.44 mmHg (SD 2.4). The 
mean time from LPI was 31.3 weeks (SD  41.9). The highest DIOP fluctuation was found in the 
PACG group. All the groups of eyes studied in the present study, even those treated eyes that 
opened after laser, showed higher DIOP fluctuations than those reported by Baskaran in the 
PAC/PACS groups and even higher than that reported for the PACG group. There may be a reason 
for this dissimilarity in DIOP fluctuation between studies. The most obvious different factor is 
ethnicity and, consequently, ocular biometry, but no current literature has studied differences in 
DIOP fluctuation in individuals of different ethnicity. One study in healthy young adults of diverse 
ethnicity (52% Caucasian, 36% Asian, 9.3% Hispanic and 12.6% Black) found an inverse correlation 
between axial ocular length and higher levels of 24 hours IOP fluctuation (Loewen, Liu and 
Weinreb, 2010) and another study has suggested that Caucasian’s eyes have a deeper anterior 
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chamber when compared to Chinese eyes (Wang, et al., 2011). Therefore, ethnicity may not have 
been responsible for these differences. 
The second possible reason was regarding the instrumentation used for measuring the DIOP. 
Baskaran and colleagues used a non-contact tonometer (Topcon CT-80), which was compared to 
Goldmann tonometry finding a mean difference of 0.2 mmHg (SD 1.5) and limits of agreement 
(95%) of -3.14 and +2.74 mmHg. It was unlikely that the differences in fluctuation were caused by 
the different instrumentation. 
The third difference was the mean age of the groups. In Baskaran’s study the groups diagnosed 
with PACS and PAC were 68 (SD 7.5) and 66.7 (SD 5.7) years old, respectively. In the present 
study, the sample presented an age of 59.6 (SD 11.3) years old at the time of recruitment. To 
assess if age had an inverse effect on fluctuation, a linear regression model was fitted between 
these two variables using the data of the present study (DIOP fluctuation at baseline for the 80 
eyes  Age of the participant at recruitment). The model showed a statistically significant 
association (Standardized Coefficient -0.246; R2 0.060; p=0.028). This association was weak and 
could not fully explain the differences.  
 
4.2.4 Conclusions 
No statistical significant difference in DIOP fluctuation between LPI treated eyes and their 
untreated fellow eyes was found. There were no significant differences in DIOP fluctuation 
between those eyes that remained closed after laser treatment and those eyes whose angles 
opened following laser.  
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4.3 Assessment of variability of the effect of the laser peripheral iridotomy 
depending on the angle section when using Ocular Coherence 
Tomography Technology 
 
4.3.1 Introduction 
As reported previously in this thesis, variability in the angle parameters exists depending on the 
angle sector/section being studied (i.e. Superior section was found to be the narrowest section). 
However, such variability is rarely mentioned in the published literature when the effects of the 
LPI are being considered involving anterior segment imaging. A recent study by Ang and Wells 
(2010) in a Caucasian population only the Nasal and Temporal sections were studied to assess the 
angle widening effect of the LPI using a 2 dimensional AS-OCT; the same sections were studied by 
Memarzadeh, et al., 2007, in a sample of mixed ethnicity. A similar study in Asian eyes using UBM 
assessed the data from Nasal, Temporal and Inferior sections (Gazzard, et al., 2003); the same 3 
sections were evaluated in a study of the effect of LPI using 2 dimensional AS-OCT (See, et al., 
2007). 
It is possible that the widening effect of the LPI is not homogeneous and that some sections may 
be more affected than others. Mansouri, Burgener, Bagnoud and Shaarawy (2009) found greater 
change in the Superior and Nasal sections than in the opposite sections when assessing TIA with 
UBM in light before and after LPI; however, this difference was not statistically tested. 
 
The aim of this section is to investigate the homogeneity of the effect of the LPI and to assess the 
relevance of quantifying at least the 4 main angle sections (Superior, Nasal, Inferior and 
Temporal) when analysed with anterior segment imaging technology.  
As the iridotomy is commonly placed in the Superior Sector, one could hypothesise that the 
widening effect of this laser would be higher in this sector when compared to the Horizontal or 
Inferior and that this effect might be related to proximity of a given sector to the iridotomy site.  
 
4.3.2 Methodology and Statistical Analysis plan 
Data from 24 eyes of 24 participants who only received LPI in the randomised eye were used in 
this analysis. Ten angle sections of the scans (light and dark conditions) of each of these eyes were 
analysed. These 10 sections account for the ones already described (Superior, Superior-Temporal, 
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Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and Superior-Temporal) plus 2 new 
sections which are the sections on both sides of the angle in the meridian of the iridotomy, one 
on the side that incorporates the iridotomy and the other on the opposing side.  Please see 
following pictures for visual information (Figures 4.35 to 4.40). 
 
Figures  4.35, 4.36, 4.37, 4.38, and 4.39. Show a visual representation of the analysis cuts used that were later 
quantified with the CASIA OCT (please, note that these are corresponding to a Left Eye). The green arrow indicates the 
direction of the cut and the two sections involved. Figures 4.35, 4.36, 4.37 and 4.38 are those corresponding to Superior 
and Inferior, Superior-Temporal and Inferior-Nasal, Nasal and Temporal and Inferior-Temporal and Superior-Nasal, 
respectively. Figure 4.39 shows the cut located where the iridotomy was placed. 
 
The CASIA OCT has the advantage of being able to quantify every sectional degree of the angle 
circumference. The manner the examiner selects the degree (angle section) that needs 
quantifying is using a rotating arrow tool (green arrow showed in Figures 4.35, 4.36, 4.37, 4.38, 
and 4.39. At the same time the examiner rotates this arrow over the eye picture, the CASIA gives 
a perpendicular cut of the angle corresponding with the head and nock of the arrow. This is how 
the iridotomy site was located. (Figure 4.40) 
 
 
 
Figure  4.35   Figure  4.36   Figure  4.37 
Figure  4.38   Figure  4.39  
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Figure 4.40. This is a section of the angle were the iridotomy was located using the CASIA software (94 degrees in the 
case of this participant’s treated eye).  
 
Only two time points Visit 1 and Visit 11 were compared. This decision was based on the results of 
Section 4.1 of this thesis, which showed a maximum increase for all the parameters between 
these two visits with very few exceptions. 
The difference in dimension for the parameters found in each sector between Visits 1 and 11, and 
one-way analysis of variance was used for statistical analysis. 
 
4.3.3 Results 
Analysis of variance followed by Tukey HSD multiple comparisons showed no statistically 
significant differences among the 10 different sections parameters dimensions included in the 
analysis. This analysis was performed first for the parameters found in light conditions and 
secondfor the same in darkness. (Tukey HSD results for this analysis can be found in the attached 
compact disc). 
The only exceptions to the paragraph above were found in light conditions and when comparing 
ARA 500 and 750 between Inferior and Nasal sections, TIA 500 between Superior and Nasal 
section and TISA 500 between Inferior section and the section opposite to the iridotomy.  For 
more information about these statistically significant differences, see Table 4.12. 
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Parameter Sections Mean Difference (SD) P values 
ARA 500 (Light) Inferior versus Nasal 0.029 (0.008) 0.022* 
ARA 750 (Light) Inferior versus Nasal 0.043 (0.013) 0.043* 
TISA 500 (Light) Inferior versus Opposite Iridotomy 0.031 (0.008) 0.012* 
TIA 500 (Light) Superior versus Nasal -4.904 (1.444) 0.027* 
Table 4.12 Parameters that were statistically significant different and details about which sections they were located  
 
The differences in dimension between Visits 1 and 11 for the 8 parameters and for the 10 sections 
studied can be found in this section in Table 4.13 for light conditions and Table 4.14 for dark 
conditions. Negative values corresponded to a decrease in dimension and positive values to an 
increase. These differences were not found using the paired samples t test, but transforming 
these two dimensions into their difference. 
The minimum effect of the LPI for the parameters measured in light condition was more 
frequently found in the Horizontal sector (Nasal section) whereas the maximum values for the 
same lighting were more frequent in the Inferior sector (Inferior and Opposite Iridotomy 
sections). In darkness, the maximum values were found, similar to light conditions, in the Inferior 
sector (Inferior-Temporal and Opposite Iridotomy sections); however, the minimum values were 
found in Superior (Iridotomy section) and Inferior sector with similar frequency (Inferior and 
Inferior-Nasal). As mentioned earlier, these values (maximums and minimums) were not 
statistically different from the rest. 
 
LIGHT MEAN VALUES OF LPI 
EFFECT 
AOD 500 
 
ARA 500 TISA 500 TIA 500 AOD 750 ARA 750 TISA 750 TIA 750 
IRIDOTOMY POSITION 
0.0451 
(0.060) 
0.0045 
(0.0188) 
-0.0033 
(0.0409) 
2,9304 
(5,8298) 
0.0708 
(0.0856) 
0.0193 
(0.0345) 
0.0193 
(0.0337) 
3,3826 
(5,5270) 
SUPERIOR 
0.0598 
(0.0703) 
0.0168 
(0.0221) 
0.0163 
(0.0218) 
5,0913 
(5,6500) 
0.0953 
(0.0805) 
0.0370 
(0.0376) 
0.0357 
(0.0375) 
6,0609 
(4,8869) 
SUPERIOR- 
NASAL 
0.0562 
(0.0811) 
0.0145 
(0.0338) 
0.0147 
(0.0306) 
3,6478 
(5,4316) 
0.0840 
(0.0855) 
0.0352 
(0.0535) 
0.0033 
(0.1729) 
4,3174 
(4,0966) 
NASAL 
0.0258 
(0.0583) 
0.0006 
(0.0268) 
0.0040 
(0.0300) 
-0.3652 
(4,9076) 
0.0486 
(0.0674) 
0.0123 
(0.0389) 
0.0179 
(0.0474) 
1,1565 
(4,9375) 
INFERIOR- 
NASAL 
0.0634 
(0.0773) 
0.0131 
(0.0283) 
0.0136 
(0.0272) 
4,3609 
(7,3844) 
0.0808 
(0.0831) 
0.0309 
(0.0444) 
0.0316 
(0.0434) 
3,5174 
(5,5343) 
OPPOSITE IRIDOTOMY 
0.0398 
(0.0713) 
0.0099 
(0.0289) 
0.0083 
(0.0267) 
0.9739 
(5,7831) 
0.4874 
(1,8940) 
0.0290 
(0.0466) 
0.0280 
(0.0446) 
3,5043 
(5,3669) 
INFERIOR 
0.0739 
(0.1032) 
0.0293 
(0.0374) 
0.0276 
(0.0354) 
4,1696 
(6,1377) 
0.1100 
(0.1231) 
0.0557 
(0.0658) 
0.0537 
(0.0645) 
4,8739 
(5,6209) 
INFERIOR-TEMPORAL 
0.0643 
(0.0838) 
0.0140 
(0.0352) 
0.0122 
(0.0277) 
2,6435 
(6,2866) 
0.0884 
(0.0858) 
0.0349 
(0.0545) 
0.0330 
(0.0481) 
3,3696 
(4,9603) 
TEMPORAL 
0.0300 
(0.0613) 
0.0048 
(0.0147) 
0.0051 
(0.0140) 
1,1435 
(6,0385) 
0.0907 
(0.0611) 
0.0198 
(0.0260) 
0.0203 
(0.0259) 
4,4609 
(3,7251) 
SUPERIOR-TEMPORAL 0.0536 0.0077 0.0081 3,8217 0.0702 0.0222 0.0226 3,5261 
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(0.0687) (0.0271) (0.0255) (5,7863) (0.0606) (0.0374) (0.0363) (3,8438) 
Table 4.13 Mean value of the LPI effect in the parameters in the 10 different sections measured in light conditions. The 
values in the table are mean values of the change between V1 (pre-laser) and V11 (post-laser). The standard deviation 
is the value within brackets. Minimum parameter mean value dimension for every section is boxed in blue and 
maximum value in red.  
 
DARK MEAN VALUES OF LPI 
EFFECT 
AOD 500 ARA 500 TISA 500 TIA 500 AOD 750 ARA 750 TISA 750 TIA 750 
IRIDOTOMY POSITION 
-0,0065 
(0,0578) 
-0,0066 
(0,0237) 
-0,0065 
(0,0227) 
-1,7174 
(5,0368) 
0,0115 
(0,0655) 
-0,0072 
(0,0359) 
-0,0073 
(0,0352) 
-0,375 
(3,8136) 
SUPERIOR 
-0,0003 
(0,0421) 
0,0033 
(0,0122) 
0,004 
(0,0117) 
-0,2375 
(3,2013) 
0,0240 
(0,0644) 
0,0054 
(0,0199) 
0,0054 
(0,0194) 
0,5739 
(2,7909) 
SUPERIOR- 
NASAL 
0,0143 
(0,0502) 
0,0058 
(0,0196) 
0,0048 
(0,0180) 
-0,0500 
(4,4243) 
0,021 
(0,0728) 
0,007 
(0,0303) 
0,0058 
(0,0283) 
0,275 
(4,5546) 
NASAL 
0,0217 
(0,0523) 
-0,0002 
(0,0243) 
-0,0013 
(0,0213) 
0,3667 
(4,5558) 
0,0309 
(0,0710) 
0,0056 
(0,0294) 
0,0037 
(0,0262) 
0,7500 
(3,6147) 
INFERIOR- 
NASAL 
0,0039 
(0,0640) 
-0,0067 
(0,0272) 
-0,0067 
(0,0244) 
-1,4042 
(5,3785) 
0,0196 
(0,0755) 
-0,0061 
(0,0397) 
-0,0062 
(0,0371) 
-0,375 
(5,2507) 
OPPOSITE IRIDOTOMY 
0,0368 
(0,0736) 
0,0086 
(0,0433) 
0,0068 
(0,0360) 
1,6333 
(6,2483) 
0,0583 
(0,1189) 
0,0193 
(0,0653) 
0,0175 
(0,0590) 
2,1625 
(7,0162) 
INFERIOR 
-0,0157 
(0,0899) 
-0,0055 
(0,0209) 
-0,0049 
(0,0202) 
-0,6208 
(4,0824) 
-0,0012 
(0,0766) 
-0,0068 
(0,0349) 
-0,0061 
(0,0341) 
-0,3417 
(3,5835) 
INFERIOR-TEMPORAL 
0,0308 
(0,0676) 
0,0083 
(0,0244) 
0,0064 
(0,0210) 
0,3500 
(6,3552) 
0,0653 
(0,1104) 
0,0242 
(0,0450) 
0,0189 
(0,0384) 
1,4875 
(5,6320) 
TEMPORAL 
0,0074 
(0,0504) 
0,0002 
(0,0192) 
-0,0020 
(0,0187) 
-0,3292 
(4,4170) 
0,0273 
(0,0667) 
0,0033 
(0,0299) 
0,0010 
(0,0292) 
0,9708 
(4,1596) 
SUPERIOR-TEMPORAL 
0,0027 
(0,0366) 
0,0009 
(0,0170) 
0,0004 
(0,0159) 
-1,0417 
(3,4279) 
0,0241 
(0,0615) 
0,0045 
(0,0249) 
0,0043 
(0,0238) 
0,3917 
(4,0714) 
Table 4.14. Mean value of the LPI effect in the parameters in the 10 different sections measured in dark conditions. The 
values in the table are mean values of the change between V1 (pre-laser) and V11 (post-laser). The standard deviation 
is the value within brackets. Minimum parameter mean value dimension for every section is boxed in blue and 
maximum value in red. 
 
4.3.4 Discussion 
The results found in this thesis objective are partially consistent with those found by Ang and 
Wells (2010) when comparing the effect of the LPI between Temporal and Nasal sections 
approximately 6 weeks post-LPI. In their study the effect was greater in the Temporal section for 
both lighting conditions, light and dark; this difference was not statistically significantly different 
apart from TIA 500 in dark.  In the present study, the effect of the LPI observed in the Temporal 
section were wider than in the Nasal section in light conditions, but not in dark.  
He, et al. (2007) found that the opening effect quantified with UBM 2 weeks after LPI was greater 
in the Superior section for AOD 250 and 500 than for the other three sectors under study (Nasal, 
Temporal and Inferior). A statistical comparison of widening effect among the 4 sections was not 
performed.  
One other study on a group of PACG patients found that, 4 weeks after LPI, on the iridotomy 
quadrant AOD 500 as measured with UBM increased from 110.2m (SD 80.9) to 170.6m (SD 
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83.4) p<0.001, and in the opposite quadrant from 117.2m (SD 65.5) to 172.2m (SD 81.7) 
p<0.001. The widening effect was, therefore very similar, although differences between 
quadrants were not statistically compared (Kaushik, et al., 2007). 
The differences with these previous studies and the results of the present study might be 
explained using the results explained earlier in this thesis. It has been shown that every 
parameter in the treated eye group seemed to vary following a slightly different trend post LPI 
treatment. Although this variation resulted to be non-statistically significant in the majority of the 
cases, a further possible next step for this objective would have been to repeat this analysis for 
the rest of the follow up visits (Visit 4, 5 and 6).  
It is important for future research to be aware that at least in the case of dark conditions there 
were some parameters sections that actually decreased, as was noted with TISA and TIA 500 
which decreased in the majority of the sections and the majority of the parameters found in the 
Iridotomy section and Inferior-Nasal and Inferior sections, while the rest of the parameters for the 
rest of the sections commonly increased. This finding is understandable given the corrugated 
nature of the peripheral iris both radially and circumferentially. As previously discussed in this 
thesis, it is not uncommon to quantify the effect of the LPI in dark conditions and it is therefore 
surprising the absence of literature regarding a decrease in the parameters dimensions in 
darkness after the LPI has been performed. 
There are no published studies showing the effect of the LPI in more than 6 sections. There is also 
a lack of publications comparing this effect between a particular section and the rest of the 
sections under study.  
There are few limitations to this specific section. While analysing the CASIA images, the iridotomy 
seemed to be found at different locations between visits. There was a variability of several 
degrees. (i.e. the iridotomy could be found to be located at 94 degrees at Visit 4 and at 96 and 92 
at Visits 6 and 11 respectively). This may have been caused by a natural rotational/fixation effect 
of the eye between visits or a possible head tilted. There are no studies addressing this issue and 
this was another novel finding that needs to be explored in future research. Visit 6 was chosen as 
the time to mark this iridotomy section, as it was the middle time point of the duration of the 
research project.  
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4.3.5 Conclusions 
The present study was unable to demonstrate a statistically significant difference in the 
dimensional change in the angle parameters in the 10 different sections under study 6 months 
post-LPI.  
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CHAPTER 5.  Effect of Argon Laser Peripheral Iridoplasty 
(ALPI) on anterior chamber angle dimensions and 
intraocular pressure 
 
5.1 Relationship between degree of angle opening post ALPI treatment 
and intraocular pressure  
 
5.1.1 Introduction 
ALPI has been found to be effective in widening the anterior chamber angles of eyes presenting 
with iris plateau syndrome where the angle remains occludable after LPI (review by Ritch, Tham 
and Lam, 2007). Using OCT, Leung, et al. (2005) described a PACG case where ALPI succeeded in 
changing the angle configuration to a non-occludable configuration. 
When treating acute angle closure cases, ALPI has shown to be more effective in lowering IOP 
than systemic medications in the early post-attack phase (Lam, et al., 2002) and an equivalent 
effect in the mid-term (Lai, et al., 2006).  In a study of 11 eyes with chronic angle glaucoma, ALPI 
initially lowered the IOP in all the 11 eyes treated with 7 remaining controlled after 6 months 
(Chew and Yeo, 1995).  
Published literature suggests that ALPI may cause further opening of a gonioscopically occludable 
angle previously treated by LPI, however, the mechanism of how the IOP is lowered is unclear. 
One may hypothesise that there may exist a relationship between the opening rate and lower 
levels of IOP and, that this effect is dependent on time. If the hypothesis is proven, it would be 
possible to predict how much an angle may open 3 months after ALPI and what would be the IOP 
lowering effect. 
 
5.1.2 Methodology and Statistical Analysis plan 
The statistical analysis was split into two statistical sub-analyses.  
The first analysis was aiming to assess the difference through time in the angle dimensions when 
assessing solely the eye that was treated with ALPI. This analysis used the paired samples t test to 
compare the parameter dimensions assessed at baseline (Visit 6, 12.55 days, SD 5.24 days, prior 
to ALPI) with the same data collected at Visit 8 (1 day after ALPI, SD 0.00 days), Visit 9 (7 days 
after ALPI, SD 0.89 days), Visit 10 (1.43 months after ALPI, SD 0.18 moths) and Visit 11 (2.39 
months after ALPI, SD 0.30 months). Second, it was of interest to assess the differences in angle 
 140 
 
parameter dimensions between those participants whose angle remained gonioscopically 
occludable 3 months after LPI but did not receive further treatment (NFT group; n=10 eyes) 
compared to those whose angles were treated with ALPI (n=11 eyes). The comparison was carried 
out at two time points, Visit 6 (12.55 days, SD 5.24 days, before ALPI) and Visit 11 (2.09 months, 
SD 0.30, months after ALPI). Only those scans taken in dark conditions were quantified. The 
statistical analysis was performed using analysis of covariance to assess the differences in angle 
parameter dimensions depending on the group at Visit 11 while being adjusted for differences at 
Visit 6 (ALPI or NFT). For more schematic information please see Figure 5.1. 
 
The second analysis aimed to assess how the angle dimensions (parameters) change through time 
and if a relationship between this change and the IOP exists. The data of those eyes whose angles 
were treated with ALPI (n=11 eyes) were used. To assess the relationship between IOP and time 
was not possible as the IOP for these participants were measured at different times of the day.  
IOP and parameters dimensions data  (scans in darkness) collected in Visit 6 (12.55 days, SD 5.241 
days, before laser), Visit 8 (1 day, SD 0.00, after ALPI), Visit 9 (7 days, SD 0.894, after ALPI), Visit 10 
(5.91 weeks, SD 0.944, after ALPI) and Visit 11 (3 months after ALPI) for those eyes treated with 
ALPI and NFT (when applicable) was statistically studied using analysis of covariance*.  
 
*Five patients were instilling pilocarpine 2% on Visit 8 and one of them remained using the drug 
on Visit 9. Their data was, therefore, not included in the model at those time points. 
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Figure 5.1. Participant pathway throughout the study. The upper half of the figure shows the pathway of those eyes 
randomised to receive Laser Peripheral Iridotomy (LPI) and the lower half of the figure shows the pathway of the 
untreated fellow eyes. Abbreviations in this figure: n= number of eyes in each group. LPI= Laser Peripheral Iridotomy. 
OCC= Post-LPI eyes with occludable angles. UNOCC= Post-LPI eyes with unoccludable eyes. ALPI= Eyes with post-LPI 
occludable angles that were further randomised into receiving ALPI. NFT= Eyes with post-LPI occludable angles that 
were further randomised into not receiving further treatment. The data within the dashed red box has not been used in 
the present section. 
 
5.1.3 Results 
The first analysis aimed to assess differences through time in the parameters dimensions in eyes 
which had received the ALPI. The paired samples t test found that there was a widening effect in 
all the sections and in all the parameters under study. There were only four exceptions out of 256 
comparisons, these were found in the Inferior section (AOD 500 at Visits 9 and 10) and in the 
Superior-Nasal section (TISA and TIA 750 at Visit 8). The detailed analysis can be found in the 
following table (Table 5.1) 
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T-Test Comparisons 
with Baseline 
Visit 8 - Visit 6 
Diff Mean (SD); P Value 
Visit 9 - Visit 6 
Mean Diff (SD); P Value 
Visit 10 - Visit 6 
Mean Diff (SD); P Value 
Visit 11 - Visit 6 
Mean Diff (SD); P Value 
 IOP -3.227 (2.284); P=0.001* -0.750 (2.072); P=0.282 0.091 (2.256); P=0.896 -2.500 (3.209); P=0.027* 
SU
P
ER
IO
R
 
AOD 500 0.038 (0.058); P=0.217 0.051 (0.082); P=0.101 0.038 (0.046); P=0.027* 0.028 (0.030); P=0.015* 
ARA 500 0.015 (0.022); P=0.208 0.017 (0.033); P=0.151 0.022 (0.035); P=0.074 0.012 (0.023); P=0.128 
TISA 500 0.014 (0.021); P=0.197 0.015 (0.035); P=0.222 0.020 (0.033); P=0.085 0.012 (0.021); P=0.112 
TIA 500 3.800 (5.105); P=0.171 4.756 (8.877); P=0.147 3.270 (3.321); P=0.012* 2.550 (2.658); P=0.014* 
AOD 750 0.055 (0.088); P=0.235 0.061 (0.124); P=0.180 0.032 (0.053); P=0.087 0.046 (0.077); P=0.110 
ARA 750 0.028 (0.041); P=0.205 0.033 (0.059); P=0.132 0.032 (0.042); P=0.040* 0.025 (0.032); P=0.044* 
TISA 750 0.028 (0.039); P=0.190 0.031 (0.061); P=0.164 0.030 (0.040); P=0.045* 0.025 (0.030); P=0.037* 
TIA 750 3.680 (5.710); P=0.223 4.078 (9.007); P=0.211 2.180 (3.169); P=0.058 2.922 (4.751); P=0.102 
IN
FE
R
IO
R
 
AOD 500 0.039 (0.068); P=0.217 -0.098 (0.121); P=0.031* -0.074 (0.089); P=0.027* 0.030 (0.068); P=0.169 
ARA 500 0.011 (0.031); P=0.414 0.036 (0.044); P=0.029* 0.028 (0.039); P=0.049* 0.001 (0.023); P=0.849 
TISA 500 0.012 (0.029); P=0.350 0.034 (0.041); P=0.028* 0.026 (0.037); P=0.052 0.002 (0.022); P=0.773 
TIA 500 4.950 (6.770); P=0.133 6.960 (6.839); P=0.011* 6.110 (7.084); P=0.023* 2.200 (5.359); P=0.203 
AOD 750 0.108 (0.149); P=0.136 0.146 (0.164); P=0.020* 0.090 (0.094); P=0.010* 0.030 (0.087); P=0.277 
ARA 750 0.032 (0.058); P=0.236 0.068 (0.077); P=0.021* 0.048 (0.059); P=0.021* 0.010 (0.043); P=0.482 
TISA 750 0.033 (0.056); P=0.212 0.065 (0.075); P=0.022* 0.046 (0.057); P=0.023* 0.010 (0.043); P=0.458 
TIA 750 7.900 (9.914); P=0.108 7.200 (7.145); P=0.011* 5.355 (5.902); P=0.013* 1.636 (5.413); P=0.340 
SU
P
ER
IO
R
-N
A
SA
L 
AOD 500 0.057 (0.055); P=0.052 0.066 (0.107); P=0.081 0.022 (0.040); P=0.099 0.029 (0.045); P=0.057 
ARA 500 0.008 (0.022); P=0.441 0.008 (0.031); P=0.451 0.010 (0.025); P=0.213 0.015 (0.027); P=0.103 
TISA 500 0.007 (0.022); P=0.455 0.007 (0.031); P=0.494 0.008 (0.022); P=0.227 0.012 (0.023); P=0.102 
TIA 500 4.467 (4.881); P=0.075 2.760 (7.525); P=0.276 1.400 (3.175); P=0.174 2.164 (3.640); P=0.077 
AOD 750 0.068 (0.107); P=0.296 0.074 (0.117); P=0.119 0.067 (0.065); P=0.015* 0.042 (0.086); P=0.181 
ARA 750 0.027 (0.036); P=0.225 0.024 (0.053); P=0.237 0.027 (0.032); P=0.035* 0.022 (0.037); P=0.106 
TISA 750 -0.026 (0.036); P=0.245 0.025 (0.054); P=0.239 0.027 (0.028); P=0.023* 0.020 (0.033); P=0.108 
TIA 750 -3.875 (6.761); P=0.335 5.050 (8.659); P=0.143 3.489 (3.621); P=0.020* 2.244 (5.338); P=0.243 
IN
FE
R
IO
R
-T
EM
P
O
R
A
L AOD 500 0.075 (0.066); P=0.040 0.051 (0.097); P=0.129 0.070 (0.072); P=0.009* 0.043 (0.072); P=0.075 
ARA 500 0.015 (0.023); P=0.166 0.007 (0.033); P=0.531 0.027 (0.042); P=0.056 0.023 (0.022); P=0.006* 
TISA 500 0.018 (0.022); P=0.109 0.009 (0.031); P=0.356 0.023 (0.030); P=0.031* 0.020 (0.018); P=0.003* 
TIA 500 6.650 (3.651); P=0.007* 4.020 (9.562); P=0.216 4.582 (5.270); P=0.016* 3.100 (6.612); P=0.151 
AOD 750 0.043 (0.065); P=0.164 0.045 (0.084); P=0.124 0.038 (0.069); P=0.096 0.044 (0.065); P=0.049* 
ARA 750 0.030 (0.036); P=0.097 0.019 (0.051); P=0.266 0.038 (0.054); P=0.044* 0.032 (0.031); P=0.007* 
TISA 750 0.033 (0.036); P=0.073 0.021 (0.049); P=0.199 0.033 (0.042); P=0.026* 0.030 (0.028); P=0.005* 
TIA 750 3.000 (2.860); P=0.050 3.240 (6.978); P=0.176 2.082 (3.514); P=0.078 2.755 (4.477); P=0.069 
N
A
SA
L 
AOD 500 0.085 (0.075); P=0.040 0.067 (0.070); P=0.014* 0.050 (0.055); P=0.013* 0.030 (0.049); P=0.068 
ARA 500 0.025 (0.032); P=0.123 0.017 (0.033); P=0.129 0.013 (0.028); P=0.173 0.015 (0.028); P=0.117 
TISA 500 0.022 (0.026); P=0.092 0.014 (0.025); P=0.108 0.010 (0.024); P=0.179 0.013 (0.024); P=0.111 
TIA 500 7.000 (6.320); P=0.042* 5.920 (7.391); P=0.032* 3.736 (4.709); P=0.025* 2.573 (4.497); P=0.087 
AOD 750 0.070 (0.085); P=0.100 0.066 (0.097); P=0.058 0.040 (0.073); P=0.102 0.056 (0.071); P=0.034* 
ARA 750 0.047 (0.049); P=0.065 0.034 (0.045); P=0.040* 0.024 (0.039); P=0.068 0.026 (0.048); P=0.118 
TISA 750 0.045 (0.044); P=0.054 0.031 (0.039); P=0.030* 0.022 (0.037); P=0.072 0.024 (0.045); P=0.122 
TIA 750 4.133 (5.906); P=0.147 4.220 (7.143); P=0.095 2.091 (4.652); P=0.167 3.370 (5.036); P=0.063 
TE
M
P
O
R
A
L 
AOD 500 0.062 (0.077); P=0.106 0.049 (0.079); P=0.082 0.060 (0.057); P=0.006* 0.056 (0.064); P=0.016* 
ARA 500 0.014 (0.033); P=0.335 0.017 (0.032); P=0.126 0.024 (0.020); P=0.003* 0.029 (0.035); P=0.019* 
TISA 500 0.011 (0.035); P=0.509 0.017 (0.035); P=0.178 0.022 (0.023); P=0.014* 0.026 (0.032); P=0.028* 
TIA 500 5.617 (7.372); P=0.121 5.120 (9.198); P=0.112 5.391 (5.677); P=0.010* 3.773 (6.445); P=0.081 
AOD 750 0.059 (0.082); P=0.141 0.066 (0.121); P=0.117 0.070 (0.055); P=0.002* 0.039 (0.060); P=0.056 
ARA 750 0.032 (0.044); P=0.142 0.030 (0.052); P=0.108 0.040 (0.031); P=0.002* 0.040 (0.044); P=0.013* 
TISA 750 0.032 (0.044); P=0.139 0.030 (0.054); P=0.108 0.039 (0.033); P=0.003* 0.036 (0.039); P=0.013* 
TIA 750 4.100 (5.430); P=0.124 4.960 (9.025); P=0.116 4.727 (3.834); P=0.002* 1.900 (4.050); P=0.151 
IN
FE
R
IO
R
-N
A
SA
L 
AOD 500 0.091 (0.069); P=0.024* 0.082 (0.093); P=0.021* 0.055 (0.050); P=0.004* 0.057 (0.041); P=0.001* 
ARA 500 0.013 (0.021); P=0.186 0.025 (0.051); P=0.162 0.025 (0.036); P=0.045* 0.019 (0.034); P=0.104 
TISA 500 0.016 (0.019); P=0.087 0.021 (0.049); P=0.205 0.021 (0.030); P=0.040* 0.017 (0.028); P=0.066 
TIA 500 7.383 (7.834); P=0.069 6.930 (10.711); P=0.071 3.364 (6.023); P=0.094 5.309 (4.647); P=0.004* 
AOD 750 0.109 (0.079); P=0.037* 0.075 (0.110); P=0.075 0.054 (0.092); P=0.094 0.035 (0.063); P=0.116 
ARA 750 0.045 (0.037); P=0.054 0.049 (0.069); P=0.065 0.041 (0.044); P=0.016* 0.029 (0.042); P=0.057 
TISA 750 0.047 (0.038); P=0.048* 0.046 (0.069); P=0.081 0.037 (0.041); P=0.019* 0.028 (0.035); P=0.034* 
TIA 750 6.320 (5.690); P=0.068 4.500 (9.132); P=0.178 2.160 (5.824); P=0.271 2.450 (4.315); P=0.106 
SU
P
ER
IO
R
-
TE
M
P
O
R
A
L AOD 500 0.035 (0.086); P=0.360 0.049 (0.079); P=0.082 0.035 (0.082); P=0.187 0.031 (0.029); P=0.006* 
ARA 500 0.011 (0.020); P=0.251 0.012 (0.016); P=0.053 0.005 (0.028); P=0.558 0.006 (0.010); P=0.082 
TISA 500 0.009 (0.022); P=0.372 0.011 (0.017); P=0.064 0.004 (0.027); P=0.650 0.005 (0.010); P=0.114 
TIA 500 2.450 (7.208); P=0.443 4.300 (7.591); P=0.107 2.091 (7.271); P=0.363 2.418 (2.354); P=0.007* 
AOD 750 0.090 (0.125); P=0.138 0.069 (0.090); P=0.038* 0.074 (0.086); P=0.018 0.055 (0.046); P=0.003* 
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ARA 750 0.027 (0.044); P=0.192 0.026 (0.035); P=0.043* 0.018 (0.042); P=0.176 0.018 (0.016); P=0.003* 
TISA 750 0.026 (0.046); P=0.224 0.027 (0.036); P=0.044* 0.018 (0.042); P=0.188 0.018 (0.016); P=0.004* 
TIA 750 5.267 (7.810); P=0.159 4.450 (6.086); P=0.046* 3.709 (4.975); P=0.033 3.373 (3.086); P=0.005* 
Table 5.1 Paired t test comparing the angle parameters in the different eight sections for ALPI treated eyes through 
visits 8, 9, 10 and 11 using visit 6 as baseline. Statistically significant values have been flagged with an asterisk, 
additionally they have been highlighted in yellow colour. 
 
When assessing the effect of the ALPI on the angle parameters at Visit 11 and adjusting for the 
untreated occludable, all of the 8 sections parameters under study showed an increase in 
dimension. Furthermore, the increase in dimension found in the Superior, Inferior-Temporal and 
Superior-Temporal were statistically significant (P<0.05). The amount of opening found at Visit 11 
for every parameter and their p-value for this analysis can be found in Table 5.2. 
 
 
Difference in Parameters at Visit 11 adjusted for Visit 6 data 
 
 Mean (SD) P values 
 SUPERIOR AOD500 0.034 (0.032) 0.014* 
 SUPERIOR ARA500 0.016 (0.000) 0.039* 
 SUPERIOR TISA500 0.015 (0.000) 0.047* 
 SUPERIOR TIA500 3.136 (2.402) 0.014* 
 SUPERIOR AOD750 0.062 (0.032) 0.053 
 SUPERIOR ARA750 0.034 (0.032) 0.010* 
 SUPERIOR TISA750 0.033 (0.000) 0.008* 
 SUPERIOR TIA750 4.101 (3.584) 0.037* 
 INFERIOR AOD500 0.049 (0.063) 0.082 
 INFERIOR ARA500 0.012 (0.000) 0.086 
 INFERIOR TISA500 0.012 (0.000) 0.091 
 INFERIOR TIA500 4.220 (4.186) 0.039* 
 INFERIOR AOD750 0.022 (0.084) 0.574 
 INFERIOR ARA750 0.019 (0.032) 0.178 
 INFERIOR TISA750 0.016 (0.032) 0.293 
 INFERIOR TIA750 1.557 (4.520) 0.458 
 SUPERIOR NASAL AOD500 0.040 (0.045) 0.063 
 SUPERIOR NASAL ARA500 0.021 (0.000) 0.051 
 SUPERIOR NASAL TISA500 0.013 (0.000) 0.156 
 SUPERIOR NASAL TIA500 2.914 (3.230) 0.061 
 SUPERIOR NASAL AOD750 0.013 (0.071) 0.710 
 SUPERIOR NASAL ARA750 0.027 (0.032) 0.064 
 SUPERIOR NASAL TISA750 0.021 (0.032) 0.100 
 SUPERIOR NASAL TIA750 0.212 (3.931) 0.910 
 INFERIOR TEMPORAL AOD500 0.066 (0.063) 0.033* 
 INFERIOR TEMPORAL ARA500 0.038 (0.032) 0.002* 
 INFERIOR TEMPORAL TISA500 0.031 (0.000) 0.002* 
 INFERIOR TEMPORAL TIA500 5.192 (5.202) 0.040* 
 INFERIOR TEMPORAL AOD750 0.068 (0.071) 0.048* 
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 INFERIOR TEMPORAL ARA750 0.054 (0.032) 0.003* 
 INFERIOR TEMPORAL TISA750 0.046 (0.032) 0.003* 
 INFERIOR TEMPORAL TIA750 4.616 (4.110) 0.023* 
 NASAL AOD500 0.034 (0.045) 0.132 
 NASAL ARA500 0.017 (0.032) 0.186 
 NASAL TISA500 0.015 (0.032) 0.153 
 NASAL TIA500 3.314 (4.151) 0.094 
 NASAL AOD750 0.064 (0.063) 0.041* 
 NASAL ARA750 0.034 (0.045) 0.105 
 NASAL TISA750 0.032 (0.032) 0.097 
 NASAL TIA750 3.848 (3.999) 0.053 
 TEMPORAL AOD500 0.047 (0.055) 0.064 
 TEMPORAL ARA500 0.026 (0.032) 0.067 
 TEMPORAL TISA500 0.024 (0.000) 0.039* 
 TEMPORAL TIA500 2.777 (4.857) 0.236 
 TEMPORAL AOD750 0.041 (0.055) 0.117 
 TEMPORAL ARA750 0.037 (0.032) 0.033* 
 TEMPORAL TISA750 0.033 (0.032) 0.029* 
 TEMPORAL TIA750 1.879 (3.803) 0.287 
 INFERIOR NASAL AOD500 0.052 (0.045) 0.028* 
 INFERIOR NASAL ARA500 0.014 (0.032) 0.294 
 INFERIOR NASAL TISA500 0.015 (0.000) 0.143 
 INFERIOR NASAL TIA500 4.596 (4.553) 0.041 
 INFERIOR NASAL AOD750 0.039 (0.071) 0.244 
 INFERIOR NASAL ARA750 0.024 (0.032) 0.185 
 INFERIOR NASAL TISA750 0.026 (0.032) 0.092 
 INFERIOR NASAL TIA750 2.482 (4.503) 0.256 
 SUPERIOR TEMPORAL AOD500 0.044 (0.032) 0.003* 
 SUPERIOR TEMPORAL ARA500 0.013 (0.071) 0.011* 
 SUPERIOR TEMPORAL TISA500 0.011 (0.071) 0.020* 
 SUPERIOR TEMPORAL TIA500 3.754 (2.307) 0.003* 
 SUPERIOR TEMPORAL AOD750 0.062 (0.055) 0.020* 
 SUPERIOR TEMPORAL ARA750 0.029 (0.000) 0.002* 
 SUPERIOR TEMPORAL TISA750 0.028 (0.000) 0.003* 
 SUPERIOR TEMPORAL TIA750 3.871 (3.575) 0.028* 
Table 5.2 Analysis of covariance for the angle parameters found in dark conditions. The response variable (parameters 
change in dimensions) has been adjusted for the untreated occludable eye using the Visit 6 data. Those p values 
statistically significant (p<0.05) have been flagged with an asterisk and highlighted in yellow colour.  
 
 
On exploring whether a relationship exists between the opening of the parameters and time, 
analysis of covariance showed a positive slope for every one of the parameters (Table 5.3; with 
this being strongest for the parameter TIA in every case. These results, although not statistically 
significant, showed a trend of opening of the parameters through time.  
For most of the parameters, the slope defined by the relationship between IOP and the rate of 
opening of the parameters was positive but weak (slope<0.03). The only two cases when this 
relationship was statistically significant (both in the Nasal section) showed an inverse relationship; 
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one of them being relatively strong (Slope=-0.022298; p=0.0020) compared to the rest of the 
values.  
For more information about the magnitude of these relationships and their p-values please see 
Table 5.3 as follows: 
 
Univariate regression where the change in parameters has been adjusted for time and IOP (two separate models) 
 
 
Time slope Time P-value IOP slope IOP P-value 
DARK SUPERIOR AOD500 0.121 0.5245 0.000123 0.3493 
DARK SUPERIOR ARA500 0.004 0.1772 0.000152 0.4725 
DARK SUPERIOR TISA500 0.012 0.1862 0.000139 0.6366 
DARK SUPERIOR TIA500 12.988 0.6757 0.007920 0.2122 
DARK SUPERIOR AOD750 0.252 0.6647 0.000132 0.0971 
DARK SUPERIOR ARA750 0.055 0.2172 0.000207 0.8218 
DARK SUPERIOR TISA750 0.062 0.2583 0.000192 0.8008 
DARK SUPERIOR TIA750 16.162 0.7447 0.007145 0.1201 
DARK INFERIOR AOD500 0.050 0.7618 0.000120 0.5926 
DARK INFERIOR ARA500 0.008 0.7788 -0.000033 0.4114 
DARK INFERIOR TISA500 0.011 0.7798 -0.000030 0.4264 
DARK INFERIOR TIA500 5.563 0.7888 0.005719 0.7137 
DARK INFERIOR AOD750 0.153 0.7688 -0.000135 0.7508 
DARK INFERIOR ARA750 0.043 0.7738 -0.000043 0.6096 
DARK INFERIOR TISA750 0.045 0.8378 -0.000042 0.6076 
DARK INFERIOR TIA750 10.728 0.7197 -0.008707 0.8138 
DARK SUP NASAL AOD500 0.211 0.8378 -0.000047 0.1231 
DARK SUP NASAL ARA500 0.055 0.1852 0.000125 0.5295 
DARK SUP NASAL TISA500 0.052 0.2543 0.000101 0.5105 
DARK SUP NASAL TIA500 14.644 0.8198 0.002696 0.1622 
DARK SUP NASAL AOD750 0.225 0.8268 -0.000005 0.2342 
DARK SUP NASAL ARA750 0.087 0.2342 0.000198 0.6256 
DARK SUP NASAL TISA750 0.084 0.2913 0.000172 0.5986 
DARK SUP NASAL TIA750 14.467 0.7658 -0.005607 0.1902 
DARK INF TEMPORAL AOD500 0.169 0.2372 0.000316 0.6587 
DARK INF TEMPORAL ARA500 0.092 0.0300* 0.000236 0.3824 
DARK INF TEMPORAL TISA500 0.095 0.0290* 0.000177 0.1622 
DARK INF TEMPORAL TIA500 15.215 0.4474 0.016566 0.5485 
DARK INF TEMPORAL AOD750 0.264 0.4204 0.000233 0.6697 
DARK INF TEMPORAL ARA750 0.155 0.0681 0.000273 0.3504 
DARK INF TEMPORAL TISA750 0.156 0.0931 0.000214 0.2392 
DARK INF TEMPORAL TIA750 15.844 0.4785 0.012840 0.6517 
DARK NASAL AOD500 0.278 0.7838 -0.000049 0.1491 
DARK NASAL ARA500 0.117 0.7508 0.000026 0.2392 
DARK NASAL TISA500 0.105 0.7578 0.000022 0.2082 
DARK NASAL TIA500 22.830 0.7538 -0.006954 0.1662 
DARK NASAL AOD750 0.367 0.4585 0.000213 0.1061 
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DARK NASAL ARA750 0.203 0.7487 0.000044 0.1502 
DARK NASAL TISA750 0.192 0.7658 0.000038 0.1101 
DARK NASAL TIA750 21.640 0.5686 0.010927 0.1081 
DARK TEMPORAL AOD500 0.157 0.0661 0.000429 0.5836 
DARK TEMPORAL ARA500 0.058 0.0060* 0.000288 0.8168 
DARK TEMPORAL TISA500 0.055 0.0160* 0.000226 0.8278 
DARK TEMPORAL TIA500 10.819 0.2232 0.028208 0.8208 
DARK TEMPORAL AOD750 0.163 0.3614 0.000284 0.7497 
DARK TEMPORAL ARA750 0.099 0.0310* 0.000366 0.8358 
DARK TEMPORAL TISA750 0.097 0.0330* 0.000312 0.8268 
DARK TEMPORAL TIA750 8.914 0.5566 0.012461 0.6066 
DARK INF NASAL AOD500 0.251 0.5335 0.000168 0.1902 
DARK INF NASAL ARA500 0.082 0.3524 0.000126 0.6747 
DARK INF NASAL TISA500 0.091 0.3934 0.000092 0.3213 
DARK INF NASAL TIA500 23.073 0.6737 0.011795 0.1682 
DARK INF NASAL AOD750 0.483 0.4024 -0.000301 0.0140* 
DARK INF NASAL ARA750 0.173 0.6476 0.000098 0.3273 
DARK INF NASAL TISA750 0.184 0.7708 0.000060 0.1702 
DARK INF NASAL TIA750 32.816 0.3053 -0.022298 0.0020* 
DARK SUP TEMPORAL AOD500 0.143 0.6346 0.000114 0.3754 
DARK SUP TEMPORAL ARA500 0.039 0.7778 0.000022 0.7638 
DARK SUP TEMPORAL TISA500 0.039 0.8188 0.000010 0.7377 
DARK SUP TEMPORAL TIA500 14.101 0.8138 0.003502 0.2563 
DARK SUP TEMPORAL AOD750 0.240 0.3433 0.000299 0.2062 
DARK SUP TEMPORAL ARA750 0.085 0.3814 0.000107 0.5656 
DARK SUP TEMPORAL TISA750 0.086 0.5646 0.000071 0.5475 
DARK SUP TEMPORAL TIA750 16.150 0.4805 0.013428 0.1171 
Table 5.3. Slopes (similar to the ustandardised coefficients, is presented as an indicator of relationship between 
widening of the parameters and time and between the same widening and IOP); P values indicating statistical 
significant relationship among parameters, time and IOP and between the treated and untreated eye groups.  
 
The mean values for every parameter (treated eyes with ALPI and occludable eyes left untreated) 
in dark for visits 6, 8, 9, 10 and 11 together with their standard deviation within brackets can be 
found in Table 5.4 (Appendix 1).  
 
The changes in the parameters through time and in the different sections for ALPI treated and 
pot-LPI occludable untreated have been visually represented in graphs 5.2 to 5.7 
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Figure 5.2 Dimensions for the parameter AOD 500 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.3 Dimensions for the parameter ARA 500 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.4 Dimensions for the parameter TISA 500 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.5 Dimensions for the parameter TIA 500 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.6 Dimensions for the parameter AOD 750 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.7 Dimensions for the parameter ARA 750 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.8 Dimensions for the parameter TISA 750 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11. 
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Figure 5.9 Dimensions for the parameter TIA 750 for all of the eight different sections in ALPI treated eye at visits 6, 8, 9, 10 and 11.
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Figure 5.10 and 5.11 Dimensions for the parameter AOD and ARA 500 for all of the eight different sections in 
Occludable Untreated eyes at Visits 6 and 11. 
 
Figure 5.11 
 
Figure 5.10 
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Figure 5.12 and 5.13 Dimensions for the parameter TISA and TIA 500 for all of the eight different sections in Occludable 
Untreated eyes at Visits 6 and 11. 
Figure 5.12 
 
Figure 5.13 
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Figure 5.14 and 5.15 Dimensions for the parameter AOD and ARA 750 for all of the eight different sections in 
Occludable Untreated eyes at Visits 6 and 11. 
Figure 5.14 
 
Figure 5.15 
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 Figure 5.16 and 5.17 Dimensions for the parameter TISA and TIA 750 for all of the eight different sections in Occludable 
Untreated eyes at Visits 6 and 11. 
 
Figure 5.16 
 
Figure 5.17 
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5.1.4 Discussion 
ALPI has shown to be effective in increasing the angle parameters dimensions when compared to 
the NFT group (the control group). This was confirmed by gonioscopy, where all the eyes that 
received the treatment changed from an occludable configuration (2 weeks before the treatment) 
to a non-occludable configuration 2.09 months after. 
The novelty of these results is the presence of a control eye (NFT) against which to adjust the 
statistical model. This means that, should there have been random external factors modifying the 
angle parameters, these have been corrected for in this model. For these reasons, it seems that 
this is a more accurate investigation of the effect of the ALPI than those described in the already 
mentioned published research. 
Furthermore the opening effect of the ALPI seemed to be, although non-statistically significant, 
correlated with time during the first two months after the procedure (time period of this follow-
up). In other words, as time progressed the angle parameters increased. The proportion for this 
relationship was given by the value of the slopes in Table 5.3. To the best of one’s knowledge 
there is only one study that has shown changes in one eye before and after ALPI using the OCT, 
but these changes were not quantified (Leung, et al., 2005).  
A relationship between IOP after the ALPI and the angle parameters dimensions was not found in 
the majority of the parameters; when found, it was weakly correlated. Consequently, a 
relationship between rate of opening and level of IOP could not be verified. The reason for not 
looking into an association between parameters dimensions, time and IOP was due to the 
difference of time during the daytime when these pressures were measured in every participant. 
It has been already explained in this thesis (Section 4.2) how the diurnal IOP fluctuates in PAC and 
PACS patients (untreated and treated with LPI) and therefore this may have given inaccurate 
possible associations. 
Chew and Yeo (1995) investigated the IOP levels of 11 PACG participants treated with ALPI who 
had already undergone LPI but whose angles remained occludable. All IOP measurements were 
made pre-laser and 1 hour, 1 week, 1 month, 3 months and 6 months post laser. They found that 
there was an initial reduction of IOP during the first week, but that it rose after 4 weeks following 
the procedure. A final comparison between the pre-laser IOP and that measured 6 months post-
laser showed a decreased of IOP in 7 eyes. Aside from the fact that the characteristics of their 
patient sample differed from those in current research, it is not possible to compare their results 
with present data on account of the fact that the authors did not specify the time of day the IOP 
was measured at every visit or if this was taken at the same time for the same participant at every 
visit.  Similar limitations may apply in a recent study by Sun, et al. (2010) who randomised 158 
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PAC/PACG participants into having LPI or LPI plus ALPI. They measured the IOP at baseline and at 
seven more visits during the following year. They found a reduction in IOP of approximately 6.66 
mmHg in the LPI treated group and 7.8 mmHg in the LPI plus ALPI group one year after the 
procedures. However, they did not specify if these IOP measurements were taken at the same 
time of the day as in the pre-laser visit. The present study data from Section 4.2 shows that a 
diurnal fluctuation exists of around 6.34 mmHg (SD 2.21 mmHg) in successfully treated LPI eyes.  
If data by Sun, et al. (2010) were collected on LPI patients at different times of the day, the 
differences in IOP between the pre and post-laser measurements could well be explained through 
the diurnal IOP fluctuation.  Diurnal fluctuation for ALPI treated patients in the present study is 
explored in the next section (Section 5.2).  
Another study carried out by Lee, Choi, Kim and Choi (2011) in bilateral PACS subjects, 
randomised one eye to receive LPI and the fellow eye to receive LPI plus ALPI (same setting). The 
anterior chamber depth measured at 4 to 6 mm from the centre of the eye was significantly 
different between the two treatment groups, being the LPI plus ALPI the treatment with the 
higher deepening efffect. These differences were measured 1 week after the procedure and 
assessed with Pentacam. There were no statistically significant differences between groups in the 
IOP measured at baseline, 1 hour, 1 day, 1 week, 1 month and 3 months after the treatment, 
however, again, the time of IOP measurement was also not specified. 
A further outcome for this thesis could have been a comparison for parameters and IOP levels 
between the ALPI treated group and the non-occludable post-LPI group. 
 
5.1.5 Conclusion 
ALPI has been shown to be effective in opening those angles that remained occludable after LPI. 
This has been tested using two techniques, gonioscopy and AS-OCT. 
Although statistically non-significant there appears to be a relationship between an increase in 
the angle parameters and an increase in time after the procedure for at least the first two 
months. 
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5.2 Effect of ALPI on the intraocular pressure diurnal fluctuation after 2 
months 
 
5.2.1 Introduction 
As explained in the introduction of section 5.1, the mechanism of lowering of IOP by ALPI is 
unclear although one would presume that reduction of the area of trabecular meshwork that is 
occludable by the iris is a major factor. In addition to measuring absolute IOP levels this thesis 
aimed to study the effect of ALPI on DIOP fluctuation. To date there is no published literature 
regarding the outcome of this objective, but it has been shown earlier in this thesis that there is 
an inverse association between DIOP fluctuation and the dimensions of the parameters in the 
different sections. It has been additionally shown that there is a widening effect caused by the 
ALPI in nearly all the parameters of 3 angle sections when compared to the untreated eye. One 
can hypothesise that there would be a decrease in such fluctuation in eyes treated with ALPI.  
 
5.2.2 Methodology and Statistical Analysis plan 
Prior to planning the statistical analysis, variability in the DIOP fluctuation due to time in this 
group of eyes was investigated: 
In the Section 4.2 of this thesis, the effect of the Laser Peripheral Iridotomy (LPI) on the DIOP 
fluctuation was studied. DIOP fluctuation due uniquely to time was additionally studied prior to 
plan the statistical analysis. It was shown that there were no statistically significant differences 
(nor clinical) in the DIOP fluctuation measured 6 months apart in the fellow untreated eyes of 
those eyes that had only received LPI as laser treatment. However, in this section the eyes acting 
as control are those with post-LPI occludable angles that did not received further treatment (NFT 
group, n=10).  There was therefore a need to know if the DIOP fluctuation was stable in this group 
of eyes. 
If there was no variability in the DIOP fluctuation in the NFT group of eyes (used as control group) 
it would mean that comparisons between two different visits (Visit 1 and 11) could be performed.  
 A paired samples t-test was performed for DIOP fluctuation, peaks and troughs for the NFT group 
at Visit 1 compared to the same group at Visit 11. The differences were all lower than 1 mm Hg 
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and not statistically significant. The results for these comparisons can be found in the results 
section of this section.  
The time elapsed between Visit 1 and Visit 11 for the NFT group was 6.61 months (SD 0.62 
months) which was similar to that of the ALPI group, 6.52 months (SD 0.60 months). 
Consequently, it was justified to use the NFT as the control group for the ALPI group (those eyes 
with post-LPI occludable angles that received ALPI as a further treatment). See the following 
figure (Figure 5.18) for a visual pathway of the participants after the two randomisations. 
 
 
 
Figure 5.18.Participant pathway throughout the study. The upper half of the figure shows the pathway of those eyes 
randomised to receive Laser Peripheral Iridotomy (LPI) and the lower half of the figure shows the pathway of the 
untreated fellow eyes. The data enclosed in red boxes was not used in this section. Abbreviations in this figure: n= 
number of eyes in each group. LPI= Laser Peripheral Iridotomy. OCC= Post-LPI eyes with occludable angles. UNOCC= 
Post-LPI eyes with unoccludable eyes. ALPI= Eyes with post-LPI occludable angles that were further randomised into 
receiving ALPI. NFT= Eyes with post-LPI occludable angles that were further randomised into not receiving further 
treatment. 
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To test the hypothesis that ALPI would decrease the DIOP fluctuation: 
 The statistical analysis was designed to investigate the differences in DIOP fluctuation within the 
same eye before and after the ALPI (time lines: Visit 1 and Visit 11).  As this group of eyes was 
already treated with LPI, it was necessary to isolate the effect of the ALPI. The way this was done 
was using the NFT (group of eyes with similar features as the ALPI group with the exception that 
they did not receive the ALPI).  This was carried out using analysis of covariance at Visit 11 and 
adjusted for the differences in DIOP fluctuation for the two groups. If a statistically difference was 
to be found, this would have been due to the effect of ALPI solely. 
The mean time between ALPI, carried out in Visit 7, and Visit 11 was 2.39 months, SD 0.29 
months.  
 
5.2.3 Results 
Investigation of variability of the data found for DIOP fluctuation in the control group of eyes 
(NFT) between Visits 1 and 11: 
Paired t-test was performed to compare the DIOP fluctuation, peaks and troughs between the 
NFT group at Visit 1 and Visit 11. No statistically significant differences existed and the differences 
in the means were lower than 1 mmHg. See following table (Table 5.5). 
 
DIOP NFT group Visit 1 
Mean (SD) 
NFT group Visit 11 
Mean (SD) 
Mean difference 
(SE) 
T test P value 
Fluctuation  6.83 (3.07) 6.61 (1.63) 0.22 (3.62) 0.859 
Peak  22.11 (4.39) 21.55 (2.52) 0.55 (3.83) 0.675 
Trough  15.28 (2.03) 14.94 (1.88) 0.33 (2.05) 0.638 
Table 5.5. Paired Samples t-test comparing DIOP fluctuation, peaks and troughs between NFT group at Visit 1 and NFT 
group at Visit 11.NFT=no further treatment. 
 
 
 
Results for the effect of ALPI on the DIOP fluctuation: 
The analysis of covariance showed that there was a difference of 1.56 mmHg between the DIOP 
fluctuation found in the two groups, ALPI (Mean DIOP fluctuation at Visit 11=5.04 mmHg; SD=1.60 
mmHg) and the post-LPI occludable angles left untreated (Mean DIOP fluctuation= 6.61 mmHg; 
SD=1.63 mmHg). This difference was statistically non-significant p=0.056.  
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To assess if this difference in fluctuation was due to a difference between peaks, troughs or due 
to both, further analyses were undertaken. One compared the peaks (Mean IOP peak at Visit 11 
for ALPI group= 19.04 mmHg, SD 2.58 mmHg; Mean IOP peak at Visit 11 for NFT group= 21.55 
mmHg, SD 2.52 mmHg) and the other compared the troughs between groups (Mean DIOP trough 
ALPI group= 14.00 mmHg, SD 2.00 mmHg; Mean DIOP trough NFT group= 14.94 mmHg, SD 1.88 
mmHg). Analysis of covariance showed no statistically significant differences when comparing the 
DIOP troughs between groups (Mean difference between DIOP troughs=0.47 mmHg; p=0.578). 
When comparing the DIOP peaks, the mean difference between groups was found to be 1.35 
mmHg, with this difference being no statistically significance, p=0.210. Table 5.6 contains all this 
information. 
 
DIOP NFT group 
Mean (SD) 
ALPI group 
Mean (SD) 
Mean difference 
(SE) 
ANCOVA P 
value 
 Visit 1 Visit 11 Visit 1 Visit 11   
Fluctuation (mmHg) 6.60 (2.99) 6.61 (1.63) 5.32 (2.20) 5.04 (1.60) 1.60 (0.78) 0.056 
Peak (mmHg) 21.75 (4.30) 21.55 (2.52) 19.32 (2.79) 19.04 (2.58) 1.35 (1.04) 0.210 
Trough (mmHg) 15.15 (1.96) 14.94 (1.88) 14.00 (2.70) 14.00 (2.00) 0.470 (0.83) 0.578 
Table 5.6. Analysis of covariance (ANCOVA) comparing DIOP fluctuation, peaks and troughs between post-LPI eyes with 
occludable angles that were left without further treatment (NFT group) and those that received further treatment with 
ALPI (ALPI group) at Visit 11 adjusted for Visit 1 data. SD= Standard deviation. SE= Standard error. 
 
5.2.4 Discussion 
In this study ALPI was effective in lowering the DIOP fluctuation by 1.56 mmHg (p=0.056) after 2.4 
months approximately after the procedure. This difference seemed to be due to the lower peaks 
in the ALPI group, meaning that those participants who were treated with ALPI seemed to have 
lower peaks than those with post-LPI participants with occludable angles who were left 
untreated.  
The advantage of this investigation is to have a control group whose levels can be used to adjust 
the statistical models to. If this group had not existed only data collected at Visit 11 would have 
been compared.  
It was interesting that the DIOP fluctuation found in Section 4.1 for the unoccludable post-LPI 
eyes (6.34 mmHg; 2.21 mmHg) was similar for those that were not treated with ALPI compared to 
those that were treated. Moreover, the ALPI treated group of eyes showed the lowest DIOP 
fluctuation compared to the other 3 groups at Visit 11 (non-treated eyes, post-LPI unoccludable 
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eyes, post-LPI occludable eyes). This would suggest that ALPI further reduced the DIOP 
fluctuation. 
As mentioned in the Section 4.2 of this thesis, there have been several studies performed in angle 
closure participants, however, this is the first study assessing DIOP fluctuation in ALPI treated 
eyes; furthermore, it is the only study having a control eye of similar characteristics.  
 
5.2.5 Conclusion 
When considering eyes with occludable angles that do not become open on gonioscopy following 
LPI, a subsequent ALPI treatment may be effective in lowering the DIOP peaks and DIOP 
fluctuation when compared to the diurnal profiles of eyes that are not offered further treatment 
post-LPI.  
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5.3 Assessment of variability of ALPI effect depending on the angle 
sector 
 
5.3.1 Introduction 
Unlike LPI where the laser is used to create an iridotomy in a single site, the ALPI is applied over 
the 360 degrees of irido-trabecular angle circumference (20 to 24 shots aimed to contract/burn 
iris tissue but not to penetrate it). There is no published research assessing the effect of ALPI on 
multiple angle sectors with AS-OCT. One may hypothesise that the evenly-spaced circumferential 
laser applications would widen the anterior chamber angle to a similar extent circumferentially. 
 
5.3.2 Methodology and Statistical Analysis plan 
Analysis of variance followed by Tukey HSD (this analysis can be found in the attached compact 
disc) was used to statistically test the differences in angle parameters for the different 10 sections 
in light and dark conditions and before and after the ALPI (time points: Visit 6 (12.55 days, SD 5.24 
days, before ALPI) and Visit 11 (2.09 months, SD 0.302, after ALPI)) in the 11 eyes that received 
the treatment.  
 
5.3.3 Results 
The analysis showed no statistically significant differences among the effect of ALPI on the 
parameters in the ten sections under study. The descriptive mean values for the difference in the 
parameter dimensions between Visit 6 and Visit 11 can be observed in Table 5.7 for the 
parameters in light conditions and in Table 5.8 for dark conditions. 
 
LIGHT MEAN VALUES OF 
ALPI EFFECT 
AOD 500 ARA 500 TISA 500 TIA 500 AOD 750 ARA 750 TISA 750 TIA 750 
IRIDOTOMY POSITION 
0.008 
(0.041) 
0.005 
(0.013) 
0.005 
(0.012) 
0.670 
(3.336) 
0.030 
(0.065) 
0.008 
(0.021) 
0.007 
(0.022) 
1.873 
(4.066) 
SUPERIOR 
0.001 
(0.034) 
0.001 
(0.013) 
0.003 
(0.012) 
0.636 
(3.611) 
0.014 
(0.044) 
0.012 
(0.029) 
0.013 
(0.028) 
1.491 
(3.233) 
SUPERIOR- NASAL 
0.022 
(0.044) 
0.004 
(0.022) 
0.005 
(0.022) 
2.740 
(4.220) 
0.014 
(0.044) 
0.012 
(0.029) 
0.013 
(0.028) 
1.491 
(3.233) 
NASAL 
0.016 
(0.063) 
0.013 
(0.033) 
0.010 
(0.025) 
2.273 
(5.658) 
0.008 
(0.076) 
0.016 
(0.048) 
0.013 
(0.043) 
1.336 
(5.221) 
INFERIOR- NASAL 
0.029 
(0.079) 
0.022 
(0.029) 
0.018 
(0.026) 
2.864 
(7.718) 
0.010 
(0.084) 
0.028 
(0.045) 
0.024 
(0.042) 
1.082 
(5.592) 
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OPPOSITE IRIDOTOMY 
0.064 
(0.103) 
0.026 
(0.040) 
0.025 
(0.036) 
3.955 
(6.004) 
0.077 
(0.083) 
0.047 
(0.062) 
0.045 
(0.059) 
3.800 
(3.333) 
INFERIOR 
0.008 
(0.053) 
0.000 
(0.030) 
0.000 
(0.030) 
1.000 
(4.468) 
0.064 
(0.089) 
0.011 
(0.040) 
0.011 
(0.041) 
3.746 
(4.436) 
INFERIOR-TEMPORAL 
0.037 
(0.036) 
0.021 
(0.028) 
0.023 
(0.025) 
4.555 
(3.749) 
0.036 
(0.046) 
0.033 
(0.036) 
0.035 
(0.032) 
3.246 
(3.056) 
TEMPORAL 
0.040 
(0.075) 
0.029 
(0.038) 
0.026 
(0.032) 
4.073 
(5.185) 
0.045 
(0.084) 
0.037 
(0.049) 
0.034 
(0.044) 
3.146 
(4.210) 
SUPERIOR-TEMPORAL 
0.048 
(0.086) 
0.017 
(0.026) 
0.017 
(0.025) 
4.382 
(7.427) 
0.064 
(0.076) 
0.033 
(0.047) 
0.034 
(0.044) 
4.127 
(4.638) 
Table 5.7. Mean value of the ALPI effect in the parameters in the 10 different sections measured in light conditions. The 
values in the table are mean values of the change between V6 (pre-ALPI) and V11 (post-ALPI). The standard deviation is 
the value within brackets. Minimum parameter mean value dimension for every section is boxed in blue and maximum 
value in red.  
 
DARK MEAN VALUES OF 
ALPI EFFECT 
AOD 500 ARA 500 TISA 500 TIA 500 AOD 750 ARA 750 TISA 750 TIA 750 
IRIDOTOMY POSITION 
0.001 
(0.043) 
0.009 
(0.032) 
0.006 
(0.024) 
0.300 
(3.024) 
-0.020 
(0.058) 
0.007 
(0.040) 
0.005 
(0.032) 
-1.180 
(3.681) 
SUPERIOR 
0.028 
(0.030) 
0.012 
(0.023) 
0.012 
(0.021) 
2.550 
(2.658) 
0.046 
(0.077) 
0.025 
(0.032) 
0.025 
(0.030) 
2.922 
(4.751) 
SUPERIOR- NASAL 
0.029 
(0.045) 
0.015 
(0.027) 
0.012 
(0.023) 
2.164 
(3.640) 
0.042 
(0.086) 
0.022 
(0.037) 
0.020 
(0.033) 
2.244 
(5.338) 
NASAL 
0.030 
(0.049) 
0.015 
(0.028) 
0.013 
(0.024) 
2.573 
(4.497) 
0.056 
(0.071) 
0.026 
(0.048) 
0.024 
(0.045) 
3.370 
(5.036) 
INFERIOR- NASAL 
0.057 
(0.041) 
0.019 
(0.034) 
0.017 
(0.028) 
5.309 
(4.647) 
0.035 
(0.063) 
0.029 
(0.042) 
0.028 
(0.035) 
2.450 
(4.315) 
OPPOSITE IRIDOTOMY 
0.019 
(0.068) 
0.009 
(0.034) 
0.008 
(0.026) 
1.109 
(4.145) 
0.021 
(0.032) 
0.014 
(0.044) 
0.013 
(0.037) 
1.055 
(1.831) 
INFERIOR 
0.031 
(0.068) 
0.001 
(0.023) 
0.002 
(0.022) 
2.200 
(5.359) 
0.030 
(0.087) 
0.010 
(0.043) 
0.010 
(0.043) 
1.636 
(5.413) 
INFERIOR-TEMPORAL 
0.043 
(0.072) 
0.023 
(0.022) 
0.020 
(0.018) 
3.100 
(6.612) 
0.044 
(0.065) 
0.032 
(0.031) 
0.030 
(0.028) 
2.755 
(4.477) 
TEMPORAL 
0.056 
(0.064) 
0.029 
(0.035) 
0.026 
(0.032) 
3.773 
(6.445) 
0.039 
(0.060) 
0.040 
(0.044) 
0.036 
(0.039) 
1.900 
(4.050) 
SUPERIOR-TEMPORAL 
0.031 
(0.029) 
0.006 
(0.010) 
0.005 
(0.010) 
2.418 
(2.354) 
0.055 
(0.046) 
0.018 
(0.016) 
0.018 
(0.016) 
3.373 
(3.086) 
Table 5.8. Mean value of the ALPI effect in the parameters in the 10 different sections measured in dark conditions. The 
values in the table are mean values of the change between V1 (pre-ALPI) and V11 (post-ALPI). The standard deviation is 
the value within brackets. Minimum parameter mean value dimension for every section is boxed in blue and maximum 
value in red. 
 
5.3.4 Discussion 
ALPI resulted in angle opening (an increase in angle parameters) for all 10 sections in light 
conditions and in the majority of the parameters for dark conditions. This is consistent with the 
results found earlier in this thesis showing the statistically significant widening of the majority of 
the parameters due to ALPI effect.  
The differences found between maximum and minimum values were relatively small and not 
statistically significant in both lighting conditions. This would appear to support the research 
hypothesis stating that there is a homogeneous effect of the ALPI throughout the angle sections. 
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However, to be able to confirm this statement one would need to obtain a perfect correlation 
between gonioscopy and AS-OCT parameters dimensions. This correlation would assert what is a 
relevant or an irrelevant change in dimension for a given parameter. Unfortunately, this 
information is not currently available in the literature, but is an interesting concept for future 
research. 
 
5.3.5 Conclusion 
There were no statistically significant differences between the 10 sectors of the anterior chamber 
angle when considering the angle-opening effect of ALPI. To date, no data exists in the literature 
to compare results of the present study with. 
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CHAPTER 6.  Effect of Nd:YAG in addition to  Argon 
energy on the corneal endothelium  
 
6.1 Effect of Laser Peripheral Iridotomy (LPI) in addition to Argon Laser 
Peripheral Iridoplasty (ALPI)on the corneal endothelium 
 
6.1.1 Introduction 
The effect of Nd:YAG energy on the corneal endothelium when performing iridotomies has been 
extensively studied. However, the additional effect of argon laser peripheral iridoplasty on the 
endothelial cells has received little attention.   
In addition, new techniques combining LPI and ALPI simultaneously as combined treatment of 
PACS (Lee, Choi, Kim and Choi, 2011), PAC and PACG (Sun, et al., 2010) have been described yet 
the possible impact of these techniques on the endothelium has been described by one report 
only (Sun, et al., 2010) who reported that the corneal endothelial cell count was not significantly 
reduced at 1 year follow up (from 2610.74/mm2   at baseline to 2610.7/mm2 after one year) but no 
details were given regarding the method used in this quantification. Little is known about how 
this cell density is affected in a shorter post-operative period. Should a patient require another 
type of intraocular surgery that may affect the endothelium after having received ALPI preceded 
by LPI, it would be advantageous to clinicians to understand or predict the changes to the 
endothelium through time. 
One can hypothesise that there would be an initial decrease in cell density from baseline, 
followed by a gradual increase in endothelial cell density until baseline levels are regained.  
 
6.1.2 Methodology and Statistical Analysis plan 
The assessment of cell density and degree of polymegethism and pleomorphism in 7 different 
regions of the corneal endothelium (1 central and 6 peripheral: Superior, Superior-Nasal, Inferior-
Nasal, Inferior, Inferior-Temporal and Superior-Temporal) were obtained with the TOMEY- 3000 
non-contact specular microscope analysis software. More information about this device can be 
found in the methodology chapter (Chapter 2 of this thesis). 
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The statistical analysis was carried out in several statistical comparisons and divided in two parts. 
The first part of the analysis was aimed to investigate the effect of the LPI on the corneal 
endothelium in terms of density of endothelial cells, pleomorphism and polymegethism 
compared to baseline. The measurements were taken before LPI was performed at Visit 1 (2.31 
weeks; SD 2.34 weeks, pre-LPI) and after LPI at the following visits: Visit 2 (1:54 hours; SD 25 
minutes, post-LPI), Visit 3 (1 day; SD 0.00, post-LPI), Visit 4 (1.10 weeks; SD 0.13 weeks, post LPI), 
Visit 5 (1.44 months; SD 0.18 months, post-LPI), Visit 6 (3.05 months; SD 0.27 months, post-LPI) 
and Visit 11 (5.83 months; SD 0.37 months, post-LPI). 
The second part of the analysis aimed to investigate the effect of the ALPI on the corneal 
endothelium (same parameters studied as for the LPI and specified in the paragraph above). The 
data used in this part of the analysis was collected from eyes whose angles remained occludable 3 
months after the LPI. Only 11 of these 21 eyes were randomised to receive the ALPI and the 
analysis focused on this group. Data from baseline, in this case Visit 6 (1.79 weeks; SD 0.75 weeks, 
pre-ALPI), and consecutive posterior visits, Visit 7 (1:32 hours; SD 31 minutes, post-ALPI), Visit 8 (1 
day; SD 0.00, post-ALPI), visit 9 (1 week; SD 0.13 weeks, post-ALPI), Visit 10 (1.43 months, SD 0.18 
months, post-ALPI) and Visit 11 (2.39 months; SD 0.29 months, post-ALPI) were used for the 
statistical analysis. 
The objective was studied in two groups of eyes: 
Group 1- Forty eyes treated with LPI and their untreated fellow eyes.  The data for those eyes that 
had received the ALPI were excluded in Visit 11. 
Group 2- 21 eyes with occludable angles after LPI, for which 11 received ALPI. Their fellow eyes 
were not included, but those occludable eyes that were randomised to not to receive ALPI (n=10) 
acted as the control eyes for the evaluation of the ALPI effect. 
With the aim of studying the effect of the lasers through time, paired samples t-test was 
performed between the baseline visit and each of the consecutive visits. This analysis was 
performed in the treated and in the untreated fellow eye, using this latter as a control. 
A second aim was to find if there were differences in the effect of these lasers when treated and 
untreated eyes were compared. This was achieved through analysis of covariance and adjusting 
all the models for the data found at baseline. 
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The mean total power used to perform the iridotomy was 16.11mJ (SD 10.879mJ), varying from 
2mJ to 48mJ. The mean number of shots was 13 (SD 8.569) and the power setting mean value was 
1.22mJ (Range 1.19 to 1.25mJ).  
In the case of the ALPI, the minimum mean power used was 170mJ (SD 24.89mJ) and the 
maximum 239.09mJ (SD 59.74mJ) giving an overall power of 204.54mJ. The mean number of 
burns was 23.08 (SD 2.08) and this number varied from 20 to 26 burns. 
 
6.1.3 Results 
The effect of the LPI and ALPI on the corneal endothelium was investigated for each laser in 4 sub-
results: 1. Effect on endothelial cell density; 2. Effect on endothelial average size 
(polymegethism); 3. Effect on percentage of hexagonal endothelial cells (pleomorphism) and 4. 
Effect on central corneal thickness. These effects were studied for LPI on Group 1 and for ALPI on 
Group 2 (these groups have already been specified above). 
Descriptive statistics for these endothelial cell parameters at the different visits for Group 1 are 
given in Tables 6.1 to 6.7. The corresponding data for Group 2 can be found in Tables 6.8 to 6.14 
in Appendix 1. 
A. Effect of LPI on the corneal endothelium 
A.1. LPI effect on endothelial cell density (number of cells/mm2) 
      The majority of paired samples t-tests showed no statistically significant differences when 
comparing baseline (Visit 1) with the rest of the visits (Visit 2, 3, 4, 5, 6 and 11) in any of the 7 
sampled areas. The only exception was found when comparing Visit 1 and Visits 3, 4 and 5 in 
the Superior area of the treated and untreated eyes, where there was a statistically significant 
loss of cell density. These statistically significant mean differences were smaller in treated eyes 
than those found in the fellow untreated eyes at Visit 3, but greater for Visits 4 and 5. 
However, when these differences between treated and untreated eyes were tested using 
analysis of covariance, there was no statistical significance.  
 Although not statistically significant, there was a trend for the endothelial cell density in the 
treated eye to start reducing at Visit 2, achieving a maximum reduction at Visit 3, begin a 
minor recovery at Visit 4, drop again at Visits 5 and 6 and achieve full recovery by Visit 11. 
Additionally, this trend seemed to be followed by the fellow untreated eye in the Superior-
Nasal and Inferior-Nasal areas and partially in the Central, Superior and Superior-Temporal 
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areas. In the case of Inferior and Inferior-Temporal areas, the fellow eye’s cell density levels 
were fluctuating in the opposite direction as to the treated eyes. See following graphs for a 
visual representation. 
 
 
 
 
Figure 6.1. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Central cornea for the 
eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.2. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior cornea for the 
eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
 
 
 
 
Figure 6.3. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-Nasal cornea for 
the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.4. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-Temporal cornea 
for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
 
 
 
Figure 6.5. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior cornea for the 
eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.6. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-Nasal cornea for 
the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
 
 
Figure 6.7. Descriptive mean values for cell density found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-Temporal cornea 
for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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       A.2. LPI effect on endothelial average size, as an indication of polymegethism (m2) 
There were very few statistically significant differences between baseline data and the rest of 
the consecutive visits: 
- Central area: A decrease in cell area of 8.536 m2 (SD 21.929), p=0.049, was found at Visit 2 
(1 hour after the LPI) 
-Inferior-Nasal area: An increase in cell area of 12.387 m2 (SD 30.827), p=0.033, was found at 
Visit 6 when compared to baseline Visit 1 
-Inferior-Temporal area: The cell area increased by 7.742 m2 (SD 21.085), p=0.050. This 
increase was found at Visit 6 when compared to baseline (Visit 1) 
The most common trend followed by the treated eye rate of polymegethism was an initial 
increase between Visits 2 and 3, a mild recovery between Visits 4 and 5, a second increase in 
Visit 6 and a dramatic drop in Visit 11 for Superior, Superior-Temporal, Inferior-Temporal and 
Inferior corneal areas. However, a lack of recovery was found for the polymegethism rates in 
Central, Superior-Nasal and Inferior-Nasal corneal areas. 
In the case of the untreated fellow eye, a trend was less obvious. Please see a visual 
representation for the different areas of cornea as follows: 
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Figure 6.8. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Central 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
Figure 6.9. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.10. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-
Nasal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
Figure 6.11. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-
Temporal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.12. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
Figure 6.13. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-
Nasal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.14. Descriptive mean values for endothelial polymegethism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-
Temporal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
 
 
A.3. LPI effect on percentage of hexagonal endothelial cells, pleomorphism (%) 
The most common trend in the case of the treated eye was an initial reduction in 
pleomorphism between Visits 2 and 3, a mild recovery in Visit 4, before reducing again at Visit 
5, ending with a more marked recovery in Visit 6 and Visit 11.  In the case of the untreated 
fellow eye, the fluctuations through the visits were very similar to the ones described for the 
treated eye. This was confirmed statistically with the analysis of covariance where the 
differences in means were of  5% approximately and not statistically significant.  
Please see a visual representation for the different areas of cornea as follows: 
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Figure 6.15. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Central 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
 
Figure 6.16. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.17. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-
Nasal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
Figure 6.19. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Inferior-
Temporal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.20. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior 
cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
Figure 6.21. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-
Nasal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
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Figure 6.22. Descriptive mean values for endothelial pleomorphism found at Vists 1, 2, 3, 4, 5, 6 and 11 in the Superior-
Temporal cornea for the eyes treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
        A.4. LPI effect on central corneal thickness (m) 
 The corneal thickness data was only given when the measurement was taken in central 
cornea.  
Paired samples t-test found statistically significant differences in central corneal thickness 
when comparing Visits 3 and 5 to Visit 1 for the treated and untreated eyes. The differences 
found for the treated eyes were not as marked as the ones found for the untreated eyes, but 
in any of the cases there seemed to be a loss in corneal thickness through those visits. Mean 
differences with paired t-test using for the treated eye, using Visit 1 as baseline, were of 
13.769 m (SD 12.206), p<0.001, at Visit 3 and of 4.852 m (SD 10.654), p=0.026, at Visit 5. 
For the untreated eyes, these differences were of 9.000 m (SD 2.685), p<0.001, at Visit 3 and 
of 3.138 m (SD 8.101), p=0.046, at Visit 5. When these differences were tested by analysis of 
covariance no statistically significant difference was found. (The adjusted mean differences 
were found of 5.012 m (SD 2.685), p=0.068, for Visit 3 and of 2.084 m (SD 2.266), p=0.362 
for Visit 5) 
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The trend followed by both groups of eyes was a very small reduction in corneal thickness in 
Visit 2, reaching a maximum reduction in Visit 3 and a very mild recovery through Visits 4 and 
5, achieving partial to good recovery at Visits 6 and 11. In the case of the untreated group of 
eyes these differences were always less marked with the exception of the Visit 2.  
 
 
 
Figure 6.23. Descriptive mean values for central corneal thickness found at Vists 1, 2, 3, 4, 5, 6 and 11 for the eyes 
treated with Laser Peripheral Iridotomy (LPI) and their untreated fellows. 
 
 
 
Paired Samples t-tests for every variable tested are given in Tables 6.8 to 6.14 (Appendix 1). The 
results for the analysis of covariance can be found in Tables 6.15 to 6.21 of the same Appendix. 
 
B. Effect of ALPI on the corneal endothelium 
B.1. ALPI effect on endothelial cell density (number of cells/mm2) 
When the mean values for cell density found at every visit for every corneal area were tested 
for statistically significant differences to baseline (Visit 1) using the paired samples t-test, few 
statistically significant results were found.  
There were two main trends of change followed through time. The first and most common 
trend was a lack of change or increase of density in Visit 7, a decrease in Visit 8, a mild 
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recovery in Visit 9, and a decrease again in Visit 10 followed by a recovery in Visit 11 where 
there were frequently better values than in baseline. This trend was followed in all the areas 
under study with the exception of Inferior-Temporal and Superior-Temporal, where there was 
an increase of density in Visit 8, decreasing in Visit 9 and 10 and a final recovery in Visit 11. 
The analysis of covariance showed a statistically significant difference (p=0.035) in the case of 
Superior and Superior-Nasal, were there was an increase of cell density (44 cells 
approximately) at Visit 11 when compared to baseline data at Visit 6.  
See following graphs for a visual representation. 
 
 
 
Figure 6.24. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Central cornea for the 
eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.25. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior cornea for the 
eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.26. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-Nasal cornea for 
the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.27. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-Temporal cornea 
for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.28. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-Temporal cornea 
for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.29. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-Nasal cornea for 
the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.30. Descriptive mean values for cell density found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-Temporal 
cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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       B.2. ALPI effect on endothelial average size, as an indication of polymegethism (m2) 
      Again very few differences tested with paired samples t-test were statistically significant and     
they were only found in the Superior-Temporal area.  
  The interesting finding with polymegethism was that there appeared to be a trend in the 
opposite direction to cell density for the same areas tested. Meaning that, as expected, when 
the density of endothelial cells increased, the polymegethism decreased in the same areas 
under study.   
      Analysis of covariance found a statistically significant difference in the polymegethism found in 
Visit 11. This was lower than that found in Visit 6 (the average size cell was 25.811 m2 smaller 
in Visit 11 when compared with Visit 6 data, p=0.033).  
 
 
 
Figure 6.31. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Central cornea 
for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.32. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior cornea 
for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.33. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-Nasal 
cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.34. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-Temporal 
cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.35. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior cornea 
for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.36. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-Nasal 
cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 Figure 6.37. Descriptive mean values for cell polymegethism found at Vists 6, 7, 8, 9, 10, and 11 in the 
Superior-Temporal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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B.3. ALPI effect on percentage of hexagonal endothelial cells, pleomorphism (%) 
Paired samples t-test showed 3 different trends for the areas under study.  
In the case of Central and Superior sectors, there was a reduction in pleomorphism in Visit 8, 
a mild recovery between Visits 9 and 10 and a mild drop at Visit 11. However, in the case of 
the Central area, the pleomorphism fluctuated with negative values after Visit 7 and in the 
case of the Superior the values were always positive. The Superior-Nasal, Inferior-Nasal and 
Inferior-Temporal areas experienced an initial drop in the pleomorphism, more frequently 
found at Visits 8 and 9 and an increased in Visits 10 and 11 until completed recovery. The 
Inferior and Superior-Temporal areas showed a decrease in Visits 7, 8 and 9, and increase in 
Visit 10 and a new decrease in Visit 11. However, this decrease achieved lower levels than 
baseline in the case of Inferior area and higher for the Superior-Temporal. 
 The only statistically significant result for these comparisons was found in the Superior-
Temporal area when comparing Visit 9 to baseline (Visit 6). Additionally, no statistically 
significant results were found with analysis of covariance when comparing Visit 11 to baseline. 
See following graphs for a visual representation. 
 
 
 
Figure 6.38. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-
Temporal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.39. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-
Temporal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
 
Figure 6.40. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-
Nasal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.41. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Inferior-
Temporal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
Figure 6.42. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior 
cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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Figure 6.43. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-
Nasal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
 
 
 
 
 
Figure 6.44. Descriptive mean values for endothelial pleomorphism found at Vists 6, 7, 8, 9, 10, and 11 in the Superior-
Temporal cornea for the eyes treated with Argon Laser Peripheral Iridoplasty (ALPI). 
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       B.4. ALPI effect on central corneal thickness (m) 
There seemed to be a decrease in the central corneal thickness at Visit 7 that recovered 
through Visits 8 and 9 until achieving an increase of thickness at Visits 10 and 11. These 
differences were not statistically significant as tested with paired samples t-test. The mean 
differences between Visit 6 (baseline) and Visit 7 was a decrease of 6.333 m (SD 23.532), 
p=0.443; at Visit 8 and 9, this difference decreased to 5.750 m (SD 8.860), p=0.109, and to 
2.714 m (11.470), p=0.554, respectively. 
      Analysis of covariance also did not show any statistically significant result. 
 
Figure 6.45. Descriptive mean values for central corneal thickness found at Vists 6, 7, 8, 9, 10, and 11 for the eyes 
treated with Argon Laser Peripheral Iridoplasty (ALPI). 
 
Paired Samples t-tests for every endothelial parameter tested can be found in Tables 6.22 to 6.28 
(Appendix 1). The results for the analysis of covariances can be found in Table 6.36, in the same 
Appendix. 
 
6.1.4 Discussion 
In the present study, LPI was found to have no statistically significant effect on the corneal 
endothelium cell density, polymegethism and pleomorphism. Furthermore, in the very few cases 
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were there was a statistically significant difference, it was unlikely to have been caused by the 
effect of the Nd:YAG laser as similar changes were occurring in the untreated eyes. 
Several published reports have shown similar outcomes when studying the effect of the LPI on the 
already mentioned corneal endothelial parameters. Pollack, et al. (1984) examined the same 
endothelial cell parameters one month after the iridotomy was performed with Nd:YAG and 
found there were no changes in the case of animal endothelium (cytomologus monkeys) and a 
lack of change in cell count in the case of human endothelium (21 eyes of 21 patients). Wishart, et 
al. (1986) found that there was no pre versus post-LPI change in the central endothelial cell 
density in 14 of 16 eyes that undertook the procedure. Two eyes of the same patient showed 
immediate and localised endothelial changes that were not persistent at 3 months after the LPI. 
The total average of energy used to perform an iridotomy with the Nd:YAG was 22mJ. The post-
LPI measurements time-points varied, for some patients these were taken immediately after the 
procedure and between 1 and 4 months and for others only the last measurements were taken. 
However, endothelial damage caused by the Nd:YAG laser iridotomy has been described in the 
literature. Kerr-Muir and Sherrard (1985) described endothelial lesions in all the 16 treated eyes 
(this sample was diagnosed with chronic narrow angle glaucoma). The average of the total energy 
used to perform the iridotomy was 42.62mJ (range from 2.04mJ to 170.4mJ- this information has 
been calculated from the data showed in their table). Specular microscopy was measured prior to 
the iridotomy and immediately after, although four of the cases were followed up several days 
after to monitor possible changes. These four eyes showed normal adjacent endothelium 
spreading into the damaged areas.  
 
More recently, some studies have shown endothelial damage secondary to iridotomies created 
with Nd:YAG lasers. Kozobolis, Detorakis, Vlachonikolis and Pallikaris (1998) found statistically 
significant changes after the LPI. All 10 eyes of 10 patients were treated with the Nd:YAG laser to 
perform an iridotomy using an average of energy of 30mJ. Five areas of cornea were sampled pre-
operatively and at 1 day, 1 week, 1 month and 6 months after the procedure. Their study found a 
statistically significant decrease in cell density in the Superior-Temporal area when comparing 
pre-LPI to the data collected 1 month after the treatment. Additionally, 6 months post-LPI Central 
and Superior-Temporal areas showed a statistically significant decrease in cell density when 
compared to the pre-operative data. The rest of the sampled corneal areas at the different visits 
showed no statistically significant changes. No information about the number of lost cells was 
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given in their report. The corneal thickness changes were statistically significant when measured 1 
week post-LPI in the Superior-Temporal quadrant. This finding was not clinically significant. 
The polymegethism and pleomorphism were measured on central endothelium only. The 
polymegethism decreased statistically significantly at 1 and 6 months post-LPI and an increase in 
pleomorphism was found only at 6 months post-LPI. The rest of the follow up visits showed 
statistically insignificant results for these endothelial parameters. 
Additionally, Wu, Jeng, Huang and Lin (2000) found a decrease in cell count when assessing the 
endothelium after Nd:YAG iridotomy. They prospectively studied 31 eyes of 21 patients with 
occludable angles who were undergoing LPI as a prophylactic treatment. The mean energy used 
to perform the iridotomies was 63.5mJ (Range from 22.4mJ to 120.3mJ). When the cell density 
was measured at 1, 3, 6 and 12 months after the YAG LPI and compared to baseline, statistically 
significant losses of cells were found in every follow up visit with the exception of the 3 months 
post-procedure visit. Their analysis was based on the average of cell density found in 5 different 
areas of cornea. The maximum loss of cells was found to be as much as 70 cells (SD 89 cells) at the 
last visit (1 year after the LPI). 
Kozobolis, Detorakis, Vlachonikolis and Pallikaris (1998) further suggested that there might be a 
relationship between endothelial damage and the amount of energy used to perform the 
iridotomy. Wu, Jeng, Huang and Lin (2000) tested this hypothesis using their data on endothelial 
cell density but their model resulted statistically insignificant. Nevertheless, if proven, this would 
have given a possible explanation for the differences between the reports supporting the idea of 
a significant change in the endothelium after Nd:YAG iridotomy and the present research thesis’ 
findings as a much lower level of energy was used to perform the iridotomies in the latter study. 
Moreover, a marked limitation of the last two mentioned publications (Kozobolis, Detorakis, 
Vlachonikolis and Pallikaris, 1998; Wu, Jeng, Huang and Lin, 2000) is the absence of a fellow 
control eye and, therefore, it would be difficult to determine if these differences were actually 
due to the effect of the Nd:YAG iridotomy or due to a normal decrease as the cornea ages with 
time. 
Marraffa, et al. (1995), found an association between the distance from the endothelium over the 
iridotomy site to the Nd:YAG iridotomy in the iris and a reduction in endothelial cell density per 
linear millimetre on the temporal corneal area. The data was taken before and 1 week after LPI. 
This agrees with the results found at Visit 4 (1 week after LPI) in the present study, where there 
was a mean loss of approximately 21 cells/mm2 in the treated eyes and 11 cells/mm2 in the 
untreated (statistically insignificant).     
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To effectively assess change in cell density the mean values for every variable measured should be 
taken into account (Descriptive statistics can be found from Tables 6.1 to 6.7 in Appendix 1). In 
the case of the density of endothelial cells lost after the LPI, the difference in cell density in the 
treated eyes compared to baseline achieved a maximum of 69 cells lost per mm2. For the fellow 
untreated eyes, this difference in cell density when compared to data at baseline was a maximum 
of 83 cells lost per mm2. If the mean value of endothelial cell density is considered, the values are 
commonly of the order of 2500 cells per square millimetre for the majority of the seven sampled 
areas.  These 69 and 83 lost cells would represent a minimal change in such values (less than a 3% 
and 3.5% respectively). The Superior or Superior-Nasal showed a significantly lower cell density at 
baseline than other sampled areas (approximately 180 cells per square millimetre), but the 
changes were lower too, representing a maximum loss of 32 cells, nearly an 18%. Nevertheless, 
this was considered a systematic error of the specular microscope; it is not plausible to have 180 
cells/mm2. A change in density of 95 cells/mm2 has been previously considered of small clinical 
significance in corneas showing baseline densities of approximately 2500 cells/mm2 (Panek, Lee 
and Christensen, 1991). Furthermore, focal corneal oedema has been observed in cases when the 
cell density reached levels of 300 to 900 cells/mm2   after argon laser iridectomy at a time interval 
from 18 to 42 months (Jeng, Lee and Huang, 1991).  
In the present study the maximum increase in polymegethism (as measured by average cell size) 
was observed in the untreated eye; values of approximately 15m2 and 14m2   larger cell 
dimensions were found in the Inferior-Temporal and Inferior area respectively. The maximum loss 
in pleomorphism was noted for the untreated eye on the Inferior cornea (approximately 7% loss 
when comparing Visit 2 and Visit 1; p=0.021). This change was a rare finding as the losses were 
expected to be found in the treated group. The pleomorphism in the treated eye was fluctuating 
without following a clear pattern. If the changes in polymegethism were compared with its 
descriptive statistical mean values found at baseline, they would represent a maximum of a 32% 
increase of the baseline polymegethism. If the same comparison is performed for the 
pleomorphism maximum losses, this would represent a maximum of 26.5% loss of the baseline 
pleomorphism.  
Changes in the human normal corneal endothelium with time have been described in the 
literature. Bourne, Nelson and Hodget (1997) followed 42 adult subjects over a period of 10 years. 
The same specular microscope was used throughout the study. The area/areas of sampled 
corneal endothelium were not specified (presumably central position). They found that, over that 
period, statistically significant losses in endothelial cell density of 176 cells/mm2 (SD 149 
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cells/mm2) were shown with an increase in polymegethism (indicated by the coefficient of 
variation of cell area) of 0.03 (SD 0.03) and a decrease in pleomorphism (percentage of hexagonal 
cells) of a 4% (SD 7%).  The change in these parameters per year was estimated to be 16 
cells/mm2 (SD 14 cells/mm2), 0.003 (SD 0.003) and 0.3% (SD 0.7%) respectively. There was no 
change in the corneal thickness.  
This agrees with results found in the present study, where a slightly greater change for the 
different endothelial parameters have been described during the 6 months follow up for the 
different sampled areas. However, at 6 months time from baseline nearly all the endothelial 
parameters found in the treated and untreated group achieved similar levels as those found at 
baseline. The most marked exception to this assertion was a decrease in cell density of 
approximately 50 cells/mm2 and an increase in the average cell area of approximately 10 m2 in 
the Inferior-Temporal position of the treated group of eyes. 
To summarise the present study; the losses or recovery of endothelial cells of eyes treated with 
the Nd:YAG laser seemed to vary in the same pattern as in the untreated eye. This was 
additionally tested with the analysis of covariance, showing that although there were some 
differences in cell density (a maximum of 84.7 cells), none of the different for the cell density in 
the seven areas resulted statistically significant.  Similar results were observed for central corneal 
thickness and degree of pleomorphism and polymegethism.  Therefore, there is a possibility that 
these endothelial cell parameters may have changed through time and that LPI performed with 
this level of energy is not affecting these changes. This would, nevertheless, need corroborating 
with a larger sample size. 
In the case of the effect of ALPI, only comparisons with the same eye with time were performed, 
as the fellow eye of the participant was not included. The eyes that were treated with ALPI had 
been previously treated with LPI. If only the ALPI effect was to be studied, only those eyes that 
despite of LPI remained occludable but received no further treatment could act as control eyes. 
The limitation of the present study results of the ALPI effect on the endothelial parameters is that 
there was no control eye for Visits 7, 8, 9 and 10. However, it was possible to have these control 
eyes data at Visits 6 and 11. 
Using the data from the control eyes, statistically significant differences between the ALPI treated 
group and the post-LPI occludable group were found. These results suggested that there is a 
higher cell density in the ALPI treated eyes than in the control eyes for the Superior and Superior-
Nasal areas and that there is a higher average of cell size in the ALPI treated group in the Inferior-
Nasal area. 
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As in the case of the LPI, there were fluctuations of corneal endothelial parameters with time. 
Very few of these changes were statistically significant and none of them were clinically 
significant based on the reports commented for the LPI (mentioned earlier in this section). The 
maximum loss of cell density found after ALPI was 89 cells/mm2. This result was statistically 
significant and was observed in the Superior-Temporal area (representing a loss of 3.7% from 
baseline data). The maximum change in polymegethism and pleomorphism was observed in the 
Inferior-Nasal and Inferior areas. When these changes were compared with baseline data, they 
represented an increase in polymegethism of a 3% and a reduction in the number of hexagonal 
cells of a 20.6% (both results were statistically non-significant). The corneal thickness changes 
represented a 0.4 to 1.1% difference from baseline. 
 
There is very little published literature regarding the effect of ALPI on the corneal endothelium. 
However, there have been at least two published reports on the effect of Argon Laser 
Trabeculoplasty (ALT) on the corneal endothelium, the only other commonly applied argon laser 
to anterior segment structures. Hong, Kitazawa and Tanishima (1983) studied 10 eyes with 
primary open angle glaucoma. They performed contact specular microscopy on central cornea 
prior to ALT and at one week, 4 weeks, 3 months, 6 months and one year after the procedure. The 
number of burns during the ALT ranged from 92 to 107 with an average energy of 200mJ. A 
statistically significant increase of cell size of approximately 12% was observed after one year. 
They attempted a correlation between the change in this parameter and the energy delivered 
during the ALT procedure, but their data were statistically insignificant. Thoming, Van Buskirk and 
Samples (1986), studied 22 eyes of 17 patients that were treated with ALT. Ten eyes were left 
untreated and acted as control. Specular microscopy was performed prior and once after the 
procedure (from 9 to 17 months after). The total mean energy delivered on the anterior 
trabecular meshwork varied from 3.5 to 0.9J with a mean number of burns of 88. No significant 
difference was found in any of the three parameters measured in central cornea, cell area, cell 
density, percentage of hexagonality and shape factor (how close the shape of the cell is to the 
shape of a circle) in the treated and control eyes. The results for these two papers are consistent 
to those found in the present study and for similar length of time. However, a longer follow up 
would be needed to assess the results that these authors found at approximately one year after 
the ALT. This could form a basis for future study. 
Therefore, the results from the present study are the first comprehensive report on the effect of 
ALPI on the corneal endothelium.  
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There are some limitations related with the instrumentation used in this section. The limitations 
for the Tomey 3000 Specular Microscope and its repeatability are explained in the Appendix 3 of 
this thesis. 
One other limitation of this study is the duration of the follow up. If there are further or stable 
changes on the endothelial parameters in Caucasian PAC and PACS treated eyes (either with LPI 
or ALPI), this remains unknown. 
 
6.1.5 Conclusion 
The endothelial cell parameters under study fluctuated during the 6.5 months that the study 
lasted and these fluctuations were not clearly related to the LPI or ALPI effects. The fluctuations 
were small compared to the mean value of the tested corneal endothelial parameter.  
Furthermore, these small variations in cell parameters are most likely to be caused by bias using 
the specular microscope (the limitations of this devices are discussed in Appendix 3 of this thesis). 
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CHAPTER 7. General Discussion 
 
The present study thesis involved Caucasian individuals with bilateral occludable anterior 
chamber angles.  
This is the only study that has described the diurnal intraocular pressure (DIOP) characteristics in 
patients with untreated Primary Angle Closure (PAC) and/or Primary Angle Closure Suspect 
(PACS).  
It has been shown that this sample of PAC/PACS Caucasian patients generally present a peak of 
IOP in the early morning and these levels decrease throughout the day, showing a moderate 
second peak in the early afternoon. When compared to previous published literature, these eyes 
had diurnal intraocular pressure curves similar to normal healthy eyes (Wilensky, 1991; Liu, et al., 
1999). When these curves were compared to those of eyes with early glaucomatous changes, the 
curves were also similar (peaks and troughs within similar diurnal times) with the glaucomatous 
DIOP curve demonstrating higher levels of IOP during the day (Liu, Zhang, Kripte and Weinreb, 
2003).   
In 24-hour IOP assessments, it has been reported that patients with early glaucomatous changes 
and without treatment presented an IOP peak at 5:30 am when the patient is lying supine during 
nocturnal hours (Liu, Zhang, Kripte and Weinreb, 2003). Hughes, Spry and Diamond (2003) also 
found that the peak of IOP occurred outside office hours in 51.7% of 29 glaucoma patients under 
therapy. Barkana, et al. (2006) found similar results to Hughes and colleagues. 69% of their 
glaucomatous sample had a peak of IOP outside office hours. However, new evidences (Quaranta 
et al., 2010) suggest that there is not a real difference between the IOP measured during the day 
and the nocturnal one. The peak of IOP in this study was situated at 10:00 hours. There is no 
published report on the 24-hour IOP behaviour for eyes with PAC/PACS. It is for future research to 
find how representative the DIOP found in this study is of a 24-hour cycle in these patients. 
Although Liu and colleagues did not specify the characteristics of the sample in terms of 
gonioscopic findings, their work suggested that DIOP within higher limits than those found in 
healthy eyes may be associated to factors related to progression to a glaucomatous stage (Liu, 
Zhang, Kripte and Weinreb, 2003). In the case of angle closure, factors such as presence of 
peripheral anterior synechiae (PAS) have been related to a more serious stage of the condition 
(Foster, Buhrmann, Quigley and Johnson, 2002). Furthermore, PAS have been associated with 
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trabecular meshwork histological damage (Sihota, et al., 2001). Therefore, the presence of PAS 
and its relationship with higher DIOP fluctuation needed to be investigated. The present study 
found a statistically significant positive relationship between higher IOP measurements taken 
during the majority of the diurnal hours and the amount of PAS present in an eye. Additionally, 
the average difference between IOPs found in the DIOP of eyes without PAS and those with PAS 
was 1.5 mmHg (p=0.043). Consequently, it can be concluded that primary angle closure patients 
with a higher presence of PAS (covered degrees of the irido-trabecular circumference) will exhibit 
higher levels of diurnal intraocular pressure.  
 
Previous literature has stated that there is an increase of IOP when a patient adopts either a 
supine or a head-down position (Friberg, Sanborn and Weinreb, 1987). It was additionally found 
that an increase in IOP due to these postural changes was directly related to an increase in the 
episcleral venous pressure. It was justified to suggest that individuals in the present study with 
narrow angles, where the aqueous humour outflow may be more limited, would exhibit higher 
IOP levels after being in the supine or prone position than those with open angles described in 
previous reports. As higher levels of IOP after postural changes have been related to a more 
advance damaged of the visual field in glaucomatous patients (Kiuchi, Motoyama and Oshika, 
2010), it was of interest to know how PACS/PAC eyes in the present study reacted to the effects 
of postural changes. The difference in IOP between the pre-supine and the post-supine levels in 
this cohort of untreated PAC/PACS individuals was 1.70 mmHg (SD 2.12; p<0.001).  
This result was similar to that found by Lam and Douthwaite (1997) for normal healthy Chinese 
eyes. They found that after 8 minutes in the supine position, the difference between the pre and 
post-supine was of approximately 1.40 mmHg. Although this difference was not analysed 
statistically, the similarity between the result found in their study and the present one is of 
interest. This may be explained when looking the differences in instrumentation. Lam and 
Douthwaite (1997) used the Pulsair 2000 which averaged IOP measurements have been found to 
be within 3mmHg 79% of the times when compared to the Goldmann tonometer (being this last 
tonometer the one used in the present study) (Moselay, et al., 1993). It is possible that the 
differences in IOP found as a result of the supine position may have been due to the variability of 
the device when compared to the Goldmann tonometer. Other studies performed in healthy eyes 
show even higher rates of change in the IOP, a difference of 4.111.82mmHg was found with 
contact tonometry (Buchanan and Williams, 1985). The duration of the test was not specified. 
However, even if it had been longer than in the present study (5 minutes in supine position), this 
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may not fully explain this difference. The reason based on the study performed by Yamabayashi, 
et al., (1991), were other group of normal eyes presented changes of 4.4 mmHg (SD 2.0) straight 
after laying on the supine position and it remained unchanged for the next 30 minutes. A possible 
explanation for these differences may be a result of the demographical differences between 
samples. The age range for the subjects participating in the study by Lam and Douthwaite (1997) 
and in Buchanan and Williams (1985) was of 19 to 26 and of 21 to 25 years old respectively. The 
age range among the participants of the present study was of 25 to 77 (Average 59.6 years old). 
Although there is no information about subjects’ age in Yamabayashi’s study, had these been 
younger subjects, it remains for future research to find a possible association between higher 
levels of IOP after adopting a supine position and age of the individual. 
 
Regarding the dark room provocation test results (DRPT), the resulting average increase in IOP 
levels was 3.05 mmHg (SD 2.85) after the patient had adopted a prone position for 15 minutes in 
the darkness (illumination <0.01 lux). Previous published reports show higher levels for normal 
eyes after a similar test and duration. Walick, Kragh, Ward and Crawford (2007) found changes of 
approximately 10 mmHg when a patient was left in a prone position for at least 10 minutes. Lam 
and Douthwaite found an increase of approximately 6.5 mmHg after 8 minutes in the same test 
with levels of illumination of 360 lux (this increase IOP was not statistically tested). It was 
surprising to find that patients with untreated PAC/PACS eyes were exhibiting lower levels in the 
DRPT as they had the additive effect of the presence of narrower angles. One probable 
explanation for this observed lack of effect may be the different methods used to measure the 
IOP. While Walick and colleagues and Lam and Douthwaite were taking the measurements with 
the patient at all times positioned prone, in the case of the present study the IOP was measured 
in the sitting position before and after the test. Although care was taken in measuring the IOP 
immediately before and after the DRPT and in darkness, it is possible that the patients in the 
present study showed higher levels while they were lying on the prone positions and that these 
may have been modified after adopting the sitting position. 
 
As mentioned earlier, the amount of PAS influenced the levels of the DIOP curve in this study 
sample. It is therefore possible that PAS may have had similar effects on the levels of IOP 
measured after the patients have been lying on the supine or prone position. This was 
investigated in the present study, finding that there were no differences between eyes with PAS 
and those without PAS for the supine IOP and the DRPT. Furthermore, when an association 
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between the degree of PAS present in the iridotrabecular angle and higher levels of IOP was 
investigated with regression statistical models, these showed no association for neither of the 
resulting IOPs, the supine or the DRPT. 
 
The results for the DIOP curve for the untreated PAC/PACS in the present study showed an 
average difference between the maximum and the minimum IOP measured during the day. This 
difference is known as DIOP fluctuation and it was of approximately 6 mmHg (SD 2.70 mmHg) in 
this study’s sample. This level of DIOP fluctuation is higher than those described for non-
glaucomatous eyes with open angles previously described in the published literature. Liu, Zhang, 
Kripte and Weinreb (2003) found a DIOP fluctuation of 4.0 mmHg (SD 0.3mmHg) for their ‘normal’ 
sample of eyes of a mixed ethnicity and Sihota, et al. (2005) found rates of 4.83mmHg (SD 2.46) 
for a sample of the same characteristics although no ethnicity was specified. These differences 
may be explained through a possible higher resistance to aqueous humour outflow in eyes with 
narrow angles compared to those presenting open angles. This suggested a possible relationship 
between higher DIOP fluctuation and narrower dimensions of the irido-trabecular angle. This 
relationship was investigated in the present study using a swept-source OCT (CASIA OCT) for 
quantifying the angle parameters.  
 
It has been found that for the vast majority of the angle parameters there was an inverse 
association between DIOP fluctuation and dimensions of the 8 angle sections sampled (Superior, 
Superior-Nasal, Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and Superior-
Temporal). Baskaran, et al. (2009) studied the DIOP fluctuation in three Asian angle closure 
groups who had previously been treated with LPI (mean time 31.3 weeks, SD 2.33 weeks, previous 
to the study). The three groups, PACS, PAC and PACG presented a DIOP fluctuation of 3.75 mmHg 
(SD 1.24 mmHg), 4.53 mmHg (SD 2.33 mmHg) and 5.44 mmHg (SD 2.4 mmHg) respectively. These 
differences in fluctuation between groups, which were statistically significant, suggested that the 
DIOP fluctuation would be higher as the condition progressed to more serious stages. This was 
further confirmed when the authors additionally found a direct association between this 
fluctuation and the clock hours of PAS and the pattern standard deviation of the visual field. 
In the present study, there was no association between the presence of degree of PAS and higher 
DIOP fluctuation. Although, it is true that Baskaran and colleagues’ data had a high degree of 
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scatter and the association PASDIOP fluctuation was weak (R2 0.139), there is not an obvious 
explanation for these differences in the outcome of both studies. 
Untreated eyes of PAC/PACS Caucasian participants in the present study exhibited similar DIOP 
curves to other ‘normal participants’ previously described, but higher DIOP fluctuation. 
 
The reason for always including the 8 angle sections in the statistical analysis of this thesis is down 
to statistically significant differences found among the 8 angle sections of the untreated group of 
eyes (Superior, Superior-Nasal, Nasal, Inferior-Nasal, Inferior, Inferior-Temporal, Temporal and 
Superior-Temporal). The Superior section was found to be the narrowest when compared with 
the rest of the sections and the Nasal, Inferior-Nasal and Temporal sections were the widest 
independently of the lighting conditions. Additionally, Superior and Superior-Nasal sections and 
the Inferior sector were statistically significantly different in light and darkness. This result would 
only affect those investigations that may not have used the data of all the sections, where 
investigators have averaged the angle dimensions and attempted to find associations with other 
parameters such as PAS. An example is the study by Su, et al. (2007) which reported a correlation 
between the mean value of the parameters in 3 sectors (Inferior, Nasal and Temporal) with AS-
OCT and the PAS found in 4 sectors (Superior, Nasal, Inferior and Temporal) on gonioscopy. It is 
unknown what contribution to the correlation the Superior sector dimensions would have made 
or if this sector was statistically similar to any other of the sectors. It is consequently important to 
study the homogeneity of the angle sections present on any study sample before averaging them 
to use regression/correlation models. 
 
Laser Peripheral Iridotomy (LPI) and Argon Laser Peripheral Iridoplasty (ALPI) have been reported 
in previous studies to have a widening effect of the irido-trabecular angle in Caucasians (Moster, 
et al., 1986; Mansouri, Buneger, Bagnoud and Shaarawy, 2009; Ang and Wells, 2010; López-
Caballero, et al., 2010; Antoniazzi, Pezzotta, Delfino and Bianchi, 2010). Therefore, it was of 
interest to assess a possible further benefit of these two lasers, a decrease in the DIOP 
fluctuation. This is another novel piece of research as this has not been studied previously, with 
the notable use of the fellow eye as a control eye to truly assess the effect of these two lasers. In 
the case of the LPI, had there been a decrease in the DIOP fluctuation, it would have explained 
the lower DIOP fluctuations found by Baskaran and colleagues. 
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In the present study, the DIOP fluctuation measured pre and post LPI was 6.46 mmHg (SD 3.02 
mmHg) and 6.43 mmHg (SD 2.02 mmHg), respectively, and in the case of ALPI was 5.32 (SD 2.20 
mmHg) pre-laser and 5.04 (SD 1.60 mmHg) post-ALP. When these differences were adjusted with 
those belonging to their corresponding untreated fellows, there were no statistically significant 
differences between the DIOP fluctuation measured pre-laser (ALPI or LPI) and the DIOP 
fluctuation found after both lasers. It can be argued that in the case of the present study the 
differences between groups were adjusted for their control eyes, but this is the only manner in 
which the effect of the lasers can be isolated. The lower levels of DIOP fluctuation described by 
Baskaran, et al. (2009) in LPI treated PAC/PACS were thought to be down to ethnicity differences 
in ocular biometry. No current literature has studied differences in DIOP fluctuation in individuals 
of different ethnicity. One study in healthy young adults of diverse ethnicity (52% Caucasian, 36% 
Asian, 9.3% Hispanic and 12.6% Black) found an inverse correlation between axial ocular length 
and higher levels of 24 hours IOP fluctuation (Loewen, Liu and Weinreb, 2010) and other study 
has suggested that Caucasians eyes have a deeper anterior chamber when compared to Chinese 
eyes (Wang, et al., 2011). Baskaran’s patient sample was mainly Chinese. It was unexpected that 
the present Caucasian sample showed higher rates of DIOP fluctuation. After comparing both 
studies in detail there is no explanation for these differences. 
 
Nevertheless, there is a considerable DIOP fluctuation in Caucasian PAC/PACS eyes even after LPI 
or ALPI treatments. It is important for future research in similar samples that if IOP is measured 
only once in the follow-ups it should be measured within similar diurnal time-hour as baseline 
(pre-procedure).  
 
This raised the question of whether the LPI and the ALPI had an effect on the IOP levels when 
these were compared to the fellow untreated eyes. This research question has never been 
addressed as in the present study since previous reports have only followed up the treated eye.  
When adjusting the data for differences in the fellow eye, the present study has demonstrated 
that there is not an evident association between rate of opening of the angle and time elapsed 
since the LPI was performed. Furthermore, such association was only statistically significant for 
the angle parameters found in the Inferior-Temporal section of the angle. There was also a lack of 
association for this rate of opening and the IOP levels, although the Inferior-Temporal section was 
an exception. In the case of Caucasian eyes, the studies generally agree in an increase of the 
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dimensions of the parameters in LPI treated eyes when compared to baseline (Moster, et al., 
1986; Mansouri, Buneger, Bagnoud and Shaarawy, 2009; Ang and Wells, 2010; López-Caballero, et 
al., 2010; Antoniazzi, Pezzotta, Delfino and Bianchi, 2010). There has been some disagreement 
about the effect of the LPI on the IOP. While López-Caballero, et al., (2010) reported a decrease in 
IOP and an association between this and the opening of the angle 1 month post-LPI, Moster, et al. 
(1986) found that the IOP of all of their LPI treated patients returned to baseline IOP levels within 
the first week and remained unchanged for 3 months. The present study’s results are more 
similar to those found by López-Caballero, et al., (2010). The most probable reason may have 
been due to the higher degree of similarity between the samples. While the patient sample in the 
study by Moster et al. comprised 80% glaucomatous eyes of different types (a mixture of primary 
open angle glaucoma, primary chronic angle-closure and primary acute angle closure glaucoma 
individuals, but only one case with occludable angles), the López-caballero study involved a 
mixture of primary angle closure glaucoma, primary angle closure or eyes presenting occludable 
angles.  
 
In the case of the ALPI, the present study investigated a relationship between the rate of opening 
caused by this laser in a given eye and the time elapsed since the procedure. Although the treated 
eye presented a significant wider angle dimensions than the control eye (not treated with ALPI, 
but previously treated with LPI), it was not possible to show an association between this 
difference in opening and time. There was again a lack of statistically significant association 
between rate of opening of the angle parameters and IOPs.   
Previous reports about the effect of the ALPI on the iridotrabecular angle are scarce and when 
looking for studies performed in Caucasian population there is no supporting published literature. 
In Asian populations there are three reports on the effect of the ALPI. The study carried out by 
Lee, Choi, Kim and Choi (2011) on PACS; on PAC and PACG eyes, performed by Sun, et al. (2010) 
and one case report on PACG by Leung, et al. (2005). 
There appears to be an agreement in the widening effect of the ALPI between the case report 
studied by Leung and the study carried out by Lee and colleagues. Furthermore, Lee, Choi, Kim 
and Choi (2011) performed the only study using the fellow eye as a control eye although the 
models were not adjusted for differences at baseline. Additionally Sun, et al. (2010) found a 
decrease in the IOP as an effect of the ALPI; but it is unclear if DIOP fluctuation was taken into 
account. 
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Due to the different rate of opening that every section presented 6 and 3 months after the LPI or 
ALPI, respectively, it was unexpected to find no statistically significant differences in the widening 
effect of these lasers depending on the angle section studied. Furthermore, the maximum 
widening effect of both lasers was commonly found in the inferior sections. As the iridotomy was 
placed in the superior sections at all times a higher widening of this section was expected. It is 
difficult to find an obvious reason for this finding and maybe fluid dynamics holds the answer. 
 
This study did not found an obvious affection of the endothelial cell density, polymegathism or 
pleomorphism after LPI or ALPI.  
Although some studies have reported corneal endothelial damage after LPI (Kerr-Muir and 
Sherrard, 1985; Kozobolis, Detorakis, Vlachonikolis and Pallikaris, 1998; Wu, Jeng, Huang and Lin, 
2000) it has been suggested that such damage is directly related to the amount energy used to 
create the iridotomy (Marraffa, et al., 1995). Due to the low levels of energy used in the present 
study to create the iridotomies, it was unsurprising to not to find clinically significant changes in 
these parameters. A change in such parameters due to time has been described (Bourne, Nelson 
and Hodget, 1997) and if there would not have been a control eye to adjust with, this may have 
had an influence in the results.  
 
This is the first study reporting on the effect of ALPI on the endothelium parameters mentioned 
earlier. There has been only been one report by Sun, et al. (2010) were the endothelial cell 
density seemed to remaine unchanged 1 year after the procedure. As in the case of the LPI, the 
changes on these parameters were of little clinical significance. 
 
There are some limitations to this study. In the case of the results showed for the effect of the LPI 
and ALPI on opening the angle, only the first 6 months and 3 months after the procedure were 
under study respectively. Therefore, the association found between the angle opening rate and 
time and between the same rate and IOP levels would only be valid for these periods of time.  
Additionally, the images obtained with the CASIA OCT were only those taken in dark conditions. 
The aim was to emulate similar lighting conditions to those in which IOP is taken.  
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It has to be addressed that in the statistical analysis use to assess the effect of the ALPI on the 
treated angle and the association between such effect and time and IOP, there was a lacking of 
some of the control eye data.  It was, therefore, not possible to provide the same precision as 
when investigating similar effects in the case of the LPI. 
The same examiner (LSP) took all the IOP measurements for this group of participants throughout 
the study. The only limitation derived from these measurements is the fact that the examiner 
recorded the measurements as they were taken, meaning the examiner was not masked to the 
IOP result.  
It needs to be also mentioned that the examiner analysing the images with the CASIA OCT (LSP) 
was not masked to the gonioscopical results after LPI treatment.  However, possible bias was 
minimised, as the scans were analysed visit by visit (i.e. 160 scans in Visit 1 After completion, 80 
scans in Visit 3. After completion, 80 scans in Visit 4 and so on). 
Intraobserver repeatability for the CASIA OCT has been described in this thesis, showing better 
results than the ones previously described in the literature for the same device and 
measurements (Appendix 3). Some limitations as natural ocular cyclotorsion have been observed 
with the CASIA OCT. Although, this cannot be acknowledged as a limitation of this device but as 
an advantage for being able to be detected, it means that there has been a limited precision when 
taken the angle measurements. Therefore, the examiner cannot be absolutely certain that the 
measurements have been taken in the exact same section of the angle at the different visits. It is 
surprising that this limitation has not been described previously. With the new technologies 
designed for iris tracking and recognition so commonly used in refractive surgery, this should be 
an enhancement to be included in the future software of the CASIA OCT. 
Regarding the specular microscopy, the benefits and limitations have been described in this thesis 
(Appendix 3). The main limitation of this device, as with any other specular microscope, is to not 
be absolutely certain that the same area of cornea is being tested (because of the same reasons 
specified in the paragraph above). The area of testing is limited to the peripheral 3mm from 
corneal apex, which might be considered to still be too close to corneal apex. 
It is still unclear the reason why the DIOP fluctuation in the present sample of treated eyes is 
higher than those described in the literature. Although the most previous literature is based in 
Asian ethnicities, it was not possible to explain these differences based on ethnical ocular 
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differences. There may still be other factors influencing DIOP fluctuation such as age in 
combination with ethnicity. It is down to future research to further explore this assumption.  
It will be interesting in future research to follow these same individuals and corroborate the 
present findings of a possible association between rate of opening with time and IOP level after 
the LPI. It would also be interesting to mimic the present study in other ethnicities with 
PAC/PACS. If statistically significant results are to be found, the rate of opening of the 
iridotrabecular angle may be predicted with regression models. 
However, there is still the problem of not being able to exactly know how ‘numerically’ 
open/wide an angle has to be when assessed with the anterior segment OCT to be diagnosed as 
non occludable by gonioscopy. There have been attempts in the literature to describe a numerical 
‘cut-off’ for occludable/ non-occludable angle while keeping good rates of sensitivity and 
specificity of the devices. Hong, et al. (2009) described a cut-off for the occludable and 
unoccludable angles based on the anterior chamber depth and angle. It was shown that the cut-
off found with Pentacam for the anterior chamber depth was of 2.27 mm and for the anterior 
chamber angle 29.5 degrees. They additionally found that the cut-off value for the anterior 
chamber depth and angle as assessed by the Slit-Lamp OCT was of 2.45 mm and 31.8 degrees 
respectively.  
Therefore, it is possible to find cut-off values to distinguish occludable from non- occludable 
angles. It is true that the study by Hong, et al. (2007) was only based in the horizontal sections 
findings (Nasal and Temporal); nevertheless, it is a good starting point. It is possible for future 
research to use the data that is already available in the present study to allow a correlation 
between these parameters dimensions and gonioscopy. The gonioscopy performed in this study 
exactly specifies the structures that were visible at every quadrant and this would enable an 
examiner to ‘match’ the dimensions found with the CASIA OCT.  
 
The CASIA OCT has shown a sensitivity of 94.3% (95% CI: 86.2%-97.7%) in diagnosing occludable 
angles when compared to gonioscopy in dark conditions. This is higher than the sensitivity 
described by Nolan, et al. (2007) for a two dimensional OCT and higher than the rates described 
by Hong, et al. (2009) for both, the Pentacam and the Slit-Lamp Anterior Segment OCT. Specificity 
of diagnosis was not attempted as the entire sample presented occludable angles diagnosed with 
gonioscopy. Although gonioscopy remains the gold standard, and the specificity of detection of 
gonioscopically occludable angles by CASIA OCT remains unstudied, this swept source technology 
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may constitute a step forward towards this goal. A mixed sample of unoccludable and occludable 
eyes would need to be assessed to understand the specificity of the CASIA OCT. 
Although this research was comprehensive in assessing changes in the angle parameters due to 
LPI and ALPI, there may still be areas to improve in further studies. There are few limitations in 
the quantifying techniques used in the present study. Only 8 sections of the angle were quantified 
and 352 other sections remain unexplored. It has been difficult to visually show how the different 
sections of the angle open at a different rate. This may not be a problem with a three-dimensional 
(3D) software developed for quantification of changes. The Swept-Source OCT (CASIA OCT) used 
in this study can build 3D images, but it cannot yet compare dimensions between two 3D images. 
This would be a great advantage in the study of changes through time due to natural progression 
of angle closure or to quantify the effect of different surgical/laser procedures. All the information 
could be build using topographic software similar to that employed to describe the corneal 
surface. 
It would be of interest for a future study to find factors that may predict those angles that do not 
open after the LPI. As an exploratory first step, the angle parameters found at Visit 1 for those 
eyes that were unoccludable post-LPI were compared against the ones that ended unoccludable. 
Those parameters found in the eyes diagnosed as occudable were statistically significantly 
narrower than those found in the unoccludable eyes at Visit 1. Aside from this finding that 
narrower pre-laser PI angles are more likely to remain occludable, the influence of other factors 
such as iris contour and ciliary body position need further investigation. From a clinical 
perspective it would be useful to define a cut-off in terms of angle dimensions that relates to 
probability of the finding of a gonioscopically occludable angle post-PI.   
The new software for the CASIA OCT permits iris volume to be calculated. The relationship 
between iris volume and angle parameters is the subject of further research work undertaken by 
the study team.  
The present study constitutes the first part of a longer follow up study that will follow this cohort 
of narrow angle patients for the next two years of its finalisation. This continuation (Investigating 
Management of Primary Angle Closure and Treatment study, IMPACT study) aims to assess 
longer-term effects of the LPI and ALPI in a similar manner as it has been described in this thesis. 
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Summary of clinical implications of this thesis results 
It has already been pointed out the importance of the IOP in glaucoma progression. Higher levels 
of office IOP are related with progression and onset of the pathology. In this thesis, it has been 
shown, not only that patients with peripheral anterior synechiae are more likely to have higher 
levels of diurnal IOP, but that this group of angle closure patients have higher levels of diurnal IOP 
diuring the mornings than during the afternoons. Therefore, it is recommended that clinicians, 
who have the choice of assessing these patients either in the morning or afternoon, will do it in 
the mornings. 
The CASIA is a useful diagnostic tool for angle closure. Clinicians should be aware that if a more 
similar diagnosis as with gonioscopy is to be achieved they should assess only the 4 main angle 
sections of the iridotracbecular angle with the CASIA OCT (Superior, Inferior, Nasal and Temporal). 
It has also been shown that ALPI is an effective method of opening the angle when it remains 
occludable after LPI. This was the case when the angle was assessed in all treated eyes with both 
gonioscopy and CASIA OCT. After these results, this method is strongly recommended. 
Regarding corneal endothelium, both lasers, LPI and ALPI have revealed themselves as safe. No 
corneal disturbances were observed at any point of the follow up. Should these patients need 
another invasive procedure, such as cataract surgery, shortly after these lasers, the risk of corneal 
decompensation would be as before the lasers were performed. 
  
Future research recommedations 
Following the results found in this theis regarding the diurnal IOP trend followed by eyes 
presenting PAC or PACS it is recommended that these patients are seen in the mornings if their 
diurnal peaks are to be observed. Additionally, it is important to remark on the DIOP fluctuation 
present in these eyes. If future research regards the study of change of IOP through time, it is 
essential that the follow up measurements are performed as close in time to baseline as possible. 
The  usefulness of adjusting IOP and/or biometric findings in the treated eye for those of the 
fellow untreated eye has been demonstrated. By doing this, we were able to report that the 
widening of the anterior chamber angle following the LPI was not as large as one would have 
found were only the pre- and post-laser measurements of the treated eye to have been 
measured.   
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Therefore, the use of the untreated eye to show changes in the treated eye either with time or 
due to a procedure is recommended. 
If a future study involves the investigation of the angle dimensions in relation to other factors 
(i.e., IOP), it is recommended to analyse at least the 4 main angular sections of the angle 
(Superior, Nasal, Temporal and Inferior). As shown in this thesis, there are dimensional 
differences between them both with and without laser procedures (LPI and ALPI) changes in light 
conditions. 
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Appendix 1. Tables 
 
Table 3.4. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for AOD 500 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
ANOVA AOD 750 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 0.0446 
p>0.05 
0.1172* 
p<0.001 
0.1253* 
p<0.001 
0.0670* 
p=0.001 
0.1136* 
p<0.001 
0.0926* 
p<0.001 
0.0311 
p>0.05 
Inf-Nasal 0.1253* 
p<0.001 
0.0807* 
p<0.001 
0.0081 
p>0.05 
---------- 0.0583* 
p=0.009 
0.0117 
p>0.05 
0.0327 
p>0.05 
0.0942* 
p<0.001 
 AOD 750 Dark 
Superior --------- 0.0336 
p>0.05 
0.1089* 
p<0.001 
0.1197* 
p<0.001 
0.0611* 
p=0.03 
0.1037* 
p<0.001 
0.07298* 
p<0.001 
0.0182 
p>0.05 
Inf-Nasal 0.1197* 
p<0.001 
0.0860* 
p<0.001 
0.0107 
p>0.05 
--------- 0.0585* 
p=0.06 
0.0159 
p>0.05 
0.0467 
p>0.05 
0.1014* 
p<0.001 
Table 3.5. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for AOD 750 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
ANOVA ARA 500 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 
 
0.0196* 
p=0.021 
0.0498* 
p<0.001 
0.0424* 
p<0.001 
0.0103 
p>0.05 
0.0424* 
p<0.001 
0.0398* 
p<0.001 
0.0101 
p>0.05 
Nasal 0.0498* 
p<0.001 
0.0301* 
p<0.001 
---------- 0.0073 
p>0.05 
0.0394* 
p<0.001 
0.0073 
p>0.05 
0.0099 
p>0.05 
0.0397 
p<0.001 
 ARA 500 Dark 
Superior ---------- 
 
0.0193* 
p=0.008 
0.0481* 
p<0.001 
0.0409* 
p<0.001 
0.0850 
p>0.05 
0.0372* 
p<0.001 
0.0340* 
p<0.001 
0.0077 
p>0.05 
Nasal 0.0481* 
p<0.001 
0.2874* 
p<0.001 
---------- 0.0071 
p>0.05 
0.0396* 
p<0.001 
0.0108 
p>0.05 
0.0140 
p>0.05 
0.0403* 
p<0.001 
Table 3.6. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for ARA 500 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
ANOVA AOD 500 Light 
 S S-N N I-N I I-T T S-T 
Superior 
-------- 
0.0289 
p>0.05 
0.0994* 
p<0.001 
0.0865* 
p<0.001 
0.415* 
p=0.021 
0.0808* 
p<0.001 
0.0710* 
p<0.001 
0.0185 
p>0.05 
Nasal 0.0994* 
p<0.001 
0.0704* 
p<0.001 
--------- 
0.0129 
p>0.05 
0.0578* 
p<0.001 
0.0185 
p>0.05 
0.0283 
p>0.05 
0.0808* 
p<0.001 
 AOD 500 Dark 
Superior ---------- 0.0285 
p>0.05 
0.0897* 
p<0.001 
0.0862* 
p<0.001 
0.0368* 
p=0.045 
0.0686* 
p<0.001 
0.0500* 
p=0.001 
0.0109 
p>0.05 
Nasal 0.0897* 
p<0.001 
0.0611* 
p<0.001 
---------- 0.0035 
p>0.05 
0.0529* 
p<0.001 
0.0211 
p>0.05 
0.0397* 
p=0.020 
0.0788* 
p<0.001 
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Table 3.7. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for ARA 750 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
Table 3.8. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for TISA 500 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
ANOVA TISA 750 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 
 
0.0374* 
p=0.005 
0.0699* 
p<0.001 
0.0672* 
p<0.001 
0.0220 
p>0.05 
0.0661* 
p<0.001 
0.0577* 
p<0.001 
0.0158 
p>0.05 
Nasal 0.0699* 
p<0.001 
0.0325* 
p=0.024 
--------- 0.0027 
p>0.05 
0.0478* 
p<0.001 
0.0038 
p>0.05 
0.0122 
p>0.05 
0.0541* 
p<0.001 
 TISA 750 Dark 
Superior --------- 0.0288* 
p=0.05 
0.0713* 
p<0.001 
0.0675* 
p<0.001 
0.0217 
p>0.05 
0.0615* 
p<0.001 
0.0497* 
p<0.001 
0.0140 
p>0.05 
Nasal 0.0713* 
p<0.001 
0.0424 
p<0.001 
--------- 0.0038 
p>0.05 
0.0496* 
p<0.001 
0.0098 
p>0.05 
0.0216 
p>0.05 
0.0573* 
p<0.001 
Table 3.9. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for TISA 750 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
 
 
 
ANOVA ARA 750 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 0.0286* 
p=0.029 
0.0775* 
p<0.001 
0.0710* 
p<0.001 
0.0236 
p>0.05 
0.0683* 
p<0.001 
0.0612* 
p<0.001 
0.0165 
p>0.05 
Nasal 0.0775* 
p<0.001 
0.0489* 
p<0.001 
--------- 0.0065 
p>0.05 
0.0539* 
p<0.001 
0.0092 
p>0.05 
0.0163 
p>0.05 
0.0610* 
p<0.001 
 ARA 750 Dark 
Superior ---------- 0.0306* 
   p=0.04 
0.0773* 
p<0.001 
0.0706* 
p<0.001 
0.0223 
p>0.05 
0.0625* 
p<0.001 
0.0525* 
p<0.001 
0.0141 
p>0.05 
Nasal 0.0773* 
p<0.001 
0.0467* 
p<0.001 
---------- 0.0067 
p>0.05 
0.0550* 
p<0.001 
0.0148 
p>0.05 
0.0248* 
p=0.044 
0.0632* 
p<0.001 
ANOVA TISA 500 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 
 
0.0177 
p>0.05 
0.0426* 
p<0.001 
0.0384* 
p<0.001 
0.0087 
p>0.05 
0.0383* 
p<0.001 
0.0428* 
p<0.001 
0.0181 
p>0.05 
Temporal 0.0428* 
p<0.001 
0.2507* 
p=0.034 
0.0002 
p>0.05 
0.0043 
p>0.05 
0.0340* 
p=0.001 
0.0044 
p>0.05 
---------- 0.0246* 
p=0.04 
 TISA 500 Dark 
Superior ---------- 
 
0.0175* 
p=0.010 
0.0420* 
p<0.001 
0.0380* 
p<0.001 
0.0078 
p>0.05 
0.0351* 
p<0.001 
0.0310* 
p<0.001 
0.0076 
p>0.05 
Nasal 0.0420* 
p<0.001 
0.0245* 
p<0.001 
-------- 0.0040 
p>0.05 
0.0342* 
p<0.001 
0.0069 
p>0.05 
0.0110 
p>0.05 
0.0344* 
p<0.001 
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ANOVA TIA 500 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 3.2616 
p>0.05 
9.4231* 
p<0.001 
8.4002* 
p<0.001 
2.8002 
p>0.05 
8.0574* 
p<0.001 
7.4531* 
p<0.001 
    2.4016 
p>0.05 
Nasal 9.4231* 
p<0.001 
6.1614* 
p<0.001 
-------- 1.0228 
p>0.05 
6.6228* 
p<0.001 
1.3657 
p>0.05 
1.9700 
p>0.05 
7.021* 
p<0.001 
 TIA 500 Dark 
Superior ---------- 3.1558 
p>0.05 
8.0944* 
p<0.001 
7.8562* 
p<0.001 
2.0515 
p>0.05 
    6.8415* 
p<0.001 
5.2230* 
p<0.001 
1.7872 
p>0.05 
Nasal 8.0944* 
p<0.001 
4.9385* 
p<0.001 
---------- 0.23814 
p>0.05 
6.0428* 
p<0.001 
1.2528 
p>0.05 
2.8714 
p>0.05 
6.3071* 
p<0.001 
Table 3.10. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for TIA 500 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk. 
 
 
Table 3.11. Differences between the widest angle sector dimension and the rest of the sections and between the 
narrowest and the rest of the sections for TIA 750 light and dark. S=Superior, S-N= Superior-Nasal, N=Nasal, I-N= 
Inferior-Nasal, I=Inferior, I-T=Inferior-Temporal, T=Temporal, S-T=Superior-Temporal. The statistically significant values 
have been flagged with an asterisk.  
 
 
 
 
ANOVA TIA 750 Light 
 S S-N N I-N I I-T T S-T 
Superior ---------- 3.5176* 
p=0.012 
8.1862* 
p<0.001 
8.7662* 
p<0.001 
3.5962* 
p=0.009 
7.9219* 
p<0.001 
6.9433* 
p<0.001 
2.8547 
p>0.05 
Inf-Nasal     8.7662* 
p<0.001 
5.2485* 
p<0.001 
0.5800 
p>0.05 
---------- 5.170* 
p<0.001 
0.8442 
p>0.05 
1.8228 
p>0.05 
5.9114* 
p<0.001 
 TIA 750 Dark 
Superior ---------- 
 
2.7516 
p>0.05 
7.1259* 
p<0.001 
47.8916* 
p<0.001 
2.9859* 
p=0.041 
7.4802* 
p<0.001 
5.4673* 
p<0.001 
2.001 
p>0.05 
Inf-Nasal 7.8916* 
p<0.001 
5.1400* 
p<0.001 
0.7657 
p>0.05 
---------- 4.9057* 
p<0.001 
0.4114 
p>0.05 
2.4242 
p>0.05 
5.8900* 
p<0.001 
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Table 3.12. Comparison between the 4 main sectors (Superior, Nasal, Inferior and Temporal) against their adjacent sectors in light and dark conditions 
 
ANOVA Superior Sector Nasal Sector Inferior Sector Temporal Sector 
 Superior-Temp 
Sector 
Superior-Nasal 
Sector 
Superior-Nasal 
Sector 
Inferior-Nasal 
Sector 
Inferior-Nasal 
Sector 
Inferior-Temp 
Sector 
Inferior-Temp 
Sector 
Superior-Temp 
Sector 
AOD 500 (light) 0.018570 
p>0.05 
0.028998 
p>0.05 
0.070429* 
p<0.001 
0.012914 
p>0.05 
0.044929* 
p=0.007 
0.039306* 
p=0.032 
0.009849 
p>0.05 
0.052471* 
p<0.001 
AOD 750 (light) 0.031104 
p>0.05 
0.044618 
p>0.05 
0.072614* 
p<0.001 
0.008143 
p>0.05 
0.058343* 
p=0.009 
0.046643 
p>0.05 
0.021043 
p>0.05 
0.061529* 
p<0.05 
ARA 500 (light) 0.010135 
p>0.05 
0.019677* 
p=0.021 
0.030157* 
p<0.001 
0.039700* 
p<0.001 
0.032100* 
p<0.001 
0.032129* 
p<0.001 
0.002586 
p>0.05 
0.029757* 
p<0.001 
ARA 750 (light) 0.016529 
p>0.05 
0.028615* 
p=0.029 
0.048957* 
p<0.001 
0.006571 
p>0.05 
0.047386* 
p>0.05 
0.044729* 
p>0.05 
0.007143 
p>0.05 
0.044671* 
p<0.001 
TISA 500 (light) 0.018175 
p>0.05 
0.017732 
p>0.05 
0.024871 
p>0.05 
0.004186 
p>0.05 
0.029647* 
p=0.005 
0.029604* 
p=0.005 
0.004429 
p>0.05 
0.024629 
p>0.05 
TISA 750 (light) 0.015879 
p>0.05 
0.037451* 
p=0.05 
0.032529* 
p=0.012 
0.002771 
p>0.05 
0.045114* 
p<0.001 
0.044071* 
p<0.001 
0.008429 
p>0.05 
0.041857* 
p<0.05 
TIA 500 (light) 2.401688 
p>0.05 
3.261688 
p>0.05 
6.161429* 
p<0.001 
1.022857 
p>0.05 
5.600000* 
p<0.001 
5.257143* 
P<0.001 
0.604286 
p>0.05 
5.051429* 
p<0.001 
TIA 750 (light) 2.854790 
p>0.05 
3.517647* 
p>0.05 
4.668571* 
p<0.001 
0.580000 
p>0.05 
5.170000* 
p<0.001 
4.325714* 
p<0.001 
0.978571 
p>0.05 
4.088571* 
p<0.05 
AOD 500 (dark) 0.010945 
p>0.05 
0.028588 
p>0.05 
0.061171* 
p<0.001 
0.003529 
p>0.05 
0.049429* 
p=0.001 
0.031800 
p>0.05 
0.018557 
p>0.05 
0.039100* 
p<0.001 
AOD 750 (dark) 0.018253 
p>0.05 
0.033667 
p>0.05 
0.075286* 
p<0.001 
0.010757 
p>0.05 
0.058543* 
p=0.006 
0.042586 
p>0.05 
0.030771 
p>0.05 
0.054729* 
p<0.05 
ARA 500 (dark) 0.007748 
p>0.05 
0.019390* 
p=0.008 
0.028743* 
p<0.001 
0.007186 
p>0.05 
0.032443* 
p<0.001 
0.028786* 
p<0.001 
0.003243 
p>0.05 
0.026300* 
p<0.001 
ARA 750 (dark) 0.014139 
p>0.05 
0.030611* 
p=0.004 
0.046743* 
p<0.001 
0.006714 
p>0.05 
0.048300* 
p<0.001 
0.040214* 
p<0.001 
0.010029 
p>0.05 
0.038386* 
p<0.001 
TISA 500 (dark) 0.007661 
p>0.05 
0.017547* 
p=0.010 
0.024543* 
p<0.001 
0.004043 
p>0.05 
0.030171* 
p<0.001 
0.027286* 
p<0.001 
0.004071 
p>0.05 
0.023429* 
p<0.001 
TISA 750 (dark) 0.014027 
p>0.05 
0.028899* 
p=0.05 
0.042486* 
p<0.001 
0.003829 
p>0.05 
0.045829* 
p<0.001 
0.039857* 
p<0.001 
0.011871 
p>0.05 
0.035686* 
p<0.001 
TIA 500 (dark) 1.787288 
p>0.05 
3.155859 
p>0.05 
4.938571* 
p<0.001 
0.238143 
p>0.05 
5.804714* 
p<0.001 
4.790000* 
p<0.001 
1.618571 
p>0.05 
3.435714 
p>0.05 
TIA 750 (dark) 2.001681 
p>0.05 
2.751681 
p>0.05 
4.374286* 
p<0.001 
0.765714 
p>0.05 
4.905714* 
p<0.001 
4.494286* 
p<0.001 
2.012857 
p>0.05 
3.465714* 
p<0.05 
 236 
 
 
 
 
 
 
Differences between Light and Dark in the parameters dimensions (Light dimensions- Dark dimensions) 
 Superior       Superior-Nasal Nasal Inferior-Nasal Inferior Inferior-Temp               Temporal Superior-Temporal 
 Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
Mean 
difference 
(SD) 
Significanc
e t test 
AOD 500 (mm) 0.002585 
(0.046936) 
0.659 0.005114 
(0.047846) 
0.374 0.014371 
(0.044436) 
0.009* 0.004986 
(0.52716) 
0.431 0.009486 
(0.062432) 
0.208 0.016991 
(0.056542) 
0.014* 0.025700 
(0.042994) 
<0.001* 0.012329 
(0.037464) 
0.008* 
AOD 750 (mm) 0.007485 
(0.054462) 
0.268 0.019157 
(0.058623) 
0.008* 0.016486 
(4.383827) 
0.035* 0.013871 
(0.077567) 
0.139 0.014071 
(0.070431) 
0.099 0.018129 
(0.072053) 
0.039* 0.027857 
(0.057561) 
<0.001* 0.021057 
(0.061029) 
0.005* 
ARA 500 (mm2) 0.001308 
(0.014278) 
0.463 0.03014 
(0.019289) 
0.195 0.004429 
(0.023321) 
0.117 0.004229 
(0.23614) 
0.139 0.004571 
(0.028795) 
0.188 0.007914 
(0.026028) 
0.013* 0.008571 
(0.019719) 
0.001* 0.005114 
(0.014983) 
0.006* 
ARA 750 (mm2) 0.005000 
(0.026847) 
0.135 0.004871 
(0.026558) 
0.129 0.007086 
(0.031369) 
0.063 0.007229 
(0.033568) 
0.076 0.008143 
(0.039547) 
0.089 0.012657 
(0.037801) 
0.039* 0.015543 
(0.029533) 
<0.001* 0.009257 
(0.023720) 
0.002* 
TISA 500 (mm2) 0.001797 
(0.013427) 
0.288 0.03429 
(0.017213) 
0.100 0.003757 
(0.020604) 
0.132 0.003614 
(0.019816) 
0.132 0.003855 
(0.023276) 
0.173 0.006457 
(0.023328) 
0.024* 0.014957 
(0.055502) 
0.027* 0.013757 
(0.076874) 
0.139 
TISA 750 (mm2) 0.005303 
(0.026251) 
0.106 0.015729 
(0.096335) 
0.176 0.005771 
(0.030083) 
0.113 0.006829 
(0.031066) 
0.070 0.007543 
(0.034421) 
0.071 0.011757 
(0.036222) 
0.008* 0.015200 
(0.027062) 
<0.001* 0.009029 
(0.023035) 
0.002* 
TIA 500 () 0.143077 
(3.886755) 
0.768 0.411429 
(4.570211) 
0.454 1.634286 
(4.383827) 
0.003* 0.849571 
(4.845169) 
0.147 1.054286 
(3.81107) 
0.024 1.521429 
(4.900928) 
0.011* 2.535714 
(4.106165) 
<0.001* 0.920000 
(3.673785) 
0.040* 
TIA 750 () 0.266667 
(3.021784) 
0.476 1.107143 
(3.941026) 
0.022* 1.401429 
(4.017840) 
0.005* 1.215714 
(4.886202) 
0.041* 0.951429 
(3.629179) 
0.032 0.782857 
(4.265431) 
0.129 1.817143 
(3.547646) 
<0.001* 1.194286 
(3.903172) 
0.013* 
Table 3.13.  Differences between light and dark for the angle parameters dimensions in the different 8 sections. 
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Table 3.17. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with AOD 500 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk. 
 
 
Table 3.18. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with AOD 750 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
AOD500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.304 0.076 0.018*  -0.112 0.101 0.094  -0.157 0.009 0.219  0.077 0.074 0.141 
Superior-Nasal  -0.360 0.116 0.003*  -0.383    -0.300 0.076 0.016*  -0.291   
Nasal  -0.138 0.003 0.276  0.382    -0.092 -0.008 0.472  0.177   
Inferior-Nasal  -0.310 0.082 0.013*  -0.242    -0.352 0.110 0.004*  -0.318   
Inferior  -0.247 0.046 0.049*  -0.143    -0.217 0.032 0.085  -0.198   
Inferior-Temporal  -0.174 0.015 0.169  0.037    -0.123 -0.001 0.331  0.147   
Temporal  -0.295 0.072 0.018*  -0.127    -0.170 0.013 0.179  -0.024   
Superior-Temporal  -0.239 0.042 0.058  0.171    -0.200 0.025 0.113  0.044   
  LIGHT  DARK 
AOD750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.328 0.093 0.009*  0.007 0.249 0.002*  -0.297 0.073 0.018*  -0.165 0.073 0.145 
Superior-Nasal  -0.384 0.134 0.002*  -0.436    -0.353 0.111 0.004*  -0.469   
Nasal  -0.208 0.028 0.099  0.242    -0.120 -0.001 0.345  0.225   
Inferior-Nasal  -0.371 0.124 0.003*  -0.373    -0.298 0.074 0.017*  -0.074   
Inferior  -0.314 0.084 0.011*  -0.248    -0.236 0.041 0.060  -0.190   
Inferior-Temporal  -0.155 0.008 0.220  0.356    -0.177 0.016 0.161  0.079   
Temporal  -0.381 0.131 0.002*  -0.338    -0.194 0.022 0.125  0.082   
Superior-Temporal  -0.187 0.020 0.138  0.325    -0.237 0.041 0.060  0.142   
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Table 3.19. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with ARA 500 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
ARA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.306 0.144 0.016*  -0.020 0.189 0.012*  -0.283 0.065 0.024*  -0.108 0.161 0.023* 
Superior-Nasal  -0.438 0.179 <0.001*  -0.526    -0.389 0.138 0.001*  -0.580   
Nasal  -0.189 0.020 0.134  0.284    -0.062 -0.012 0.625  0.365   
Inferior-Nasal  -0.293 0.071 0.019*  -0.203    -0.341 0.102 0.006*  0.016   
Inferior  -0.212 0.030 0.092  -0.253    -0.221 0.034 0.079  -0.292   
Inferior-Temporal  -0.035 -0.015 0.784  0.236    -0.208 0.028 0.099  -0.009   
Temporal  -0.296 0.073 0.018  -0.113    -0.151 0.007 0.234  0.037   
Superior-Temporal  -0.212 0.029 0.093  0.127    -0.178 0.016 0.158  0.120   
Table 3.20. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with ARA 750 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk. 
 
  LIGHT  DARK 
ARA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.254 0.048 0.050*  -0.027 0.131 0.052  -0.193 0.021 0.130  -0.054 0.097 0.091 
Superior-Nasal  -0.429 0.171 <0.001*  -0.559    -0.318 0.086 0.011*  -0.327   
Nasal  -0.161 0.010 0.205  0.193    -0.028 -0.015 0.827  0.266   
Inferior-Nasal  -0.216 0.031 0.086  -0.102    -0.348 0.107 0.005*  -0.215   
Inferior  -0.172 0.014 0.174  -0.194    -0.210 0.029 0.096  -0.194   
Inferior-Temporal  0.030 -0.015 0.814  0.166    -0.173 0.014 0.172  0.023   
Temporal  -0.206 0.027 0.103  -0.003    -0.093 -0.007 0.463  -0.02   
Superior-Temporal  -0.182 0.018 0.149  0.146    -0.140 0.004 0.272  0.061   
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  LIGHT  DARK 
TISA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.265 0.054 0.043*  -0.195 0.164 0.029*  -0.184 0.018 0.149  -0.062 0.093 0.098 
Superior-Nasal  -0.408 0.153 0.001*  -0.419    -0.325 0.091 0.009*  -0.337   
Nasal  -0.138 0.003 0.270  0.288    -0.038 -0.015 0.766  0.253   
Inferior-Nasal  -0.251 0.048 0.045*  -0.142    -0.349 0.108 0.005*  -0.22   
Inferior  -0.158 0.009 0.215  -0.124    -0.2O1 0.025 0.112  -0.176   
Inferior-Temporal  0.024 -0.016 0.848  0.12    -0.146 0.005 0.251  0.067   
Temporal  0.189 0.020 0.135  -0.092    -0.125 0.000 0.326  -0.057   
Superior-Temporal  0.050 0.018 0.149  0.33    -0.138 0.003 0.277  0.086   
Table 3.21. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with TISA 500 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
TISA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.335 0.097 0.008*  -0.039 0.253 0.002*  -0.295 0.072 0.018*  -0.197 0.100 0.086 
Superior-Nasal  -0.354 0.111 0.004*  -0.407    -0.393 0.141 0.001*  -0.571   
Nasal  -0.195 0.022 0.123  0.389    -0.073 -0.011 0.566  0.189   
Inferior-Nasal  -0.314 0.084 0.011*  -0.422    -0.345 0.105 0.005*  -0.056   
Inferior  -0.267 0.056 0.033*  -0.179    -0.283 0.065 0.023*  -0.180   
Inferior-Temporal  -0.056 0.013 0.662  0.178    -0.173 0.014 0.172  0.201   
Temporal  -0.291 0.070 0.020*  -0.259    -0.174 0.015 0.168  -0.083   
Superior-Temporal  -0.206 0.027 0.102  0.047    -0.177 0.016 0.162  0.032   
Table 3.22. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with TISA 750 adjusted for the 8 different sections. Statistically significant p 
values have been flagged with an asterisk.
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Table 3.23. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with TIA 500 adjusted for the 8 different sections. Statistically significant p values 
have been flagged with an asterisk. 
 
 
 
  LIGHT  DARK 
TIA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.335 0.097 0.008*  -0.039 0.253 0.002*  -0.302 0.076 0.015    -0.008 0.173 0.016* 
Superior-Nasal  -0.405 0.151 0.001*  -0.407    -0.371 0.124 0.003*  -0.569   
Nasal  -0.121 -0.01 0.340  0.389    -0.177 0.016 0.161  0.362   
Inferior-Nasal  -0.363 0.118 0.003*  -0.422    -0.312 0.083 0.012*  0.025   
Inferior  -0.267 0.056 0.033*  -0.179    -0.190 0.020 0.134  -0.331   
Inferior-Temporal  -0.169 0.013 0.182  0.178    -0.152 0.007 0.231  0.089   
Temporal  -0.365 0.120 0.003*  -0.259    -0.221 0.034 0.079  -0.083   
Superior-Temporal  -0.188 0.020 0.137  0.260    -0.239 0.042 0.057     0.032   
Table 3.24. Univariate and multivariate regression models over DIOP fluctuation for light and dark conditions with TIA 750 adjusted for the 8 different sections. Statistically significant p values 
have been flagged with an asterisk. 
  LIGHT  DARK 
TIA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.313 0.084 0.012*    -0.188 0.185 0.012*  -0.236 0.040 0.061    -0.076 0.079 0.126 
Superior-Nasal  -0.360 0.115 0.004*  -0.326    -0.314 0.084 0.012*  -0.281   
Nasal  -0.032 -0.015 0.801  0.471    -0.129 0.001 0.308  0.088   
Inferior-Nasal  -0.321 0.088 0.010*  -0.256    -0.348 0.107 0.005*  -0.178   
Inferior  -0.317 0.086 0.011*  -0.282    -0.252 0.049 0.044*  -0.201   
Inferior-Temporal  -0.149 0.007 0.239  0.108    -0.075 -0.010 0.558  0.245   
Temporal  -0.262 0.054 0.037*  -0.200    -0.196 0.023 0.120  -0.070   
Superior-Temporal  -0.229 0.037 0.069    0.158    -0.204 0.026 0.106     0.037   
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Table 3.25. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with AOD 500 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
 
  LIGHT  DARK 
AOD750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.100 0.005 0.424  0.235 0.124 0.045*  -0.032 0.015 0.797  0.046 -0.016 0.546 
Superior-Nasal  -0.177 0.017 0.149  -0.112    -0.046 -0.013 0.712  -0.045   
Nasal  -0.241 0.044 0.048*  -0.174    -0.152 0.008 0.215  -0.17   
Inferior-Nasal  -0.100 -0.005 0.418  0.225    -0.101 -0.005 0.412  -0.107   
Inferior  -0.382 0.133 0.001*  -0.449    -0.230 0.039 0.059  -0.326   
Inferior-Temporal  -0.248 0.047 0.041*  -0.018    -0.052 -0.012 0.673  0.138   
Temporal  -0.204 0.027 0.095  -0.193    -0.150 0.008 0.222  0.058   
Superior-Temporal  -0.094 -0.006 0.444  0.171    0.022 -0.015 0.861  0.273   
Table 3.26. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with AOD 750 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
AOD500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.019 -0.016 0.879  0.040 0.086 0.108  -0.068 -0.011 0.583  0.160 -0.026 0.611 
Superior-Nasal  -0.151 0.008 0.219  -0.041    0.048 -0.013 0.699  -0.028   
Nasal  -0.103 -0.004 0.402  0.202    -0.018 -0.015 0.884  0.041   
Inferior-Nasal  -0.071 -0.010 0.566  0.131    -0.013 -0.015 0.917  -0.110   
Inferior  -0.367 0.121 0.002*  -0.383    -0.232 -0.040 0.057  -0.312   
Inferior-Temporal  -0.135 0.003 0.271  0.049    0.026 -0.014 0.834  0.104   
Temporal  -0.296 0.074 0.014*  -0.353    -0.016 -0.015 0.895  -0.058   
Superior-Temporal  -0.137 0.004 0.264  0.045    0.071 -0.010 0.567  0.103   
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  LIGHT  DARK 
ARA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.013 -0.016 0.920  0.075 0.158 0.023*  0.138 0.004 0.266  0.271 0.042 0.234 
Superior-Nasal  -0.151 0.008 0.218  -0.199    0.014 -0.015 0.912  -0.065   
Nasal  -0.167 0.013 0.173  0.124    -0.117 -0.001 0.341  -0.076   
Inferior-Nasal  -0.070 -0.010 0.571  0.147    -0.011 -0.015 0.932  0.006   
Inferior  -0.411 0.156 0.001*  -0.322    -0.187 -0.020 0.126  -0.270   
Inferior-Temporal  -0.141 0.005 0.250  -0.087    -0.069 -0.010 0.574  0.046   
Temporal  -0.307 0.081 0.011*  -0.374    -0.218 0.033 0.074  -0.221   
Superior-Temporal  -0.056 -0.012 0.651  0.233    0.109 -0.003 0.375  0.145   
Table 3.27. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with ARA 500 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
 
  LIGHT  DARK 
ARA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.062 -0.012 0.621  0.162 0.161 0.019*  0.025 -0.015 0.841  0.132 0.062 0.166 
Superior-Nasal  -0.185 0.020 0.130  -0.280    -0.038 -0.014 0.760  -0.301   
Nasal  -0.180 0.018 0.142  0.211    -0.134 0.003 0.278  -0.030   
Inferior-Nasal  -0.084 -0.008 0.498  0.126    -0.024 -0.015 0.844  0.176   
Inferior  -0.431 0.174 <0.001*  -0.424    -0.114 -0.002 0.355  -0.344   
Inferior-Temporal  -0.190 0.022 0.121  0.019    -0.041 -0.013 0.738  0.094   
Temporal  -0.322 0.090 0.007*  -0.331    -0.225 0.036 0.065  -0.175   
Superior-Temporal  -0.112 -0.002 0.363  0.108    0.108 -0.003 0.380  0.242   
Table 3.28. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with ARA 750 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
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  LIGHT  DARK 
TISA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.035 -0.014 0.774  0.096 0.023 0.315  -0.132 0.003 0.283  0.217 0.012 0.374 
Superior-Nasal  -0.145 0.006 0.238  -0.111    0.033 -0.014 0.792  -0.029   
Nasal  -0.169 0.014 0.169  0.115    -0.086 -0.008 0.487  -0.060   
Inferior-Nasal  -0.068 -0.011 0.584  0.153    -0.008 -0.015 0.950  -0.006   
Inferior  -0.253 0.050 0.037*  -0.336    -0.081 -0.008 0.511  -0.260   
Inferior-Temporal  -0.141 0.005 0.251  -0.022    -0.044 -0.013 0.723  0.060   
Temporal  -0.283 0.066 0.019*  -0.330    -0.191 0.022 0.119  -0.219   
Superior-Temporal  0.021 -0.015 0.864  0.131    0.106 -0.004 0.388  0.145   
Table 3.29. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with TISA 500 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
 
  LIGHT  DARK 
TISA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.146 0.006 0.235  0.083 0.067 0.144  -0.176 0.016 0.152  0.122 0.002 0.435 
Superior-Nasal  -0.269 0.058 0.026*  -0.232    -0.028 -0.014 0.823  -0.298   
Nasal  -0.184 0.019 0.133  0.038    -0.110 -0.003 0.370  -0.009   
Inferior-Nasal  -0.082 -0.008 0.504  0.145    -0.026 -0.014 0.830  0.174   
Inferior  -0.254 0.050 0.037  -0.420    -0.101 -0.005 0.412  -0.349   
Inferior-Temporal  -0.151 0.008 0.218  0.076    -0.046 -0.013 0.708  0.09   
Temporal  -0.307 0.080 0.011*  -0.232    -0.205 0.027 0.094  -0.17   
Superior-Temporal  -0.107 -0.003 0.384  0.034    0.102 -0.005 0.409  0.244   
Table 3.30. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with TISA 750 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
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  LIGHT  DARK 
TIA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.022 -0.015 0.897  0.038 0.099 0.085  0.077 -0.009 0.534  0.131 -0.039 0.700 
Superior-Nasal  -0.152 0.008 0.217  -0.093    0.056 -0.012 0.652  -0.059   
Nasal  -0.093 -0.006 0.451  0.198    0.010 -0.015 0.936  0.127   
Inferior-Nasal  -0.078 -0.009 0.528  0.111    -0.030 -0.014 0.809  -0.103   
Inferior  -0.347 0.107 0.004*  -0.419    -0.221 0.035 0.070  -0.267   
Inferior-Temporal  -0.099 -0.005 0.422  0.094    0.030 -0.014 0.806  0.095   
Temporal  -0.300 0.077 0.013*  -0.341    -0.025 -0.015 0.838  -0.099   
Superior-Temporal  -0.125 0.001 0.310  0.072    0.085 -0.008 0.490  0.064   
Table 3.31. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with TIA 500 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
 
  LIGHT  DARK 
TIA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.095 0.007 0.450  0.185 0.147 0.026*  -0.051 -0.013 0.686  0.062 -0.034 0.665 
Superior-Nasal  -0.181 0.018 0.141  -0.171    -0.032 -0.014 0.793  0.074   
Nasal  -0.223 0.036 0.067  -0.170    -0.151 0.008 0.220  -0.194   
Inferior-Nasal  -0.112 -0.002 0.364  0.232    -0.118 -0.001 0.336  -0.124   
Inferior  -0.386 0.136 0.001*  -0.476    -0.231 0.039 0.058  -0.234   
Inferior-Temporal  -0.228 0.037 0.062  0.051    -0.072 -0.010 0.562  0.092   
Temporal  -0.227 0.037 0.062  -0.246    -0.163 0.012 0.184  -0.007   
Superior-Temporal  -0.087 -0.007 0.480  0.214    -0.001 -0.015 0.995  0.169   
Table 3.32. Univariate and multivariate regression models over Dark room provocation test result (DRPT) for light and dark conditions with TIA 750 adjusted for the 8 different sections. 
Statistically significant p values have been flagged with an asterisk. 
 
 
 245 
 
Table 3.33. Univariate and multivariate regression models over the Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with AOD 500 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
AOD750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.024 -0.015 0.847  -0.058 -0.074 0.890  0.050 -0.013 0.691  0.016 -0.008 0.498 
Superior-Nasal  -0.076 -0.009 0.538  -0.100    -0.015 -0.015 0.901  0.003   
Nasal  -0.035 -0.014 0.774  0.003    -0.089 -0.007 0.470  -0.178   
Inferior-Nasal  0.040 -0.014 0.748  0.117    0.141 0.005 0.250  0.423   
Inferior  0.007 -0.015 0.952  0.034    0.083 -0.008 0.501  0.159   
Inferior-Temporal  -0.032 -0.014 0.796  -0.054    0.014 -0.015 0.911  -0.076   
Temporal  0.033 -0.014 0.789  0.295    -0.017 -0.015 0.892  -0.103   
Superior-Temporal  -0.114 -0.002 0.353  -0.250    -0.059 -0.012 0.630  -0.251   
Table 3.34. Univariate and multivariate regression models over the Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with AOD 750 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk.
  LIGHT  DARK 
AOD500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.100 -0.006 0.431  -0.079 0.039 0.253  -0.029 -0.015 0.818  -0.008 -0.066 0.859 
Superior-Nasal  -0.180 0.018 0.141  -0.184    -0.064 -0.011 0.606  -0.040   
Nasal  -0.019 -0.015 0.877  0.090    -0.064 -0.011 0.603  0.015   
Inferior-Nasal  0.089 -0.007 0.468  0.384    0.078 -0.009 0.528  0.257   
Inferior  -0.015 -0.006 0.959  0.181    -0.046 -0.013 0.712  -0.001   
Inferior-Temporal  -0.189 0.021 0.123  -0.295    -0.082 -0.008 0.507  -0.060   
Temporal  -0.081 -0.008 0.511  -0.104    -0.131 0.002 0.285  -0.194   
Superior-Temporal  -0.182 0.018 0.137  -0.135    -0.091 -0.007 0.460  -0.119   
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Table 3.35. Univariate and multivariate regression models over the Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with ARA 500 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
 
Table 3.36. Univariate and multivariate regression models over The Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with ARA 750 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk.
  LIGHT  DARK 
ARA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.085 -0.009 0.506  0.069 -0.026 0.603  -0.080 -0.009 0.521  -0.150 -0.036 0.679 
Superior-Nasal  -0.170 0.014 0.165  -0.268    -0.019 -0.015 0.881  0.094   
Nasal  0.037 -0.014 0.767  0.196    -0.026 -0.014 0.832  0.118   
Inferior-Nasal  0.027 -0.014 0.827  0.168    0.094 -0.006 0.448  0.201   
Inferior  -0.016 -0.015 0.898  0.026    -0.088 -0.007 0.473  -0.031   
Inferior-Temporal  -0.136 0.004 0.268  -0.137    -0.166 0.013 0.176  -0.252   
Temporal  -0.099 -0.005 0.422  -0.053    -0.158 0.010 0.198  -0.159   
Superior-Temporal  -0.201 0.026 0.099  -0.142    -0.083 -0.008 0.501  -0.001   
  LIGHT  DARK 
ARA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.082 -0.009 0.514  0.001 -0.010 0.510  -0.025 -0.015 0.841  0.132 0.062 0.166 
Superior-Nasal  -0.143 0.006 0.244  -0.247    -0.011 -0.015 0.928  -0.301   
Nasal  -0.002 -0.015 0.989  0.186    -0.064 -0.011 0.605  -0.030   
Inferior-Nasal  0.043 -0.013 0.726  0.298    0.103 -0.004 0.403  0.176   
Inferior  -0.008 -0.015 0.951  0.122    -0.243 0.045 0.046*  -0.344   
Inferior-Temporal  -0.135 0.003 0.271  -0.214    -0.103 -0.004 0.402  0.094   
Temporal  -0.100 -0.005 0.418  -0.174    -0.135 0.003 0.274  -0.175   
Superior-Temporal  -0.170 0.014 0.166  -0.101    -0.112 -0.002 0.361  0.242   
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Table 3.37. Univariate and multivariate regression models over the Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with TISA 500 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
 
 
 
Table 3.38. Univariate and multivariate regression models over the Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with TISA 750 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
 
  LIGHT  DARK 
TISA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.094 -0.007 0.465  0.034 -0.035 0.653  -0.067 -0.011 0.589  -0.126 -0.051 0.773 
Superior-Nasal  -0.191 0.022 0.120  -0.294    -0.040 0.014 0.744  0.094   
Nasal  0.000 -0.015 0.998  0.161    -0.055 -0.012 0.657  0.079   
Inferior-Nasal  0.005 -0.015 0.969  0.176    0.058 -0.012 0.636  0.159   
Inferior  -0.026 -0.015 0.832  0.074    -0.066 -0.011 0.594  -0.002   
Inferior-Temporal  -0.164 0.012 0.181  -0.223    -0.167 0.013 0.174  -0.216   
Temporal  -0.123 0.000 0.319  -0.129    -0.192 0.022 0.116  -0.195   
Superior-Temporal  -0.094 -0.006 0.448  0.027    -0.087 -0.007 0.481  0.009   
  LIGHT  DARK 
TISA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.081 -0.009 0.518  -0.065 -0.015 0.541  -0.020 -0.015 0.873  0.033 -0.018 0.561 
Superior-Nasal  0.067 -0.011 0.587  0.100    -0.029 -0.014 0.814  0.122   
Nasal  -0.028 -0.014 0.821  0.042    -0.089 -0.007 0.472  -0.037   
Inferior-Nasal  0.030 -0.014 0.810  0.253    0.082 -0.008 0.506  0.247   
Inferior  -0.011 -0.015 0.931  0.163    -0.002 -0.015 0.988  0.118   
Inferior-Temporal  -0.173 0.015 0.159  -0.239    -0.128 0.001 0.299  -0.178   
Temporal  -0.115 -0.002 0.351  -0.213    -0.157 0.010 0.201  -0.241   
Superior-Temporal  -0.174 0.016 0.155  -0.127    -0.119 -0.001 0.334  -0.156   
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  LIGHT  DARK 
TIA500  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.145 0.005 0.253  -0.097 0.014 0.371  -0.035 -0.014 0.777  0.025 -0.046 0.741 
Superior-Nasal  -0.220 0.034 0.072  -0.197    -0.111 -0.003 0.368  -0.082   
Nasal  -0.053 -0.012 0.665  0.045    -0.110 -0.003 0.371  -0.045   
Inferior-Nasal  0.041 -0.013 0.738  0.308    0.052 -0.012 0.674  0.239   
Inferior  -0.016 -0.015 0.898  0.077    -0.023 -0.015 0.855  0.024   
Inferior-Temporal  -0.208 0.029 0.089  -0.23    -0.124 0.000 0.315  -0.092   
Temporal  -0.117 -0.001 0.340  -0.051    -0.174 0.015 0.157  -0.207   
Superior-Temporal  -0.192 0.022 0.117  -0.103    -0.103 -0.004 0.405  -0.067   
Table 3.39. Univariate and multivariate regression models over The Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with TIA 500 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
 
 
Table 3.40. Univariate and multivariate regression models over The Supine Intraocular Pressure Test Result (SIOP) for light and dark conditions with TIA 750 adjusted for the 8 different 
sections. Statistically significant p values have been flagged with an asterisk. 
 
  LIGHT  DARK 
TIA750  Single Predictor  Multiple Predictor  Single Predictor  Multiple Predictor 
  Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 
Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
 Standardised 
Coefficients 
Adj. R2 
Significance 
P Value 
Superior  -0.081 -0.009 0.519  -0.114 -0.091 0.954  0.065 -0.011 0.606  0.017 -0.006 0.480 
Superior-Nasal  -0.095 -0.006 0.439  -0.092    -0.058 -0.012 0.638  -0.050   
Nasal  -0.069 -0.010 0.575  0.007    -0.143 0.006 0.245  -0.257   
Inferior-Nasal  -0.019 -0.015 0.876  0.042    0.114 -0.002 0.353  0.428   
Inferior  -0.003 -0.015 0.979  0.054    0.072 -0.010 0.561  0.111   
Inferior-Temporal  -0.058 -0.012 0.638  -0.079    0.009 -0.015 0.943  -0.008   
Temporal  0.007 -0.015 0.954  0.271    -0.060 -0.012 0.630  -0.140   
Superior-Temporal  -0.107 -0.004 0.385  -0.143    -0.035 -0.014 0.778  -0.130   
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VISIT 1 VISIT 4 VISIT 5 VISIT 6 VISIT 11 
TR UNTR TR UNTR TR UNTR TR UNTR TR UNTR 
IOP 16.3 
(4.058) 
16.3 
(3.695) 
18.7 
(3.805) 
18.3 
(4.032) 
18.5 
(3.378) 
18.6 
(3.927) 
18.1 
(3.543) 
18.7 
(4.136) 
16.5 
(3.604) 
17.092 
(4.139) 
SU
P
ER
IO
R
 
AOD500 0.056 
(0.056) 
0.031 
(0.037) 
0.047 
(0.062) 
0.040 
(0.054) 
0.050 
(0.063) 
0.042 
(0.050) 
0.057 
(0.065) 
0.041 
(0.049) 
0.063 
(0.078) 
0.046 
(0.055) 
ARA500 0.023 
0.023) 
0.011 
(0.025) 
0.013 
(0.022) 
0.014 
(0.025) 
0.015 
(0.022) 
0.011 
(0.022) 
0.016 
(0.027) 
0.012 
(0.021) 
0.022 
(0.029) 
0.013 
(0.020) 
TISA500 0.021 
0.021) 
0.010 
(0.022) 
0.012 
(0.021) 
0.012 
(0.022) 
0.015 
(0.022) 
0.010 
(0.021) 
0.015 
(0.026) 
0.011 
(0.019) 
0.022 
(0.028) 
0.013 
(0.020) 
TIA500 4.247 
(4.247) 
2.435 
(2.815) 
3.829 
(5.226) 
3.013 
(4.155) 
4.049 
(5.190) 
3.379 
(4.196) 
4.226 
(4.671) 
3.074 
(3.619) 
4.734 
(5.671) 
3.821 
(4.629) 
AOD750 0.074 
(0.074) 
0.071 
(0.082) 
0.101 
(0.095) 
0.078 
(0.081) 
0.101 
(0.091) 
0.079 
(0.067) 
0.121 
(0.095) 
0.075 
(0.063) 
0.137 
(0.107) 
0.092 
(0.085) 
ARA750 0.036 
(0.036) 
0.022 
(0.030) 
0.033 
(0.040) 
0.031 
(0.039) 
0.034 
(0.037) 
0.029 
(0.034) 
0.040 
(0.045) 
0.029 
(0.032) 
0.050 
(0.052) 
0.033 
(0.036) 
TISA750 0.034 
(0.034) 
0.021 
(0.029) 
0.032 
(0.039) 
0.029 
(0.037) 
0.034 
(0.037) 
0.028 
(0.033) 
0.039 
(0.043) 
0.028 
(0.030) 
0.049 
(0.051) 
0.032 
(0.036) 
TIA750 4.079 
(4.079) 
3.906 
(4.094) 
5.897 
(5.498) 
4.328 
(4.405) 
5.759 
(5.065) 
4.468 
(3.826) 
6.713 
(4.887) 
4.305 
(3.468) 
7.360 
(5.535) 
5.400 
(4.898) 
IN
FE
R
IO
R
 
AOD500 0.079 
(0.079) 
0.067 
(0.068) 
0.076 
(0.067) 
0.054 
(0.068) 
0.081 
(0.070) 
0.066 
(0.076) 
0.079 
(0.076) 
0.055 
(0.065) 
0.078 
(0.072) 
0.067 
(0.074) 
ARA500 0.027 
(0.027) 
0.019 
(0.032) 
0.024 
(0.033) 
0.016 
(0.023) 
0.025 
(0.029) 
0.022 
(0.033) 
0.022 
(0.031) 
0.017 
(0.025) 
0.020 
(0.023) 
0.021 
(0.031) 
TISA500 0.026 
(0.026) 
0.017 
(0.028) 
0.022 
(0.028) 
0.015 
(0.021) 
0.024 
(0.027) 
0.022 
(0.030) 
0.020 
(0.028) 
0.016 
(0.024) 
0.019 
(0.022) 
0.019 
(0.027) 
TIA500 5.110 
(5.110) 
4.829 
(5.163) 
5.374 
(4.492) 
3.495 
(4.371) 
5.523 
(4.775) 
4.395 
(4.681) 
5.656 
(5.698) 
3.782 
(4.287) 
5.476 
(5.079) 
4.718 
(4.864) 
AOD750 0.103 
(0.103) 
0.132 
(0.106) 
0.150 
(0.086) 
0.116 
(0.102) 
0.146 
(0.103) 
0.131 
(0.108) 
0.163 
(0.099) 
0.121 
(0.108) 
0.159 
(0.093) 
0.121 
(0.108) 
ARA750 0.046 
(0.046) 
0.045 
(0.045) 
0.056 
(0.048) 
0.038 
(0.041) 
0.055 
(0.047) 
0.048 
(0.051) 
0.054 
(0.049) 
0.042 
(0.042) 
0.051 
(0.042) 
0.046 
(0.050) 
TISA750 0.045 
(0.045) 
0.043 
(0.043) 
0.053 
(0.043) 
0.037 
(0.041) 
0.055 
(0.045) 
0.047 
(0.049) 
0.052 
(0.047) 
0.040 
(0.041) 
0.052 
(0.041) 
0.044 
(0.046) 
TIA750 5.315 
(5.315) 
6.977 
(5.303) 
7.958 
(4.195) 
5.862 
(4.828) 
7.533 
(5.105) 
6.721 
(5.007) 
8.759 
(5.311) 
6.287 
(5.355) 
8.511 
(4.709) 
6.489 
(5.392) 
SU
P
ER
IO
R
-N
A
SA
L 
AOD500 0.061 
(0.061) 
0.075 
(0.067) 
0.080 
(0.074) 
0.076 
(0.075) 
0.077 
(0.072) 
0.076 
(0.068) 
0.077 
(0.071) 
0.091 
(0.075) 
0.085 
(0.075) 
0.083 
(0.066) 
ARA500 0.028 
(0.028) 
0.036 
(0.033) 
0.042 
(0.033) 
0.039 
(0.035) 
0.038 
(0.032) 
0.036 
(0.035) 
0.038 
(0.033) 
0.040 
(0.033) 
0.042 
(0.037) 
0.037 
(0.034) 
TISA500 0.026 
(0.026) 
0.032 
(0.030) 
0.038 
(0.030) 
0.036 
(0.031) 
0.034 
(0.029) 
0.033 
(0.031) 
0.034 
(0.030) 
0.037 
(0.030) 
0.039 
(0.033) 
0.034 
(0.031) 
TIA500 6.124 
(6.124) 
6.666 
(6.312) 
7.058 
(6.815) 
6.413 
(6.521) 
6.451 
(6.189) 
6.663 
(6.157) 
5.913 
(5.245) 
7.519 
(6.475) 
7.150 
(6.049) 
6.864 
(5.614) 
AOD750 0.093 
(0.093) 
0.108 
(0.080) 
0.142 
(0.094) 
0.124 
(0.094) 
0.129 
(0.094) 
0.123 
(0.081) 
0.140 
(0.096) 
0.127 
(0.083) 
0.148 
(0.093) 
0.123 
(0.084) 
ARA750 0.045 
(0.045) 
0.062 
(0.049) 
0.074 
(0.050) 
0.067 
(0.053) 
0.067 
(0.050) 
0.065 
(0.049) 
0.068 
(0.051) 
0.070 
(0.049) 
0.074 
(0.055) 
0.065 
(0.050) 
TISA750 0.043 
(0.043) 
0.059 
(0.046) 
0.069 
(0.048) 
0.064 
(0.050) 
0.063 
(0.047) 
0.061 
(0.046) 
0.064 
(0.048) 
0.067 
(0.047) 
0.070 
(0.051) 
0.062 
(0.047) 
TIA750 6.354 
(6.354) 
6.877 
(5.190) 
8.939 
(5.966) 
7.434 
(5.616) 
7.795 
(5.753) 
7.726 
(5.181) 
7.930 
(5.055) 
7.585 
(4.667) 
9.021 
(5.339) 
7.322 
(4.828) 
IN
FE
R
IO
R
-T
EM
P
O
R
A
L 
AOD500 0.086 
(0.086) 
0.101 
(0.067) 
0.150 
(0.093) 
0.109 
(0.066) 
0.143 
(0.098) 
0.121 
(0.078) 
0.157 
(0.086) 
0.111 
(0.077) 
0.162 
(0.095) 
0.122 
(0.074) 
ARA500 0.032 
(0.032) 
0.048 
(0.030) 
0.065 
(0.041) 
0.051 
(0.031) 
0.068 
(0.041) 
0.057 
(0.032) 
0.071 
(0.045) 
0.053 
(0.031) 
0.074 
(0.042) 
0.053 
(0.032) 
TISA500 0.031 
(0.031) 
0.045 
(0.028) 
0.059 
(0.037) 
0.046 
(0.027) 
0.060 
(0.036) 
0.053 
(0.030) 
0.063 
(0.038) 
0.047 
(0.028) 
0.067 
(0.038) 
0.048 
(0.029) 
TIA500 8.575 
(8.575) 
8.903 
(5.814) 
12.739 
(8.163) 
8.695 
(5.637) 
10.638 
(7.343) 
10.532 
(7.215) 
12.321 
(6.682) 
8.423 
(5.763) 
13.339 
(7.945) 
9.918 
(5.998) 
AOD750 0.101 
(0.101) 
0.180 
(0.088) 
0.249 
(0.117) 
0.184 
(0.094) 
0.242 
(0.120) 
0.197 
(0.103) 
0.253 
(0.108) 
0.202 
(0.096) 
0.265 
(0.124) 
0.194 
(0.101) 
ARA750 0.046 
(0.046) 
0.087 
(0.045) 
0.119 
(0.065) 
0.091 
(0.047) 
0.122 
(0.067) 
0.099 
(0.049) 
0.127 
(0.065) 
0.095 
(0.049) 
0.132 
(0.066) 
0.095 
(0.049) 
TISA750 0.048 
(0.048) 
0.084 
(0.043) 
0.113 
(0.061) 
0.086 
(0.044) 
0.115 
(0.063) 
0.095 
(0.049) 
0.119 
(0.060) 
0.090 
(0.046) 
0.125 
(0.062) 
0.090 
(0.046) 
TIA750 6.165 
(6.165) 
11.146 
(5.344) 
15.061 
(6.971) 
10.542 
(5.375) 
13.364 
(6.628) 
12.069 
(6.527) 
14.456 
(6.072) 
11.324 
(5.138) 
15.705 
(7.739) 
11.374 
(5.745) 
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  Continuation table 4.1.  
  
 VISIT 1 VISIT 4 VISIT 5 VISIT 6 VISIT 11 
TR UNTR TR UNTR TR UNTR TR UNTR TR UNTR 
N
A
SA
L 
AOD500 0.075 
(0.075) 
0.125 
(0.092) 
0.148 
(0.076) 
0.140 
(0.091 
0.145 
(0.074) 
0.139 
(0.091) 
0.150 
(0.075) 
0.144 
(0.092) 
0.164 
(0.079) 
0.147 
(0.092) 
ARA500 0.040 
(0.040) 
0.058 
(0.044) 
0.068 
(0.038) 
0.072 
(0.053) 
0.067 
(0.038) 
0.067 
(0.048) 
0.069 
(0.036) 
0.070 
(0.052) 
0.070 
(0.038) 
0.070 
(0.050) 
TISA500 0.036 
(0.036) 
0.051 
(0.038) 
0.061 
(0.034) 
0.063 
(0.044) 
0.059 
(0.034) 
0.059 
(0.040) 
0.061 
(0.032) 
0.062 
(0.046) 
0.062 
(0.033) 
0.062 
(0.041) 
TIA500 6.387 
(6.387) 
10.491 
(7.601) 
12.853 
(7.253) 
11.597 
(7.673) 
11.592 
(6.605) 
11.351 
(7.603) 
12.356 
(6.774) 
11.503 
(7.320) 
12.961 
(6.637) 
11.086 
(6.394) 
AOD750 0.091 
(0.091) 
0.178 
(0.109) 
0.234 
(0.092) 
0.189 
(0.110) 
0.214 
(0.105) 
0.205 
(0.112) 
0.236 
(0.106) 
0.196 
(0.114) 
0.246 
(0.098) 
0.212 
(0.121) 
ARA750 0.053 
(0.053) 
0.100 
(0.065) 
0.121 
(0.051) 
0.116 
(0.073) 
0.115 
(0.056) 
0.113 
(0.068) 
0.121 
(0.054) 
0.113 
(0.074) 
0.126 
(0.055) 
0.116 
(0.072) 
TISA750 0.049 
(0.049) 
0.093 
(0.060) 
0.114 
(0.047) 
0.110 
(0.063) 
0.107 
(0.052) 
0.105 
(0.061) 
0.113 
(0.050) 
0.105 
(0.068) 
0.118 
(0.051) 
0.108 
(0.063) 
TIA750 4.926 
(4.926) 
10.851 
(6.423) 
14.324 
(5.821) 
11.274 
(6.344) 
12.469 
(6.613) 
12.011 
(6.421) 
13.921 
(6.660) 
11.433 
(6.314) 
14.211 
(5.510) 
11.857 
(5.906) 
TE
M
P
O
R
A
L 
AOD500 0.057 
(0.057) 
0.087 
(0.066) 
0.115 
(0.066) 
0.102 
(0.069) 
0.114 
(0.072) 
0.110 
(0.057) 
0.113 
(0.074) 
0.106 
(0.062) 
0.128 
(0.072) 
0.114 
(0.070) 
ARA500 0.024 
(0.024) 
0.047 
(0.033) 
0.053 
(0.028) 
0.050 
(0.033) 
0.053 
(0.032) 
0.049 
(0.029) 
0.054 
(0.032) 
0.055 
(0.031) 
0.061 
(0.036) 
0.056 
(0.033) 
TISA500 0.023 
(0.023) 
0.042 
(0.029) 
0.048 
(0.026) 
0.045 
(0.030) 
0.047 
(0.027) 
0.045 
(0.027) 
0.050 
(0.029) 
0.052 
(0.028) 
0.055 
(0.030) 
0.050 
(0.029) 
TIA500 5.180 
(5.180) 
8.046 
(6.417) 
9.911 
(5.386) 
8.868 
(6.048) 
9.461 
(6.570) 
9.300 
(5.255) 
9.382 
(5.998) 
9.421 
(5.555) 
10.786 
(5.736) 
9.886 
(6.077) 
AOD750 0.080 
(0.080) 
0.145 
(0.086) 
0.178 
(0.081) 
0.157 
(0.085) 
0.178 
(0.086) 
0.169 
(0.083) 
0.188 
(0.095) 
0.175 
(0.094) 
0.192 
(0.093) 
0.172 
(0.109) 
ARA750 0.035 
(0.035) 
0.076 
(0.047) 
0.093 
(0.041) 
0.085 
(0.048) 
0.092 
(0.047) 
0.088 
(0.041) 
0.094 
(0.048) 
0.092 
(0.047) 
0.102 
(0.050) 
0.091 
(0.053) 
TISA750 0.034 
(0.034) 
0.072 
(0.044) 
0.089 
(0.039) 
0.081 
(0.045) 
0.086 
(0.042) 
0.083 
(0.039) 
0.089 
(0.047) 
0.088 
(0.044) 
0.096 
(0.045) 
0.086 
(0.049) 
TIA750 5.125 
(5.125) 
9.543 
(5.819) 
11.111 
(4.942) 
9.758 
(5.266) 
10.805 
(5.273) 
10.290 
(5.181) 
11.295 
(5.303) 
11.118 
(5.967) 
11.855 
(5.615) 
10.616 
(6.362) 
IN
FE
R
IO
R
-N
A
SA
L 
AOD500 0.084 
(0.084) 
0.123 
(0.100) 
0.144 
(0.090) 
0.119 
(0.097) 
0.138 
(0.106) 
0.137 
(0.108) 
0.151 
(0.080) 
0.121 
(0.101) 
0.166 
(0.085) 
0.132 
(0.096) 
ARA500 0.037 
(0.037) 
0.051 
(0.043) 
0.058 
(0.036) 
0.057 
(0.046) 
0.060 
(0.048) 
0.061 
(0.056) 
0.066 
(0.046) 
0.054 
(0.047) 
0.066 
(0.042) 
0.058 
(0.049) 
TISA500 0.035 
(0.035) 
0.047 
(0.039) 
0.053 
(0.033) 
0.052 
(0.041) 
0.053 
(0.042) 
0.053 
(0.046) 
0.058 
(0.037) 
0.048 
(0.042) 
0.060 
(0.037) 
0.052 
(0.042) 
TIA500 7.557 
(7.557) 
10.383 
(8.858) 
12.276 
(7.673) 
9.616 
(8.242) 
10.828 
(8.425) 
10.579 
(8.575) 
11.403 
(6.360) 
9.649 
(8.385) 
13.432 
(7.614) 
10.695 
(7.774) 
AOD750 0.107 
(0.107) 
0.188 
(0.127) 
0.223 
(0.115) 
0.196 
(0.119) 
0.222 
(0.119) 
0.204 
(0.132) 
0.252 
(0.105) 
0.193 
(0.126) 
0.252 
(0.116) 
0.216 
(0.136) 
ARA750 0.059 
(0.059) 
0.093 
(0.070) 
0.108 
(0.056) 
0.101 
(0.071) 
0.108 
(0.074) 
0.105 
(0.084) 
0.120 
(0.064) 
0.096 
(0.073) 
0.120 
(0.061) 
0.104 
(0.074) 
TISA750 0.058 
(0.058) 
0.088 
(0.067) 
0.103 
(0.055) 
0.097 
(0.066) 
0.102 
(0.068) 
0.098 
(0.075) 
0.112 
(0.057) 
0.091 
(0.069) 
0.114 
(0.057) 
0.098 
(0.068) 
TIA750 6.790 
(6.790) 
11.334 
(7.729) 
13.574 
(6.999) 
11.449 
(7.238) 
12.679 
(6.696) 
11.774 
(7.639) 
14.153 
(5.654) 
11.359 
(7.639) 
14.821 
(7.329) 
12.578 
(7.655) 
SU
P
ER
IO
R
-T
EM
P
O
R
A
L 
AOD500 0.060 
(0.060) 
0.042 
(0.046) 
0.083 
(0.075) 
0.061 
(0.066) 
0.085 
(0.073) 
0.049 
(0.056) 
0.071 
(0.067) 
0.054 
(0.057) 
0.078 
(0.072) 
0.055 
(0.065) 
ARA500 0.024 
(0.024) 
0.019 
(0.022) 
0.032 
(0.035) 
0.031 
(0.033) 
0.033 
(0.028) 
0.024 
(0.030) 
0.027 
(0.028) 
0.023 
(0.026) 
0.028 
(0.029) 
0.022 
(0.027) 
TISA500 0.024 
(0.024) 
0.018 
(0.021) 
0.029 
(0.031) 
0.028 
(0.030) 
0.031 
(0.028) 
0.022 
(0.028) 
0.026 
(0.027) 
0.022 
(0.024) 
0.027 
(0.028) 
0.020 
(0.025) 
TIA500 6.189 
(6.189) 
3.897 
(4.306) 
7.026 
(6.205) 
5.042 
(5.796) 
6.686 
(5.537) 
4.489 
(5.444) 
5.751 
(5.416) 
4.818 
(5.453) 
6.584 
(6.365) 
4.333 
(5.110) 
AOD750 0.074 
(0.074) 
0.089 
(0.087) 
0.141 
(0.103) 
0.116 
(0.099) 
0.138 
(0.089) 
0.096 
(0.086) 
0.133 
(0.091) 
0.101 
(0.090) 
0.144 
(0.085) 
0.099 
(0.095) 
ARA750 0.038 
(0.038) 
0.037 
(0.036) 
0.063 
(0.054) 
0.061 
(0.052) 
0.062 
(0.046) 
0.046 
(0.045) 
0.054 
(0.044) 
0.043 
(0.039) 
0.059 
(0.045) 
0.043 
(0.046) 
TISA750 0.038 
(0.038) 
0.035 
(0.035) 
0.061 
(0.051) 
0.056 
(0.050) 
0.060 
(0.045) 
0.044 
(0.043) 
0.055 
(0.044) 
0.044 
(0.041) 
0.058 
(0.044) 
0.042 
(0.044) 
TIA750 5.168 
(5.168) 
5.717 
(5.485) 
8.663 
(6.062) 
6.753 
(6.143) 
7.966 
(4.529) 
6.092 
(5.610) 
7.813 
(5.020) 
6.258 
(5.666) 
8.789 
(5.115) 
5.825 
(5.442) 
 Table 4.1. Mean values for every parameter (treated eyes with LPI only and fellow untreated eyes) in dark for 
visits 1, 4, 5, 6 and 11 together with their standard deviation within brackets. 
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Figure 4.2 AOD 500 and 750µm in the Superior section for LPI Treated and Untreated eyes through Visits 1,4 ,5 ,6 and 
11 
 
 
Figure 4.3 AOD 500 and 750µm in the Superior-Nasal section for LPI Treated and Untreated eyes through Visits 1,4 ,5 ,6 
and 11. 
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Figure 4.4 AOD 500 and 750µm in the Nasal section for LPI Treated and Untreated eyes through Visits 1,4 ,5 ,6 and 11. 
 
 
 
Figure 4.5 AOD 500 and 750µm in the Inferior-Nasal section for LPI Treated and Untreated eyes through Visits 1,4 ,5 ,6 
and 11. 
  253 
 
Figure 4.6 AOD 500 and 750µm in the Inferior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.7 AOD 500 and 750µm in the Inferior –Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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Figure 4.8 AOD 500 and 750µm in the Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.9 AOD 500 and 750µm in the Superior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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Figure 4.10 ARA 500 and 750µm in the Superior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.11 ARA 500 and 750µm in the Superior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 
6 and 11. 
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Figure 4.12 ARA 500 and 750µm in the Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 11. 
 
 
 
Figure 4.13 ARA 500 and 750µm in the Inferior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 
and 11. 
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Figure 4.14 ARA 500 and 750µm in the Inferior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.15 ARA 500 and 750µm in the Inferior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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Figure 4.16 ARA 500 and 750µm in the Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.17 ARA 500 and 750µm in the Superior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 
4, 5, 6 and 11. 
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Figure 4.18 TISA 500 and 750µm in the Superior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.19 TISA 500 and 750µm in the Superior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 
6 and 11. 
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Figure 4.20 TISA 500 and 750µm in the Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 11. 
 
 
 
Figure 4.21 TISA 500 and 750µm in the Inferior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 
and 11. 
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Figure 4.22 TISA 500 and 750µm in the Inferior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.23 TISA 500 and 750µm in the Inferior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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Figure 4.24 TISA 500 and 750µm in the Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.25 TISA 500 and 750µm in the Superior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 
4, 5, 6 and 11. 
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Figure 4.26 TSA 500 and 750µm in the Superior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.27 TIA 500 and 750µm in the Superior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 
and 11. 
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Figure 4.28 TIA 500 and 750µm in the Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 11. 
 
 
 
Figure 4.29 TIA 500 and 750µm in the Inferior-Nasal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 
and 11. 
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Figure 4.30 TIA 500 and 750µm in the Inferior section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.31 TIA 500 and 750µm in the Inferior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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Figure 4.32 TIA 500 and 750µm in the Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 5, 6 and 
11. 
 
 
Figure 4.33 TIA 500 and 750µm in the Superior-Temporal section for LPI Treated and Untreated eyes through Visits 1, 4, 
5, 6 and 11. 
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 VISIT 6 VISIT 8 VISIT 9 VISIT 10 VISIT 11 
TR UNTR TR UNTR TR UNTR TR UNTR TR UNTR 
 
IOP 
18.3 
(3.4) 
18.7 
(2.8) 
15.0 
(3.2) 
NA 
17.4 
(3.2) 
NA 
18.4 
(2.3) 
NA 
15.8 
(2.7) 
17.2 
(3.2) 
 
AOD 500 0.052 
(0.073) 
0.020 
(0.036) 
0.109 
(0.118) 
NA 
0.106 
(0.134) 
NA 
0.084 
(0.099) 
NA 
0.075 
(0.080) 
0.017 
(0.026) 
ARA500 
0.018 
(0.038) 
0.007 
(0.016) 
0.046 
(0.046) 
NA 
0.043 
(0.058) 
NA 
0.042 
(0.049) 
NA 
0.031 
(0.032) 
0.006 
(0.015) 
TISA500 
0.017 
(0.037) 
0.006 
(0.015) 
0.045 
(0.046) 
NA 
0.039 
(0.053) 
NA 
0.039 
(0.046) 
NA 
0.030 
(0.032) 
0.006 
(0.015) 
TIA500 
4.150 
(6.265) 
1.690 
(3.078) 
10.282 
(10.960) 
NA 
8.682 
(10.973) 
NA 
6.936 
(7.881) 
NA 
6.355 
(7.108) 
1.311 
(1.877) 
AOD750 
0.103 
(0.100) 
0.078 
(0.063) 
0.180 
(0.147) 
NA 
0.159 
(0.169) 
NA 
0.125 
(0.111) 
NA 
0.160 
(0.110) 
0.071 
(0.059) 
ARA750 
0.038 
(0.057) 
0.022 
(0.029) 
0.086 
(0.076) 
NA 
0.082 
(0.092) 
NA 
0.070 
(0.071) 
NA 
0.068 
(0.054) 
0.019 
(0.026) 
TISA750 
0.037 
(0.055) 
0.022 
(0.028) 
0.085 
(0.076) 
NA 
0.078 
(0.089) 
NA 
0.067 
(0.068) 
NA 
0.066 
(0.054) 
0.019 
(0.026) 
TIA750 
5.970 
(5.890) 
4.540 
(3.660) 
11.645 
(9.566) 
NA 
9.464 
(10.148) 
NA 
7.582 
(6.449) 
NA 
9.556 
(6.440) 
4.000 
(3.216) 
   
   
   
   
   
   
   
   
   
   
  I
N
FE
R
IO
R
 
AOD500 
0.049 
(0.074) 
0.051 
(0.064) 
0.181 
(0.106) 
NA 
0.165 
(0.134) 
NA 
0.127 
(0.086) 
NA 
0.079 
(0.069) 
0.031 
(0.049) 
ARA500 
0.020 
(0.037) 
0.013 
(0.023) 
0.069 
(0.043) 
NA 
0.066 
(0.049) 
NA 
0.050 
(0.043) 
NA 
0.022 
(0.024) 
0.007 
(0.010) 
TISA500 
0.019 
(0.035) 
0.012 
(0.023) 
0.065 
(0.039) 
NA 
0.061 
(0.045) 
NA 
0.046 
(0.040) 
NA 
0.021 
(0.023) 
0.007 
(0.010) 
TIA500 
4.018 
(6.249) 
3.820 
(4.914) 
14.600 
(8.735) 
NA 
11.955 
(8.972) 
NA 
10.520 
(7.355) 
NA 
6.218 
(5.550) 
2.011 
(2.732) 
AOD750 
0.108 
(0.100) 
0.144 
(0.099) 
0.285 
(0.140) 
NA 
0.274 
(0.190) 
NA 
0.197 
(0.126) 
NA 
0.138 
(0.096) 
0.140 
(0.111) 
ARA750 
0.041 
(0.057) 
0.040 
(0.042) 
0.133 
(0.071) 
NA 
0.124 
(0.086) 
NA 
0.089 
(0.066) 
NA 
0.051 
(0.043) 
0.032 
(0.031) 
TISA750 
0.040 
(0.055) 
0.039 
(0.041) 
0.128 
(0.068) 
NA 
0.119 
(0.083) 
NA 
0.086 
(0.064) 
NA 
0.049 
(0.042) 
0.035 
(0.031) 
TIA750 
6.400 
(6.003) 
7.660 
(5.497) 
16.955 
(8.766) 
NA 
14.382 
(8.716) 
NA 
11.755 
(7.777) 
NA 
8.036 
(5.651) 
7.389 
(5.454) 
SU
P
ER
IO
R
-N
A
SA
L 
AOD500 
0.058 
(0.072) 
0.051 
(0.044) 
0.157 
(0.081) 
NA 
0.129 
(0.135) 
NA 
0.080 
(0.081) 
NA 
0.087 
(0.074) 
0.047 
(0.054) 
ARA500 
0.033 
(0.041) 
0.029 
(0.027) 
0.063 
(0.038) 
NA 
0.042 
(0.041) 
NA 
0.043 
(0.040) 
NA 
0.048 
(0.049) 
0.026 
(0.025) 
TISA500 
0.031 
(0.038) 
0.025 
(0.023) 
0.060 
(0.036) 
NA 
0.040 
(0.039) 
NA 
0.039 
(0.035) 
NA 
0.043 
(0.041) 
0.029 
(0.024) 
TIA500 
5.191 
(6.697) 
4.170 
(3.633) 
13.982 
(6.525) 
NA 
8.564 
(8.746) 
NA 
6.591 
(6.394) 
NA 
7.355 
(6.137) 
4.000 
(4.222) 
AOD750 
0.095 
(0.070) 
0.098 
(0.076) 
0.217 
(0.121) 
NA 
0.166 
(0.132) 
NA 
0.136 
(0.098) 
NA 
0.118 
(0.092) 
0.132 
(0.087) 
ARA750 
0.053 
(0.056) 
0.051 
(0.041) 
0.113 
(0.062) 
NA 
0.071 
(0.071) 
NA 
0.075 
(0.058) 
NA 
0.076 
(0.068) 
0.052 
(0.040) 
TISA750 
0.050 
(0.054) 
0.047 
(0.037) 
0.110 
(0.060) 
NA 
0.069 
(0.070) 
NA 
0.071 
(0.052) 
NA 
0.071 
(0.059) 
0.051 
(0.040) 
TIA750 
5.944 
(4.553) 
5.750 
(4.215) 
13.682 
(7.191) 
NA 
10.527 
(8.161) 
NA 
7.973 
(5.176) 
NA 
7.136 
(4.832) 
8.056 
(4.843) 
IN
FE
R
IO
R
-T
EM
P
O
R
A
L 
AOD500 
0.104 
(0.058) 
0.120 
(0.052) 
0.234 
(0.113) 
NA 
0.183 
(0.124) 
NA 
0.173 
(0.092) 
NA 
0.147 
(0.080) 
0.092 
(0.072) 
ARA500 
0.059 
(0.034) 
0.055 
(0.049) 
0.097 
(0.055) 
NA 
0.078 
(0.061) 
NA 
0.086 
(0.057) 
NA 
0.081 
(0.043) 
0.038 
(0.034) 
TISA500 
0.053 
(0.033) 
0.046 
(0.036) 
0.093 
(0.048) 
NA 
0.073 
(0.051) 
NA 
0.076 
(0.046) 
NA 
0.073 
(0.037) 
0.035 
(0.028) 
TIA500 
9.027 
(6.089) 
9.510 
(4.631) 
20.891 
(9.408) 
NA 
14.800 
(8.575) 
NA 
13.609 
(5.337) 
NA 
12.127 
(6.613) 
7.011 
(5.645) 
AOD750 
0.199 
(0.086) 
0.208 
(0.073) 
0.301 
(0.183) 
NA 
0.279 
(0.185) 
NA 
0.238 
(0.125) 
NA 
0.243 
(0.104) 
0.180 
(0.095) 
ARA750 
0.101 
(0.046) 
0.100 
(0.060) 
0.168 
(0.090) 
NA 
0.141 
(0.096) 
NA 
0.138 
(0.079) 
NA 
0.133 
(0.060) 
0.075 
(0.050) 
TISA750 
0.095 
(0.045) 
0.090 
(0.048) 
0.164 
(0.084) 
NA 
0.135 
(0.086) 
NA 
0.128 
(0.067) 
NA 
0.125 
(0.054) 
0.071 
(0.046) 
TIA750 
11.755 
(5.293) 
12.020 
(4.684) 
18.718 
(10.561) 
NA 
16.518 
(9.929) 
NA 
13.836 
(6.015) 
NA 
14.509 
(6.352) 
9.911 
(4.595) 
 
Continues in next page 
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Continuation Table 5.4 
 
VISIT 6 VISIT 8 VISIT 9 VISIT 10 VISIT 11 
TR UNTR TR UNTR TR UNTR TR UNTR TR UNTR 
N
A
SA
L 
AOD500 
0.136 
(0.081) 
0.129 
(0.062) 
0.245 
(0.108) 
NA 
0.202 
(0.113) 
NA 
0.185 
(0.106) 
NA 
0.166 
(0.097) 
0.133 
(0.062) 
ARA500 
0.072 
(0.042) 
0.057 
(0.037) 
(0.108 
(0.053) 
NA 
0.091 
(0.049) 
NA 
0.084 
(0.053) 
NA 
0.086 
(0.049) 
0.057 
(0.035) 
TISA500 
0.063 
(0.037) 
0.050 
(0.031) 
0.097 
(0.042) 
NA 
0.080 
(0.041) 
NA 
0.074 
(0.045) 
NA 
0.076 
(0.040) 
0.050 
(0.030) 
TIA500 
10.573 
(6.215) 
9.940 
(6.207) 
21.491 
(9.872) 
NA 
16.945 
(9.886) 
NA 
14.309 
(8.213) 
NA 
13.145 
(8.029) 
9.867 
(5.433) 
AOD750 
0.194 
(0.111) 
0.210 
(0.100) 
0.302 
(0.153) 
NA 
0.256 
(0.159) 
NA 
0.234 
(0.157) 
NA 
0.264 
(0.128) 
0.207 
(0.080) 
ARA750 
0.116 
(0.064) 
0.105 
(0.052) 
0.180 
(0.079) 
NA 
0.150 
(0.073) 
NA 
0.140 
(0.081) 
NA 
0.153 
(0.067) 
0.103 
(0.048) 
TISA750 
0.107 
(0.058) 
0.097 
(0.047) 
0.170 
(0.070) 
NA 
0.139 
(0.066) 
NA 
0.129 
(0.073) 
NA 
0.142 
(0.059) 
0.096 
(0.043) 
TIA500 
10.973 
(5.308) 
11.610 
(6.174) 
18.827 
(9.703) 
NA 
15.464 
(9.705) 
NA 
13.064 
(7.933) 
NA 
15.110 
(6.920) 
11.544 
(4.714) 
TE
M
P
O
R
A
L 
AOD500 
0.093 
(0.077) 
0.096 
(0.062) 
0.198 
(0.107) 
NA 
0.148 
(0.113) 
NA 
0.154 
(0.089) 
NA 
0.149 
(0.089) 
0.102 
(0.052) 
ARA500 
0.055 
(0.042) 
0.047 
(0.035) 
0.090 
(0.051) 
NA 
0.073 
(0.044) 
NA 
0.078 
(0.043) 
NA 
0.084 
(0.047) 
0.054 
(0.032) 
TISA500 
0.054 
(0.038) 
0.042 
(0.030) 
0.083 
(0.043) 
NA 
0.069 
(0.043) 
NA 
0.071 
(0.036) 
NA 
0.074 
(0.037) 
0.050 
(0.030) 
TIA500 
8.218 
(6.749) 
8.778 
(5.718) 
18.064 
(8.752) 
NA 
14.627 
(12.045) 
NA 
13.609 
(7.397) 
NA 
11.991 
(6.894) 
9.413 
(5.040) 
AOD750 
0.148 
(0.077) 
0.140 
(0.081) 
0.257 
(0.140) 
NA 
0.226 
(0.172) 
NA 
0.218 
(0.098) 
NA 
0.187 
(0.102) 
0.140 
(0.098) 
ARA750 
0.088 
(0.057) 
0.078 
(0.047) 
0.150 
(0.079) 
NA 
0.121 
(0.077) 
NA 
0.127 
(0.060) 
NA 
0.127 
(0.064) 
0.083 
(0.047) 
TISA750 
0.081 
(0.055) 
0.072 
(0.043) 
0.144 
(0.071) 
NA 
0.117 
(0.077) 
NA 
0.119 
(0.054) 
NA 
0.116 
(0.055) 
0.078 
(0.046) 
TIA 750 
9.118 
(4.764) 
8.960 
(4.978) 
16.609 
(8.356) 
NA 
15.173 
(11.796) 
NA 
13.845 
(5.968) 
NA 
11.018 
(5.408) 
9.122 
(6.337) 
IN
FE
R
IO
R
-N
A
SA
L 
AOD500 
0.103 
(0.090) 
0.134 
(0.070) 
0.232 
(0.082) 
NA 
0.197 
(0.125) 
NA 
0.158 
(0.080) 
NA 
0.160 
(0.105) 
0.135 
(0.084) 
ARA500 
0.052 
(0.041) 
0.058 
(0.052) 
0.088 
(0.040) 
NA 
0.081 
(0.056) 
NA 
0.077 
(0.054) 
NA 
0.071 
(0.042) 
0.055 
(0.051) 
TISA500 
0.046 
(0.036) 
0.051 
(0.043) 
0.083 
(0.037) 
NA 
0.071 
(0.050) 
NA 
0.067 
(0.042) 
NA 
0.063 
(0.037) 
0.048 
(0.040) 
TIA500 
7.855 
(7.674) 
10.350 
(5.627) 
20.455 
(8.069) 
NA 
15.291 
(9.356) 
NA 
11.218 
(4.589) 
NA 
13.164 
(9.500) 
10.789 
(6.605) 
AOD750 
0.188 
(0.116) 
0.221 
(0.087) 
0.326 
(0.151) 
NA 
0.252 
(0.190) 
NA 
0.222 
((0.148) 
NA 
0.203 
(0.139) 
0.213 
(0.075) 
ARA750 
0.091 
(0.063) 
0.105 
(0.067) 
0.163 
(0.061) 
NA 
0.140 
(0.090) 
NA 
0.129 
(0.074) 
NA 
0.118 
(0.064) 
0.101 
(0.073) 
TISA750 
0.085 
(0.059) 
0.098 
(0.059) 
0.158 
(0.060) 
NA 
0.131 
(0.086) 
NA 
0.118 
(0.063) 
NA 
0.110 
(0.061) 
0.093 
(0.061) 
TIA750 
10.770 
(5.931) 
12.610 
(5.235) 
20.200 
(9.273) 
NA 
14.382 
(10.592) 
NA 
11.855 
(7.114) 
NA 
12.073 
(8.516) 
12.511 
(4.153) 
SU
P
ER
IO
R
-T
EM
P
O
R
A
 
AOD500 
0.060 
(0.088) 
0.048 
(0.043) 
0.138 
(0.123) 
NA 
0.116 
(0.091) 
NA 
0.095 
(0.090) 
NA 
0.090 
(0.095) 
0.042 
(0.050) 
ARA500 
0.028 
(0.042) 
0.023 
(0.021) 
0.055 
(0.050) 
NA 
0.043 
(0.040) 
NA 
0.034 
(0.038) 
NA 
0.034 
(0.038) 
0.017 
(0.021) 
TISA500 
0.027 
(0.041) 
0.021 
(0.020) 
0.052 
(0.046) 
NA 
0.042 
(0.038) 
NA 
0.031 
(0.035) 
NA 
0.032 
(0.037) 
0.016 
(0.020) 
TIA500 
5.255 
(8.190) 
4.510 
(4.057) 
11.109 
(9.286) 
NA 
10.491 
(8.105) 
NA 
7.345 
(6.519) 
NA 
7.673 
(8.667) 
3.725 
(4.560) 
AOD750 
0.094 
(0.096) 
0.089 
(0.066) 
0.210 
(0.153) 
NA 
0.174 
(0.128) 
NA 
0.167 
(0.133) 
NA 
0.149 
(0.094) 
0.091 
(0.068) 
ARA750 
0.050 
(0.062) 
0.040 
(0.032) 
0.101 
(0.081) 
NA 
0.083 
(0.063) 
NA 
0.070 
(0.056) 
NA 
0.070 
(0.059) 
0.037 
(0.032) 
TISA750 
0.052 
(0.064) 
0.042 
(0.033) 
0.098 
(0.077) 
NA 
0.082 
(0.061) 
NA 
0.068 
(0.054) 
NA 
0.068 
(0.058) 
0.035 
(0.031) 
TIA750 
5.691 
(5.590) 
5.860 
(4.529) 
12.255 
(8.211) 
NA 
10.982 
(7.963) 
NA 
9.400 
(7.203) 
NA 
9.064 
(5.634) 
5.789 
(4.217) 
Table 5.4. Mean values for every parameter (treated eyes with ALPI and occludable eyes left untreated) in 
dark for visits 6, 8, 9, 10 and 11 together with their standard deviation within brackets. TR= ALPI Treated. 
UNTR= Post PI Occludable, but not treated with ALPI. NA= Not applicable. 
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CENTRAL POSITION  
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2436.065 (247.543) 2353.636 (336.982) 2420.914 (299.817) 2381.314 (341.859) 2404.649 (300.126) 2405.590 (331.241) 2430.565 (250.658) 
Untreated eye 2434.125 (255.205) 2403.677 (351.032) 2467.167 (339.975) 2406.750 (405.572) 2458.973 (370.328) 2416.200 (355.480) 2402.364 (282.834) 
Average Cell 
Size 
Treated eye 414.548 (41.462) 437.030 (92.524) 421.086 (69.635) 430.057 (75.858) 422.892 (59.850) 425.718 (78.085) 415.913 (45.622) 
Untreated eye 415.250 (43.961) 431.441 (117.250) 417.333 (95.478) 434.500 (128.814) 420.081 (98.710) 428.625 (112.098) 422.909 (60.795) 
Percentage of 
Hexagonal Cells 
Treated eye 49.323 (07.799) 46.625 (12.760) 50.971 (06.798) 48.882 (07.690) 47.865 (10.122) 43.757 (12.205) 47.409 (07.799) 
Untreated eye 46.774 (9.482) 48.515 (9.484) 49.583 (9.912) 48.314 (7.959) 49.579 (7.800) 41.737 (15.425) 50.000 (8.950) 
Corneal 
Thickness 
Treated eye 536.000 (40.127) 534.781 (39.761) 547.849 (34.978) 545.343 (35.991) 543.162 (36.892) 533.030 (34.312) 540.818 (33.768) 
Untreated eye 532.000 (38.796) 539.242 (43.661) 539.457 (34.781) 542.235 (38.296) 542.784 (37.665) 552.933 (36.067) 535.905 (34.106) 
Table 6.1. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the CENTRAL 
area of cornea. SD= Standard Deviation. 
 
 
 
 
 
SUPERIOR-NASAL POSITION  
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 173.000 (47.516) 174.188 (69.209) 191.171 (61.856) 183.306 (57.545) 184.622 (58.141) 174.875 (68.658) 180.348 (59.161) 
Untreated eye 171.697 (51.027) 176.212 (63.476) 184.200 (66.773) 177.028 (49.345) 187.405 (51.428) 180.632 (52.863) 181.546 (56.768) 
Average Cell 
Size 
Treated eye 408.813 (60.049) 407.933 (71.101) 408.314 (71.431) 408.056 (63.950) 405.946 (59.463) 402.436 (63.018) 403.091 (53.768) 
Untreated eye 411.091 (62.479) 423.849 (133.988) 408.088 (96.467) 419.667 (106.217) 413.054 (98.726) 403.053 (62.080) 407.046 (55.370) 
Percentage of 
Hexagonal Cells 
Treated eye 49.938 (8.743) 48.867 (8.012) 52.800 (10.448) 49.371 (7.021) 47.405 (8.694) 41.026 (13.602) 42.909 (15.632) 
Untreated eye 49.849 (6.681) 49.656 (7.934) 51.000 (5.852) 46.444 (8.337) 48.333 (8.698) 45.763 (11.098) 40.546 (14.289) 
Table 6.2. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the SUPERIOR-NASAL area of 
cornea. SD= Standard Deviation. 
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INFERIOR-NASAL POSITION  
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit  Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2459.742 (358.862) 2487.807 (339.826) 2501.743 (353.398) 2486.886 (382.925) 2519.286 (402.753) 2552.250 (356.341) 2510.381 (328.113) 
Untreated eye 2478.273 (321.884) 2538.906 (402.858) 2531.086 (394.798) 2477.059 (423.937) 2569.657 (408.513) 2539.564 (406.787) 2468.546 (356.520) 
Average Cell 
Size 
Treated eye 415.258 (63.943) 410.516 (65.914) 408.571 (66.508) 412.686 (73.100) 409.829 (87.060) 400.125 (62.441) 405.381 (57.761) 
Untreated eye 410.849 (60.229) 406.625 (87.069) 412.457 (127.372) 421.677 (117.356) 403.343 (99.260) 408.769 (104.689) 415.455 (77.635) 
Percentage of 
Hexagonal Cells 
Treated eye 48.871 (8.253) 49.933 (8.658) 52.618 (7.766) 48.794 (7.260) 51.743 (9.030) 50.550 (7.699) 37.905 (15.336) 
Untreated eye 50.219 (8.194) 51.300 (5.472) 53.029 (10.815) 52.353 (11.023) 50.971 (5.512) 50.154 (6.900) 43.476 (15.677) 
Table 6.3. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the INFERIOR-NASAL area of 
cornea. SD= Standard Deviation. 
 
 
 
 
 
INFERIOR POSITION  
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2426.936 (320.485) 2441.333 (341.352) 2479.147 (386.573) 2434.139 (375.919) 2475.973 (362.859) 2457.575 (359.506) 2450.957 (315.945) 
Untreated eye 2432.485 (283.451) 2510.219 (379.473) 2460.971 (397.334) 2477.667 (441.196) 2473.973 (431.898) 2436.564 (411.892) 2466.000 (279.882) 
Average Cell 
Size 
Treated eye 419.581 (60.495) 418.121 (63.877) 416.029 (88.287) 422.167 (78.219) 413.189 (66.582) 416.375 (68.439) 414.913 (57.641) 
Untreated eye 417.000 (52.451) 411.531 (95.117) 420.853 (99.111) 424.694 (134.881) 426.027 (146.238) 427.410 (112.231) 410.381 (45.614) 
Percentage of 
Hexagonal Cells 
Treated eye 49.800 (8.826) 49.500 (8.016) 51.235 (6.120) 49.306 (9.844) 49.730 (8.352) 46.692 (9.825) 47.783 (9.075) 
Untreated eye 45.455 (8.768) 52.781 (12.122) 49.939 (11.792) 49.000 (8.441) 48.865 (7.056) 47.947 (7.939) 48.000 (11.238) 
Table 6.4. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the INFERIOR area of cornea.        
SD= Standard Deviation. 
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INFERIOR-TEMPORAL POSITION 
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2433.290 (312.000) 2455.406 (358.123) 2480.029 (343.401) 2451.444 (346.259) 2481.778 (330.545) 2500.075 (366.850) 2495.826 (277.928) 
Untreated eye 2403.969 (328.698) 2466.667 (430.222) 2441.394 (448.658) 2473.265 (406.444) 2464.297 (405.835) 2444.447 (429.503) 2428.909 (308.614) 
Average Cell 
Size 
Treated eye 418.161 (59.041) 417.188 (70.948) 411.912 (66.273) 416.556 (63.978) 411.056 (63.865) 410.075 (72.313) 405.478 (44.903) 
Untreated eye 424.500 (64.931) 421.400 (99.293) 431.212 (131.536) 422.294 (123.416) 426.892 (146.387) 429.947 (130.402) 418.546 (58.114) 
Percentage of 
Hexagonal Cells 
Treated eye 46.032 (8.701) 46.419 (10.318) 51.091 (6.979) 47.528 (8.052) 49.472 (9.204) 48.385 (8.400) 49.696 (7.570) 
Untreated eye 46.200 (8.339) 46.448 (11.236) 50.182 (13.563) 49.971 (12.518) 48.757 (7.879) 47.083 (9.123) 49.409 (6.299) 
Table 6.5. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the INFERIOR-TEMPORAL area of 
cornea. SD= Standard Deviation. 
 
 
 
 
 
SUPERIOR-TEMPORAL POSITION 
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2466.031 (299.244) 2499.156 (344.312) 2507.514 (372.323) 2514.441 (354.363) 2520.270 (344.132) 2522.974 (357.095) 2511.739 (351.878) 
Untreated eye 2476.061 (312.830) 2436.355 (473.741) 2518.286 (376.967) 2506.286 (433.156) 2497.270 (393.849) 2467.282 (417.233) 2508.364 (325.309) 
Average Cell 
Size 
Treated eye 411.938 (55.383) 408.750 (66.097) 410.686 (86.633) 406.794 (68.711) 403.405 (60.299) 405.795 (69.842) 406.870 (67.065) 
Untreated eye 410.576 (56.148) 435.871 (151.727) 407.171 (72.468) 412.229 (81.113) 414.865 (101.611) 421.744 (108.751) 404.682 (49.656) 
Percentage of 
Hexagonal Cells 
Treated eye 45.813 (9.630) 47.710 (8.478) 47.486 (10.362) 48.029 (9.134) 50.378 (9.190) 48.949 (7.643) 50.348 (7.145) 
Untreated eye 47.406 (8.032) 49.129 (7.424) 50.794 (8.545) 49.824 (7.082) 48.757 (9.194) 46.821 (7.887) 47.273 (9.346) 
Table 6.6. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the SUPERIOR-TEMPORAL area of 
cornea. SD= Standard Deviation. 
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SUPERIOR POSITION  
LPI Treated Eyes and Fellows 
Descriptive Statistics 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 184.438 (46.362) 186.000 (64.077) 212.171 (59.301) 192.444 (62.192) 199.027 (61.461) 178.949 (62.873) 183.130 (75.977) 
Untreated eye 179.303 (57.713) 180.794 (75.231) 199.917 (66.328) 192.611 (67.967) 205.368 (57.924) 181.975 (59.604) 193.773 (65.642) 
Average Cell 
Size 
Treated eye 394.844 (60.845) 392.094 (73.666) 390.914 (80.626) 392.086 (66.610) 379.972 (55.204) 410.205 (85.836) 399.333 (73.746) 
Untreated eye 389.182 (60.826) 378.933 (60.678) 388.514 (75.273) 406.944 (140.052) 390.351 (93.593) 403.775 (109.514) 382.286 (67.875) 
Percentage of 
Hexagonal Cells 
Treated eye 48.531 (8.651) 51.813 (7.639) 50.324 (7.474) 51.000 (8.582) 49.417 (7.721) 46.410 (11.396) 48.286 (8.719) 
Untreated eye 48.849 (7.918) 51.600 (7.147) 49.382 (7.177) 49.853 (7.003) 49.722 (6.864) 42.513 (13.062) 49.000 (6.693) 
Table 6.7. Descriptive statistics for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size and percentage of hexagonal cells for the SUPERIOR area of cornea.                
SD= Standard Deviation. 
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CENTRAL POSITION  
LPI Effect 
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye 54.036 (147.544); P=0.063 10.172 (88.055); P=0.539 22.074 (99.352); P=0.259 24.690 (139.607); P=0.349 -6.467 (132.256); P=0.791 4.895 (147.245); P=0.886 
Untreated eye 3.667 (143.755); P=0.890 -31.600 (148.536); P=0.253 8.621 (125.408); P=0.714 -14.033 (135.005); P=0.574 1.938 (143.622); P=0.940 28.947 (143.398); P=0.390 
Average Cell 
Size 
Treated eye -8.536 (21.920); P=0.049* -2.000 (14.360); P=0.460 -4.370 (17.625); P=0.209 -5.000 (24.527); P=0.282 1.000 (22.455); P=0.809 -0.316 (24.543); P=0.956 
Untreated eye 0.200 (24.646); P=0.965 5.367 (24.657); P=0.243 -2.517 (22.534); P=0.552 1.667 (22.196); P=0.684 -0.031 (25.440); P=0.995 -3.842 (25.065); P=0.513 
Percentage of 
Hexagonal Cells  
Treated eye 4.036 (11.475); P=0.074 -2.483 (8.249); P=0.116 -0.296 (9.318); P=0.870 0.000 (12.230); P=1.000 4.172 (13.486); P=0.107 1.211 (9.578); P=0.588 
Untreated eye -1.207 (9.652); P=0.506 -3.172 (11.285); P=0.141 -0.929 (10.579); P=0.646 -4.200 (10.908); P=0.044* 5.167 (15.232); P=0.073 -2.389 (14.641); P=0.498 
Corneal 
Thickness 
Treated eye -0.320 (9.118); P=0.862 -13.769 (12.206); P<0.001* -5.840 (10.246); P=0.009* -4.852 (10.654); P=0.026* -2.045 (11.652); P=0.420 -0.389 (7.586); P=0.830 
Untreated eye -0.500 (10.567); P=0.804 -9.000 (7.897); P<0.001* -3.200 (8.874); P=0.084 -3.138 (8.101); P=0.046* -1.909 (7.752); P=0.261 -0.353 (8.631); P=0.868 
Table 6.8. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the CENTRAL 
area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation 
 
 
 
 
 
SUPERIOR-NASAL POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye 2.966 (44.680); P=0.723 -16.533 (43.168); P=0.045 -12.000 (37.925); P=0.099 -17.138 (40.428); P=0.030* -7.625 (34.308); P=0.218 -5.650 (47.490); P=0.601 
Untreated eye -5.367 (43.879); P=0.508 -14.935 (43.337); P=0.065 -12.533 (35.938); P=0.066 -24.533 (40.737); P=0.003* -11.875 (38.308); P=0.089 -7.850 (41.476); P=0.408 
Average Cell 
Size 
Treated eye -3.815 (27.673); P=0.480 -2.433 (25.569); P=0.606 -1.000 (27.087); P=0.844 -5.931 (33.845); P=0.353 -2.031 (18.234); P=0.533 0.105 (22.038); P=0.984 
Untreated eye 0.200 (29.421); P=0.971 3.000 (23.134); P=0.483 5.167 (22.240); P=0.213 1.800 (20.997); P=0.642 4.906 (22.801); P=0.233 -3.900 (21.662); P=0.431 
Percentage of 
Hexagonal Cells  
Treated eye 2.741 (6.976); P=0.051 -1.200 (8.413); P=0.441 -0.345 (9.367); P=0.844 1.379 (7.552); P=0.334 9.125 (14.983); P=0.002* 5.368 (16.697); P=0.178 
Untreated eye 0.200 (10.274); P=0.916 -1.000 (8.749); P=0.536 2.033 (9.342); P=0.243 0.733 (9.892); P=0.688 3.875 (12.613); P=0.092 11.000 (18.313); P=0.015* 
Table 6.9. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR-
NASAL area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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INFERIOR-NASAL POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -19.269 (162.291); P=0.550 -10.000 (128.420); P=0.678 -1.704 (161.784); P=0.957 -34.481 (120.674); P=0.150 -65.677 (174.924); P=0.045* 19.684 (176.691); P=0.633 
Untreated eye -67.414(149.709); P=0.022* -42.710 (195.540); P=0.233 -14.964 (169.586); P=0.644 -58.464 (169.274); P=0.079 -69.719 (149.911); P=0.013* 60.700 (196.400); P=0.183 
Average Cell 
Size 
Treated eye 3.769 (29.347); P=0.519 3.138 (21.891); P=0.447 1.593 (32.086); P=0.799 5.926 (21.532); P=0.165 12.387 (30.827); P=0.033* -2.421 (31.081); P=0.738 
Untreated eye 12.034 (24.860); P=0.014* 9.742 (40.105); P=0.186 2.857 (36.765); P=0.684 7.464 (27.811); P=0.167 12.156 (24.073); P=0.008* -13.800 (37.815); P=0.119 
Percentage of 
Hexagonal Cells  
Treated eye -1.120 (9.409); P=0.557 -3.143 (11.971); P=0.176 -0.231 (8.449); P=0.890 -3.333 (9.747); P=0.087 -2.548 (8.895); P=0.121 11.053 (16.748); P=0.010* 
Untreated eye -2.444 (7.192); P=0.089 -1.200 (10.723); P=0.545 -2.667 (9.207); P=0.144 -2.519 (9.870); P=0.196 0.129 (10.317); P=0.945 7.000 (16.145); P=0.075 
Table 6.10. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR-
NASAL area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
 
 
 
 
 
INFERIOR POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -1.179 (166.877); P=0.970 -17.643 (202.329); P=0.648 3.821 (206.487); P=0.923 -40.036 (170.679); P=0.225 -23.677 (181.445); P=0.473 45.684 (175.170); P=0.271 
Untreated eye -83.724(177.608); P=0.017* -37.667 (185.548); P=0.275 -47.033 (177.842); P=0.158 -40.500 (202.869); P=0.283 -15.406 (158.764); P=0.587 -26.842 (146.757); P=0.436 
Average Cell 
Size 
Treated eye 0.857 (26.393); P=0.865 -1.214 (42.150); P=0.880 -0.607 (32.318); P=0.922 4.571 (27.676); P=0.390 2.226 (30.532); P=0.688 -8.579 (27.637); P=0.193 
Untreated eye 14.379 (33.476); P=0.028* 4.133 (35.030); P=0.523 5.167 (32.486); P=0.391 4.533 (35.936); P=0.495 0.781 (30.059); P=0.884 5.474 (26.966); P=0.388 
Percentage of 
Hexagonal Cells  
Treated eye 0.333 (8.138); P=0.833 -1.963 (8.506); P=0.241 -0.429 (10.772); P=0.835 -2.185 (8.629); P=0.200 1.241 (11.398); P=0.562 1.889 (10.943); P=0.474 
Untreated eye -7.034 (15.424); P=0.021* -4.933 (14.105); P=0.065 -2.933 (10.998); P=0.155 -3.700 (9.904); P=0.050 -2.563 (9.476); P=0.136 -2.211 (12.354); P=0.446 
Table 6.11. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR 
area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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INFERIOR-TEMPORAL POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -30.179 (99.715); P=0.121 -47.036 (135.148); P=0.077 1.750 (136.552); P=0.946 -46.259 (130.459); P=0.077 -54.645 (125.169); P=0.021* -50.684 (136.515); P=0.123 
Untreated eye -74.192 (199.952); P=0.070 -32.483 (171.370); P=0.316 -74.714(159.628); P=0.020* -51.862 (201.515); P=0.177 -55.032 (213.091); P=0.161 22.450 (140.914); P=0.485 
Average Cell 
Size 
Treated eye 3.893 (16.952); P=0.235 7.964 (24.976); P=0.103 -1.071 (22.737); P=0.805 5.704 (23.229); P=0.213 7.742 (21.085); P=0.050* 10.105 (27.799); P=0.130 
Untreated eye 12.692 (40.010); P=0.118 3.552 (40.891); P=0.644 15.714 (32.844); P=0.017* 10.552 (40.037); P=0.167 6.516 (54.089); P=0.508 -5.150 (28.251); P=0.425 
Percentage of 
Hexagonal Cells  
Treated eye -1.250 (9.717); P=0.502 -3.667 (7.071); P=0.012* -3.143 (9.156); P=0.080 -3.926 (11.770); P=0.095 -1.800 (8.660); P=0.264 -6.053 (10.685); P=0.024* 
Untreated eye 0.391 (12.773); P=0.885 -4.593 (14.872); P=0.121 -5.889 (14.734); P=0.048* -3.333 (8.367); P=0.049* -0.857 (8.927); P=0.616 -2.263 (10.697); P=0.369 
Table 6.12. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR-
TEMPORAL area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
 
 
 
 
 
SUPERIOR-TEMPORAL POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -34.621 (135.521); P=0.180 -35.500 (129.056); P=0.143 -21.893 (140.963); P=0.418 -30.586 (131.978); P=0.222 -43.774 (144.632); P=0.102 20.150 (133.704); P=0.508 
Untreated eye 49.107 (261.768); P=0.330 -15.903 (146.199); P=0.549 -11.433 (154.527); P=0.688 -1.267 (243.111); P=0.977 34.500 (137.819); P=0.167 -0.400 (193.258); P=0.993 
Average Cell 
Size 
Treated eye 5.241 (22.532); P=0.221 5.300 (19.679); P=0.151 4.036 (22.499); P=0.351 4.379 (19.505); P=0.237 6.548 (21.903); P=0.106 -7.350 (29.810); P=0.284 
Untreated eye -8.964 (40.093); P=0.247 2.645 (24.656); P=0.555 -1.967 (27.163); P=0.695 0.767 (37.476); P=0.912 -6.000 (21.418); P=0.123 -0.900 (29.727); P=0.894 
Percentage of 
Hexagonal Cells  
Treated eye -2.448 (9.653); P=0.183 -2.300 (13.641); P=0.363 -1.679 (11.595); P=0.450 -5.966 (10.752); P=0.006* -4.194 (10.663); P=0.036* -3.200 (11.176); P=0.216 
Untreated eye 0.107 (9.964); P=0.955 -2.903 (9.361); P=0.094 -2.200 (10.437); P=0.258 -3.069 (8.689); P=0.067 1.094 (9.296); P=0.511 0.650 (12.642); P=0.821 
Table 6.13. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR-
TEMPORAL area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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SUPERIOR POSITION  
LPI Effect  
Paired Sample T-test 
Visit 2-Visit 1 Visit 3- Visit 1 Visit 4- Visit 1 Visit 5- Visit 1 Visit 6- Visit 1 Visit 11- Visit 1 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -2.966 (46.904); P=0.736 -32.333 (48.849); P=0.001* -17.414 (36.327); P=0.015* -20.103 (38.934); P=0.010* -2.742 (39.330); P=0.701 1.850 (63.554); P=0.898 
Untreated eye -2.258 (67.581); P=0.854 -28.290 (42.095); P=0.001* -21.133 (49.042); P=0.025* -28.613 (49.328); P=0.003* -6.364 (45.026); P=0.423 -16.550 (80.026); P=0.367 
Average Cell 
Size 
Treated eye -3.517 (23.928); P=0.435 0.467 (23.301); P=0.913 -1.552 (23.496); P=0.725 3.862 (18.322); P=0.266 -12.806 (40.279); P=0.087 -11.389 (56.200); P=0.402 
Untreated eye 1.929 (27.936); P=0.718 -1.194 (28.074); P=0.814 -0.100 (29.866); P=0.985 -0.133 (32.841); P=0.982 -9.727 (35.136); P=0.122 6.789 (53.689); P=0.588 
Percentage of 
Hexagonal Cells  
Treated eye -2.862 (7.044); P=0.037* -1.133 (7.807); P=0.433 -2.310 (6.929); P=0.083 -1.310 (6.257); P=0.269 -2.031 (11.010); P=0.305             -0.333 (10.261); P=0.892 
Untreated eye -3.250 (7.127); P=0.023* -0.484 (9.563); P=0.780 -1.069 (10.559); P=0.590 -1.533 (10.702); P=0.439 7.030 (14.152); P=0.008* -0.316 (08.583); P=0.874 
Table 6.14. Paired Samples t test for the LPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR 
area of cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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CENTRAL POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  51.258 (34.031); P=0.138 41.252 (31.116); P=0.190 13.520 (30.657); P=0.661 39.004 (35.752); P=0.280 -8.738 (33.742); P=0.797 -25.371 (41.034); P=0.540 
Average Cell Size -8.867 (5.598); P=0.119 -7.224 (5.177); P=0.168 -1.855 (5.485); P=0.737 -6.683 (6.121); P=0.280 1.132 (5.860); P=0.848 3.883 (6.955); P=0.580 
Percentage of Hexagonal Cells 3.534 (2.181); P=0.111 -1.098 (1.843); P=0.554 -1.003 (2.071); P=0.630 2.125 (2.050); P=0.304 -2.543 (3.492); P=0.470 0.935 (2.729); P=0.734 
Corneal Thickness 0.193 (2.746); P=0.944 -5.012 (2.685); P=0.068 -3.351 (2.444); P=0.177 -2.084 (2.266); P=0.362 1.100 (3.116); P=0.726 -0.016 (2.792); P=0.995 
Table 6.15. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Central area of endothelium. (Diff=difference; SE= Standard Error) 
 
 
 
 
SUPERIOR-NASAL POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  8.379 (11.540); P=0.471 -1.207 (10.704); P=0.911 -0.727 (8.782); P=0.934 6.718 (10.023); P=0.505 4.139 (8.961); P=0.646 2.336 (13.676); P=0.865 
Average Cell Size -4.182 (7.512); P=0.580 -5.645 (6.216); P=0.368 -5.696 (6.251); P=0.366 -7.573 (7.317); P=0.305 -6.885 (5.198); P=0.190 3.870 (6.951); P=0.581 
Percentage of Hexagonal Cells 1.644 (2.012); P=0.418 -0.539 (1.573); P=0.733 -2.145 (1.912); P=0.267 0.152 (2.143); P=0.944 5.080 (3.226); P=0.121 -3.363 (5.047); P=0.509 
Table 6.16. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Superior-Nasal area of endothelium. (Diff=difference; SE= Standard Error) 
 
 
 
 
 
INFERIOR-NASAL POSITION 
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  51.478 (39.356); P=0.197 36.559 (37.246); P=0.330 10.904 (42.354); P=0.798 26.564 (39.900); P=0.508 7.263 (38.698); P=0.852 -40.420 (59.064); P=0.498 
Average Cell Size -8.779 (7.016); P=0.216 -7.786 (6.674); P=0.248 -1.229 (8.746); P=0.889 -2.030 (6.784); P=0.766 -0.675 (6.161); P=0.913 11.433 (11.260); P=0.317 
Percentage of Hexagonal Cells 1.635 (1.893); P=0.392 -0.317 (2.039); P=0.877 3.398 (2.353); P=0.155 0.370 (1.746); P=0.833 -1.302 (1.850); P=0.484 5.433 (5.031); P=0.288 
Table 6.17. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Inferior-Nasal area of endothelium. (Diff=difference; SE= Standard Error) 
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INFERIOR POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  84.720 (43.060); P=0.054 19.604 (51.412); P=0.704 51.528 (50.612); P=0.313 0.175 (49.929); P=0.997 -8.311 (43.231); P=0.848 72.544 (50.324); P=0.158 
Average Cell Size -14.182 (7.573); P=0.067 -5.877 (10.104); P=0.563 -6.023 (8.533); P=0.483 -0.055 (8.556); P=0.995 1.463 (7.695); P=0.850 -13.799 (8.478); P=0.112 
Percentage of Hexagonal Cells 4.734 (2.800); P=0.097 0.156 (2.612); P=0.952 -0.258 (2.326); P=0.912 -0.587 (2.040); P=0.775 0.767 (2.097); P=0.716 0.017 (3.298); P=0.996 
Table 6.18. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Inferior area of endothelium. (Diff=difference; SE= Standard Error) 
 
 
 
 
 
 
INFERIOR-TEMPORAL POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  41.965(42.652); P=0.330 -15.722 (41.186); P=0.704 72.881 (38.416); P=0.063 2.740 (44.614); P=0.951 -1.802 (44.774); P=0.968 -74.079 (43.644); P=0.098 
Average Cell Size -8.158 (8.238); P=0.327 4.830 (9.039); P=0.595 -15.617 (6.948); P=0.029 -4.056 (8.632); P=0.640 1.130 (10.546); P=0.915 15.358 (8.687); P=0.086 
Percentage of Hexagonal Cells -1.351 (2.974); P=0.652 1.488 (2.816); P=0.599 3.199 (2.650); P=0.233 -0.695 (2.258); P=0.760 -1.156 (2.047); P=0.575 -2.391 (2.175); P=0.279 
Table 6.19. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Inferior-Temporal area of endothelium. (Diff=difference; SE= Standard Error) 
 
 
 
 
 
 
SUPERIOR-TEMPORAL POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff (SE); P Value 
Visit 3 
Mean Diff (SE); P Value 
Visit 4 
Mean Diff (SE); P Value 
Visit 5 
Mean Diff (SE); P Value 
Visit 6 
Mean Diff (SE); P Value 
Visit 11 
Mean Diff (SE); P Value 
Density  -80.417(53.326);P=0.137 -18.581(34.990); P=0.597 -10.226 (39.241); P=0.795 -26.837 (48.854); P=0.585 -77.284 (35.336); P=0.033 20.838 (53.102); P=0.697 
Average Cell Size 14.002 (8.531); P=0.107 2.577 (5.685); P=0.652 5.872 (6.603); P=0.378 3.393 (7.527); P=0.654 12.475 (5.469); P=0.026 -6.529 (9.388); P=0.491 
Percentage of Hexagonal Cells -0.016 (2.097); P=0.994 1.438 (2.435); P=0.557 1.480 (2.205); P=0.505 -1.460 (1.725); P=0.401 -4.010 (1.821); P=0.031 -2.653 (2.801); P=0.350 
Table 6.20. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Superior-Temporal area of endothelium. (Diff=difference; SE= Standard Error) 
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SUPERIOR POSITION  
Effect of LPI 
Analysis of Covariance 
Visit 2 
Mean Diff; SE (p Value) 
Visit 3 
Mean Diff; SE (p Value) 
Visit 4 
Mean Diff; SE (p Value) 
Visit 5 
Mean Diff; SE (p Value) 
Visit 6 
Mean Diff; SE (p Value) 
Visit 11 
Mean Diff; SE (p Value) 
Density  -1.255 (14.833); P=0.933 -5.656 (10.831); P=0.603 2.889 (11.047); P=0.795 6.427 (11.086); P=0.564 2.722 (10.248); P=0.791 14.391 (21.520); P=0.508 
Average Cell Size -5.414 (6.960); P=0.440 1.780 (6.676); P=0.791 -1.309 (7.070); P=0.854 4.100 (7.005); P=0.561 -2.077 (9.233); P=0.823 -18.848 (18.016); P=0.303 
Percentage of Hexagonal Cells 0.197 (1.679); P=0.907 -0.631 (1.774); P=0.723 -1.040 (1.881); P=0.583 0.339 (1.881); P=0.858 -4.863 (3.051); P=0.116 0.527 (2.412); P=0.828 
Table 6.21. Analysis of Covariance where the response variable has been adjusted using the Visit 1 data for the Superior area of endothelium. (Diff=difference; SE= Standard Error) 
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CENTRAL POSITION  
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2377.000 (417.212) 2345.273 (411.047) 2384.546 (462.114) 2269.500 (375.167) 2389.111 (375.384) 2465.889 (338.453) 
Untreated eye 2482.000 (275.809) N/A N/A N/A N/A 2513.833 (247.022) 
Average Cell 
Size 
Treated eye 434.500 (90.440) 441.273 (94.974) 437.000 (103.183) 455.200 (99.609) 429.333 (78.580) 412.222 (56.242) 
Untreated eye 407.800 (49.924) N/A N/A N/A N/A 400.833 (37.494) 
Percentage of 
Hexagonal Cells 
Treated eye 45.100 (12.270) 45.182 (13.826) 48.727 (8.344) 48.800 (11.003) 50.222 (6.099) 50.444 (6.366) 
Untreated eye 43.500 (13.697) N/A N/A N/A N/A 44.000 (6.663) 
Corneal 
Thickness 
Treated eye 525.889 (35.385) 543.727 (43.614) 552.800 (40.041) 551.222 (43.791) 540.625 (53.711) 539.778 (52.664) 
Untreated eye 534.222 (48.823) N/A N/A N/A N/A 528.400 (50.841) 
Table 6.22. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the CENTRAL area of cornea. SD= 
Standard Deviation. 
 
 
 
 
 
SUPERIOR-NASAL POSITION  
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 162.727 (63.525) 161.909 (60.970) 185.727 (66.192) 181.700 (53.922) 176.889 (71.822) 176.222 (52.141) 
Untreated eye 182.900 (86.288) N/A N/A N/A N/A 152.667 (48.430) 
Average Cell 
Size 
Treated eye 409.500 (58.849) 399.500 (58.935) 405.900 (59.752) 446.700 (110.044) 396.250 (67.502) 402.778 (63.675) 
Untreated eye 399.200 (79.465) N/A N/A N/A N/A 422.167 (33.145) 
Percentage of 
Hexagonal Cells 
Treated eye 41.500 (15.869) 47.300 (9.141) 48.400 (8.566) 49.667 (9.798) 51.500 (8.669) 38.333 (15.182) 
Untreated eye 40.800 (11.821) N/A N/A N/A N/A 38.500 (17.410) 
Table 6.23. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR-NASAL area of cornea. 
SD= Standard Deviation. 
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INFERIOR-NASAL POSITION 
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2456.636 (408.211) 2482.700 (330.250) 2467.818 (401.756) 2382.200 (381.063) 2475.444 (371.545) 2445.000 (357.317) 
Untreated eye 2565.400 (417.621) N/A N/A N/A N/A 2494.000 (384.094) 
Average Cell 
Size 
Treated eye 419.546 (83.981) 410.100 (60.929) 416.727 (79.514) 432.400 (87.285) 413.444 (71.514) 418.000 (71.791) 
Untreated eye 399.700 (67.802) N/A N/A N/A N/A 408.833 (62.952) 
Percentage of 
Hexagonal Cells 
Treated eye 50.364 (7.632) 51.100 (6.999) 52.182 (6.524) 52.100 (10.148) 48.333 (15.580) 44.000 (14.392) 
Untreated eye 51.700 (7.196) N/A N/A N/A N/A 36.167 (16.167) 
Table 6.24. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for INFERIOR-NASAL area of cornea. SD= 
Standard Deviation. 
 
 
 
 
 
INFERIOR POSITION  
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2413.818 (424.498) 2388.182 (488.528) 2440.727 (454.219) 2334.000 (433.945) 2487.111 (465.163) 2577.556 (415.413) 
Untreated eye 2516.000 (368.745) N/A N/A N/A N/A 2410.667 (263.879) 
Average Cell 
Size 
Treated eye 426.727 (79.284) 439.091 (113.390) 424.546 (89.342) 445.100 (101.231) 415.444 (82.219) 397.889 (70.458) 
Untreated eye 405.400 (63.186) N/A N/A N/A N/A 419.000 (46.109) 
Percentage of 
Hexagonal Cells 
Treated eye 43.182 (13.906) 46.455 (8.768) 46.727 (9.519) 51.600 (6.328) 46.667 (13.360) 50.667 (8.093) 
Untreated eye 49.444 (4.065) N/A N/A N/A N/A 50.000 (10.752) 
Table 6.25. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for INFERIOR area of cornea. SD= Standard 
Deviation. 
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INFERIOR-TEMPORAL POSITION 
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2461.727 (459.098) 2468.546 (468.813) 2429.182 (457.767) 2388.800 (414.529) 2522.556 (461.612) 2564.375 (343.854) 
Untreated eye 2541.100 (359.250) N/A N/A N/A N/A 2444.333 (223.838) 
Average Cell 
Size 
Treated eye 423.091 (100.930) 422.818 (103.923) 427.273 (93.596) 432.800 (92.394) 409.778 (83.997) 397.125 (60.737) 
Untreated eye 401.900 (65.336) N/A N/A N/A N/A 412.000 (37.731) 
Percentage of 
Hexagonal Cells 
Treated eye 47.727 (7.525) 49.091 (11.597) 47.727 (8.956) 48.300 (7.775) 47.111 (8.418) 43.375 (6.760) 
Untreated eye 48.200 (9.259) N/A N/A N/A N/A 50.000 (4.472) 
Table 6.26. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR-TEMPORAL area of 
cornea. SD= Standard Deviation. 
 
 
 
 
 
SUPERIOR-TEMPORAL POSITION 
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 10 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 2433.500 (441.932) 2435.546 (419.404) 2445.600 (294.566) 2387.600 (411.234) 2447.667 (410.151) 2511.111 (326.532) 
Untreated eye 2548.800 (394.566) N/A N/A N/A N/A 2389.833 (389.900) 
Average Cell 
Size 
Treated eye 426.800 (99.027) 425.364 (95.374) 414.700 (54.408) 433.200 (93.615) 420.333 (80.167) 405.444 (62.698) 
Untreated eye 402.000 (70.233) N/A N/A N/A N/A 428.167 (72.824) 
Percentage of 
Hexagonal Cells 
Treated eye 45.200 (9.247) 45.000 (7.603) 48.200 (7.084) 51.100 (4.701) 46.750 (7.265) 45.250 (11.671) 
Untreated eye 53.100 (4.280) N/A N/A N/A N/A 50.333 (5.645) 
Table 6.27. Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR-TEMPORAL area of 
cornea. SD= Standard Deviation. 
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SUPERIOR POSITION  
ALPI Treated and Fellow Eyes 
Descriptive Statistics 
Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Density  Treated eye 184.000 (49.891) 188.636 (66.634) 207.636 (69.773) 197.000 (73.062) 218.000 (80.416) 211.222 (35.570) 
Untreated eye 168.600 (62.399) N/A N/A N/A N/A 149.500 (31.628) 
Average Cell 
Size 
Treated eye 410.700 (100.222) 385.100 (53.295) 371.100 (62.788) 389.000 (56.105) 379.375 (55.939) 368.667 (35.433) 
Untreated eye 412.400 (57.163) N/A N/A N/A N/A 432.333 (65.479) 
Percentage of 
Hexagonal Cells 
Treated eye 155.778 (207.235) 48.200 (8.162) 51.100 (8.736) 49.778 (7.546) 49.000 (8.586) 52.333 (7.053) 
Untreated eye 316.222 (263.688) N/A N/A N/A N/A 49.167 (4.262) 
Table 6.28 Descriptive statistics for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR area of cornea. SD= 
Standard Deviation. 
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CENTRAL POSITION  
ALPI Treated  
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density Treated eye 43.500 (126.321); P=0.304 -18.000 (175.620); P=0.753 32.889 (089.058); P=0.300 -17.250 (151.278); P=0.756 -9.778 (076.785); P=0.712 
Average Cell 
Size 
Treated eye -10.300 (23.457); P=0.198 -2.300 (34.545); P=0.838 -11.222 (23.134); P=0.184 8.125 (28.276); P=0.443 0.333 (14.595); P=0.947 
Percentage of 
Hexagonal Cells  
Treated eye 1.200 (21.540); P=0.864 -3.900 (11.846); P=0.325 -3.000 (16.101); P=0.591 -3.875 (13.964); P=0.458 -5.222 (12.194); P=0.235 
Corneal 
Thickness 
Treated eye -6.333 (23.532); P=0.443 -5.750 (8.860); P=0.109 -2.714 (11.470); P=0.554 1.167 (9.827); P=0.783 2.250 (8.876); P=0.497 
Table 6.29. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the CENTRAL area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
 
 
 
 
 
SUPERIOR-NASAL POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye 0.818 (22.899); P=0.908 -23.000 (32.441); P=0.041* -19.600 (31.837); P=0.083 -11.889 (33.554); P=0.319 0.667 (15.305); P=0.899 
Average Cell 
Size 
Treated eye 10.000 (26.554); P=0.264 3.600 (24.708); P=0.656 -3.556 (31.592); P=0.744 12.000 (12.166); P=0.027* 4.444 (18.056); P=0.481 
Percentage of 
Hexagonal Cells  
Treated eye -5.800 (12.700); P=0.183 -6.900 (12.931); P=0.126 -5.889 (15.390); P=0.284 -7.750 (14.489); P=0.174 2.222 (14.007); P=0.647 
Table 6.30. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR-NASAL area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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INFERIOR-NASAL POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density Treated eye 52.700 (149.045); P=0.292 -11.182 (133.737); P=0.787 15.100 (110.582); P=0.676 -46.222 (162.239); P=0.418 80.000 (167.470); P=0.219 
Average Cell 
Size 
Treated eye -8.500 (24.681); P=0.304 2.818 (21.600); P=0.674 -3.700 (21.884); P=0.606 13.000 (41.331); P=0.373 -13.250 (27.139); P=0.210 
Percentage of 
Hexagonal Cells  
Treated eye 0.500 (9.490); P=0.871 -1.818 (7.373); P=0.432 -1.600 (14.049); P=0.727 1.667 (12.083); P=0.690 6.500 (12.059); P=0.171 
Table 6.31. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR-NASAL area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
 
 
 
 
 
INFERIOR POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density Treated eye 25.636 (175.702); P=0.639 -26.909 (99.281); P=0.390 0.500 (135.635); P=0.991 -64.556 (140.462); P=0.205 -52.889 (132.797); P=0.266 
Average Cell 
Size 
Treated eye -12.364 (51.411); P=0.444 2.182 (22.036); P=0.749 -6.900 (37.743); P=0.577 11.667 (25.298); P=0.204 7.000 (20.549); P=0.337 
Percentage of 
Hexagonal Cells  
Treated eye -3.273 (13.282); P=0.433 -3.545 (13.064); P=0.389 -8.900 (13.609); P=0.069 -1.444 (11.991); P=0.727 -4.667 (10.308); P=0.211 
Table 6.32. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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INFERIOR-TEMPORAL POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -6.818 (83.090); P=0.791 32.545 (209.827); P=0.618 21.500 (129.505); P=0.612 -92.444 (121.089); P=0.051 -11.875 (144.813); P=0.823 
Average Cell 
Size 
Treated eye 0.273 (17.263); P=0.959 -4.182 (38.217); P=0.724 -1.000 (21.034); P=0.884 22.000 (32.133); P=0.074 5.500 (30.350); P=0.624 
Percentage of 
Hexagonal Cells  
Treated eye -1.364 (11.465); P=0.702 0.000 (9.940); P=1.000 0.000 (9.238); P=1.000 0.889 (9.020); P=0.775 9.375 (12.293); P=0.068 
Table 6.33. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the INFERIOR-TEMPORAL area of 
cornea. Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
 
 
 
 
SUPERIOR TEMPORAL POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye 9.000 (123.586); P=0.823 89.000 (96.029); P=0.024* 1.111 (122.972); P=0.979 -8.625 (166.176); P=0.887 59.250 (59.249); P=0.025* 
Average Cell 
Size 
Treated eye -1.800 (18.110); P=0.760 -14.778 (16.029); P=0.024* -1.111 (21.619); P=0.881 8.125 (43.930); P=0.617 -10.625 (11.904); P=0.040* 
Percentage of 
Hexagonal Cells  
Treated eye 0.100 (6.757); P=0.964 -1.778 (8.700); P=0.557 -7.000 (8.602); P=0.040* 3.429 (7.368); P=0.264 1.500 (11.916); P=0.732 
Table 6.34. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the CENTRAL area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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SUPERIOR POSITION  
ALPI Treated 
Paired Sample T-test 
Visit 7-Visit 6 Visit 8- Visit 6 Visit 9- Visit 6 Visit 10- Visit 6 Visit 11- Visit 6 
Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value Mean Diff (SD); P Value 
Density  Treated eye -0.100 (50.316); P=0.995 -20.400 (45.906); P=0.194 -6.222 (51.205); P=0.725 -27.250 (68.329); P=0.296 -15.375 (40.746); P=0.321 
Average Cell 
Size 
Treated eye -5.444 (20.659); P=0.452 10.778 (29.991); P=0.312 -2.000 (27.449); P=0.843 0.571 (26.532); P=0.956 12.250 (40.351); P=0.419 
Percentage of 
Hexagonal Cells  
Treated eye 64.250 (168.560); P=0.317 61.375 (168.088); P=0.336 69.857 (178.770); P=0.341 81.333 (193.904); P=0.351 67.000 (181.744); P=0.367 
Table 6.35. Paired Samples t test for the ALPI treated eyes and fellow untreated eyes for the endothelial cell density, average cell size, percentage of hexagonal cells and corneal thickness for the SUPERIOR area of cornea. 
Statistically significant results (P0.05) are flagged with an asterisk. Mean Diff= Mean Difference; SD= Standard Deviation. 
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ALPI 
Analysis of Covariance 
CENTRAL 
Visit 11 
Mean Diff (SE); P Value 
SUPERIOR-NASAL 
Visit 11 
Mean Diff (SE); P Value 
INFERIOR-NASAL 
Visit 11 
Mean Diff (SE); P Value 
INFERIOR 
Visit 11 
Mean Diff (SE); P Value 
INFERIOR-TEMPORAL 
Visit 11 
Mean Diff (SE); P Value 
SUPERIOR-TEMPORAL 
Visit 11 
Mean Diff (SE); P Value 
SUPERIOR 
Visit 11 
Mean Diff (SE); P Value 
Density  5.915 (49.823); P=0.908 44.417 (18.486); P=0.035* 13.095 (13.486); P=0.351 -73.939 (75.242); P=0.347 -105.960 (73.664); P=0.176 96.006 (61.123); P=0.145 44.417 (18.486); P=0.035* 
Average 
 Cell Size -0.004 (8.316); P=1.000 -58.158 (29.937); P=0.078 -25.811 (10.697); P=0.033* 10.772 (12.538); P=0.409 17.964 (12.403); P=0.173 -16.923 (9.929); P=0.116 -58.158 (29.937); P=0.078 
Percentage 
 of Hexagonal Cells 6.028 (3.771); P=0.138 4.480 (3.848); P=0.274 -1.337 (7.054); P=0.853 8.260 (7.835); P=0.314 -0.153 (5.143); P=0.977 -6.691 (3.291); P=0.067 4.480 (3.848); P=0.274 
Corneal Thickness -0.152 (5.355); P=0.978 N/A N/A N/A N/A N/A N/A 
Table 6.36. Analysis of Covariance where the response variable has been adjusted using the Visit 6 data for the Central. Superior-Nasal. Inferior-Nasal. Inferior. Inferior-Temporal. Superior-Temporal and Superior areas of 
endothelium. (Diff=difference; SE= Standard Error)
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Appendix 2. Justification for using the data of both eyes 
of every patient 
 
This appendix was designed with the aim of testing the equality of the data collected for right and 
left eyes at baseline. If equality was found (no statistically significant differences between right 
and left) then both eyes could be included in the sample. 
 
The only chapter of this thesis that used both eyes in the same sample was Chapter 3, where data 
of the Diurnal Intraocular Pressure (DIOP), the DIOP fluctuation, the Supine Intraocular Pressure 
(SIOP) and the Dark Room Provocation Test (DRPT) previous to any treatment was collected. 
Additionally, the irido-trabecular angle parameters of both eyes were used to explore associations 
with other factors such as Peripheral Anterior Synechiae (PAS) and DIOP fluctuation, SIOP and 
DRPT. 
 
In the rest of this thesis Chapters, the sample of eyes was already randomly divided (50% block 
randomisation) into treated and untreated eyes. All the participants had two eyes and therefore 
there was always a fellow eye acting as a control eye through time in the statistical models. This 
gave the great advantage of adjusting the models for differences found between treated and 
fellows at baseline. Therefore, to look for equality after the first randomisation (Visit 1, baseline) 
was not necessary. 
 
Consequently, the equality of the data for right and left eyes was studied only for that collected at 
Visit 1 (baseline). The parameters tested for equality were the IOP (DIOP, DIOP fluctuation, SIOP 
and DRPT) and the irido-trabecular angle parameters (as measured with the CASIA OCT).  
 
 
1. Equality of baseline IOP measurements between Right and Left eyes  
There is not a clear consensus whether the IOP measured in the two eyes of a given subject vary 
or not independently.  Several examples defending an equal variation between eyes can be found 
in the studies performed by Ederer (1973) and Newcombe (1987). on the other hand, Wilensky, in 
a very extensive study of diurnal and nocturnal variations of IOP in different types of glaucoma, 
found a between-eye variation in the diurnal patterns. However, this variation was not specified 
and none of the cases were angle closure glaucoma (Wilensky, 1991). More recently, in 2001, 
Realini found what was considered a clinically significant asymmetry in IOP fluctuation between 
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eyes of the same patient. Asymmetry of at least 3mmHg in two consecutive visits was observed in 
50% of the normal subjects (non-glaucomatous, no prior surgery and not using topical 
medication) and 63% of the glaucomatous (Realini, Barber and Burton, 2002). 
 
As asymmetry between the IOP for right and left eyes of the same individual has been reported in 
the past, it was of interest to test the hypothesis of symmetry in the case of this sample of 
participants. 
 
The aim of this part of this Appendix 2 is to justify the use of both eyes data from the same 
individual for the different IOP outcomes.  
 
Equivalence of IOP measurements for left and right eyes was explored in order to ascertain 
whether all eyes could be included in the statistical analysis. This equality was studied in terms of 
the mean value of the IOP for the 3 following tests: 
 
1.A. Equality assumption for the right and left eyes in the DIOP: 
In order to perform this assessment, the means for the DIOP for right and left eyes were plotted 
(Figure A.2.1 below). There was no statistically significant difference between means for right and 
left eyes at all time points (Analysis Of Variance Between-Groups, P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A.2.1. Mean IOP value for right and left eyes of each patient during Visit 1. 
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Next, the diurnal fluctuation of IOP between two consecutive measurements was tested for right 
versus left eyes.  
The P-values for the paired sample t-test analysis of the fluctuation between consecutive 
measurements for right versus left eyes during the day are shown in the following table:  
 
IOP FLUCTUATION 
9H-10H 10H-11H 11H-12H 12H-13H 13H-14H 14H-15H 15H-16H 
RE/ 
LE* 
1.64.5/ 
1.65.0 
1.78.5/ 
1.43.5 
1.88.0/ 
1.76.0 
1.76.5/ 
2.18.0 
1.65.5/ 
1.85.0 
1.86.0/ 
1.85.5 
1.526.0/ 
1.56.5 
Paired Sample P value      0.791 0.278 0.666 0.394 0.581 0.914 0.905 
 
* RE /LE = MEAN REIOP(XH) - REIOP(XH-1H))  RANGE(REIOP(XH) - REIOP(XH-1H))  versus MEAN LEIOP(XH) - LEIOP(XH-1H))   RANGE(LEIOP(XH) - 
LEIOP(XH-1H))  
 
 
Where the highest fluctuation between right and left eyes mean IOP was found to be 0.3 mmHg 
at the interval of time between 10:00 and 11:00h measurements. However, and as shown in the 
table this difference was not statistically significant. 
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1.B Equality assumption for right and left eyes in the Supine IOP (SIOP) 
The graph below (Figure A.2.2) shows how the data for right and left eyes was distributed in this 
outcome. The mean and standard deviation for the SIOP result of right and left were 1.58 (1.84 
SD) and 1.80 mmHg (2.39 SD) respectively. The difference between the means was found to be 
0.21 mmHg (and statistically non-significant p=0.528 with the paired sample t-test). The SIOP 
result values represents the ‘Supine Result’ which is the difference in IOP between the IOP found 
5 minutes laying in the supine position and the previous diurnal IOP measurement in the sitting 
position (SIOP minus DIOP previous measurement). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            
 Figure A.2.2. Distribution of the SIOP result for right and left eyes. 
 
 
 
1.C. Equality assumption for right and left eyes in the Dark Room Provocation Test (DRPT) 
The DRPT had a similar effect over right and left eyes. The mean difference between right and left 
eyes IOP values for the DRPT was found to be non-statistically significant with the Paired Samples 
T-test, mean difference 0.15 mmHg, (p=0.664). The mean and standard deviation for right and left 
eyes were 2.94 (2.44 SD) and 3.1 (3.22 SD) respectively. The table below shows how the data was 
distributed for both eyes (figure A.2.3).  
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Figure A.2.3.  Distribution of the SIOP for right and left eyes 
 
Conclusion: 
 
It was concluded that, due to the small variation between the mean values for the IOP levels 
found for right and left eyes and the fact that differences between eyes were statistically non-
significant, all eyes were to be included in the subsequent analyses regarding IOP. 
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2. Equality of baseline angle parameters measurements between Right and Left eyes in dark and 
light conditions 
 
 
The angle parameters to be used at baseline (Visit 1) where compared between the right and 
the left eyes. The comparison was carried out for Angle Opening Distance (AOD (mm)), Angle 
Recess Area (ARA (mm2)), Trabecular Iris Space Area (TISA (mm2)) and Trabecular-Iris Angle 
(TIA ()) in dark and light conditions. The paired samples t test showed no statistically 
significant differences between the parameters measured for right and those measured for 
left in light or dark lighting conditions. This is shown in the following table (Table A.2.4): 
 
Right versus Left eyes at Visit 1 LIGHT DARK 
Paired Samples t test Mean Diff  (SD); P Value Mean Diff   (SD); P Value 
SUPERIOR AOD500 -0.004(0.074); P=0.760 0.008(0.064); P=0.497 
SUPERIOR ARA500 0.006(0.030); P=0.282 0.000(0.033); P=0.935 
SUPERIOR TISA500 0.005(0.029); P=0.329 0.000(0.030); P=0.936 
SUPERIOR TIA500 -0.223(5.684); P=0.829 0.632(4.885); P=0.456 
SUPERIOR AOD750 -0.009(0.106); P=0.641 -0.006(0.099); P=0.715 
SUPERIOR ARA750 -0.001(0.052); P=0.895 -0.005(0.043); P=0.484 
SUPERIOR TISA750 -0.002(0.051); P=0.851 -0.005(0.042); P=0.521 
SUPERIOR TIA750 -0.327(5.851); P=0.750 -0.212(5.206); P=0.816 
INFERIOR AOD500 0.016(0.126); P=0.456 0.000(0.097); P=0.992 
INFERIOR ARA500 0.018(0.057); P=0.074 0.011(0.041); P=0.129 
INFERIOR TISA500 0.015(0.050); P=0.084 0.010(0.038); P=0.134 
INFERIOR TIA500 1.254(8.894); P=0.410 1.111(6.941); P=0.350 
INFERIOR AOD750 0.010(0.150); P=0.709 0.009(0.135); P=0.694 
INFERIOR ARA750 0.021(0.088); P=0.162 0.013(0.061); P=0.221 
INFERIOR TISA750 0.018(0.080); P=0.194 0.012(0.059); P=0.238 
INFERIOR TIA750 0.606(7.686); P=0.644 0.760(6.960); P=0.523 
SUPERIOR-NASAL AOD500 -0.005(0.095); P=0.753 -0.004(0.083); P=0.773 
SUPERIOR-NASAL ARA500 0.001(0.043); P=0.941 -0.005(0.041); P=0.486 
SUPERIOR-NASAL TISA500 0.000(0.040); P=0.960 -0.004(0.038); P=0.498 
SUPERIOR-NASAL TIA500 -0.937(9.092); P=0.546 -0.023(8.343); P=0.987 
SUPERIOR-NASAL AOD750 -0.001(0.131); P=0.947 0.010(0.116); P=0.619 
SUPERIOR-NASAL ARA750 -0.002(0.070); P=0.841 -0.006(0.065); P=0.604 
SUPERIOR-NASAL TISA750 0.018(0.153); P=0.500 -0.005(0.061); P=0.607 
SUPERIOR-NASAL TIA750 -0.631(8.578); P=0.666 0.789(7.811); P=0.554 
INFERIOR-TEMPORAL AOD500 -0.006(0.104); P=0.722 -0.005(0.089); P=0.758 
INFERIOR-TEMPORAL ARA500 0.001(0.050); P=0.927 -0.003(0.040); P=0.618 
INFERIOR-TEMPORAL TISA500 0.002(0.046); P=0.812 -0.004(0.039); P=0.564 
INFERIOR-TEMPORAL TIA500 0.186(9.623); P=0.910 -0.457(9.645); P=0.781 
INFERIOR-TEMPORAL AOD750 0.012(0.141); P=0.619 -0.019(0.126); P=0.375 
INFERIOR-TEMPORAL ARA750 0.001(0.074); P=0.915 -0.008(0.055); P=0.393 
INFERIOR-TEMPORAL TISA750 0.006(0.073); P=0.659 -0.006(0.056); P=0.507 
INFERIOR-TEMPORAL TIA750 1.263(9.084); P=0.417 -0.834(7.567); P=0.519 
NASAL AOD500 -0.019(0.114); P=0.343 -0.010(0.124); P=0.621 
NASAL ARA500 -0.008(0.056); P=0.391 -0.005(0.058); P=0.634 
NASAL TISA500 -0.009(0.050); P=0.304 -0.002(0.052); P=0.827 
NASAL TIA500 -0.889(10.581); P=0.623 -0.397(10.719); P=0.828 
NASAL AOD750 0.002(0.135); P=0.944 -0.011(0.142); P=0.644 
NASAL ARA750 -0.011(0.084); P=0.451 -0.006(0.084); P=0.656 
NASAL TISA750 -0.013(0.079); P=0.343 -0.004(0.079); P=0.756 
NASAL TIA750 0.551(8.805); P=0.713 -0.217(7.975); P=0.873 
TEMPORAL AOD500 0.003(0.076); P=0.813 0.001(0.073); P=0.936 
TEMPORAL ARA500 0.006(0.041); P=0.393 0.005(0.036); P=0.448 
TEMPORAL TISA500 0.017(0.085); P=0.256 0.003(0.032); P=0.555 
TEMPORAL TIA500 -0.240(7.534); P=0.852 -0.391(7.255); P=0.752 
TEMPORAL AOD750 0.000(0.095); P=0.990 0.010(0.092); P=0.535 
TEMPORAL ARA750 0.006(0.057); P=0.564 0.007(0.050); P=0.436 
  295 
TEMPORAL TISA750 0.003(0.053); P=0.743 0.005(0.047); P=0.505 
TEMPORAL TIA750 -0.489(6.639); P=0.666 0.203(6.405); P=0.852 
INFERIOR-NASAL AOD500 -0.011(0.116); P=0.570 -0.016(0.118); P=0.419 
INFERIOR-NASAL ARA500 -0.003(0.054); P=0.757 -0.009(0.053); P=0.326 
INFERIOR-NASAL TISA500 -0.003(0.049); P=0.686 -0.006(0.049); P=0.472 
INFERIOR-NASAL TIA500 -1.071(10.481); P=0.549 -0.759(10.856); P=0.682 
INFERIOR-NASAL AOD750 -0.016(0.154); P=0.536 -0.028(0.139); P=0.240 
INFERIOR-NASAL ARA750 -0.004(0.080); P=0.753 -0.014(0.081); P=0.314 
INFERIOR-NASAL TISA750 -0.005(0.077); P=0.714 -0.012(0.078); P=0.367 
INFERIOR-NASAL TIA750 -1.066(9.769); P=0.523 -0.977(8.809); P=0.516 
SUPERIOR-TEMPORAL AOD500 0.000(0.086); P=0.974 0.001(0.075); P=0.968 
SUPERIOR-TEMPORAL ARA500 -0.001(0.037); P=0.859 -0.002(0.031); P=0.697 
SUPERIOR-TEMPORAL TISA500 0.017(0.116); P=0.386 -0.001(0.030); P=0.799 
SUPERIOR-TEMPORAL TIA500 0.194(8.264); P=0.890 0.246(7.503); P=0.848 
SUPERIOR-TEMPORAL AOD750 0.003(0.117); P=0.891 -0.009(0.093); P=0.565 
SUPERIOR-TEMPORAL ARA750 -0.002(0.058); P=0.872 -0.003(0.049); P=0.707 
SUPERIOR-TEMPORAL TISA750 -0.001(0.057); P=0.923 -0.003(0.048); P=0.758 
SUPERIOR-TEMPORAL TIA750 0.249 7.751); P=0.851 -0.197 6.172); P=0.851 
  Table A.2.4. Paired Samples t test comparing the parameters found for right eyes versus left eyes  
 
 
Conclusion: 
 
There were no statistically significant differences between right and left eyes angle parameters at 
baseline and therefore it was justified to use them in the same sample. 
 
After the baseline visit (Visit 1) the eyes were randomly allocated at Visit 2 to receive laser 
peripheral iridotomy or to act as fellow untreated eyes. Differences between right and left eyes 
would not affect the results after the randomisation took place. 
  296 
Appendix 3. Benefits and Limitations of the 
Instrumentation  
 
Cornea/Anterior Segment Optical Coherent Tomography: CASIA SS-1000, 
Tomey GmbH 
 
The benefits of the CASIA SS-1000 and the Swept Source technology have already been discussed 
in depth in the present thesis.  
 
Limitations of this device: 
This device do not present many limitations, but as any other current anterior segment OCT that 
provides quantification of the iridotrabecular angle, the scleral spur needs to be identified by the 
examiner. Other limitations such as fixation control may be improved in the future. 
 
1. Fixation Control:  
One other limitation that may not be attributable to the device is that there was a variation of the 
location of the iridotomy between visits. For example, participant 1002 receives laser peripheral 
iridotomy and when the scans taken with the OCT are analysed, the iridotomy appears to be 
placed at 95. The same patient’s eye is scanned at Visits 3, 4, 5,…, and the iridotomy has now 
varied positions in the scans, being 100, 92, 89,…, respectively. 
 
A solution for this limitation could be the implementation for customised iris tracking devices 
similar to the technology used in refractive surgery to follow the uncontrolled ocular movements.  
 
2. Intraobserver repeatability 
Only one examiner (LSP) analysed all the scans used in the present study. To perform an 
intraobserever study, 35 scans taken at Visit 1 in light and dark were analysed twice. 
These scans belonged to those eyes randomised to be left untreated in Visit 2. The scans were 
quantified in the Superior, Inferior, Temporal and Nasal sections. AOD (Angle Opening Distance), 
ARA (angle Recess Are), TISA (Trabecular-Iris Space Area) and TIA (Trabecular-Iris Angle) at 500 
and 750m were quantified for these four sections. 
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The quantifications were performed in two different settings separated by two days to avoid 
memorisation bias. The first day all the 35 eyes were quantified in dark and light and the same 
was repeated in the second setting. 
 
Tables A.3.1 shows the intraobserver repeatability for the parameters in light conditions and 
Tables A.3.2 shows the same for the dark conditions. 
Repeatability is assessed in terms of differences between pairs of values of two measurements. 
The mean of the differences indicates the bias between the two assessments and should be close 
to zero. 
In general, the Bland-Altman (B-A) mean difference between visits found for the eight parameters 
in the Superior, Nasal, Inferior and Temporal sections were quite close to zero.  
There is another study showing intraobserver repeatability in similar examinations with the CASIA 
OCT. Liu et al. (2011), quantified the scans in 30 healthy individuals in the same four quadrants 
and in the darkness. Their intraobserver repeatability coefficients were higher than in the present 
study with only one exception (Inferior TIA 500).  This finding can be observed in the following 
tables: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This intraobserver repeatability study showed a good agreement within the examiner judgment 
(LSP) in the quantification of the majority of the parameters for light and dark conditions.
PARAMETER in Dark PRESENT STUDY  
Repeatability 
(95% confidence limits) 
 Liu et al. (2011) 
Repeatability 
(95% confidence limits) 
SUPERIOR AOD 500 0.043 (0.032-0.053)  0.140 (0.115-0.156) 
SUPERIOR TISA 500 0.016 (0.012-0.020)  0.074 (0.061-0.087) 
SUPERIOR TIA 500 4.265 (3.214-5.317)  7.7 (6.4-9.1) 
INFERIOR AOD 500 0.128 (0.097-0.160)  0.252 (0.207-0.297) 
INFERIOR TISA 500 0.046 (0.035-0.058)  0.090 (0.074-0.106) 
INFERIOR TIA 500 13.351 (10.007-16.694)  9.5 (7.8-11.2) 
NASAL AOD 500 0.046 (0.035-0.057)  0.141 (0.116-0.166) 
NASAL TISA 500 0.021 (0.016-0.026)  0.050 (0.041-0.059) 
NASAL TIA 500 4.983 (3.755-6.211)  8.9 (7.3-10.5) 
TEMPORAL AOD 500 0.047 (0.035-0.058)  0.224 (0.184-0.265) 
TEMPORAL TISA 500 0.018 (0.013-0.023)  0.086 (0.071-0.101) 
TEMPORAL TIA 500 4.294 (3.236-5.353)  8.2 (6.8-9.8) 
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First variable Second variable Number 
of pairs 
Mean 
difference 
Limits of agreement Repeatability Standard 
error 
95% confidence limits 
Lower Upper Lower Upper 
REPIT_LIGHT_SUPERIOR_AOD500 LIGHT_SUPERIOR_AOD500 35 -0.005200 -0.058777 0.048377 0.053577 0.006497 0.040373 0.066781 
REPIT_LIGHT_SUPERIOR_ARA500 LIGHT_SUPERIOR_ARA500 35 -0.001457 -0.024231 0.021317 0.022774 0.002762 0.017162 0.028387 
REPIT_LIGHT_SUPERIOR_TISA500 LIGHT_SUPERIOR_TISA500 35 -0.002543 -0.024795 0.019709 0.022252 0.002698 0.016768 0.027736 
REPIT_LIGHT_SUPERIOR_TIA500 LIGHT_SUPERIOR_TIA500 35 -0.780000 -5.725063 4.165063 4.945063 0.599677 3.726373 6.163753 
REPIT_LIGHT_SUPERIOR_AOD750 LIGHT_SUPERIOR_AOD750 35 -0.000829 -0.060286 0.058629 0.059457 0.007210 0.044804 0.074110 
REPIT_LIGHT_SUPERIOR_ARA750 LIGHT_SUPERIOR_ARA750 35 -0.000400 -0.040547 0.039747 0.040147 0.004869 0.030253 0.050042 
REPIT_LIGHT_SUPERIOR_TISA750 LIGHT_SUPERIOR_TISA750 35 -0.001486 -0.039546 0.036574 0.038060 0.004615 0.028680 0.047440 
REPIT_LIGHT_SUPERIOR_TIA750 LIGHT_SUPERIOR_TIA750 35 -0.362857 -4.333954 3.608240 3.971097 0.481566 2.992437 4.949758 
REPIT_LIGHT_INFERIOR_AOD500 LIGHT_INFERIOR_AOD500 35 0.006314 -0.069294 0.081923 0.075609 0.009169 0.056975 0.094242 
REPIT_LIGHT_INFERIOR_ARA500 LIGHT_INFERIOR_ARA500 35 0.005943 -0.030512 0.042397 0.036454 0.004421 0.027470 0.045439 
REPIT_LIGHT_INFERIOR_TISA500 LIGHT_INFERIOR_TISA500 35 0.004086 -0.024870 0.033042 0.028956 0.003511 0.021820 0.036092 
REPIT_LIGHT_INFERIOR_TIA500 LIGHT_INFERIOR_TIA500 35 -0.100000 -5.050104 4.850104 4.950104 0.600288 3.730171 6.170037 
REPIT_LIGHT_INFERIOR_AOD750 LIGHT_INFERIOR_AOD750 35 0.000771 -0.083039 0.084582 0.083811 0.010164 0.063156 0.104466 
REPIT_LIGHT_INFERIOR_ARA750 LIGHT_INFERIOR_ARA750 35 0.006000 -0.046029 0.058029 0.052029 0.006309 0.039207 0.064852 
REPIT_LIGHT_INFERIOR_TISA750 LIGHT_INFERIOR_TISA750 35 0.004457 -0.041423 0.050338 0.045881 0.005564 0.034573 0.057188 
REPIT_LIGHT_INFERIOR_TIA750 LIGHT_INFERIOR_TIA750 35 -0.297143 -4.616316 4.022031 4.319174 0.523777 3.254731 5.383616 
REPIT_LIGHT_NASAL_AOD500 LIGHT_NASAL_AOD500 35 0.000171 -0.045432 0.045775 0.045603 0.005530 0.034364 0.056842 
REPIT_LIGHT_NASAL_ARA500 LIGHT_NASAL_ARA500 35 -0.000457 -0.024751 0.023837 0.024294 0.002946 0.018307 0.030281 
REPIT_LIGHT_NASAL_TISA500 LIGHT_NASAL_TISA500 35 -0.000829 -0.024376 0.022719 0.023547 0.002856 0.017744 0.029350 
REPIT_LIGHT_NASAL_TIA500 LIGHT_NASAL_TIA500 35 -0.288571 -4.902813 4.325670 4.614242 0.559559 3.477081 5.751402 
REPIT_LIGHT_NASAL_AOD750 LIGHT_NASAL_AOD750 35 -0.005057 -0.058823 0.048709 0.053766 0.006520 0.040516 0.067017 
REPIT_LIGHT_NASAL_ARA750 LIGHT_NASAL_ARA750 35 -0.001486 -0.032353 0.029382 0.030867 0.003743 0.023260 0.038474 
REPIT_LIGHT_NASAL_TISA750 LIGHT_NASAL_TISA750 35 -0.002057 -0.032018 0.027903 0.029961 0.003633 0.022577 0.037344 
REPIT_LIGHT_NASAL_TIA750 LIGHT_NASAL_TIA750 35 -0.625714 -4.984436 3.733007 4.358722 0.528573 3.284533 5.432910 
REPIT_LIGHT_TEMPORAL_AOD500 LIGHT_TEMPORAL_AOD500 35 -0.004171 -0.039064 0.030722 0.034893 0.004231 0.026294 0.043492 
REPIT_LIGHT_TEMPORAL_ARA500 LIGHT_TEMPORAL_ARA500 35 -0.003771 -0.027728 0.020185 0.023956 0.002905 0.018052 0.029860 
REPIT_LIGHT_TEMPORAL_TISA500 LIGHT_TEMPORAL_TISA500 35 -0.003400 -0.021224 0.014424 0.017824 0.002161 0.013431 0.022217 
REPIT_LIGHT_TEMPORAL_TIA500 LIGHT_TEMPORAL_TIA500 35 -0.534286 -4.985840 3.917269 4.451554 0.539830 3.354487 5.548621 
REPIT_LIGHT_TEMPORAL_AOD750 LIGHT_TEMPORAL_AOD750 35 -0.005143 -0.070043 0.059757 0.064900 0.007870 0.048906 0.080895 
REPIT_LIGHT_TEMPORAL_ARA750 LIGHT_TEMPORAL_ARA750 35 -0.004486 -0.035242 0.026271 0.030757 0.003730 0.023177 0.038336 
REPIT_LIGHT_TEMPORAL_TISA750 LIGHT_TEMPORAL_TISA750 35 -0.004314 -0.029676 0.021048 0.025362 0.003076 0.019112 0.031613 
REPIT_LIGHT_TEMPORAL_TIA750 LIGHT_TEMPORAL_TIA750 35 -0.522857 -5.316501 4.270787 4.793644 0.581315 3.612271 5.975018 
Table A.3.1. The Limits of Agreement indicate the interval within which 95% of the differences are expected to fall. The Repeatability Coefficient indicates the distance that the Limits of Agreement are from the 
mean. A judgement needs to be made as to whether this distance is acceptable in practice. 
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First variable Second variable Number 
of pairs 
Mean 
difference 
Limits of agreement Repeatability Standard error 95% confidence limits 
Lower Upper Lower Upper 
REPIT_DARK_SUPERIOR_AOD500 DARK_SUPERIOR_AOD500 35 -0.007257 -0.050230 0.035716 0.042973 0.005211 0.032382 0.053563 
REPIT_DARK_SUPERIOR_ARA500 DARK_SUPERIOR_ARA500 35 -0.001114 -0.019178 0.016949 0.018064 0.002191 0.013612 0.022515 
REPIT_DARK_SUPERIOR_TISA500 DARK_SUPERIOR_TISA500 35 -0.001400 -0.017686 0.014886 0.016286 0.001975 0.012272 0.020299 
REPIT_DARK_SUPERIOR_TIA500 DARK_SUPERIOR_TIA500 35 -0.951429 -5.216849 3.313992 4.265421 0.517258 3.214226 5.316616 
REPIT_DARK_SUPERIOR_AOD750 DARK_SUPERIOR_AOD750 35 0.005800 -0.063250 0.074850 0.069050 0.008374 0.052033 0.086068 
REPIT_DARK_SUPERIOR_ARA750 DARK_SUPERIOR_ARA750 35 -0.000000 -0.030498 0.030498 0.030498 0.003698 0.022982 0.038014 
REPIT_DARK_SUPERIOR_TISA750 DARK_SUPERIOR_TISA750 35 -0.000571 -0.030186 0.029043 0.029614 0.003591 0.022316 0.036913 
REPIT_DARK_SUPERIOR_TIA750 DARK_SUPERIOR_TIA750 35 -0.057143 -4.433627 4.319341 4.376484 0.530727 3.297918 5.455050 
REPIT_DARK_INFERIOR_AOD500 DARK_INFERIOR_AOD500 35 0.023429 -0.104785 0.151642 0.128213 0.015548 0.096616 0.159811 
REPIT_DARK_INFERIOR_ARA500 DARK_INFERIOR_ARA500 34 0.007412 -0.041178 0.056002 0.048590 0.005981 0.036422 0.060759 
REPIT_DARK_INFERIOR_TISA500 DARK_INFERIOR_TISA500 34 0.005147 -0.041428 0.051722 0.046575 0.005733 0.034911 0.058239 
REPIT_DARK_INFERIOR_TIA500 DARK_INFERIOR_TIA500 34 1.544118 -11.806737 14.894972 13.350854 1.643377 10.00738 16.69432 
REPIT_DARK_INFERIOR_AOD750 DARK_INFERIOR_AOD750 35 0.027629 -0.164907 0.220165 0.192536 0.023348 0.145086 0.239986 
REPIT_DARK_INFERIOR_ARA750 DARK_INFERIOR_ARA750 35 0.013629 -0.068068 0.095325 0.081697 0.009907 0.061563 0.101831 
REPIT_DARK_INFERIOR_TISA750 DARK_INFERIOR_TISA750 35 0.006743 -0.091545 0.105031 0.098288 0.011919 0.074065 0.122511 
REPIT_DARK_INFERIOR_TIA750 DARK_INFERIOR_TIA750 35 1.154286 -11.415739 13.724310 12.570024 1.524339 9.472194 15.66785 
REPIT_DARK_NASAL_AOD500 DARK_NASAL_AOD500 35 0.000629 -0.045499 0.046756 0.046128 0.005594 0.034760 0.057496 
REPIT_DARK_NASAL_ARA500 DARK_NASAL_ARA500 35 0.000486 -0.024496 0.025467 0.024982 0.003029 0.018825 0.031138 
REPIT_DARK_NASAL_TISA500 DARK_NASAL_TISA500 35 0.001343 -0.019956 0.022642 0.021299 0.002583 0.016050 0.026548 
REPIT_DARK_NASAL_TIA500 DARK_NASAL_TIA500 35 -0.442857 -5.426191 4.540476 4.983334 0.604318 3.755212 6.211455 
REPIT_DARK_NASAL_AOD750 DARK_NASAL_AOD750 35 -0.002686 -0.068528 0.063157 0.065843 0.007985 0.049616 0.082069 
REPIT_DARK_NASAL_ARA750 DARK_NASAL_ARA750 35 -0.000743 -0.033374 0.031888 0.032631 0.003957 0.024589 0.040673 
REPIT_DARK_NASAL_TISA750 DARK_NASAL_TISA750 35 0.000143 -0.027996 0.028282 0.028139 0.003412 0.021204 0.035074 
REPIT_DARK_NASAL_TIA750 DARK_NASAL_TIA750 35 -0.588571 -4.293503 3.116361 3.704932 0.449289 2.791867 4.617997 
REPIT_DARK_TEMPORAL_AOD500 DARK_TEMPORAL_AOD500 35 0.000543 -0.046437 0.047523 0.046980 0.005697 0.035402 0.058558 
REPIT_DARK_TEMPORAL_ARA500 DARK_TEMPORAL_ARA500 35 -0.000171 -0.022744 0.022401 0.022573 0.002737 0.017010 0.028136 
REPIT_DARK_TEMPORAL_TISA500 DARK_TEMPORAL_TISA500 35 0.000943 -0.016700 0.018586 0.017643 0.002140 0.013295 0.021991 
REPIT_DARK_TEMPORAL_TIA500 DARK_TEMPORAL_TIA500 35 -0.405714 -4.700429 3.889000 4.294714 0.520811 3.236300 5.353129 
REPIT_DARK_TEMPORAL_AOD750 DARK_TEMPORAL_AOD750 35 0.001171 -0.049593 0.051936 0.050765 0.006156 0.038254 0.063275 
REPIT_DARK_TEMPORAL_ARA750 DARK_TEMPORAL_ARA750 35 0.002486 -0.043841 0.048813 0.046327 0.005618 0.034910 0.057744 
REPIT_DARK_TEMPORAL_TISA750 DARK_TEMPORAL_TISA750 35 0.003114 -0.039621 0.045850 0.042735 0.005182 0.032203 0.053267 
REPIT_DARK_TEMPORAL_TIA750 DARK_TEMPORAL_TIA750 35 -0.540000 -3.576716 2.496716 3.036716 0.368256 2.288330 3.785103 
Table A.3.2. The Limits of Agreement indicate the interval within which 95% of the differences are expected to fall. The Repeatability Coefficient indicates the distance that the Limits of Agreement are from the 
mean. A judgement needs to be made as to whether this distance is acceptable in practice.  
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Benefits and Limitations of the Tomey 3000 Specular Microscope 
 
The main benefits of this specular microscope are the non-contact nature of the measurements 
and that it permits to sample the endothelium in 7 different areas of cornea.   
It additionally has analysis and storage software that permits to have a quantification of the data. 
 
Limitations of this device: 
 
1. Fixation Control:  
The device does not possess recognition software that allows identifying the exact same area as 
scanned as baseline (similar to the technology used in the Heidelberg Retinal Tomography for 
recognition of the optic nerve head contour at baseline). Although the participants were carefully 
instructed on how to perform the test and to keep fixating at the set target while the 
measurement was taken, micro-movements of the eye could not be controlled.  This may have 
led to a slightly different testing location within the same area of corneal endothelium. 
 
2. Peripheral Sampling: 
The Tomey 3000 specular microscope can test in 6 peripheral areas of cornea (Superior, Superior-
Nasal, Inferior-Nasal, Inferior, Inferior-Temporal and Superior-Temporal). Its technology is based 
on corneal specular reflection. When there is a sufficient distance between the anterior surface of 
the iris and the endothelium, the device can take the sample with a good quality of image. 
However, when a more peripheral area of the endothelium is intended to be sampled (the 
distance between iris and endothelium becomes narrower), the image experience a high degree 
of scatter of light and the device cannot sample the area. The Tomey 3000 can reach a maximum 
of approximately 3mm radius from the corneal apex, dependent on the keratometrical 
measurements of the subject’s eye (Tomey Corporation, 2006). 
 
3. Automatic analysis reliability 
This specular microscope allows performing a manual or an automatic analysis of the endothelial 
scans. In the manual analysis the examiner has to select the area of the scan that wishes to 
analyse and has to manually trace or modify the contour of the cells if the examiner does not 
agree with the device judgement. In the automated analysis, the software runs its own analysis.  
The automated option was selected in the present thesis due to logistical reasons (approximately 
4500 scans were quantified). Although it would have been interesting to know the differences 
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between manual and automatic quantification, this would have not had any effect on the 
outcome of the present study. The main reason being the presence of a control eye.  
If the automatic analysis would have been less or more accurate than the manual analysis for the 
endothelial cells, it would have been equally accurate for treated and untreated eyes. 
 
4. Repeatability 
The Bland-Altman (B-A) coefficients were found for the three parameters under measurement for 
the central area. The data was obtained from the untreated eye and using Visit 1 as baseline. The 
comparisons were carried out with the same parameters measured at the subsequent visits (Visits 
2, 3, 4, 5, 6, 7, 8, 9, 10 and 11). The closer the B-A mean value was to zero the closer the value for 
Visit 1 was to another visit. It is down to the examiner to judge if this differences from cero can 
have a clinical relevance. More information can be found in the Table A.3.3 (next page). 
 
Repeatability indicates the level of clinical trust that an examiner can have regarding a tested 
device. Basically, it answers the question, if I test a patient today and I test the same patient 
tomorrow, what are the chances of getting the same value? 95% of the times the mean difference 
for the parameter tested today and the same parameter tested tomorrow will fall within the 
plus/minus B-A repeatability coefficients. 
 
In the present study, repeatability of the Tomey 3000 Specular Microscope was of a limited 
relevance as what was used to calculate differences in the parameters within visits was the mean 
value of many measurements (n participants). Differences found for the mean value given by 
many participants’ endothelial cells between visits could only be explainable with repeatability if 
all the participants measurements would have deviated from the mean in the same direction 
(positive or negative).
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Table A.3.3. Bland-Altman mean, coefficients and limits of agreement for the three parameters under study (Polymegethism, Pleomorphism, Cell Density and Corneal Thickness). They were studied comparing every visit to 
baseline (Visit 1). 
Bland-Altman 
For Central 
Corneal 
measurements 
Corneal Thickness Cell density Polymegethism Pleomorphism 
Mean Coefficient 
Limit of agreement 
(Lower-Upper) 
Mean Coefficient 
Limit of agreement 
(Lower-Upper) 
Mean Coefficient 
Limit of agreement 
(Lower-Upper) 
Mean Coefficient 
Limit of agreement 
(Lower-Upper) 
Visit 1-Visit 2 0.65 37.09 (-36.44-37.74) 3.67 287.51 (-291.18-283.84) 0.20 49.29 (-49.49-49.09) 1.21 19.30 (-18.09-20.51) 
Visit 1-Visit 3 7.41 38.30 (-30.89-45.70) 31.60 297.07 (-265.47-328.67) -5.36 49.31 (-54.68-43.95) 3.17 22.57 (-19.40-25.74) 
Visit 1-Visit 4 -0.21 38.27 (-38.48-38.06) -8.62 250.82 (-259.44-242.19) 2.52 45.06 (-42.55-47.58) 0.93 21.16 (-20.23-22.09) 
Visit 1-Visit 5 1.33 35.62 (-34.29-36.95) 14.03 270.01 (-255.98-284.04) -1.67 44.39 (-46.06-42.72) 4.20 21.82 (-17.62-26.02) 
Visit 1-Visit 6 3.61 32.80 (-29.18-36.42) -1.94 287.24 (-289.18-285.31) 0.03 50.87 (-50.85-50.91) -5.17 30.46 (-35.63-25.30) 
Visit 1-Visit 7 1.00 31.75 (-30.75-32.75) 60.40 318.41 (-258.01-378.81) -9.00 48.02 (-57.03-39.03) 1.21 19.30 (-18.09-20.51) 
Visit 1-Visit 8 -8.55 18.00 (-26.56-9.45) 63.00 260.41 (-197.41-323.41) -9.00 44.61 (-53.61-35.61) 3.17 22.57 (-19.40-25.74) 
Visit 1-Visit 9 -6.33 29.84 (-36.18-23.51) 30.55 257.15 (-226.60-287.71) -3.44 46.85 (-50.30-43.41) 0.93 21.16 (-20.23-22.09) 
Visit 1-Visit 10 13.42 70.05 (-56.63-83.48) -100.89 735.39 (-836.28-634.50) 18.33 117.52 (-99.18-135.85) 4.20 21.82 (-17.62-26.02) 
Visit 1-Visit 11 -0.17 40.21 (-40.38-40.04) -16.00 284.12 (-300.12-268.11) 2.37 49.93 (-47.56-52.30) -5.17 30.46 (-35.63-25.30) 
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Appendix 4. Forms 
 
Letter for General Practitioner 
 
REC Reference: 10/H0301/14  
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Information for General Practitioner 
 
Dear Dr  … 
 
 
 
Re:   insert patient sticker with patient demographics 
 
 
 
This is to inform you that your patient (details above) has agreed to participate in a 
research study named: 
 
Investigating Management of Primary Angle Closure and 
Treatment Study (IMPACT) 
 
The explanation of the study provided to this patient is attached in addition to a 
record of the patient‟s consent to participate in the study. 
 
This study has been approved by Essex 1 Research Ethics Committee. 
 
Yours sincerely 
 
 
 
 
 
Professor Rupert Bourne  
BSc MD, FRCOphth 
Consultant Ophthalmic Surgeon 
Chief Investigator 
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A copy of the explanation of the study given to the patient. 
 
1. Title of Study: Investigating Management of Primary Angle Closure and Treatment Study 
(IMPACT) 
 
2. An invitation 
 
You are being invited to take part in a research study.  Before you decide if you wish to take part, it 
is important for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
Thank you for reading this. 
 
3.Background to the condition 
 
Inside the eye there is fluid which keeps the shape of the eye and helps it function. There are two 
types of fluid, aqueous and vitreous humour which create a pressure inside the eye. This eye 
pressure is of interest to this study.  
Aqueous humour is found in the front part of the eye between the front window of the eye (the 
cornea) and the lens, in an area known as the „anterior chamber‟. Aqueous humour is continuously 
produced by the „ciliary body‟, and drained by the „trabecular meshwork‟, which is located at the 
base of the corner of the anterior chamber. When access to the trabecular meshwork is narrow or 
closed, the eye is said to have an „occludable angle‟ and patients are designated “primary angle 
closure suspects (PACS)”. A further stage, termed “primary angle closure (PAC)” involves 
permanent closure of this area and/or a rise in eye pressure. A persistently raised eye pressure 
may lead on to damage to the optic nerve, “primary angle closure glaucoma (PACG)”. 
 
4. What is the current (“standard”) treatment for PAC/PACS patients? 
Many patients are found to have the features of PAC or PACS and unaware of it. There are 
different ways of looking after these patients but among the medical profession there is no 
agreement on how care should be delivered. Current care is therefore quite varied and, among 
others, it includes the decision of simply to watch these patients in hospital clinics, discharge them 
from the hospital or treat them with laser procedures aimed to open the access to the drainage 
area. These laser procedures are called Peripheral Iridotomy (PI) and Argon Laser Peripheral 
Iridoplasty (ALPI), and involve the following: 
PI = Laser Peripheral Iridotomy = a laser procedure used to make a microscopic hole in the 
upper part of the iris. 
ALPI = Argon Laser Peripheral Iridotomy = a laser procedure that stretches the iris away from 
the drainage area of the eye to open it to drain fluid from the eye 
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5. What is the purpose of the study? 
 
The current study is designed to find out how best to care for these patients through a better 
understanding of how an eye with PACS can change to a state of PAC and then to PACG and how 
laser procedures mentioned above can affect this risk of change by altering the dimensions of the 
front chamber of the eye and drainage of fluid from the eye. 
 
6. How is this going to be done? 
 
The study will involve patients with PAC or PACS in both eyes, with no symptoms, who will receive 
a PI in one eye while the other eye is left untreated. This treated eye will be randomly chosen using 
computer software; this means neither the participant nor the doctors will be able to decide which 
eye will receive the laser. Examination of your eyes before and after laser treatment will allow us to 
gather information about how the conditions of PAC and PACS can be affected by laser.  
If the drainage area does not open up after laser treatment („an occludable angle‟), the eye will be 
either left with no further laser treatment or will receive a further different type of laser treatment, an 
ALPI. The decision whether to offer no further treatment or ALPI will be made by the computer 
programme in a randomised process.  
 
 
This process of laser procedures is illustrated below: 
 
 
 
 
 
 
 
 
 
 
                                                                                                                
 
 
 
 
 
Laser PI = Laser Peripheral Iridotomy = a laser procedure used to make a microscopic hole in the upper part of 
the iris. 
 ALPI = Argon Laser Peripheral Iridotomy = a laser procedure that stretches the iris away from the drainage 
area of the eye to open it to drain fluid from the eye  
   Patients with PACS or   
PAC give consent to take 
part in study to study 
Patient receives laser 
PI in right or left eye 
The drainage 
area does not 
open 
The drainage 
area opens 
Half of these eyes 
receive ALPI laser and 
the other half no further 
laser procedures 
(random process of 
allocation*)  
No further 
laser 
procedures 
to this eye 
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* „‟random process of allocation‟ involves a computer programme randomly selecting an eye for treatment with the 
laser procedure. Neither the participant nor the doctors will be able to decide which eye will receive the laser 
 
 
 
 
7. Why have I been invited to participate in this study? 
 
You have been invited to take part in this study because we believe that you are a suitable 
participant. You have been recently diagnosed with PACS/ PAC in both eyes and you have no 
signs of glaucoma in either.   
 
8. Do I have to take part? 
 
Taking part in this research is entirely voluntary. You can decide whether or not to take part. If you 
do decide to take part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any time without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
9. What will happen to me if I take part? 
 
After being informed about the study you will be given an appointment to return to the eye clinic. 
This will happen within the next 3 weeks. At that appointment you will be able to ask any other 
questions you have about the study. If you agree to take part, we will ask you to sign a consent 
form so that you can be enrolled into the study.  
You will be asked to attend on various dates. If you undergo laser PI only this will be done in 7 
visits and if you receive ALPI as well it will be done in 11 visits. 
 
What type of tests/laser procedures are going to be done when I attend the research clinic (visits) 
and what do they involve? 
1. Visual acuity- this is an evaluation of the sharpness of your vision 
2. Visual field- measures the quality of your eyesight in central and surrounding areas 
3. Slit- lamp examination- we will use a microscope to evaluate the health of the front and the 
back of your eye, to assess what is the interior of the front chamber of the eye and to 
measure the eye pressure of each eye. 
4. Laser PI (laser peripheral iridotomy)- an explanation is given above. 
5. Supine and darkroom provocation tests- these measurements of eye pressure are made to 
understand how your eye pressure behaves when lying down on your back and also after 
10 minutes in a dark environment (to simulate the conditions at night).   
6. Cameras and other devices that take images of the front part of the eye 
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7. Cameras and other devices that take images of the surface of the eye and the fluid in the 
front chamber of the eye 
8. Measurement of thickness of the surface of the eye- this is important because the 
thickness of the surface has an effect on the accuracy of eye pressure measurements. 
9. Subjective refraction- this is the same procedure as when you go to see an optometrist for 
an assessment for glasses. We need to know if the laser procedures have an effect on the 
power of the eye 
10. Retinal examination, eye pressure measurement and laser and photographic imaging after 
pupil dilation- we need to widen the pupil using eyedrops to have a better view of the back 
of the eye and to allow more detailed pictures of the back of the eye to be taken. At the 
same time we will be able to see if eye pressure changes when your pupil is bigger. 
11. Argon Laser Peripheral Iridoplasty- described in sections above. 
 
Are all of these tests going to be done at every visit? 
No. We have designed the following table where you can see what we are going to do at each of 
the visits. Please note that we have numbered the tests/laser procedures using the same sequence 
given above.   
 
 VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT  
7 
VISIT 
8 
VISIT 
9 
VISIT 
10 
VISIT 
11 
Test 
1 
X X X X X X X X X X X 
Test 
2 
X          X 
Test 
3 
X  X X X X  X X X X 
Test 
4 
 X          
Test 
5 
X     X     X 
Test 
6 
X  X X X X  X X X X 
Test 
7 
X X X X X X X X X X X 
Test 
8 
X  X X X X  X X X X 
Test 
9 
X     X     X 
Test 
10 
X   X    X   X 
Test 
11 
      X     
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How many of these tests would be done on me as part of my routine care at the Eye Clinic? 
 
 Number of tests/procedures to be received 
as part of the study 
Number of tests/procedures to be received 
as part of routine care if I was not part of 
the research study 
Test 1 11 4 
Test 2 2 1 
Test 3 9 4 
Test 4 1 0 or 1 
Test 5 3 0 
Test 6 9 2 
Test 7 11 0 
Test 8 9 1 
Test 9 3 0 
Test 10 4 0 or 1 
Test 11 1 0 or 1 
 
 
When exactly are those visits going to be done? 
 
VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT 
7* 
VISIT 
8* 
VISIT 
9* 
VISIT 
10* 
VISIT 
11 
This 
is 
your 
start 
date. 
4 
weeks 
since 
visit 1 
4 
weeks 
+ 1 
day 
since 
visit1 
5 
weeks 
since 
visit 1 
10 
weeks 
since 
visit 1  
16 
weeks 
since 
visit 1 
18  
weeks 
since 
visit 1 
18  
weeks 
+ 1 
day 
since 
visit 1 
19  
weeks 
since 
visit 1 
24  
weeks 
since 
visit 1 
28 
weeks 
since 
visit 1 
* these visits are only attended by patients who undergo an ALPI laser treatment. 
 
How long is each visit going to take approximately? 
 
VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT 
7 
VISIT 
8 
VISIT 
9 
VISIT 
10 
VISIT 
11 
2 
hours 
2 
hours 
1 hour 1 hour 1 hour 3.5 
hours 
2 
hours 
1 hour 1 
hour 
1 hour 2 
hours 
 
  
Please note that we advise patients who have appointments at the routine (non-research) eye clinic 
expect to spend up to 3 hours at the clinic. 
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10.  What are the possible disadvantages and risks of taking part? 
 
1. Risks to the eye that receives laser treatment. 
a. In the case of laser Peripheral Iridotomy (PI): 
Complications are uncommon. The most common complications are a rise in eye pressure 
shortly after the treatment. The pressure will be checked before you go home and if very 
high you will need extra treatment (usually eye drops or tablets). You will also need to 
remain in the Eye Clinic until the pressure has dropped to a safe level. 
Other rarer risks include: 
 Slight haze lasting up to a few hours due to blood in the front of the eye  
 Some research has suggested cataract can be caused by laser PI while other 
studies have contradicted this.  
 Detachment of the retina (very rare). 
 Possible mild discomfort during the laser treatment 
  
b. In the case of Argon Laser Peripheral Iridoplasty (ALPI) 
 
Complications are the same as those described for PI with the exception that there is no risk of 
bleeding in this procedure. Pigmented burn marks may develop at the sites of laser applications in 
some eyes treated with ALPI, although this is unusual. 
 
 
2. Risks to the eye that does not receive laser treatment. 
The risk of not treating an eye with your condition over a 24 week period from first diagnosis is 
unknown. Many patients do not receive laser procedures during routine care. The close follow-up 
of eyes that have not received laser treatment over 24 weeks is more intensive than that of routine 
care and will detect eyes that develop a rise in eye pressure or increasing closure of the drainage 
area of the eye.  
Patients will be withdrawn from the study if the eye pressure rises above a certain level (35mmHg) 
or if they develop signs of glaucoma in either eye. 
 
3. Risks associated with measuring devices: 
 
The measuring devices used in this study carry no additional risk to that involved in routine 
standard care. In the case of devices in contact with the surface of the eye (cornea) the possible 
risks are irritation of the cornea or a scratch to the cornea. These symptoms/signs are very rare 
after a single measurement per visit as this study proposes. If any of these symptoms/signs are 
noticed by the researchers during the measurements they will be confirmed and the measurements 
will be stopped. Patients will be asked to stay in the clinic for a few hours and the abrasions 
allowed to heal with or without the use of an antibiotic eye drop. Patients will be followed up by an 
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ophthalmologist/eye nurse in the eye clinic.   
 
4. Confidentiality: 
 
In order to minimize the potential loss of confidentiality, each participant in this study will  have the 
information collected from them anonymised. Thus it will not be possible to track to an individual 
without access to the hospital records.  
 
 
 
 
11. What are the possible benefits of taking part?  
 
Benefits to the eye treated by laser: 
Prevention of a possible acute angle-closure episode, which involves a sudden painful rise in eye 
pressure. This would be a rare event in such a short period of follow-up. The laser peripheral 
iridotomy may lower the eye pressure which may reduce the risk of glaucoma in the future. The 
laser iridotomy may also prevent new/further areas of closure of the drainage area of the eye, 
which may also reduce the risk of glaucoma in the future.  
 
Benefits to the eye untreated by laser: 
No laser treatment will be undertaken therefore the eye concerned will not be exposed to the risks 
detailed above.  
 
Other benefits: 
The potential benefits of this study for society are a better understanding of the behaviour of eyes 
with the conditions of PAC and PACS and the short-term effects of the laser iridotomy or argon 
laser peripheral iridoplasty, the practice of which is variable within the UK due to lack of  substantial 
evidence. 
  
 
12. What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes available about the 
treatment that is being studied.  If this happens, your research doctor will tell you about it and 
discuss with you whether you want to continue in the study.  If you decide to withdraw your 
research doctor will make arrangements for your care to continue.  If you decide to continue in the 
study you will be asked to sign an updated consent form. 
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Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He will explain the reasons and arrange for your care to 
continue. 
 
13. What happens when the research study stops? 
You will be followed regularly in the glaucoma clinic and you may be contacted to have a 
Peripheral Iridotomy in your observed eye. 
 
 
14. What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone‟s negligence, then you may have grounds for 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms should be available to you. 
They can be contacted as follows: 
  
Patient Advice and Liaison Service (PALS) 
Hinchingbrooke Healthcare NHS Trust 
Hinchingbrooke Park 
Huntingdon 
Cambs PE29 6NT 
Telephone: 01480 428964 
E-mail: pals@hinchingbrooke.nhs.uk 
 
15. Will my taking part in this study be kept confidential? 
 
For this study, we will need to ask your permission to have access to your medical notes.  All 
information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital/ surgery will have your name and 
address removed so that you cannot be recognised from it.  An exception to this is correspondence 
to your GP, who, with your permission, will be informed about your participation in the study. 
 
 
 
16. What will happen to the results of the research study? 
The results of the study will be published in a scientific journal. The results are likely to be 
published several months after the study has ended.  Basic information will be accessible from any 
university or hospital library.  The complete paper will be obtainable from the British Library, 
although a fee may be charged.  You will not be personally identified in the published study. 
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17. Who is organising and funding the research? 
 
The study is being funded by a pharmaceutical company. The research doctor will receive no 
personal payment for conducting the study and looking after patients during its course. 
 
 
 
 
18. Who has reviewed the study? 
 
This study has received ethics approval by the Essex 1 Research Ethics Committee. 
 
Thank you 
Thank you for reading this information leaflet, we hope it has helped you in making your decision. 
The research team is really appreciative of you taking the time to read this document. 
 
Contact for Further Information 
If you have any questions about the study or your participation in the study, please do not hesitate 
to contact us: 
Miss Laura Sánchez Parra (Research optometrist , 079 838 379032) 
Professor Rupert Bourne (Chief Investigator, 01480 418757) 
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Appendix 4 Forms 
 
Patient Information Sheet 
 
REC Reference: 10/H0301/14 
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Hinchingbrooke Park 
Huntingdon 
Cambs PE29 6NT 
 
Patient Information Sheet  
For patients with a diagnosis of Primary Angle Closure and/or 
Primary Angle Closure Suspect in both eyes 
 
Dear ……………………………….. 
 
 
 
  insert patient sticker with patient demographics 
 
 
 
This letter gives you information about the following research study in which your 
eye doctor has suggested that you may like to be involved. 
 
 
Investigating Management of Primary Angle 
Closure and Treatment study 
(IMPACT) 
 
  
A full explanation is given in subsequent pages. The last page gives contact 
details for the individuals running the study if you require more information. If you 
decide to participate in the study your local doctor (general practitioner) will also 
be given the same information.  
 
This study has been approved by the Essex 1 Research Ethics Committee. 
 
Yours sincerely 
 
 
Professor Rupert Bourne  
BSc MD, FRCOphth 
Consultant Ophthalmic Surgeon 
Chief Investigator 
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Summary of this document 
 
You are being invited to take part in a research study that involves patients whose eyes 
are at risk of glaucoma, which involves damage to the optic nerve. These risk factors 
involve a shallow front chamber to the eye which may lead on to high pressure in the eye 
and subsequent damage to the nerve. Some doctors treat eyes at risk of this form of 
glaucoma (angle-closure glaucoma) with a laser (laser iridotomy), however there is limited 
evidence to support the use of laser in this situation. The purpose of the study is to 
compare the effect of laser in one eye with no treatment in the fellow eye if both of your 
eyes are at risk. Various painless tests will be performed to establish the effect of laser. 
Patients will be followed up for a period of 6 months after the treatment and will then 
return to normal NHS follow-up as appropriate. 
 
An Invitation 
 
You are being invited to take part in a research study.  Before you decide if you wish to take part, it 
is important for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
Background to the condition 
 
Inside the eye there is fluid which keeps the shape of the eye and helps it function. There are two 
types of fluid, aqueous and vitreous humour which create a pressure inside the eye. This eye 
pressure is of interest to this study.  
 
Aqueous humour is found in the front part of the eye between the front window of the eye (the 
cornea) and the lens, in an area known as the „anterior chamber‟. Aqueous humour is continuously 
produced by the „ciliary body‟, and drained by the „trabecular meshwork‟, which is located at the 
base of the corner of the anterior chamber. When access to the trabecular meshwork is narrow or 
closed, the eye is said to have an „occludable angle‟ and patients are designated “primary angle 
closure suspects (PACS)”. A further stage, termed “primary angle closure (PAC)” involves 
permanent closure of this area and/or a rise in eye pressure. A persistently raised eye pressure 
may lead on to damage to the optic nerve, “primary angle closure glaucoma (PACG)”. 
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What is the current (“standard”) treatment for PAC/PACS patients? 
 
Many patients are found to have the features of PAC or PACS and unaware of it. There are 
different ways of looking after these patients but among the medical profession there is no 
agreement on how care should be delivered. Current care is therefore quite varied and, among 
others, it includes the decision of simply to watch these patients in hospital clinics, discharge them 
from the hospital or treat them with laser procedures aimed to open the access to the drainage 
area. These laser procedures are called Peripheral Iridotomy (PI) and Argon Laser Peripheral 
Iridoplasty (ALPI), and involve the following: 
PI = Laser Peripheral Iridotomy = a laser procedure used to make a microscopic hole in the 
upper part of the iris. 
ALPI = Argon Laser Peripheral Iridotomy = a laser procedure that stretches the iris away from 
the drainage area of the eye to open it to drain fluid from the eye 
 
 
What is the purpose of the study? 
 
The current study is designed to find out how best to care for these patients through a better 
understanding of how an eye with PACS can change to a state of PAC and then to PACG and how 
laser procedures mentioned above can affect this risk of change by altering the dimensions of the 
front chamber of the eye and drainage of fluid from the eye. 
 
How is this going to be done? 
 
The study will involve patients with PAC or PACS in both eyes, with no symptoms, who will receive 
a PI in one eye while the other eye is left untreated. This treated eye will be randomly chosen using 
computer software; this means neither the participant nor the doctors will be able to decide which 
eye will receive the laser. Examination of your eyes before and after laser treatment will allow us to 
gather information about how the conditions of PAC and PACS can be affected by laser.  
If the drainage area does not open up after laser treatment („an occludable angle‟), the eye will be 
either left with no further laser treatment or will receive a further different type of laser treatment, an 
ALPI. The decision whether to offer no further treatment or ALPI will be made by the computer 
programme in a randomised process.  
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This process of laser procedures is illustrated below: 
 
 
 
 
 
 
 
 
 
 
                                                                                                                
 
 
 
 
 
 
 
 
 
 
 
  Laser PI = Laser Peripheral Iridotomy = a laser procedure used to make a microscopic hole in the upper part of 
the iris. 
 ALPI = Argon Laser Peripheral Iridotomy = a laser procedure that stretches the iris away from the drainage 
area of the eye to open it to drain fluid from the eye  
* „‟random process of allocation‟ involves a computer programme randomly selecting an eye for treatment with the 
laser procedure. Neither the participant nor the doctors will be able to decide which eye will receive the laser 
 
 
Why have I been invited to participate in this study? 
 
You have been invited to take part in this study because we believe that you are a suitable 
participant. You have been recently diagnosed with PACS/ PAC in both eyes and you have no 
signs of glaucoma in either.   
 
 
Do I have to take part? 
 
Taking part in this research is entirely voluntary. You can decide whether or not to take part. If you 
do decide to take part you will be given this information sheet to keep and be asked to sign a 
 
Patients with PACS or 
PAC give consent to take 
part in study to study 
The drainage 
area does not 
open 
The drainage 
area opens 
Patient receives laser 
PI in right or left eye 
Half of these eyes receive 
ALPI laser and the other 
half no further laser 
procedures (random 
process of allocation*)  
No further 
laser 
procedures 
to this eye 
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consent form. If you decide to take part you are still free to withdraw at any time without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
 
After being informed about the study you will be given an appointment to return to the eye clinic. 
This will happen within the next 3 weeks. At that appointment you will be able to ask any other 
questions you have about the study. If you agree to take part, we will ask you to sign a consent 
form so that you can be enrolled into the study.  
 
You will be asked to attend on various dates. If you undergo laser PI only this will be done in 7 
visits and if you receive ALPI as well it will be done in 11 visits. 
 
What type of tests/laser procedures are going to be done when I attend the research clinic (visits) 
and what do they involve? 
The co-researchers will perform the following measurements/procedures: 
12. Visual acuity- this is an evaluation of the sharpness of your vision 
13. Visual field- measures the quality of your eyesight in central and surrounding areas 
14. Slit- lamp examination- we will use a microscope to evaluate the health of the front and the 
back of your eye, to assess the interior of the front chamber of the eye and to measure the 
eye pressure of each eye. 
15. Laser PI (laser peripheral iridotomy)- an explanation is given above. 
16. Supine and darkroom provocation tests- these measurements of eye pressure are made to 
understand how your eye pressure behaves when lying down on your back and also after 
10 minutes in a dark environment (to simulate the conditions at night).   
17. Cameras and other devices that take images of the front part of the eye 
18. Cameras and other devices that take images of the surface of the eye and the fluid in the 
front chamber of the eye 
19. Measurement of thickness of the surface of the eye- this is important because the 
thickness of the surface has an effect on the accuracy of eye pressure measurements. 
20. Subjective refraction- this is the same procedure as when you go to see an optometrist for 
an assessment for glasses. We need to know if the laser procedures have an effect on the 
power of the eye 
21. Retinal examination, eye pressure measurement and laser and photographic imaging after 
pupil dilation- we need to widen the pupil using eyedrops to have a better view of the back 
of the eye and to allow more detailed pictures of the back of the eye to be taken. At the 
same time we will be able to see if eye pressure changes when your pupil is bigger. 
22. Argon Laser Peripheral Iridoplasty- described in sections above. 
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Are all of these tests going to be done at every visit? 
No. We have designed the following table where you can see what we are going to do at each of 
the visits. Please note that we have numbered the tests/laser procedures using the same sequence 
given above.   
 VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT  
7 
VISIT 
8 
VISIT 
9 
VISIT 
10 
VISIT 
11 
Test 
1 
X X X X X X X X X X X 
Test 
2 
X          X 
Test 
3 
X  X X X X  X X X X 
Test 
4 
 X          
Test 
5 
X     X 
 
    X 
Test 
6 
X  X X  X  X X X X 
Test 
7 
X X X X X X X X X X X 
Test 
8 
X  X X X X  X X X X 
Test 
9 
X     X     X 
Test 
10 
X   X     X  X 
Test 
11 
      X     
Crosses marked in bold type above indicate that the test is only performed on the eye that has 
received laser treatment. 
 
How many of these tests would be done on me as part of my routine care at the Hinchingbrooke 
Hospital Eye Clinic? 
 
 Number of tests/procedures to be received 
as part of the study 
Number of tests/procedures to be received 
as part of routine care if I was not part of 
the research study 
Test 1 11 4 
Test 2 2 1 
Test 3 9 4 
Test 4 1 0 or 1 
Test 5 3 0 
Test 6 9 2 
Test 7 11 0 
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Test 8 9 1 
Test 9 3 0 
Test 10 4 0 or 1 
Test 11 1 0 or 1 
 
 
When exactly are those visits going to be done? 
 
VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT 
7* 
VISIT 
8* 
VISIT 
9* 
VISIT 
10* 
VISIT 
11 
This 
is 
your 
start 
date. 
4 
weeks 
since 
visit 1 
4 
weeks 
+ 1 
day 
since 
visit1 
5 
weeks 
since 
visit 1 
10 
weeks 
since 
visit 1  
16 
weeks 
since 
visit 1 
18  
weeks 
since 
visit 1 
18  
weeks 
+ 1 
day 
since 
visit 1 
19  
weeks 
since 
visit 1 
24  
weeks 
since 
visit 1 
28 
weeks 
since 
visit 1 
* These visits are only attended by patients who undergo an ALPI laser treatment. 
 
 
How long is each visit going to take approximately? 
 
VISIT 
1 
VISIT 
2 
VISIT 
3 
VISIT 
4 
VISIT 
5 
VISIT 
6 
VISIT 
7 
VISIT 
8 
VISIT 
9 
VISIT 
10 
VISIT 
11 
8 
hours 
2 
hours 
1 hour 1 hour 1 hour 3.5 
hours 
2 
hours 
1 hour 1 
hour 
1 hour 8 
hours 
 
  
Please note that we advise patients who have appointments at the routine (non-research) eye clinic 
expect to spend up to 3 hours at the clinic. 
 
Travel and parking expenses 
Travel and parking expenses will be reimbursed either at the end of each visit or alternatively at 
the end of the study, whichever is more convenient to you. Refreshments will be provided on the 
two full-day visits. 
 
 
 What are the possible disadvantages and risks of taking part? 
 
2. Risks to the eye that receives laser treatment. 
a. In the case of laser Peripheral Iridotomy (PI): 
Complications are uncommon. The most common complications are a rise in eye pressure 
shortly after the treatment. The pressure will be checked before you go home and if very 
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high you will need extra treatment (usually eye drops or tablets). You will also need to 
remain in the Eye Clinic until the pressure has dropped to a safe level. 
Other rarer risks include: 
 Slight haze lasting up to a few hours due to blood in the front of the eye  
 Some research has suggested cataract can be caused by laser PI while other 
studies have contradicted this.  
 Detachment of the retina (very rare). 
 Possible mild discomfort during the laser treatment 
 Change in the inner layer of the front surface of the eye (the corneal endothelium). 
Previous studies involving small numbers of eyes have noted a change in the inner 
lining of the front surface of the eye (corneal endothelial cells) that occurs after 
laser iridotomy treatment. It is unknown whether this has an effect on eyesight in 
the long-term. The risk is likely to very low as this procedure has been performed 
for several decades with adverse effects to vision being very rare.  
 
  
b. In the case of Argon Laser Peripheral Iridoplasty (ALPI) 
 
Complications are the same as those described for PI with the exception that there is no risk of 
bleeding in this procedure. Pigmented burn marks may develop at the sites of laser applications in 
some eyes treated with ALPI, although this is unusual. 
 
 
2. Risks to the eye that does not receive laser treatment. 
 
The risk of not treating an eye with your condition over a 28 week period from first diagnosis is 
unknown. Many patients do not receive laser procedures during routine care. The close follow-up 
of eyes that have not received laser treatment over 28 weeks is more intensive than that of routine 
care and will detect eyes that develop a rise in eye pressure or increasing closure of the drainage 
area of the eye.  
Patients will be withdrawn from the study if the eye pressure rises above a certain level (35mmHg) 
or if they develop signs of glaucoma in either eye. 
 
3. Risks associated with measuring devices: 
 
The co-researchers will be taking the measurements. The measuring devices used in this study 
carry no additional risk to that involved in routine standard care. In the case of devices in contact 
with the surface of the eye (cornea) the possible risks are irritation of the cornea or a scratch to the 
cornea. These symptoms/signs are very rare after a single measurement per visit as this study 
proposes. If any of these symptoms/signs are noticed by the researchers during the measurements 
they will be confirmed and the measurements will be stopped. Patients will be asked to stay in the 
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clinic for a few hours and the abrasions allowed to heal with or without the use of an antibiotic eye 
drop. Patients will be followed up by an ophthalmologist/eye nurse in the eye clinic.   
 
4. Confidentiality: 
 
In order to minimize the potential loss of confidentiality, each participant in this study will  have the 
information collected from them anonymised. All information that is collected about you during the 
course of the research will be kept strictly confidential. Each participant in this 
study will have the information collected from them anonymised using a unique study code which 
will be used on all the data collection forms. It will not possible to identify you from the code. Only 
the Research Team will have access to the code. If you take part in the research we will inform 
your GP of your participation, unless you prefer your GP is not informed. 
 
 
What are the possible benefits of taking part?  
 
Benefits to the eye treated by laser: 
Prevention of a possible acute angle-closure episode, which involves a sudden painful rise in eye 
pressure. This would be a rare event in such a short period of follow-up. The laser peripheral 
iridotomy may lower the eye pressure which may reduce the risk of glaucoma in the future. The 
laser iridotomy may also prevent new/further areas of closure of the drainage area of the eye, 
which may also reduce the risk of glaucoma in the future.  
 
Benefits to the eye untreated by laser: 
No laser treatment will be undertaken therefore the eye concerned will not be exposed to the risks 
detailed above.  
 
Other benefits: 
The potential benefits of this study for society are a better understanding of the behaviour of eyes 
with the conditions of PAC and PACS and the short-term effects of the laser iridotomy or argon 
laser peripheral iridoplasty, the practice of which is variable within the UK due to lack of  substantial 
evidence. 
  
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes available about the 
treatment that is being studied.  If this happens, your research doctor will tell you about it and 
discuss with you whether you want to continue in the study.  If you decide to withdraw your 
research doctor will make arrangements for your care to continue.  If you decide to continue in the 
study you will be asked to sign an updated consent form. 
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Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He will explain the reasons and arrange for your care to 
continue. 
 
 
What happens when the research study stops? 
 
You will be followed regularly in the glaucoma clinic and you may be contacted to have a 
Peripheral Iridotomy in the eye that did not receive laser treatment in the study. 
 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone‟s negligence, then you may have grounds for 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms should be available to you. 
They can be contacted as follows: 
  
Patient Advice and Liaison Service (PALS) 
Hinchingbrooke Healthcare NHS Trust 
Hinchingbrooke Park 
Huntingdon 
Cambs PE29 6NT 
Telephone: 01480 428964 
E-mail: pals@hinchingbrooke.nhs.uk 
 
 
Will my taking part in this study be kept confidential? 
 
For this study, we will need to ask your permission to have access to your medical notes.  All 
information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital/ surgery will have your name and 
address removed so that you cannot be recognised from it.  An exception to this is correspondence 
to your GP, who, with your permission, will be informed about your participation in the study. 
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What will happen to the results of the research study? 
 
The results of the study will be published in a scientific journal. The results are likely to be 
published several months after the study has ended.  Basic information will be accessible from any 
university or hospital library.  Results of the study will be provided free of charge if requested. You 
will not be personally identified in the published study. 
 
 
Who is organising and funding the research? 
 
The study is being funded by a pharmaceutical company by providing an educational grant. The 
research doctor will receive no personal payment for conducting the study and looking after 
patients during its course. 
 
 
Who has reviewed the study? 
 
This study has received ethics approval by the Essex 1 Research Ethics Committee. 
 
 
Thank you 
 
Thank you for reading this information leaflet, we hope it has helped you in making your 
decision. The research team is really appreciative of you taking the time to read this 
document. 
 
 
Contact for Further Information 
 
If you have any questions about the study or your participation in the study, please do not hesitate 
to contact us: 
Miss Laura Sánchez Parra (Research optometrist, 01480 416416 ext 8437) 
Professor Rupert Bourne (Chief Investigator, 01480 418757) 
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Glossary of Terms 
Primary angle closure suspects (PACS) and primary angle closure (PAC) 
these are „diagnostic labels‟ given to patients who have a shallow front chamber to the eye which is 
a risk factor for a form of glaucoma, named primary angle closure glaucoma (PACG).  
PI = Laser Peripheral Iridotomy = a laser procedure used to make a microscopic hole in the 
upper part of the iris. 
ALPI = Argon Laser Peripheral Iridotomy = a laser procedure that stretches the iris away from 
the drainage area of the eye to open it to drain fluid from the eye
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Appendix 4 Forms 
 
Randomization Forms
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Form 1 
 
 
 
 
 
 
Randomized Allocation 
1st Randomization 
IMPACT Pilot Study 
 
 
Patient Study No 
 
 
 
Patient Initials 
 
 
 
Date of Birth 
 
 
 
Hinchingbrooke Hospital Medical 
Records No. 
 
  
Date of Consent/Randomisation 
 
 
 
Eye which will undertake PI 
 
 
 
 
 
 
 
 
 
This envelope and slip should be returned to:  
 
Laura Sanchez Parra 
Research Coordinator  
Eye Clinic 
Hinchingbrooke Hospital 
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Form 2 
 
 
 
 
 
 
 
Randomized Allocation 
2nd Randomisation 
IMPACT Pilot Study 
 
 
 
Randomisation Patient Number  
 
 
Patient Study No 
 
 
 
Patient Initials 
 
 
 
Date of Birth 
 
 
 
Hinchingbrooke Hospital Medical 
Records No. 
 
  
Date of Consent/Randomisation 
 
 
 
Outcome 
 
 
 
 
 
 
 
 
This envelope and slip should be returned to:  
 
Laura Sanchez Parra 
Research Coordinator  
Eye Clinic 
Hinchingbrooke Hospital 
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